Cohort_id	Trait_onto_ID	Cancer_type	Cancer_subtype	Cancer_DOID	Case_name	Case_age_group	Case_sex	Case_size	Control_name	Control_age_group	Control_sex	Control_size	Condition	Conclusion	Platform	Tissue	Type	pubmed_id
METAC_1	104	breast cancer	early stage breast cancer	1612	Keto diet group		F	29	Standard diet (SD) group		F	30	Blood parameters at baseline in the ketogenic diet (KD) and standard diet (SD) group.	consuming a KD during radiotherapy is safe for women with breast cancer and has the potential to improve quality of life and metabolic health	515/514 medical Body Composition Analyzer	Blood	case vs.control group	33551218
METAC_2	104	breast cancer	early stage breast cancer	1612	Keto diet group		F	29	Standard diet (SD) group		F	30	Blood parameters at end of the study in the ketogenic diet (KD) and standard diet (SD) group.	consuming a KD during radiotherapy is safe for women with breast cancer and has the potential to improve quality of life and metabolic health	515/514 medical Body Composition Analyzer	Blood	case vs.control group	33551218
METAC_6	103	breast cancer	breast cancer with invasive ductal carcinoma (IDC)	1612	Invasive ductal carcinoma (IDC)	47.71±9.12	F	25	Healthy control		F	19	Breast cancer patients with invasive ductal carcinoma (IDC)	Five types of fatty acids may be potential tumor markers in IDC(invasive ductal carcinoma)	GC-MS	Serum	case vs.control group	33240433
METAC_7	76	breast cancer	breast cancer with invasive ductal carcinoma (IDC)	1612	High FASN expression		F	12	No/low FASN expression		F	13	FASN expression of breast cancer patients with invasive ductal carcinoma (IDC)	FASN expression affected the serum fatty acid profiles of patients with IDC(invasive ductal carcinoma). FASN-mediated changes in specific fatty acids promoted tumor cell migration	GC-MS	Serum	case vs.control group	33240433
METAC_8	93	breast cancer	Estrogen receptor (ER)-positive breast cancers	1612	HER2 positive breast cancer		F	10	HER2 negative breast cancer		F	52	Relative metabolite quantification levels between HER2-positive and negative	HER2-positive group was shown to have higher levels of glycine and glutamate, compared to the HER2-negative group	HR-MAS MRS	Breast tissue	case vs.control group	28969000
METAC_9	105	breast cancer	Estrogen receptor (ER)-positive breast cancers	1612	Ki-67 highbreast cancer		F	23	Ki-67 low breast cancer		F	39	Relative metabolite quantification levels between Ki-67 high and low	high Ki-67 group showed higher levels of glutamate than the low Ki-67 group without statistical significance.	HR-MAS MRS	Breast tissue	case vs.control group	28969000
METAC_10	112	breast cancer	Estrogen receptor (ER)-positive breast cancers	1612	Luminal B breast cancer		F	26	Luminal A breast cancer		F	36	Relative metabolite quantification levels between Luminal B and Luminal A	Luminal B cancers showed higher levels of glycine (P=0.01) than luminal A cancers	HR-MAS MRS	Breast tissue	case vs.control group	28969000
METAC_11	128	breast cancer	early breast cancer patients (EBC)	1612	Pre-menopause	42.5 ± 5.5	F	173	Post-menopause	54.3 ± 6.8	F	28	Metabolic characteristics stratified by menopausal status	At diagnosis, compared with post?menopausal women, pre-menopausal patients were more likely to have lower glucose, HbA1c, and triglyceride levels and a lower HOMA score.	Laboratory assays	Blood	case vs.control group	26424165
METAC_12	27	breast cancer	nan	1612	breast cancer patients	63 (27-92)	F	78	controls	39 (21-65)	F	30	metabolites differentiating breast cancer patients from the controls	Eight metabolites showed a significant discriminatory power between breast cancer and controls. High concentrations of lysoPCaC26:0 and PCaaC38:5 were associated with shorter overall survival.	LC-MS;UPLC-MSMS	Blood-Derived Microvesicles	case vs.control group	34948336
METAC_14	93	breast cancer	Her2-enriched,Luminal B	1612	Her2-enriched breast cancer		F	4	Luminal B breast cancer		F	34	metabolites between Her2-enriched and Luminal B	nan	LC-MS;UPLC-MSMS	Blood-Derived Microvesicles	case vs.control group	34948336
METAC_16	107	breast cancer	Luminal A,Luminal B	1612	Luminal A breast cancer		F	31	Luminal B breast cancer		F	34	metabolites between Luminal A and Luminal B	24 metabolites were differentially expressed between luminal A and luminal B	LC-MS;UPLC-MSMS	Blood-Derived Microvesicles	case vs.control group	34948336
METAC_17	107	breast cancer	Luminal A	1612	Luminal A breast cancer		F	31	control	39 (21-65)	F	30	metabolites between Luminal A and control	metabolites was identified that distinguished between breast cancer and controls as well as between molecular subtypes	LC-MS;UPLC-MSMS	Blood-Derived Microvesicles	case vs.control group	34948336
METAC_18	108	breast cancer	Luminal B	1612	Luminal B breast cancer		F	34	control	39 (21-65)	F	30	metabolites between Luminal B and control	metabolites was identified that distinguished between breast cancer and controls as well as between molecular subtypes	LC-MS;UPLC-MSMS	Blood-Derived Microvesicles	case vs.control group	34948336
METAC_19	93	breast cancer	Her2-enriched	1612	Her2-enriched breast cancer		F	4	control	39 (21-65)	F	30	metabolites between Her2-enriched and control	metabolites was identified that distinguished between breast cancer and controls as well as between molecular subtypes	LC-MS;UPLC-MSMS	Blood-Derived Microvesicles	case vs.control group	34948336
METAC_20	128	breast cancer	Luminal A, Luminal B, HER2-enriched, TNBC	1612	Invasive breast cancer		F	39	Breast fibroadenoma		F	24	Estrogen metabolism in premenopausal patients	lower urinary levels of 4-OHE2 and 4-MeOE1 had predictive value for breast cancer	HPLC-MS/MS	Urine	case vs.control group	34812737
METAC_21	128	breast cancer	Luminal A, Luminal B, HER2-enriched, TNBC	1612	Invasive breast cancer		F	45	Breast fibroadenoma		F	23	Estrogen metabolism in postmenopausal patients	lower urinary levels of 4-OHE2 and 4-MeOE1 had predictive value for breast cancer	HPLC-MS/MS	Urine	case vs.control group	34812737
METAC_22	98	breast cancer	Luminal A, Luminal B, HER2-enriched, TNBC	1612	HR+ breast cancer		F		HR- breast cancer		F		hormone receptor status and estrogen metabolism in premenopausal breast cancer patients	higher 2-OHE1 were associated with HR+ breast cancer in premenopausal women	HPLC-MS/MS	Urine	case vs.control group	34812737
METAC_23	98	breast cancer	Luminal A, Luminal B, HER2-enriched, TNBC	1612	HR+ breast cancer		F		HR- breast cancer		F		hormone receptor status and estrogen metabolism in postmenopausal breast cancer patients	nan	HPLC-MS/MS	Urine	case vs.control group	34812737
METAC_24	40	breast cancer	Triple-negative breast cancer (TNBC)	1612	pathological partial response (pPR)	49.2 (32-63)	F	28	pathological stable disease (pSD)	47.8 (29-65)	F	16	Metabolite between patients with pathological partial response and pathological stable disease (pPR and pSD)	Three significantly disturbed metabolic pathways of glycine, serine, and threonine metabolism, valine, leucine, and isoleucine biosynthesis, and alanine, aspartate, and glutamate metabolism could be used as potential predictive models to distinguish three types of TNBC patients. These results indicate that a metabolic phenotype could be used to predict whether a patient is suitable for NAC.	NMR	Serum	case vs.control group	34796199
METAC_25	40	breast cancer	Triple-negative breast cancer (TNBC)	1612	pathological partial response (pPR)	49.2 (32-63)	F	28	pathological complete response (pCR)	46.7 (33-62 )	F	8	Metabolite between patients with pathological partial response and  pathological complete response (pPR and pCR)	Three significantly disturbed metabolic pathways of glycine, serine, and threonine metabolism, valine, leucine, and isoleucine biosynthesis, and alanine, aspartate, and glutamate metabolism could be used as potential predictive models to distinguish three types of TNBC patients. These results indicate that a metabolic phenotype could be used to predict whether a patient is suitable for NAC.	NMR	Serum	case vs.control group	34796199
METAC_26	40	breast cancer	Triple-negative breast cancer (TNBC)	1612	pathological complete response (pCR)	46.7 (33-62 )	F	8	pathological stable disease (pSD)	47.8 (29-65)	F	16	Metabolite between patients with pathological complete response and pathological stable disease (pCR and pSD)	Three significantly disturbed metabolic pathways of glycine, serine, and threonine metabolism, valine, leucine, and isoleucine biosynthesis, and alanine, aspartate, and glutamate metabolism could be used as potential predictive models to distinguish three types of TNBC patients. These results indicate that a metabolic phenotype could be used to predict whether a patient is suitable for NAC.	NMR	Serum	case vs.control group	34796199
METAC_27	196	breast cancer	breast cancer-related lymphedema (BCRL)	1612	selenium-treated(SE) group	48.87 ± 11.25	F	15	placebo-controlled(CTRL)	51.29 ± 14.48 	F	14	metabolites significantly altered in selenium-treated (SE) group than placebo-controlled (CTRL)	selenium IV injection improved the arm ECW/SW ratio and altered the serum metabolic profiles in patients with BCRL, and improved the anti-inflammatory process in lipid, nucleotide and vitamin pathways, which might alleviate the symptoms of BCRL..	LC-MS/MS	Serum	case vs.control group	34579131
METAC_28	27	breast cancer	nan	1612	Breast Cancer	44 (37-50)	F	171	Control 	43 (38-54)	F	69	Characteristics Between breast cancer and controls	nan	¹H NMR	Plasma	case vs.control group	34503091
METAC_29	27	breast cancer	nan	1612	Breast cancer (BC) 	43 ± 8 	F	20	benign breast diseases (BBD).	46 ± 13 	F	13	Comparisons for concentrations of individual bile acids and semi-quantified levels of identified serum bile acids in benign breast diseases (BBD) and breast cancer (BC) groups	The serum BAs profile in BC group was quite different from that in BBD group. Compared with the BBD group, BC group had higher level of chenodeoxycholic acid (CDCA)	UPLC-QTOF-MS	Blood	case vs.control group	34481814
METAC_30	27	breast cancer	nan	1612	Breast Cancer	46±10	F	8	Healthy young females (HY females with normal BMIs)	21 ± 2 	F	10	Metabolic characteristics between Breast cancer and Healthy young females (HY females with normal BMIs)	nan	Biochemical analyses	Blood	case vs.control group	24011971
METAC_31	139	breast cancer	non-malignant females	1612	HM females(non-malignant females of similar age and BMI) 	47 ± 10	F	8	Healthy young females (HY females with normal BMIs)	21 ± 2 	F	10	Metabolic characteristics between HM females(non-malignant females of similar age and BMI) and Healthy young females (HY females with normal BMIs)	nan	Biochemical analyses	Blood	case vs.control group	24011971
METAC_32	140	breast cancer	nan	1612	Non-metastatic breast cancer		F	129	Control		F	32	Serological markers in healthy control and non-metastatic breast cancer	nan	ELISA	Blood	case vs.control group	23275142
METAC_33	132	breast cancer	nan	1612	Metastatic breast cancer		F	88	Non-metastatic breast cancer		F	129	Serological markers in non-metastatic, and metastatic breast cancer	nan	ELISA	Blood	case vs.control group	23275142
METAC_34	25	breast cancer	nan	1612	BRCA1+ breast cancer		F	11	BRCA1- breast cancer		F	11	Metabolic Status of Breast Cancer Patients between BRCA1 positive and negative	BRCA1 gene mutations in breast cancer patients were associated with signs of estrogenization and a pro-genotoxic shift in the estrogen and glucose system, which could modulate the disease course and requires correction	nan	Blood	case vs.control group	22803146
METAC_35	72	breast cancer	ER positive and negative	1612	ER- breast cancer		F	34	ER+ breast cancer		F	125	Positive ion mode (ESI+) results for all investigated lipids in ER- vs. ER+	nan	UPLC-MS	Breast tissue	case vs.control group	21415164
METAC_36	29	breast cancer	nan	1612	Grade 3 breast cancer		F	63	Grade 1&2 breast cancer		F	106	Positive ion mode (ESI+) results for all investigated lipids in Grade 3 vs 1&2	nan	UPLC-MS	Breast tissue	case vs.control group	21415164
METAC_37	27	breast cancer	nan	1612	breast cancer tumor tissue		F	173	breast cancer normal tissue		F	10	Positive ion mode (ESI+) results for all investigated lipids in Tumor vs. normal	nan	UPLC-MS	Breast tissue	case vs.control group	21415164
METAC_38	164	breast cancer	PR positive and negative	1612	PR- breast cancer		F	46	PR+ breast cancer		F	111	Positive ion mode (ESI+) results for all investigated lipids in PR- vs. PR+	nan	UPLC-MS	Breast tissue	case vs.control group	21415164
METAC_39	93	breast cancer	HER2 positive and negative	1612	HER2 positive breast cancer		F	33	HER2 negative breast cancer		F	116	Positive ion mode (ESI+) results for all investigated lipids in HER2+ vs. HER2-	nan	UPLC-MS	Breast tissue	case vs.control group	21415164
METAC_40	72	breast cancer	ER positive and negative	1612	ER- breast cancer		F	34	ER+ breast cancer		F	125	Negative ion mode (ESI-) results for all investigated lipids in ER- vs. ER+	nan	UPLC-MS	Breast tissue	case vs.control group	21415164
METAC_41	29	breast cancer	nan	1612	Grade 3 breast cancer		F	63	Grade 1&2 breast cancer		F	106	Negative ion mode (ESI-) results for all investigated lipids in Grade 3 vs 1&2	nan	UPLC-MS	Breast tissue	case vs.control group	21415164
METAC_42	27	breast cancer	nan	1612	breast cancer tumor tissue		F	173	breast cancer normal tissue		F	10	Negative ion mode (ESI-) results for all investigated lipids in Tumor vs. normal	nan	UPLC-MS	Breast tissue	case vs.control group	21415164
METAC_43	164	breast cancer	PR positive and negative	1612	PR- breast cancer		F	46	PR+ breast cancer		F	111	Negative ion mode (ESI-) results for all investigated lipids in PR- vs. PR+	nan	UPLC-MS	Breast tissue	case vs.control group	21415164
METAC_44	93	breast cancer	HER2 positive and negative	1612	HER2 positive breast cancer		F	33	HER2 negative breast cancer		F	116	Negative ion mode (ESI-) results for all investigated lipids in HER2+ vs. HER2-	nan	UPLC-MS	Breast tissue	case vs.control group	21415164
METAC_45	129	breast cancer	Postmenopausal Breast Cancer	1612	Metabolic syndrome	67.8 ± 1.8	F	42	No metabolic syndrome	65.3 ± 1.4	F	63	Metabolic profile of postmenopausal breast cancer patients between Metabolic syndrome and non-Metabolic syndrome	metabolic syndrome may be associated with a more aggressive tumour biology	nan	Venous blood	case vs.control group	20189371
METAC_46	129	breast cancer	nan	1612	Overweight/Obese Breast Cancer Survivors	55.9 ±9.4	F	42					Clinical Measurements and Metabolic Syndrome Diagnostic Criteria among Overweight=Obese Breast Cancer Survivors	In our sample, overweight breast cancer survivors commonly have MetS and elevated CRP that place them at increased risk for cardiovascular and other metabolic diseases	nan	Blood	profiling group	20044868
METAC_47	128	breast cancer	nan	1612	Premenopausal women 	40.3	F	108	Controls	39.6	F	125	Metabolic and Endocrine Parameters in a Sample of Premenopausal Women in Southern Spain	The metabolic profile differed between pre- and postmenopausal patients, and metabolic alterations were greater in postmenopausal than in premenopausal women. The differences between healthy subjects and breast cancer patients were clearly significant.	Laboratory assays	Peripheral blood	case vs.control group	18665244
METAC_48	128	breast cancer	nan	1612	Postmenopausal women 	62.9	F	96	Controls	62.5	F	125	Metabolic and Endocrine Parameters in a Sample of Postmenopausal Women in Southern SPAIN	The metabolic profile differed between pre- and postmenopausal patients, and metabolic alterations were greater in postmenopausal than in premenopausal women. The differences between healthy subjects and breast cancer patients were clearly significant.	Laboratory assays	Peripheral blood	case vs.control group	18665244
METAC_49	126	breast cancer	nan	1612	High MBD (Mammographic breast density) cases	51.6 ± 6.9	F	87	Low MBD (Mammographic breast density) cases	54.3 ± 6.7	F	87	Metabolites concentration among low- and high-MBD (Mammographic breast density) BC cases	This case–case study suggested a possible role for pre-diagnostic levels of tyrosine in modulating the risk of BC in high- versus low-MBD women.	¹H NMR	Serum	case vs.control group	34158597
METAC_50	36	breast cancer	nan	1612	Staged I breast cancer		F	30	Controls	52.74 ± 11.86	F	86	Significant Metabolites for Comparison of Staged I Breast Cancer Patients and Healthy Controls	nan	LC-QTOF-MS	Plasma	case vs.control group	34033488
METAC_51	36	breast cancer	nan	1612	stage II breast cancer		F	53	Controls	52.74 ± 11.86	F	86	Significant Metabolites for Comparison of Staged II Breast Cancer Patients and Healthy Controls	nan	LC-QTOF-MS	Plasma	case vs.control group	34033488
METAC_52	36	breast cancer	nan	1612	stages I + II breast cancer		F	83	Controls	52.74 ± 11.86	F	86	Significant Metabolites for Comparison of Staged I + II Breast Cancer Patients and Healthy Controls	nan	LC-QTOF-MS	Plasma	case vs.control group	34033488
METAC_53	36	breast cancer	nan	1612	stage III breast cancer		F	41	Controls	52.74 ± 11.86	F	86	Significant Metabolites for Comparison of Staged III Breast Cancer Patients and Healthy Controls	nan	LC-QTOF-MS	Plasma	case vs.control group	34033488
METAC_54	27	breast cancer	nan	1612	Breast cancer	55.68 ± 10.97	F	124	Controls	52.74 ± 11.86	F	86	Significant metabolites/features detected by LC-QTOF-MS for comparison of breast cancer and controls.	nan	LC-QTOF-MS	Plasma	case vs.control group	34033488
METAC_55	27	breast cancer	nan	1612	Breast cancer	55.68 ± 10.97	F	124	Controls	52.74 ± 11.86	F	86	Significant metabolites detected by LC-QQQ-MS for comparison of breast cancer and controls.	nan	LC-QQQ-MS	Plasma	case vs.control group	34033488
METAC_56	72	breast cancer	nan	1612	ER+ breast cancer		F	115	Controls	52.74 ± 11.86	F	86	Metabolite differences of patients with varying ER+ and healthy controls	nan	LC-QTOF-MS	Plasma	case vs.control group	34033488
METAC_57	72	breast cancer	nan	1612	ER- breast cancer		F	9	Controls	52.74 ± 11.86	F	86	Metabolite differences of patients with varying ER- and healthy controls	nan	LC-QTOF-MS	Plasma	case vs.control group	34033488
METAC_58	164	breast cancer	ER positive	1612	PR+ breast cancer		F	105	Controls	52.74 ± 11.86	F	86	Metabolite differences of patients with varying PR+ status and healthy controls	nan	LC-QTOF-MS	Plasma	case vs.control group	34033488
METAC_59	164	breast cancer	ER negative	1612	PR- breast cancer		F	19	Controls	52.74 ± 11.86	F	86	Metabolite differences of patients with varying PR- status and healthy controls	nan	LC-QTOF-MS	Plasma	case vs.control group	34033488
METAC_60	93	breast cancer	HER2 positive	1612	HER2 positive breast cancer		F	22	Controls	52.74 ± 11.86	F	86	Metabolite differences of patients with varying HER2+ versus healthy controls	nan	LC-QTOF-MS	Plasma	case vs.control group	34033488
METAC_61	93	breast cancer	HER2 negative	1612	HER2- breast cancer		F	80	Controls	52.74 ± 11.86	F	86	Metabolite differences of patients with varying HER2- versus healthy controls	nan	LC-QTOF-MS	Plasma	case vs.control group	34033488
METAC_62	72	breast cancer	ER positive and negative	1612	ER+ breast cancer		F	115	ER- breast cancer		F	9	Differences in metabolites of breast cancer patients of varying ER status	nan	LC-QTOF-MS	Plasma	case vs.control group	34033488
METAC_63	164	breast cancer	PR positive and negative	1612	PR+ breast cancer		F	105	PR- breast cancer		F	19	Differences in metabolites of breast cancer patients of varying PR status	nan	LC-QTOF-MS	Plasma	case vs.control group	34033488
METAC_64	108	breast cancer	luminal B	1612	LB: luminal B breast cancer	49 (27-75)	F	61	HC: healthy control	50 (42-56)	F	64	Differences in metabolites of luminal B and healthy control: positive electrospray ionization modes (ESI+)	We found a biomarker panel of 5 candidates in LA, 7 in LB, 5 in HER2 and 3 in TN that were able to discriminate each breast cancer subtype with a false discovery range corrected p-value < 0.05 and a fold-change cutoff value > 1.3	LC-HRMS	Plasma	case vs.control group	33466323
METAC_65	108	breast cancer	luminal B	1612	LB: luminal B breast cancer	49 (27-75)	F	61	HC: healthy control	50 (42-56)	F	64	Differences in metabolites of luminal B and healthy control: negative electrospray ionization modes (ESI-)	We found a biomarker panel of 5 candidates in LA, 7 in LB, 5 in HER2 and 3 in TN that were able to discriminate each breast cancer subtype with a false discovery range corrected p-value < 0.05 and a fold-change cutoff value > 1.3	LC-HRMS	Plasma	case vs.control group	33466323
METAC_66	107	breast cancer	luminal A	1612	LA: luminal A breast cancer	50 (32-81)	F	21	HC: healthy control	49 (34-60)	F	21	Differences in metabolites of luminal A and healthy control: positive electrospray ionization modes (ESI+)	We found a biomarker panel of 5 candidates in LA, 7 in LB, 5 in HER2 and 3 in TN that were able to discriminate each breast cancer subtype with a false discovery range corrected p-value < 0.05 and a fold-change cutoff value > 1.3	LC-HRMS	Plasma	case vs.control group	33466323
METAC_67	107	breast cancer	luminal A	1612	LA: luminal A breast cancer	50 (32-81)	F	21	HC: healthy control	49 (34-60)	F	21	Differences in metabolites of luminal A and healthy control: negative electrospray ionization modes (ESI-)	We found a biomarker panel of 5 candidates in LA, 7 in LB, 5 in HER2 and 3 in TN that were able to discriminate each breast cancer subtype with a false discovery range corrected p-value < 0.05 and a fold-change cutoff value > 1.3	LC-HRMS	Plasma	case vs.control group	33466323
METAC_68	210	breast cancer	triple negative	1612	TN: triple negative breast cancer	49 (29-71)	F	15	HC: healthy control	51 (26-63)	F	15	Differences in metabolites of triple negative and healthy control: positive electrospray ionization modes (ESI+)	We found a biomarker panel of 5 candidates in LA, 7 in LB, 5 in HER2 and 3 in TN that were able to discriminate each breast cancer subtype with a false discovery range corrected p-value < 0.05 and a fold-change cutoff value > 1.3	LC-HRMS	Plasma	case vs.control group	33466323
METAC_70	93	breast cancer	HER2 positive	1612	HER2: human epidermal growth factor receptor 2 positive breast cancer	51 (33-70)	F	34	HC: healthy control	49 (28-62)	F	34	Differences in metabolites of HER2 positive and healthy control: positive electrospray ionization modes (ESI+)	We found a biomarker panel of 5 candidates in LA, 7 in LB, 5 in HER2 and 3 in TN that were able to discriminate each breast cancer subtype with a false discovery range corrected p-value < 0.05 and a fold-change cutoff value > 1.3	LC-HRMS	Plasma	case vs.control group	33466323
METAC_71	93	breast cancer	HER2 positive	1612	HER2: human epidermal growth factor receptor 2 positive breast cancer	51 (33-70)	F	34	HC: healthy control	49 (28-62)	F	34	Differences in metabolites of HER2 positive and healthy control: negative electrospray ionization modes (ESI-)	We found a biomarker panel of 5 candidates in LA, 7 in LB, 5 in HER2 and 3 in TN that were able to discriminate each breast cancer subtype with a false discovery range corrected p-value < 0.05 and a fold-change cutoff value > 1.3	LC-HRMS	Plasma	case vs.control group	33466323
METAC_72	27	breast cancer	nan	1612	Breast Cancers	47.52 ± 9.79	F	23	Healthy Controls	42.00 ± 13.83	F	35	Potential salivary metabolites of breast cancer.	Using the METLIN database, 31 compounds that were upregulated in the breast cancer group (p < 0.05) were identified, including seven oligopeptides and six glycerophospholipids (PG14:2, PA32:1, PS28:0, PS40:6, PI31:1, and PI38:7)	LC/MS	Saliva	case vs.control group	33322065
METAC_73	40	breast cancer	nan	1612	Breast cancer After treatment	51 ± 1	F	99	Breast cancer baseline	51 ± 1	F	99	Effects of chemotherapy on body composition and physical activity in women receiving treatment for breast cancer.	CT was associated with an increase in total and central adiposity, insulin resistance, and all lipid-related markers, and a decrease in appendicular lean mass index, BMD and HDL-c concentration.	Biochemical analyses	Blood	case vs.control group	33309160
METAC_74	40	breast cancer	nan	1612	Breast cancer After treatment	42 ± 1	F	40	Breast cancer baseline	42 ± 1	F	40	Effects of chemotherapy on body composition and physical activity in Premenopausal women receiving treatment for breast cancer.	nan	Biochemical analyses	Blood	case vs.control group	33309160
METAC_75	40	breast cancer	nan	1612	Breast cancer After treatment	57 ± 1	F	59	Breast cancer baseline	57 ± 1	F	59	Effects of chemotherapy on body composition and physical activity in Postmenopausal women receiving treatment for breast cancer.	nan	Biochemical analyses	Blood	case vs.control group	33309160
METAC_76	27	breast cancer	nan	1612	Breast cancer patients		F	10	Healthy subjects		F	12	nail lysates metabolites between Breast cancer patients and Healthy subjects	The analysis on collected data of nail metabolites clearly suggested that FAAAs including tryptophan, tyrosine, phenylalanine, and histidine were undetectable in nail lysates of breast cancer over healthy subjects. This is a first report that showed highly reduced levels of FAAAs in nails of breast cancer patients. Furthermore, the present observation is in consonance with previous findings that showed cancer cachexia and high amino acid catabolism in breast cancer patients that drive metabolite-led cancer growth and proliferation	LC-HRMS	Nail lysate	case vs.control group	32695662
METAC_77	27	breast cancer	nan	1612	Breast cancer		F	59	control		F	40	To identify significant compounds comparing breast cancer vs. controls by using GC-TOF-MS	nan	GC-TOF-MS	Breast tissue	case vs.control group	32344578
METAC_78	27	breast cancer	nan	1612	Breast cancer		F	59	control		F	40	To identify significant compounds comparing breast cancer vs. controls by using HILIC-ESI-QTOF-MS/MS	nan	HILIC-ESI-QTOF-MS/MS	Breast tissue	case vs.control group	32344578
METAC_79	27	breast cancer	nan	1612	breast cancer patients		F	25	benign breast disease as controls		F	25	differences identified by positive ion mode between breast cancer and control groups	1-myristoyl-sn-glycero-3-phosphocholine, 1-palmitoyl-2-hydroxy-sn-glycero-3-phosphoethanolamine and 1-stearoyl-2-hydroxy-sn-glycero-3-phosphocholine were different with lower P value.	LC-MS	Blood	case vs.control group	32272885
METAC_80	210	breast cancer	ER-, PR-, HER2-	1612	TN: triple negative breast cancer	51.5 ± 10.2	F	31	health controls	51.7 ± 10.6	F	31	Signifcantly altered metabolites in TNBC vs. healthy controls in the analysis of LC-MS positive mode and LC-MS negative mode	77 metabolites, whose levels were signifcantly diferent between TNBC with CN, were confrmed.	UHPLC-HRMS	Serum	case vs.control group	31941951
METAC_81	161	breast cancer	nan	1612	Carbohydrate group		F	25	Fasting group		F	35	Serum metabolites with p-values from t-tests, fasting group versus carbohydrate (CH), for all patients	Fourteen of 28 metabolites were differently expressed between fasting and carbohydrate groups. Partial least squares discriminant analysis showed a significant difference in the metabolic profile between the fasting and carbohydrate groups, compatible with the endocrine effects of insulin (i.e., increased serum-lactate and pyruvate and decreased ketone bodies and amino acids in the carbohydrate group). Among ER-positive tumors (n = 18), glutathione was significantly elevated in the carbohydrate group compared to the fasting group (p = 0.002), with a positive correlation between preoperative S-insulin levels and the glutathione content in tumors (r = 0.680; p = 0.002). In all tumors (n = 29), glutamate was increased in tumors with high proliferation (t-test; p = 0.009), independent of intervention group.	¹H NMR	Serum	case vs.control group	31801490
METAC_82	161	breast cancer	ER positive	1612	ER+ Carbohydrate group		F	20	ER+ Fasting group		F	29	Serum metabolites with p-values from t-tests, fasting group versus carbohydrate (CH) for the ER positive subset	Fourteen of 28 metabolites were differently expressed between fasting and carbohydrate groups. Partial least squares discriminant analysis showed a significant difference in the metabolic profile between the fasting and carbohydrate groups, compatible with the endocrine effects of insulin (i.e., increased serum-lactate and pyruvate and decreased ketone bodies and amino acids in the carbohydrate group). Among ER-positive tumors (n = 18), glutathione was significantly elevated in the carbohydrate group compared to the fasting group (p = 0.002), with a positive correlation between preoperative S-insulin levels and the glutathione content in tumors (r = 0.680; p = 0.002). In all tumors (n = 29), glutamate was increased in tumors with high proliferation (t-test; p = 0.009), independent of intervention group.	¹H NMR	Serum	case vs.control group	31801490
METAC_83	161	breast cancer	nan	1612	Carbohydrate group		F	16	Fasting group		F	13	Tumor metabolites with fold changes and t-test p-values in carbohydrate vs fasting groups	Fourteen of 28 metabolites were differently expressed between fasting and carbohydrate groups. Partial least squares discriminant analysis showed a significant difference in the metabolic profile between the fasting and carbohydrate groups, compatible with the endocrine effects of insulin (i.e., increased serum-lactate and pyruvate and decreased ketone bodies and amino acids in the carbohydrate group). Among ER-positive tumors (n = 18), glutathione was significantly elevated in the carbohydrate group compared to the fasting group (p = 0.002), with a positive correlation between preoperative S-insulin levels and the glutathione content in tumors (r = 0.680; p = 0.002). In all tumors (n = 29), glutamate was increased in tumors with high proliferation (t-test; p = 0.009), independent of intervention group.	HR-MAS MRS	Breast tissue	case vs.control group	31801490
METAC_84	161	breast cancer	ER positive	1612	ER+ Carbohydrate group		F	11	ER+ Fasting group		F	9	Tumor metabolites with fold changes and t-test p-values in carbohydrate vs fasting groups for the ER positive subset	Fourteen of 28 metabolites were differently expressed between fasting and carbohydrate groups. Partial least squares discriminant analysis showed a significant difference in the metabolic profile between the fasting and carbohydrate groups, compatible with the endocrine effects of insulin (i.e., increased serum-lactate and pyruvate and decreased ketone bodies and amino acids in the carbohydrate group). Among ER-positive tumors (n = 18), glutathione was significantly elevated in the carbohydrate group compared to the fasting group (p = 0.002), with a positive correlation between preoperative S-insulin levels and the glutathione content in tumors (r = 0.680; p = 0.002). In all tumors (n = 29), glutamate was increased in tumors with high proliferation (t-test; p = 0.009), independent of intervention group.	HR-MAS MRS	Breast tissue	case vs.control group	31801490
METAC_85	27	breast cancer	nan	1612	Breast Cancer (BC)	59 ± 10	F	40	Control (CTL)	53 ± 8	F	38	Metabolites found in urine samples from breast cancer (BC) patients and healthy controls	A total of 10 metabolites exhibited the highest contribution towards discriminating breast cancer patients from healthy controls (variable importance in projection (VIP) >1, p < 0.05).	¹H NMR	Urine	case vs.control group	31703396
METAC_86	190	breast cancer	nan	1612	Partial response breast cancer patients (pre-RT stage)		F	24	Control		F	40	Partial response breast cancer patients (pre-RT stage) VS control	Our results highlight the importance of metabolism in the outcomes of patients with BC	GC-EI-QTOF-MS	Serum	case vs.control group	31679126
METAC_87	190	breast cancer	nan	1612	Complete response breast cancer patients (pre-RT)		F	13	Control		F	40	Complete response breast cancer patients (post-RT) VS control	Our results highlight the importance of metabolism in the outcomes of patients with BC	GC-EI-QTOF-MS	Serum	case vs.control group	31679126
METAC_88	190	breast cancer	nan	1612	Partial response breast cancer patients (post-RT)		F	24	Control		F	40	Partial response breast cancer patients (post-RT) VS control	Our results highlight the importance of metabolism in the outcomes of patients with BC	GC-EI-QTOF-MS	Serum	case vs.control group	31679126
METAC_89	190	breast cancer	nan	1612	Complete response breast cancer patients (post-RT)		F	13	Control		F	40	Complete response breast cancer patients (post-RT) VS control	Our results highlight the importance of metabolism in the outcomes of patients with BC	GC-EI-QTOF-MS	Serum	case vs.control group	31679126
METAC_90	190	breast cancer	nan	1612	Complete response (breast cancer patients post-RT)		F	13	Partial response (BC patients post-RT)		F	24	Complete response vs Partial response (breast cancer patients post-RT)	Our results highlight the importance of metabolism in the outcomes of patients with BC	GC-EI-QTOF-MS	Serum	case vs.control group	31679126
METAC_94	103	breast cancer	IDC(invasive ductal carcinoma)	1612	IDC(invasive ductal carcinoma) patients	44 (36-68)	F	20	Control	48 (35-63)	F	20	differentially expressed metabolites in IDC patients vs control	two classes of signaling lipids, lysophosphatidylethanolamine and ceramide, may play an important role in IDC development and progression	LC/MS	Serum	case vs.control group	26179699
METAC_95	27	breast cancer	nan	1612	breast cancer	40 (31-45)	F	35	healthy control	38 (35-40)	F	35	differences in plasma metabolites of patients of breast cancer and healthy control: training set	lowed circulating aspartate is a key metabolic feature of human breast cancer	LC-TOFMS/GC-TOF-MS	Plasma	case vs.control group	26452258
METAC_96	27	breast cancer	nan	1612	breast cancer	58 (46-73)	F	103	healthy control	30 (21-35)	F	41	differences in plasma metabolites of patients of breast cancer and healthy control: validation set	nan	LC-TOFMS/GC-TOF-MS	Plasma	case vs.control group	26452258
METAC_97	27	breast cancer	nan	1612	Breast cancer		F	111	Control		F	61	differences in saliva polyamines of patients and healthy control	The saliva polyamines discrimination equation appears to be useful for the diagnosis of breast cancer patients	UPLC-ESI-MS/MS	Saliva	case vs.control group	26523874
METAC_98	93	breast cancer	Her2 positive and negative	1612	HER2 positive breast cancer	52.3 (31-82)	F	36	HER2 negative breast cancer	53.1 (31-78)	F	60	Differences in metabolites of patients of Her2 positive vs Her2 negative	Compared to human epidermal growth factor receptor 2 (HER2)-negative patients, HER2-positive group showed elevated aerobic glycolysis, gluconeogenesis, and increased fatty acid biosynthesis with reduced Krebs cycle	UPLC-Q/TOF-MS;GC-Q/MS	Plasma	case vs.control group	26848530
METAC_99	72	breast cancer	ER positive and negative	1612	ER positive breast cancer		F	53	ER negative breast cancer		F	43	Differences in metabolites of patients of ER positive vs ER negative	Compared with estrogen receptor (ER)-negative group, ER-positive patients showed elevated alanine, aspartate and glutamate metabolism, decreased glycerolipid catabolism, and enhanced purine metabolism.	UPLC-Q/TOF-MS;GC-Q/MS	Plasma	case vs.control group	26848530
METAC_100	27	breast cancer	nan	1612	Breast cancer	53 (32-79)	F	30	Control		F	25	differences in saliva metabolites of patients and healthy control	An integrated metabonomics analysis in human saliva for identifying potential biomarkers to diagnose and stage BC was successfully eastablished, which was non-invasive, reliable, low-cost, and simple.	RPLC/HILIC UPLC-ESI-MS	Saliva	case vs.control group	27343615
METAC_101	3	breast cancer	ER and/or PR positive; or HER2 negative	1612	adjuvant endocrine therapy (ET)		F	10	metastatic endocrine therapy (ET)		F	19	differences in serum oxysterols of patients respectively in adjuvant and metastatic treatment	nan	GC-MS	Serum	case vs.control group	27343991
METAC_102	22	breast cancer	ER and/or PR positive; or HER2 negative	1612	BMI>25		F	17	BMI≤25		F	15	differences in serum oxysterols of patients with different BMI	nan	GC-MS	Serum	case vs.control group	27343991
METAC_103	70	breast cancer	ER and/or PR positive; or HER2 negative	1612	after endocrine therapy		F		before endocrine therapy		F		changes in serum oxysterols of patients after endocrine therapy	nan	GC-MS	Serum	case vs.control group	27343991
METAC_104	33	breast cancer	ER and/or PR positive; or HER2 negative	1612	after Tam therapy	58 (40-75)	F	15	before Tam therapy	58 (40-75)	F	15	changes in serum oxysterols of patients after Tamoxifen (Tam) therapy	Interestingly, we found that, in contrast to AI, Tam therapy significantly decreased blood levels of 24-hydroxycholesterol (24-HC), 7a-HC and 25-HC (a tumor promoter) (p = 0.0007, p = 0.0231 and p = 0.0231, respectively), whereas 4b HC levels increased (p = 0.0010). Interestingly, levels of 27-HC (a tumor promoter) significantly increased in response to AI (p = 0.0342), but not Tam treatment. According to these results, specific OS are promising candidate markers of Tam and AI efficacy	GC-MS	Serum	case vs.control group	27343991
METAC_105	9	breast cancer	ER and/or PR positive; or HER2 negative	1612	after AI therapy		F		before AI therapy		F		changes in serum oxysterols of patients after Aromatase Inhibitors (AI) therapy	Interestingly, we found that, in contrast to AI, Tam therapy significantly decreased blood levels of 24-hydroxycholesterol (24-HC), 7a-HC and 25-HC (a tumor promoter) (p = 0.0007, p = 0.0231 and p = 0.0231, respectively), whereas 4b HC levels increased (p = 0.0010). Interestingly, levels of 27-HC (a tumor promoter) significantly increased in response to AI (p = 0.0342), but not Tam treatment. According to these results, specific OS are promising candidate markers of Tam and AI efficacy	GC-MS	Serum	case vs.control group	27343991
METAC_110	30	breast cancer	nan	1612	breast cancer intervention group		F	43	breast cancer control group		F	42	ANCOVA results for breast cancer intervention vs breast cancer control group	nan	ELISA	Urine	case vs.control group	31612110
METAC_111	30	breast cancer	nan	1612	breast cancer intervention group		F	44	breast cancer control group		F	41	ANCOVA results for breast cancer intervention vs breast cancer control group	nan	ELISA	Urine	case vs.control group	31612110
METAC_112	30	breast cancer	nan	1612	breast cancer intervention group		F	35	breast cancer control group		F	39	ANCOVA results for breast cancer intervention vs breast cancer control group	nan	ELISA	Urine	case vs.control group	31612110
METAC_113	30	breast cancer	nan	1612	breast cancer intervention group		F	36	breast cancer control group		F	34	ANCOVA results for breast cancer intervention vs breast cancer control group	nan	ELISA	Urine	case vs.control group	31612110
METAC_114	27	breast cancer	nan	1612	breast cancer control group		F	42	healthy intervention group		F	24	ANCOVA results for healthy intervention group vs breast cancer control group	nan	ELISA	Urine	case vs.control group	31612110
METAC_115	27	breast cancer	nan	1612	breast cancer control group		F	41	healthy intervention group		F	24	ANCOVA results for healthy intervention group vs breast cancer control group	nan	ELISA	Urine	case vs.control group	31612110
METAC_116	27	breast cancer	nan	1612	breast cancer control group		F	39	healthy intervention group		F	24	ANCOVA results for healthy intervention group vs breast cancer control group	nan	ELISA	Urine	case vs.control group	31612110
METAC_117	27	breast cancer	nan	1612	breast cancer control group		F	34	healthy intervention group		F	23	ANCOVA results for healthy intervention group vs breast cancer control group	nan	ELISA	Urine	case vs.control group	31612110
METAC_118	27	breast cancer	nan	1612	breast cancer		F	42	Control		F	37	Estrogen metabolites of premenopausal patients with breast cancer and normal controls	4-hydroxy estrogen (4-OH-E) metabolite was found to be significantly increased in the urine samples of patients with breast cancer compared with the normal healthy controls	GC-MS	Urine	case vs.control group	31497216
METAC_119	27	breast cancer	nan	1612	breast cancer		F	29	Control		F	22	Androgen and progesterone metabolites of patients with breast cancer and normal controls	nan	GC-MS	Urine	case vs.control group	31497216
METAC_120	214	breast cancer	nan	1612	prior to treatment (TP1)		F	132	12 weeks into treatment (TP2)		F	132	breast cancer treatment on the serum metabolome between prior to treatment (TP1) and 12 weeks into treatment (TP2)	nan	NMR	Serum	case vs.control group	31483662
METAC_121	214	breast cancer	nan	1612	12 weeks into treatment (TP2)		F	132	surgically removed tumor (TP3)		F	132	breast cancer treatment on the serum metabolome between 12 weeks into treatment (TP2) and surgically removed tumor (TP3)	nan	NMR	Serum	case vs.control group	31483662
METAC_122	214	breast cancer	nan	1612	surgically removed tumor (TP3)		F	132	6 weeks after surgery (TP4)		F	132	breast cancer treatment on the serum metabolome between surgically removed tumor (TP3) and 6 weeks after surgery (TP4)	nan	NMR	Serum	case vs.control group	31483662
METAC_123	27	breast cancer	Ductal; Lobular; Ductal and lobular	1612	breast cancer	54.6	F	102	Control	51.6	F	99	Significant metabolites for comparison of breast cancer patients and healthy controls.	There were significant changes in plasma metabolites in breast cancer patients and healthy controls.	LC-MS/MS	Plasma	case vs.control group	30562627
METAC_124	36	breast cancer	Ductal; Lobular; Ductal and lobular	1612	breast cancer: Stage I		F	24	Control	51.6	F	99	Significant metabolites for comparison of breast cancer patients at stage I and controls.	There were significant changes in plasma metabolites in stage I breast cancer patients and healthy controls.	LC-MS/MS	Plasma	case vs.control group	30562627
METAC_125	36	breast cancer	Ductal; Lobular; Ductal and lobular	1612	breast cancer: Stage II		F	42	Control	51.6	F	99	Significant metabolites for comparison of breast cancer patients at stage II and controls.	There were significant changes in plasma metabolites in stage II breast cancer patients and healthy controls.	LC-MS/MS	Plasma	case vs.control group	30562627
METAC_126	36	breast cancer	Ductal; Lobular; Ductal and lobular	1612	breast cancer: Stage I & II		F	66	Control	51.6	F	99	Significant metabolites for comparison of breast cancer patients at stage I & II and controls.	There were significant changes in plasma metabolites in stage I & II breast cancer patients and healthy controls.	LC-MS/MS	Plasma	case vs.control group	30562627
METAC_127	36	breast cancer	Ductal; Lobular; Ductal and lobular	1612	breast cancer: Stage III		F	36	Control	51.6	F	99	Significant metabolites for comparison of breast cancer patients at stage III and controls.	There were significant changes in plasma metabolites in stage III breast cancer patients and healthy controls.	LC-MS/MS	Plasma	case vs.control group	30562627
METAC_128	36	breast cancer	Ductal; Lobular; Ductal and lobular	1612	stage II breast cancer		F	42	stage I breast cancer		F	24	Differences in metabolites of patients between stage I breast cancer patients and stage II breast cancer patients.	No significant difference in metabolites between stage I and stage II breast cancer.	LC-MS/MS	Plasma	case vs.control group	30562627
METAC_129	36	breast cancer	Ductal; Lobular; Ductal and lobular	1612	stage III breast cancer		F	36	stage I breast cancer		F	24	Differences in metabolites of patients between stage I breast cancer patients and stage III breast cancer patients.	No significant difference in metabolites between stage I and stage III breast cancer.	LC-MS/MS	Plasma	case vs.control group	30562627
METAC_130	72	breast cancer	Ductal; Lobular; Ductal and lobular	1612	ER+ breast cancer		F	95	ER− breast cancer		F	7	Differences in metabolites of patients between different ER status (ER+/ER-).	No significant difference in metabolites between ER+ and ER− breast cancer.	LC-MS/MS	Plasma	case vs.control group	30562627
METAC_131	164	breast cancer	Ductal; Lobular; Ductal and lobular	1612	PR+ breast cancer		F	88	PR− breast cancer		F	14	Differences in metabolites of patients between different PR status (PR+/PR-).	No significant difference in metabolites between PR+ and PR− breast cancer.	LC-MS/MS	Plasma	case vs.control group	30562627
METAC_132	93	breast cancer	Ductal; Lobular; Ductal and lobular	1612	HER2 positive breast cancer		F	20	HER2 negative breast cancer		F	69	Differences in metabolites of patients between different HER2 status (HER2+/HER2-).	No significant difference in metabolites between HER2+ and HER2− breast cancer.	LC-MS/MS	Plasma	case vs.control group	30562627
METAC_133	27	breast cancer	nan	1612	breast cancer patients	51.1 ± 12.0	F	134	healthy controls	51.1 ± 6.7	F	57	Metabolites differed between breast cancer cases and controls(discovery)	lipids may play a key role in breast carcinogenesis	LC-MS/GC-MS	Serum	case vs.control group	30771047
METAC_134	27	breast cancer	nan	1612	breast cancer patients	50.6 ± 10.7	F	224	healthy controls	58.4 ± 14.8	F	81	Metabolites differed between breast cancer cases and controls(validation)	nan	LC-MS/GC-MS	Serum	case vs.control group	30771047
METAC_135	156	breast cancer	nan	1612	Palbociclib		F	4	control		F		Panel of significantly altered metabolites 2 days after dosing with palbociclib when comparing dosed groups to control	Individually , palbociclib and fulvestrant caused disruption to shared metabolic pathways, however only fulvestrant acts on the PPP and has a more profound effect on amino acid biosynthesis. The combined effect of dosing with both drugs enables a comprehensive attenuation of metabolic pathways involved in co-enzyme production, energy metabolism, and macromolecule biosynthesis.	HPLC-MS	MCF-7 cell line	case vs.control group	30609717
METAC_136	78	breast cancer	nan	1612	Fulvestrant 		F	4	control		F		Panel of significantly altered metabolites 2 days after dosing with fulvestrant when comparing dosed groups to control	Individually , palbociclib and fulvestrant caused disruption to shared metabolic pathways, however only fulvestrant acts on the PPP and has a more profound effect on amino acid biosynthesis. The combined effect of dosing with both drugs enables a comprehensive attenuation of metabolic pathways involved in co-enzyme production, energy metabolism, and macromolecule biosynthesis.	HPLC-MS	MCF-7 cell line	case vs.control group	30609717
METAC_137	54	breast cancer	nan	1612	Combination		F	4	control		F		Panel of significantly altered metabolites 2 days after dosing with a combination dose of both palbociclib and fulvestrant (n = 4) when comparing dosed groups to control	Individually , palbociclib and fulvestrant caused disruption to shared metabolic pathways, however only fulvestrant acts on the PPP and has a more profound effect on amino acid biosynthesis. The combined effect of dosing with both drugs enables a comprehensive attenuation of metabolic pathways involved in co-enzyme production, energy metabolism, and macromolecule biosynthesis.	HPLC-MS	MCF-7 cell line	case vs.control group	30609717
METAC_138	156	breast cancer	nan	1612	Palbociclib		F	4	control		F		Panel of significantly altered metabolites 7 days after dosing with palbociclib (n = 4) when comparing dosed groups to control	Individually , palbociclib and fulvestrant caused disruption to shared metabolic pathways, however only fulvestrant acts on the PPP and has a more profound effect on amino acid biosynthesis. The combined effect of dosing with both drugs enables a comprehensive attenuation of metabolic pathways involved in co-enzyme production, energy metabolism, and macromolecule biosynthesis.	HPLC-MS	MCF-7 cell line	case vs.control group	30609717
METAC_139	78	breast cancer	nan	1612	Fulvestrant 		F	4	control		F		Panel of significantly altered metabolites 7 days after dosing with fulvestrant (n = 4) when comparing dosed groups to control	Individually , palbociclib and fulvestrant caused disruption to shared metabolic pathways, however only fulvestrant acts on the PPP and has a more profound effect on amino acid biosynthesis. The combined effect of dosing with both drugs enables a comprehensive attenuation of metabolic pathways involved in co-enzyme production, energy metabolism, and macromolecule biosynthesis.	HPLC-MS	MCF-7 cell line	case vs.control group	30609717
METAC_140	54	breast cancer	nan	1612	Combination		F	4	control		F		Panel of significantly altered metabolites 7 days after dosing with a combination dose of both palbociclib and fulvestrant (n = 4) when comparing dosed groups to control	Individually , palbociclib and fulvestrant caused disruption to shared metabolic pathways, however only fulvestrant acts on the PPP and has a more profound effect on amino acid biosynthesis. The combined effect of dosing with both drugs enables a comprehensive attenuation of metabolic pathways involved in co-enzyme production, energy metabolism, and macromolecule biosynthesis.	HPLC-MS	MCF-7 cell line	case vs.control group	30609717
METAC_142	35	breast cancer	nan	1612	The Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO) study (277 cases and 423 controls)		F	700					metabolite concentrations for The Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO) study	Higher total estrogen levels were strongly associated with increased postmenopausal breast cancer risk.	LC-MS/MS	Blood	profiling group	28011624
METAC_143	35	breast cancer	nan	1612	Columbia (215 cases and 215 controls)		F	430					metabolite concentrations for Columbia study	Higher total estrogen levels were strongly associated with increased postmenopausal breast cancer risk.	LC-MS/MS	Blood	profiling group	28011624
METAC_144	35	breast cancer	nan	1612	Breast and Bone Follow-up to the Fracture Intervention Trial (B~FIT) (407 cases and 487 controls)		F	894					"metabolite concentrations for 	The Breast and Bone Follow-up to the Fracture Intervention Trial (B~FIT) study"	Higher total estrogen levels were strongly associated with increased postmenopausal breast cancer risk.	LC-MS/MS	Blood	profiling group	28011624
METAC_145	35	breast cancer	nan	1612	Shanghai Women’s Health Study (SWHS) (399 cases and 399 controls)		F	798					metabolite concentrations for The Shanghai Women’s Health Study (SWHS) study	Higher total estrogen levels were strongly associated with increased postmenopausal breast cancer risk.	LC-MS/MS	Urine	profiling group	28011624
METAC_146	94	breast cancer	nan	1612	high IP3R patient group	58.6 ± 12.4	F	40	healthy controls	58.6 ± 12.4	F	15	Metabolites contributing to the difference between healthy control and high IP3R patient group.	Resonances arising from lipids were significantly higher in patients with high tissue expression of IP3R as compared to healthy control. Patients with low tissue expression of IP3R showed no significant difference compared to healthy control.	¹H NMR	Blood	case vs.control group	28072864
METAC_147	27	breast cancer	nan	1612	breast cancer patients	62 (34-91)	F	91	healthy control subjects	48 (22-64)	F	20	Altered metabolites and canonical pathways in plasma of breast cancer patients and healthy control subjects	There are 1269 metabolites with different concentration in plasma from healthy controls and cancer patients.	LC-ESI-QTOF MS/MS	Plasma	case vs.control group	28076849
METAC_148	33	breast cancer	nan	1612	breast cancer patients with TAM treatment	51.6 ± 11.6	F	134					Metabolites in Thai breast cancer patients with Tamoxifen (Tam) Treatment	CYP2D6 polymorphisms appear to affect END concentration through an NDMT subpathway and potentially affect 4OHT concentrations through a 4OHT subpathway in CYP3A5-PM group.	HPLC	Plasma	profiling group	28450788
METAC_149	57	breast cancer	nan	1612	CYP2D6*1/*1		F	13					The concentrations of TAM and its metabolites (ng/mL) among different CYP2D6 polymorphisms	nan	HPLC	Plasma	profiling group	28450788
METAC_150	57	breast cancer	nan	1612	CYP2D6*1/*10		F	21					The concentrations of TAM and its metabolites (ng/mL) among different CYP2D6 polymorphisms	The concentrations of TAM and its metabolites were not significantly affected byCYP2D6genotype or phenotype	HPLC	Plasma	profiling group	28450788
METAC_151	57	breast cancer	nan	1612	CYP2D6*10/*10		F	72					The concentrations of TAM and its metabolites (ng/mL) among different CYP2D6 polymorphisms	The concentrations of TAM and its metabolites were not significantly affected byCYP2D6genotype or phenotype	HPLC	Plasma	profiling group	28450788
METAC_152	57	breast cancer	nan	1612	CYP2D6*2/*2		F	5					The concentrations of TAM and its metabolites (ng/mL) among different CYP2D6 polymorphisms	The concentrations of TAM and its metabolites were not significantly affected byCYP2D6genotype or phenotype	HPLC	Plasma	profiling group	28450788
METAC_153	57	breast cancer	nan	1612	CYP2D6*2/*10		F	13					The concentrations of TAM and its metabolites (ng/mL) among different CYP2D6 polymorphisms	The concentrations of TAM and its metabolites were not significantly affected byCYP2D6genotype or phenotype	HPLC	Plasma	profiling group	28450788
METAC_154	57	breast cancer	nan	1612	CYP2D6*1/*2		F	3					The concentrations of TAM and its metabolites (ng/mL) among different CYP2D6 polymorphisms	The concentrations of TAM and its metabolites were not significantly affected byCYP2D6genotype or phenotype	HPLC	Plasma	profiling group	28450788
METAC_155	57	breast cancer	nan	1612	CYP2D6*4/*4		F	2					The concentrations of TAM and its metabolites (ng/mL) among different CYP2D6 polymorphisms	The concentrations of TAM and its metabolites were not significantly affected byCYP2D6genotype or phenotype	HPLC	Plasma	profiling group	28450788
METAC_156	57	breast cancer	nan	1612	CYP2D6*4/*10		F	4					The concentrations of TAM and its metabolites (ng/mL) among different CYP2D6 polymorphisms	The concentrations of TAM and its metabolites were not significantly affected byCYP2D6genotype or phenotype	HPLC	Plasma	profiling group	28450788
METAC_157	60	breast cancer	nan	1612	CYP3A5*1/*1		F	18					The concentrations of TAM and its metabolites (ng/mL) among different CYP3A5 polymorphisms	The concentrations metabolites were not significantly different between differentCYP3A5genotypes or phenotypes.	HPLC	Plasma	profiling group	28450788
METAC_158	60	breast cancer	nan	1612	CYP3A5*1/*3		F	64					The concentrations of TAM and its metabolites (ng/mL) among different CYP3A5 polymorphisms	The concentrations metabolites were not significantly different between differentCYP3A5genotypes or phenotypes.	HPLC	Plasma	profiling group	28450788
METAC_159	60	breast cancer	nan	1612	CYP3A5*3/*3		F	51					The concentrations of TAM and its metabolites (ng/mL) among different CYP3A5 polymorphisms	The concentrations metabolites were not significantly different between differentCYP3A5genotypes or phenotypes.	HPLC	Plasma	profiling group	28450788
METAC_160	27	breast cancer	nan	1612	breast cancer patients 	46.69 ± 10.53 	F	152	healthy controls	44.56 ± 10.85	F	155	List of metabolites (07 entities) distinguishing between healthy controls (H) and breast cancer patients (Ds) at fold change > 1.5 and p < 0.05	Serum was collected from 152 pre-operative breast cancer (BC) patients and 155 healthy controls in this case-controlled study. Gas chromatography-mass spectrometry (GC-MS) was used to obtain metabolic profiles followed by chemometric analysis with the identification of significantly differentiated metabolites including 7 for diagnosis, 18 for grading, 23 for staging, 15 for stage III subcategory and 10 for neoadjuvant status (p-value < 0.05).	GC-MS	Blood	case vs.control group	28496143
METAC_161	29	breast cancer	nan	1612	grade I of breast cancer 		F		healthy controls	44.56 ± 10.85	F	155	List of metabolites (18 entities) distinguishing between healthy controls (H) and grade I of breast cancer.	Serum was collected from 152 pre-operative breast cancer (BC) patients and 155 healthy controls in this case-controlled study. Gas chromatography-mass spectrometry (GC-MS) was used to obtain metabolic profiles followed by chemometric analysis with the identification of significantly differentiated metabolites including 7 for diagnosis, 18 for grading, 23 for staging, 15 for stage III subcategory and 10 for neoadjuvant status (p-value < 0.05).	GC-MS	Blood	case vs.control group	28496143
METAC_162	29	breast cancer	nan	1612	grade II of breast cancer 		F		healthy controls	44.56 ± 10.85	F	155	List of metabolites (18 entities) distinguishing between healthy controls (H) and grade II of breast cancer.	Serum was collected from 152 pre-operative breast cancer (BC) patients and 155 healthy controls in this case-controlled study. Gas chromatography-mass spectrometry (GC-MS) was used to obtain metabolic profiles followed by chemometric analysis with the identification of significantly differentiated metabolites including 7 for diagnosis, 18 for grading, 23 for staging, 15 for stage III subcategory and 10 for neoadjuvant status (p-value < 0.05).	GC-MS	Blood	case vs.control group	28496143
METAC_163	29	breast cancer	nan	1612	grade III of breast cancer 		F		healthy controls	44.56 ± 10.85	F	155	List of metabolites (18 entities) distinguishing between healthy controls (H) and grade III of breast cancer.	Serum was collected from 152 pre-operative breast cancer (BC) patients and 155 healthy controls in this case-controlled study. Gas chromatography-mass spectrometry (GC-MS) was used to obtain metabolic profiles followed by chemometric analysis with the identification of significantly differentiated metabolites including 7 for diagnosis, 18 for grading, 23 for staging, 15 for stage III subcategory and 10 for neoadjuvant status (p-value < 0.05).	GC-MS	Blood	case vs.control group	28496143
METAC_164	36	breast cancer	nan	1612	stage I of breast cancer 		F		healthy controls	44.56 ± 10.85	F	155	List of metabolites (20 entities) distinguishing between healthy controls (H) and stage I of breast cancer	Serum was collected from 152 pre-operative breast cancer (BC) patients and 155 healthy controls in this case-controlled study. Gas chromatography-mass spectrometry (GC-MS) was used to obtain metabolic profiles followed by chemometric analysis with the identification of significantly differentiated metabolites including 7 for diagnosis, 18 for grading, 23 for staging, 15 for stage III subcategory and 10 for neoadjuvant status (p-value < 0.05).	GC-MS	Blood	case vs.control group	28496143
METAC_165	36	breast cancer	nan	1612	stage II of breast cancer 		F		healthy controls	44.56 ± 10.85	F	155	List of metabolites (20 entities) distinguishing between healthy controls (H) and stage II of breast cancer	Serum was collected from 152 pre-operative breast cancer (BC) patients and 155 healthy controls in this case-controlled study. Gas chromatography-mass spectrometry (GC-MS) was used to obtain metabolic profiles followed by chemometric analysis with the identification of significantly differentiated metabolites including 7 for diagnosis, 18 for grading, 23 for staging, 15 for stage III subcategory and 10 for neoadjuvant status (p-value < 0.05).	GC-MS	Blood	case vs.control group	28496143
METAC_166	36	breast cancer	nan	1612	stage III of breast cancer 		F		healthy controls	44.56 ± 10.85	F	155	List of metabolites (20 entities) distinguishing between healthy controls (H) and stage III of breast cancer	Serum was collected from 152 pre-operative breast cancer (BC) patients and 155 healthy controls in this case-controlled study. Gas chromatography-mass spectrometry (GC-MS) was used to obtain metabolic profiles followed by chemometric analysis with the identification of significantly differentiated metabolites including 7 for diagnosis, 18 for grading, 23 for staging, 15 for stage III subcategory and 10 for neoadjuvant status (p-value < 0.05).	GC-MS	Blood	case vs.control group	28496143
METAC_167	36	breast cancer	nan	1612	stage IV of breast cancer 		F		healthy controls	44.56 ± 10.85	F	155	List of metabolites (20 entities) distinguishing between healthy controls (H) and stage IV of breast cancer	Serum was collected from 152 pre-operative breast cancer (BC) patients and 155 healthy controls in this case-controlled study. Gas chromatography-mass spectrometry (GC-MS) was used to obtain metabolic profiles followed by chemometric analysis with the identification of significantly differentiated metabolites including 7 for diagnosis, 18 for grading, 23 for staging, 15 for stage III subcategory and 10 for neoadjuvant status (p-value < 0.05).	GC-MS	Blood	case vs.control group	28496143
METAC_168	203	breast cancer	nan	1612	stage IIIA of breast cancer 		F		healthy controls	44.56 ± 10.85	F	155	List of metabolites (14 entities) distinguishing between healthy controls (H) and stage IIIA of breast cancer at fold change > 2 and p < 0.05.	Serum was collected from 152 pre-operative breast cancer (BC) patients and 155 healthy controls in this case-controlled study. Gas chromatography-mass spectrometry (GC-MS) was used to obtain metabolic profiles followed by chemometric analysis with the identification of significantly differentiated metabolites including 7 for diagnosis, 18 for grading, 23 for staging, 15 for stage III subcategory and 10 for neoadjuvant status (p-value < 0.05).	GC-MS	Blood	case vs.control group	28496143
METAC_169	203	breast cancer	nan	1612	stage IIIB of breast cancer 		F		healthy controls	44.56 ± 10.85	F	155	List of metabolites (14 entities) distinguishing between healthy controls (H) and stage IIIB of breast cancer at fold change > 2 and p < 0.05.	Serum was collected from 152 pre-operative breast cancer (BC) patients and 155 healthy controls in this case-controlled study. Gas chromatography-mass spectrometry (GC-MS) was used to obtain metabolic profiles followed by chemometric analysis with the identification of significantly differentiated metabolites including 7 for diagnosis, 18 for grading, 23 for staging, 15 for stage III subcategory and 10 for neoadjuvant status (p-value < 0.05).	GC-MS	Blood	case vs.control group	28496143
METAC_170	203	breast cancer	nan	1612	stage IIIC of breast cancer 		F		healthy controls	44.56 ± 10.85	F	155	List of metabolites (14 entities) distinguishing between healthy controls (H) and three IIIC of breast cancer at fold change > 2 and p < 0.05.	Serum was collected from 152 pre-operative breast cancer (BC) patients and 155 healthy controls in this case-controlled study. Gas chromatography-mass spectrometry (GC-MS) was used to obtain metabolic profiles followed by chemometric analysis with the identification of significantly differentiated metabolites including 7 for diagnosis, 18 for grading, 23 for staging, 15 for stage III subcategory and 10 for neoadjuvant status (p-value < 0.05).	GC-MS	Blood	case vs.control group	28496143
METAC_171	27	breast cancer	nan	1612	breast cancer patients		F		healthy controls	44.56 ± 10.85	F	155	List of metabolites (10 entities) distinguishing between healthy controls (H) and breast cancer patients (BC) at fold change 1.5 and p < 0.05.	Serum was collected from 152 pre-operative breast cancer (BC) patients and 155 healthy controls in this case-controlled study. Gas chromatography-mass spectrometry (GC-MS) was used to obtain metabolic profiles followed by chemometric analysis with the identification of significantly differentiated metabolites including 7 for diagnosis, 18 for grading, 23 for staging, 15 for stage III subcategory and 10 for neoadjuvant status (p-value < 0.05).	GC-MS	Blood	case vs.control group	28496143
METAC_172	32	breast cancer	nan	1612	breast cancer patients on neoadjuvant therapy (Neo)		F		healthy controls	44.56 ± 10.85	F	155	List of metabolites (10 entities) distinguishing between healthy controls (H) and breast cancer patients on neoadjuvant therapy (Neo) at fold change 1.5 and p < 0.05.	Serum was collected from 152 pre-operative breast cancer (BC) patients and 155 healthy controls in this case-controlled study. Gas chromatography-mass spectrometry (GC-MS) was used to obtain metabolic profiles followed by chemometric analysis with the identification of significantly differentiated metabolites including 7 for diagnosis, 18 for grading, 23 for staging, 15 for stage III subcategory and 10 for neoadjuvant status (p-value < 0.05).	GC-MS	Blood	case vs.control group	28496143
METAC_173	62	breast cancer	Luminal A; Luminal B; Luminal B Neu amplified	1612	early breast cancer(EBC) LR-1	61.5 (48-76)	F	8					Levels (AUC) of discriminant metabolites in EBC clusters LR-1.	Lactate, pyruvate, alanine levels were significantly higher and acetate, glucose and glutamine levels were significantly lower in cluster LR-1 compared to clusters LR-2 and LR-3.	¹H NMR	Blood	profiling group	28611296
METAC_174	62	breast cancer	Luminal A; Luminal B; Luminal B Neu amplified; Neu amplified; Triple Receptor Negative	1612	early breast cancer(EBC) LR-2	"50.2 (29-65)	"	F	19					Levels (AUC) of discriminant metabolites in EBC clusters LR-2.	Lactate, pyruvate, alanine levels were significantly higher and acetate, glucose and glutamine levels were significantly lower in cluster LR-1 compared to clusters LR-2 and LR-3.	¹H NMR	Blood	profiling group	28611296
METAC_175	62	breast cancer	Luminal A; Luminal B; Neu amplified; Triple Receptor Negative	1612	early breast cancer(EBC) LR-3	59 (44-82)	F	16					Levels (AUC) of discriminant metabolites in EBC clusters LR-3.	Lactate, pyruvate, alanine levels were significantly higher and acetate, glucose and glutamine levels were significantly lower in cluster LR-1 compared to clusters LR-2 and LR-3.	¹H NMR	Blood	profiling group	28611296
METAC_176	132	breast cancer	Luminal A /B; Triple Receptor Negative	1612	metastatic breast cancer(MBC) MT-1	"66 (58-75)	"	F	5					Levels (AUC) of discriminant metabolites in MBC clusters MT-1.	There is none significant clinical difference between MT-1 and MT-2.	¹H NMR	Blood	profiling group	28611296
METAC_177	132	breast cancer	Luminal A /B; Neu Amplified; Triple Receptor Negative	1612	metastatic breast cancer(MBC) MT-2	"61 (44-83)	"	F	8					Levels (AUC) of discriminant metabolites in MBC clusters MT-2.	There is none significant clinical difference between MT-1 and MT-2.	¹H NMR	Blood	profiling group	28611296
METAC_178	31	breast cancer	nan	1612	breast cancer patients after tumor removal		F	24	breast cancer patients with tumor removal		F	24	Levels of oxysterols in breast cancer patients-comparison of paired samples before and after tumor removal	Analysis by the independent Mann-Whitney test showed that the level of 27-hydroxycholesterol was significantly lower and that the level of 7-ketocholesterol was higher in the second sampling compared to the first sampling. Analysis by the paired Wilcoxon test showed non-significant results for both oxysterols as well as for others.	HPLC	Plasma	case vs.control group	28915107
METAC_141	191	breast cancer	nan	1612	pathologic complete response	49.5 (37-60)	F	8	stable disease	43.7 (37-59)	F	6	pathologic complete response vs. stable disease	The concentrations of four metabolites, three (threonine, isoleucine, glutamine) from NMR and one (linolenic acid) from LCeMS were significantly different when compar-ing response to chemotherapy	NMR	Serum	case vs.control group	23142658
METAC_179	191	breast cancer	nan	1612	pathologic complete response	49.5 (37-60)	F	8	partial response	48.7 (34-64)	F	14	pathologic complete response vs. partial response	The concentrations of four metabolites, three (threonine, isoleucine, glutamine) from NMR and one (linolenic acid) from LCeMS were significantly different when compar-ing response to chemotherapy	NMR	Serum	case vs.control group	23142658
METAC_180	191	breast cancer	nan	1612	partial response	48.7 (34-64)	F	14	stable disease	43.7 (37-59)	F	6	partial response vs. stable disease	The concentrations of four metabolites, three (threonine, isoleucine, glutamine) from NMR and one (linolenic acid) from LCeMS were significantly different when compar-ing response to chemotherapy	NMR	Serum	case vs.control group	23142658
METAC_181	191	breast cancer	nan	1612	pathologic complete response	49.5 (37-60)	F	8	stable disease	43.7 (37-59)	F	6	pathologic complete response vs. stable disease	The concentrations of four metabolites, three (threonine, isoleucine, glutamine) from NMR and one (linolenic acid) from LCeMS were significantly different when compar-ing response to chemotherapy	LC-MS	Serum	case vs.control group	23142658
METAC_182	191	breast cancer	nan	1612	pathologic complete response	49.5 (37-60)	F	8	partial response	48.7 (34-64)	F	14	pathologic complete response vs. partial response	The concentrations of four metabolites, three (threonine, isoleucine, glutamine) from NMR and one (linolenic acid) from LCeMS were significantly different when compar-ing response to chemotherapy	LC-MS	Serum	case vs.control group	23142658
METAC_183	191	breast cancer	nan	1612	partial response	48.7 (34-64)	F	14	stable disease	43.7 (37-59)	F	6	partial response vs. stable disease	The concentrations of four metabolites, three (threonine, isoleucine, glutamine) from NMR and one (linolenic acid) from LCeMS were significantly different when compar-ing response to chemotherapy	LC-MS	Serum	case vs.control group	23142658
METAC_184	27	breast cancer	nan	1612	breast cancer patients		F	86					Concentrations of nine metabolites in 86 breast cancer patients.	nan	LC-MS/MS	Plasma	profiling group	29183390
METAC_185	58	breast cancer	nan	1612	UM ultra-rapid metabolizer		F						Concentrations of tamoxifen metabolites stratified by metabolizer group(ultra-rapid metabolizers).	No significant association between CYP2D6 phenotype and tamoxifen metabolites.	LC-MS/MS	Plasma	profiling group	29183390
METAC_186	58	breast cancer	nan	1612	EM extensive/normal metabolizers		F						Concentrations of tamoxifen metabolites stratified by metabolizer group(extensive/normal metabolizers).	No significant association between CYP2D6 phenotype and tamoxifen metabolites.	LC-MS/MS	Plasma	profiling group	29183390
METAC_187	58	breast cancer	nan	1612	IM intermediate metabolizer		F						Concentrations of tamoxifen metabolites stratified by metabolizer group(intermediate metabolizers).	No significant association between CYP2D6 phenotype and tamoxifen metabolites.	LC-MS/MS	Plasma	profiling group	29183390
METAC_188	58	breast cancer	nan	1612	PM poor metabolizer		F						Concentrations of tamoxifen metabolites stratified by metabolizer group(poor metabolizers).	No significant association between CYP2D6 phenotype and tamoxifen metabolites.	LC-MS/MS	Plasma	profiling group	29183390
METAC_189	27	breast cancer	nan	1612	breast cancer patients		F	55	healthy controls 		F	25	Differentiating metabolites between breast cancer patients and healthy controls identified from the learning dataset.	lower levels of lysophosphatidylcholines and higher levels of sphingomyelins and acylcarnitines in breast cancer patients.	ESI-MS/MS	Plasma	case vs.control group	23584023
METAC_190	128	breast cancer	nan	1612	postmenopausal breast cancer patients	59.0 ± 7.1 	F	86	postmenopausal healthy female	59.5 ± 7.9	F	36	Urinary endogenous estrogens and their metabolites excretion in postmenopausal healthy female (H-post) and breast cancer patients (BC-post).	The levels for E1, E2, 2-OHE2, 4-OHE2, 16α-OHE1 and 2-MeOE2 were significantly different between the postmenopausal healthy female (H-post) and breast cancer patients (BC-post).	UFLC-MS/MS	Urine	case vs.control group	22152797
METAC_191	27	breast cancer	nan	1612	Breast cancer	48.6 (26-73)	F	21	Healthy control		F	25	the metabolic profiles in urine from breast cancer patients and healthy volunteer	Urinary metabolic products may be new potential predictive markers for therapy efficacy	CE-MS	Urine	case vs.control group	23726806
METAC_192	40	breast cancer	nan	1612	partial response patients (after vs before chemotherapy)		F	8			F		the metabolic profiles in urine from breast cancer patients who are partial response (PR) after chemotherapy compared with before chemotherapy	Urinary metabolic products may be new potential predictive markers for therapy efficacy	CE-MS	Urine	case vs.control group	23726806
METAC_193	40	breast cancer	nan	1612	maintained stable+progressed disease (after vs before chemotherapy)		F	13			F		the metabolic profiles in urine from breast cancer patients who are maintained stable (SD) and progressed disease (PD) after chemotherapy compared with before chemotherapy	Urinary metabolic products may be new potential predictive markers for therapy efficacy	CE-MS	Urine	case vs.control group	23726806
METAC_194	27	breast cancer	nan	1612	Normal breast cancer tissue	56 ± 10	F	19					metabolites quantified in normal breast tissues from breast cancer patients	nan	UPLC-ESI-QTOF-MS/MS	Breast tissue	profiling group	30690879
METAC_195	27	breast cancer	nan	1612	Malignant breast cancer tissue	56 ± 10	F	19					metabolites quantified in malignant breast tissues from breast cancer patients	nan	UPLC-ESI-QTOF-MS/MS	Breast tissue	profiling group	30690879
METAC_196	27	breast cancer	nan	1612	Breast cancer urine	56 ± 10	F	19					metabolites quantified in urine from breast cancer patients	nan	UPLC-ESI-QTOF-MS/MS	Urine	profiling group	30690879
METAC_197	27	breast cancer	nan	1612	Breast cancer plasma	56 ± 10	F	19					metabolites quantified in plasma from breast cancer patients	nan	UPLC-ESI-QTOF-MS/MS	Plasma	profiling group	30690879
METAC_198	181	breast cancer	nan	1612	Pre-RT breast cancer patients	55 ± 14	F	151	Healthy controls		F		Pre-radiotherapy breast cancer patients VS healthy controls	Before RT, patients had major alterations in the serum concentrations of metabolites involved in glycolysis, citric acid cycle and amino acid metabolism	GC-EI-QTOF-MS	Serum	case vs.control group	30444915
METAC_199	181	breast cancer	nan	1612	post-RT breast cancer patients	55 ± 14	F	151	Healthy controls		F		Post-radiotherapy breast cancer patients VS healthy controls	RT produced changes in metabolite levels that tended towards the control group values	GC-EI-QTOF-MS	Serum	case vs.control group	30444915
METAC_200	181	breast cancer	nan	1612	post-RT breast cancer patients	55 ± 14	F	151	Pre-RT breast cancer patients	55 ± 14	F	151	Post-radiotherapy breast cancer patients VS Pre-radiotherapy breast cancer patients	RT was associated with further increases in the levels of pyruvate, fumarate, malate, citrate and glutamine, and did not modify the pre-RT levels of hydroxybutyrate, oxaloacetate, aspartate, glutamate, and aconitate;treatment normalized (or almost normalized) the serum concentrations of lactate, alanine, valine, leucine, isoleucine, proline, malonyl coenzyme A, glycine, succinate, serine and ketoglutarate.	GC-EI-QTOF-MS	Serum	case vs.control group	30444915
METAC_201	181	breast cancer	nan	1612	patients received hormone therapy		F	114	patients without hormone therapy		F	37	patients received hormone therapy VS patients without hormone therapy(post-RT)	Adjuvant hormone therapy was associated with mild changes in serum glycine concentrations post-RT	GC-EI-QTOF-MS	Serum	case vs.control group	30444915
METAC_202	181	breast cancer	nan	1612	patients received chemotherapy		F	77	patients without chemotherapy		F	74	patients received chemotherapy VS patients without chemotherapy (post-RT)	Additionally, adjuvant chemotherapy was associated with mild changes in lactate, oxaloacetate and glutamine concentrations post-RT	GC-EI-QTOF-MS	Serum	case vs.control group	30444915
METAC_203	27	breast cancer	nan	1612	primary breast cancer patients	55.6 (30.6-84.4)	F	80	Healthy controls		F	100	metabolites differentially expressed between primary breast cancer patients and healthy controls (training cohort)	Two metabolites were found to be upregulated, while 16 metabolites were downregulated in primary breast cancer patients compared to healthy controls in both the training and validation cohorts	UHPLC-MS/MS;FIA-MS/MS	Serum	case vs.control group	30426507
METAC_204	27	breast cancer	nan	1612	primary breast cancer patients	50 (26.8-77.4)	F	109	Healthy controls		F	50	metabolites differentially expressed between primary breast cancer patients and healthy controls (validation cohort)	Two metabolites were found to be upregulated, while 16 metabolites were downregulated in primary breast cancer patients compared to healthy controls in both the training and validation cohorts	UHPLC-MS/MS;FIA-MS/MS	Serum	case vs.control group	30426507
METAC_205	40	breast cancer	nan	1612	chemotherapy recipients after 6 months	52.8 (38-69)	F	35	recipients before chemotherapy	52.8 (38-69)	F	35	Metabolic changes in patients receiving chemotherapy	alpha-AAA,ADMA,PC aa C38:3, PC ae C42:1,hexoses and lipid2 were significantly increased,as well as decreases in 18 different metabolites	NMR;MS	Serum	case vs.control group	30401977
METAC_206	27	breast cancer	nan	1612	patients without chemotherapy(6 months after surgery)	58.9 (46-68)	F	25	patients without chemotherapy(before surgery)	58.9 (46-68)	F	25	Metabolic changes in patients not receiving chemotherapy	glutamate remained significantly increased after 6 months	NMR;MS	Serum	case vs.control group	30401977
METAC_207	27	breast cancer	nan	1612	Weight gainers	54.1 (42-68)	F	17	Non-weight gainers	54.6 (38-69)	F	35	differential metabolites in patients with weight gain relative to patients without weight gain	patients who later gained weight had lower levels of acylcarnitines, phosphatidylcholines, sphingolipids and lipid1	NMR;MS	Serum	case vs.control group	30401977
METAC_208	27	breast cancer	nan	1612	Breast Cancer Patients	46.2 ± 4.8	F	44	Healthy controls	45.8 ± 5.5	F	34	organic acids amino acids and biogenic amines between breast cancer patients and healthy controls	The levels of 30 metabolites changed signif?icantly in the BC group when compared to the controlgroup	GC-MS/MS;UPLC-MS/MS	Serum	case vs.control group	30103303
METAC_209	27	breast cancer	nan	1612	Breast Cancer Patients	46.2 ± 4.8	F	44	patients suffered from Chromic fibroadenosis of breast	45.1 ± 5.5	F	38	organic acids amino acids and biogenic amines between breast cancer patients and patients of Chromic fibroadenosis of breast	significantdifferences in 21 metabolites were observed between the BE and BC individuals	GC-MS/MS;UPLC-MS/MS	Serum	case vs.control group	30103303
METAC_210	132	breast cancer	nan	1612	metastatic breast cancer group	58.3 (37‐66)	F	41	localized breast cancer group	54.1 (33‐64)	F	46	differential metabolites in metastatic breast cancer serum samples relative to localized breast cancer serum samples	13 metabolites were found to be elevated in the MT samples compared to the LC samples whereas 8 metabolites were downregulated	UPLC/MS	Serum	case vs.control group	29737597
METAC_211	140	breast cancer	nan	1612	localized breast cancer group	54.1 (33‐64)	F	46	normal control group	50.5 (30‐59)	F	49	differential metabolites in localized breast cancer serum samples relative to normal control samples	A total of 57 metabolites were identified as differential variables between the LC and NC samples	UPLC/MS	Serum	case vs.control group	29737597
METAC_212	36	breast cancer	nan	1612	Breast cancer Patient	60.7 ± 8	F	56	Healthy control	59.1 ± 7.3	F	56	Bile acid composition of the human serum samples (breast cancer patients vs healthy controls)	Total bile acid, CDCA and LCA levels were reduced in serum from breast cancer patients as compared to age and sex matched healthy individuals	HPLC	Serum	case vs.control group	29655782
METAC_213	36	breast cancer	nan	1612	Stage 1 breast cancer	61.8 ± 5.5	F	16	Healthy control	59.1 ± 7.3	F	56	Bile acid composition of the human serum samples (breast cancer stage 1 vs healthy controls)	nan	HPLC	Serum	case vs.control group	29655782
METAC_214	36	breast cancer	nan	1612	Stage 2 breast cancer	61.5 ± 8.6	F	25	Healthy control	59.1 ± 7.3	F	56	Bile acid composition of the human serum samples (breast cancer stage 2 vs healthy controls)	nan	HPLC	Serum	case vs.control group	29655782
METAC_215	36	breast cancer	nan	1612	Stage 3 breast cancer	60.6 ± 8.2	F	10	Healthy control	59.1 ± 7.3	F	56	Bile acid composition of the human serum samples (breast cancer stage 3 vs healthy controls)	nan	HPLC	Serum	case vs.control group	29655782
METAC_216	27	breast cancer	TNBC or LABC	1612	breast cancer tumor tissue		F	47	normal adjacent tissue		F	35	Metabolites significantly (p<0.05) expressed between all breast tumor and all normal tissues(All ages)	lipids, unsaturated lipids, and ATP levels were lower in the tumors; however, the methionine, choline, and phosphocholine levels were higher in the tumors compared to the adjacent normal tissues	HR-MAS NMR;¹H NMR	Breast tissue	case vs.control group	29545929
METAC_217	27	breast cancer	TNBC or LABC	1612	breast cancer tumor tissue		F	10	normal adjacent tissue		F		Metabolites significantly (p<0.05) expressed between all breast tumor and all normal tissues(below 50 year-old patients)	phosphocholine, myo-inositol and uridine metabolites were significantly higher in the tumors compared to the normal adjacent tissues of premenopausal women	HR-MAS NMR;¹H NMR	Breast tissue	case vs.control group	29545929
METAC_218	27	breast cancer	TNBC or LABC	1612	breast cancer tumor tissue		F	37	normal adjacent tissue		F		Metabolites significantly (p<0.05) expressed between all breast tumor and all normal tissues(above 50 year-old patients)	nan	HR-MAS NMR;¹H NMR	Breast tissue	case vs.control group	29545929
METAC_219	27	breast cancer	TNBC or LABC	1612	breast cancer tumor tissue		F	30	normal adjacent tissue		F	18	Metabolites significantly (p<0.05) expressed between all breast tumor and all normal tissues(African-American women)	nan	HR-MAS NMR;¹H NMR	Breast tissue	case vs.control group	29545929
METAC_220	107	breast cancer	LABC	1612	breast cancer tumor tissue		F	29	normal adjacent tissue		F		Metabolites significantly expressed (p<0.05) in luminal A breast cancer (LABC)	nan	HR-MAS NMR;¹H NMR	Breast tissue	case vs.control group	29545929
METAC_221	107	breast cancer	LABC	1612	breast cancer tumor tissue		F	17	normal adjacent tissue		F		Metabolites significantly expressed (p<0.05) in luminal A breast cancer (African-American women)	nan	HR-MAS NMR;¹H NMR	Breast tissue	case vs.control group	29545929
METAC_222	107	breast cancer	LABC	1612	African American		F	17	Caucasian		F	12	metabolites with p-values < 0.05 between tumor tissues from African American and Caucasian in luminal A breast cancer (LABC)	nan	HR-MAS NMR;¹H NMR	Breast tissue	case vs.control group	29545929
METAC_223	210	breast cancer	TNBC	1612	breast cancer tumor tissue		F	18	normal adjacent tissue		F		Metabolites significantly expressed (p<0.05) in triple-negative breast cancer (TNBC)	nan	HR-MAS NMR;¹H NMR	Breast tissue	case vs.control group	29545929
METAC_224	210	breast cancer	TNBC	1612	breast cancer tumor tissue		F	13	normal adjacent tissue		F		Metabolites significantly expressed (p<0.05) in triple-negative breast cancer (African-American women)	nan	HR-MAS NMR;¹H NMR	Breast tissue	case vs.control group	29545929
METAC_225	210	breast cancer	TNBC	1612	African American		F	13	Caucasian		F	5	metabolites with p-values < 0.05 between tumor tissues from African American and Caucasian in triple-negative breast cancer (TNBC)	nan	HR-MAS NMR;¹H NMR	Breast tissue	case vs.control group	29545929
METAC_226	72	breast cancer	TNBC or LABC	1612	TNBC(ER-)		F	13	LABC(ER+)		F	17	metabolites with p-values < 0.05 between TNBC(ER-) vs. LABC(ER+) in African Americans	only ATP was found be lower in TNBC and higher in the LABC tissues	HR-MAS NMR;¹H NMR	Breast tissue	case vs.control group	29545929
METAC_227	26	breast cancer	TNBC or RH positive(MCF-7)	1612	BRCA1-like cell lines(HCC70;MDA-MB-436;MDA-MB-468)				non-BRCA1-like cell lines(MCF-7;MDA-MB-231)				metabolites identified in the breast cancer cell lines to discriminate BRCA1-like and non BRCA1-like breast cancer profile	All metabolites were significantly under-represented in BRCA1-like BC cell lines compared withBRCA1wild-type (wt) BC cell lines	LC/ESI-QTOF-MS	Plasma	case vs.control group	29259228
METAC_228	26	breast cancer	TNBC or RH positive(MCF-7)	1612	BRCA1-like cell lines(HCC70;MDA-MB-436;MDA-MB-468)				non-BRCA1-like cell lines(MCF-7;MDA-MB-231)				metabolites identified in secretome of the breast cancer cell lines to discriminate BRCA1-like and non BRCA1-like breast cancer profile	nan	LC/ESI-QTOF-MS	Plasma	case vs.control group	29259228
METAC_229	33	breast cancer	nan	1612	Tam therapy	45.4 (27.3-73.7)	F	281					distributions of concentrations of tamoxifen and its metabolites in 550 plasma specimens of 281 breast cancer patients	NDM (230 ng/mL) had the highest mean concentration compared with endoxifen (25.0 ng/mL) and 4-OH tamoxifen (8.53 ng/mL)	LC-MS	Plasma	profiling group	29245979
METAC_238	27	breast cancer	nan	1612	breast cancer patients(tumor)	52.7 ± 12.3	F	60	healthy subjects(control)	51.9 ± 11.1	F	40	the alteration of metabolites identified between breast cancer patients and healthy controls	17 metabolites (glycerophosphocholine, phenyllactic acid, pentosidine, and so forth) showed the differential expression between tumor group and control group	LC-MS	Plasma	case vs.control group	30556899
METAC_239	32	breast cancer	nan	1612	survivors(post-treatment)	61 ± 10	F	14	survivors(pre-treatment)	61 ± 10	F	18	metabolites determined in pre- and post-treatment doxorubicin biopsies for the survivor(≥5 years) group	Paired Wilcoxon Signed Ranks test showed significant decrease of GPC and Cho concentrations in survivors post-treatment	HR MAS MR	Breast tissue	case vs.control group	21823183
METAC_240	32	breast cancer	nan	1612	non-survivors(post-treatment)	60 ± 13	F	8	non-survivors(pre-treatment)	60 ± 13	F	8	metabolites determined in pre- and post-treatment doxorubicin biopsies for the non-survivor(<5 years) group	non-survivors showed no significant changes in metabolites when comparing pre- and post-treatment samples	HR MAS MR	Breast tissue	case vs.control group	21823183
METAC_241	32	breast cancer	nan	1612	partial response(post-treatment)	65 ± 12	F	11	partial response(pre-treatment)	65 ± 12	F	11	metabolites determined in pre- and post-treatment doxorubicin biopsies for the partial response group	tCho showed a trend to decrease in patients with PR post-treatment(not significant);GPC was significantly decreased in patients with PR post-treatment	HR MAS MR	Breast tissue	case vs.control group	21823183
METAC_242	32	breast cancer	nan	1612	stable disease(post-treatment)	62 ± 11	F	14	stable disease(pre-treatment)	62 ± 11	F	19	metabolites determined in pre- and post-treatment doxorubicin biopsies for the stable disease group	patients with SD showed no significant metabolic changes when comparing pre- and post-treatment samples	HR MAS MR	Breast tissue	case vs.control group	21823183
METAC_244	57	breast cancer	nan	1612	wt/wt (‘‘wt’’ includes all extensive metabolizer alleles (CYP2D6*1, CYP2D6*2, CYP2D6*35))		F	78					Concentrations of tamoxifen and its metabolites detected in patients with the CYP2D6	Significant differences were observed among CYP2D6 genotypes in plasma concentration ratios of endoxifen/NDM-TAM (p,0.001)but not of 4OH-TAM/TAM.	HPLC-MS	Plasma	profiling group	23922954
METAC_245	57	breast cancer	nan	1612	wtxN/P (‘‘wtxN’’ includes all ultraextensive metabolizer alleles (CYP2D6*1xN, CYP2D6*2xN),‘P’’ includes all null alleles (CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*7, CYP2D6*8))		F	2					Concentrations of tamoxifen and its metabolites detected in patients with the CYP2D6	Significant differences were observed among CYP2D6 genotypes in plasma concentration ratios of endoxifen/NDM-TAM (p,0.001)but not of 4OH-TAM/TAM.	HPLC-MS	Plasma	profiling group	23922954
METAC_246	57	breast cancer	nan	1612	wt/P (‘‘wt’’ includes all extensive metabolizer alleles (CYP2D6*1, CYP2D6*2, CYP2D6*35),‘‘P’’ includes all null alleles (CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*7, CYP2D6*8))		F	26					Concentrations of tamoxifen and its metabolites detected in patients with the CYP2D6	Significant differences were observed among CYP2D6 genotypes in plasma concentration ratios of endoxifen/NDM-TAM (p,0.001)but not of 4OH-TAM/TAM.	HPLC-MS	Plasma	profiling group	23922954
METAC_247	57	breast cancer	nan	1612	wt/I (‘‘wt’’ includes all extensive metabolizer alleles (CYP2D6*1, CYP2D6*2, CYP2D6*35),‘‘I’’ includes all intermediate metabolizer alleles (CYP2D6*9, CYP2D6*10, CYP2D6*17, CYP2D6*41))		F	4					Concentrations of tamoxifen and its metabolites detected in patients with the CYP2D6	Significant differences were observed among CYP2D6 genotypes in plasma concentration ratios of endoxifen/NDM-TAM (p,0.001)but not of 4OH-TAM/TAM.	HPLC-MS	Plasma	profiling group	23922954
METAC_248	57	breast cancer	nan	1612	I/I (‘‘I’’ includes all intermediate metabolizer alleles (CYP2D6*9, CYP2D6*10, CYP2D6*17, CYP2D6*41))		F	1					Concentrations of tamoxifen and its metabolites detected in patients with the CYP2D6	Significant differences were observed among CYP2D6 genotypes in plasma concentration ratios of endoxifen/NDM-TAM (p,0.001)but not of 4OH-TAM/TAM.	HPLC-MS	Plasma	profiling group	23922954
METAC_249	57	breast cancer	nan	1612	I/P(‘‘I’’ includes all intermediate metabolizer alleles (CYP2D6*9, CYP2D6*10, CYP2D6*17, CYP2D6*41),‘P’’ includes all null alleles (CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*7, CYP2D6*8))		F	8					Concentrations of tamoxifen and its metabolites detected in patients with the CYP2D6	Significant differences were observed among CYP2D6 genotypes in plasma concentration ratios of endoxifen/NDM-TAM (p,0.001)but not of 4OH-TAM/TAM.	HPLC-MS	Plasma	profiling group	23922954
METAC_250	57	breast cancer	nan	1612	P/P (‘P’’ includes all null alleles (CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*7, CYP2D6*8))		F	2					Concentrations of tamoxifen and its metabolites detected in patients with the CYP2D6	Significant differences were observed among CYP2D6 genotypes in plasma concentration ratios of endoxifen/NDM-TAM (p,0.001)but not of 4OH-TAM/TAM.	HPLC-MS	Plasma	profiling group	23922954
METAC_251	59	breast cancer	nan	1612	wt/wt 		F	107					Concentrations of tamoxifen and its metabolites detected in patients with the CYP3A4	No significant differences in TAM metabolite levels were observed among the genotypes for CYP3A4 and CYP3A5.	HPLC-MS	Plasma	profiling group	23922954
METAC_252	59	breast cancer	nan	1612	wt/*1B		F	3					Concentrations of tamoxifen and its metabolites detected in patients with the CYP3A4	No significant differences in TAM metabolite levels were observed among the genotypes for CYP3A4 and CYP3A5.	HPLC-MS	Plasma	profiling group	23922954
METAC_253	59	breast cancer	nan	1612	wt/*3		F	2					Concentrations of tamoxifen and its metabolites detected in patients with the CYP3A4	No significant differences in TAM metabolite levels were observed among the genotypes for CYP3A4 and CYP3A5.	HPLC-MS	Plasma	profiling group	23922954
METAC_254	59	breast cancer	nan	1612	wt/*17 		F	9					Concentrations of tamoxifen and its metabolites detected in patients with the CYP3A4	No significant differences in TAM metabolite levels were observed among the genotypes for CYP3A4 and CYP3A5.	HPLC-MS	Plasma	profiling group	23922954
METAC_255	60	breast cancer	nan	1612	wt/*3 		F	6					Concentrations of tamoxifen and its metabolites detected in patients with the CYP3A5	No significant differences in TAM metabolite levels were observed among the genotypes for CYP3A4 and CYP3A5.	HPLC-MS	Plasma	profiling group	23922954
METAC_256	60	breast cancer	nan	1612	*3/*3		F	117					Concentrations of tamoxifen and its metabolites detected in patients with the CYP3A5	No significant differences in TAM metabolite levels were observed among the genotypes for CYP3A4 and CYP3A5.	HPLC-MS	Plasma	profiling group	23922954
METAC_257	204	breast cancer	nan	1612	wt/wt 		F	60					Concentrations of tamoxifen and its metabolites detected in patients with the SULT1A1	no significant differences in metabolite concentrations for the SULT1A1 and SULT1E1 genotypes	HPLC-MS	Plasma	profiling group	23922954
METAC_258	204	breast cancer	nan	1612	wt/*2		F	46					Concentrations of tamoxifen and its metabolites detected in patients with the SULT1A1	no significant differences in metabolite concentrations for the SULT1A1 and SULT1E1 genotypes	HPLC-MS	Plasma	profiling group	23922954
METAC_259	204	breast cancer	nan	1612	*2/*2 		F	15					Concentrations of tamoxifen and its metabolites detected in patients with the SULT1A1	no significant differences in metabolite concentrations for the SULT1A1 and SULT1E1 genotypes	HPLC-MS	Plasma	profiling group	23922954
METAC_260	205	breast cancer	nan	1612	wt/wt 		F	38					Concentrations of tamoxifen and its metabolites detected in patients with the SULT1A2	the SULT1A2 genotype also seems to play an important role in maintaining optimal levels of both 4OH-TAM and endoxifen	HPLC-MS	Plasma	profiling group	23922954
METAC_261	205	breast cancer	nan	1612	wt/*2 		F	33					Concentrations of tamoxifen and its metabolites detected in patients with the SULT1A2	the SULT1A2 genotype also seems to play an important role in maintaining optimal levels of both 4OH-TAM and endoxifen	HPLC-MS	Plasma	profiling group	23922954
METAC_262	205	breast cancer	nan	1612	wt/*3		F	16					Concentrations of tamoxifen and its metabolites detected in patients with the SULT1A2	the SULT1A2 genotype also seems to play an important role in maintaining optimal levels of both 4OH-TAM and endoxifen	HPLC-MS	Plasma	profiling group	23922954
METAC_263	205	breast cancer	nan	1612	*2/*2		F	16					Concentrations of tamoxifen and its metabolites detected in patients with the SULT1A2	the SULT1A2 genotype also seems to play an important role in maintaining optimal levels of both 4OH-TAM and endoxifen	HPLC-MS	Plasma	profiling group	23922954
METAC_264	205	breast cancer	nan	1612	*2/*3		F	13					Concentrations of tamoxifen and its metabolites detected in patients with the SULT1A2	the SULT1A2 genotype also seems to play an important role in maintaining optimal levels of both 4OH-TAM and endoxifen	HPLC-MS	Plasma	profiling group	23922954
METAC_265	205	breast cancer	nan	1612	*3/*3		F	5					Concentrations of tamoxifen and its metabolites detected in patients with the SULT1A2	the SULT1A2 genotype also seems to play an important role in maintaining optimal levels of both 4OH-TAM and endoxifen	HPLC-MS	Plasma	profiling group	23922954
METAC_266	206	breast cancer	nan	1612	wt/wt		F	88					Concentrations of tamoxifen and its metabolites detected in patients with the SULT1E1	no significant differences in metabolite concentrations for the SULT1A1 and SULT1E1 genotypes	HPLC-MS	Plasma	profiling group	23922954
METAC_267	206	breast cancer	nan	1612	wt/*2 		F	28					Concentrations of tamoxifen and its metabolites detected in patients with the SULT1E1	no significant differences in metabolite concentrations for the SULT1A1 and SULT1E1 genotypes	HPLC-MS	Plasma	profiling group	23922954
METAC_268	206	breast cancer	nan	1612	*2/*2		F	5					Concentrations of tamoxifen and its metabolites detected in patients with the SULT1E1	no significant differences in metabolite concentrations for the SULT1A1 and SULT1E1 genotypes	HPLC-MS	Plasma	profiling group	23922954
METAC_269	178	breast cancer	ER+/PR+, Triple negative breast cancer	1612	A-C: AA(African Americans) control subjects		F	24	C-C: CA(Caucasian Americans) control subjects		F	36	Comparison of metabolites between AA (African Americans) and  CA (Caucasian Americans) controls	A total of 375 named metabolites were observed, with 117 metabolites whose levels were significantly different between African American and Caucasian American women (P < .05 and q < 0.10) and 78 that differed between breast cancer cases and healthy controls (P < .05 and q < 0.10).	UPLC/MS/MS2;GC-MS	Plasma	case vs.control group	24466379
METAC_270	178	breast cancer	ER+/PR+, Triple negative breast cancer	1612	A-P: AA(African Americans) breast cancer patients with ER+/PR+ breast tumors		F	14	C-P: CA(Caucasian Americans) breast cancer patients with ER+/PR+ breast tumors		F	15	Comparison of metabolites between AA (African Americans) breast cancer patients with ER+/PR+ breast tumors and CA (Caucasian Americans) breast cancer patients with ER+/PR+ breast tumors	A total of 375 named metabolites were observed, with 117 metabolites whose levels were significantly different between African American and Caucasian American women (P < .05 and q < 0.10) and 78 that differed between breast cancer cases and healthy controls (P < .05 and q < 0.10).	UPLC/MS/MS2;GC-MS	Plasma	case vs.control group	24466379
METAC_271	178	breast cancer	ER+/PR+, Triple negative breast cancer	1612	A-3N: AA(African Americans) breast cancer patients with triple-negative breast tumors		F	15	C-3N: CA(Caucasian Americans) breast cancer patients with triple-negative breast tumors		F	15	Comparison of metabolites between AA (African Americans) breast cancer patients with triple-negative breast tumors and CA (Caucasian Americans) breast cancer patients with triple-negative breast tumors	A total of 375 named metabolites were observed, with 117 metabolites whose levels were significantly different between African American and Caucasian American women (P < .05 and q < 0.10) and 78 that differed between breast cancer cases and healthy controls (P < .05 and q < 0.10).	UPLC/MS/MS2;GC-MS	Plasma	case vs.control group	24466379
METAC_272	178	breast cancer	ER+/PR+, Triple negative breast cancer	1612	A-cancer: AA(African Americans) breast cancer patients		F	30	C-cancer: CA(Caucasian Americans) breast cancer patients		F	30	Comparison of metabolites between AA (African Americans) breast cancer patients and CA (Caucasian Americans) breast cancer patients	A total of 375 named metabolites were observed, with 117 metabolites whose levels were significantly different between African American and Caucasian American women (P < .05 and q < 0.10) and 78 that differed between breast cancer cases and healthy controls (P < .05 and q < 0.10).	UPLC/MS/MS2;GC-MS	Plasma	case vs.control group	24466379
METAC_273	74	breast cancer	ER+/PR+, Triple negative breast cancer	1612	A-P: AA(African Americans) breast cancer patients with ER+/PR+ breast tumors		F	14	A-C: AA(African Americans) control subjects		F	24	Comparison of metabolites between AA (African Americans) breast cancer patients with ER+/PR+ breast tumors and  AA (African Americans) control subjects	A total of 375 named metabolites were observed, with 117 metabolites whose levels were significantly different between African American and Caucasian American women (P < .05 and q < 0.10) and 78 that differed between breast cancer cases and healthy controls (P < .05 and q < 0.10).	UPLC/MS/MS2;GC-MS	Plasma	case vs.control group	24466379
METAC_274	74	breast cancer	ER+/PR+, Triple negative breast cancer	1612	C-P: CA(Caucasian Americans) breast cancer patients with triple-negative breast tumors		F	15	C-C: CA(Caucasian Americans) control subjects		F	36	Comparison of metabolites between CA (Caucasian Americans) breast cancer patients with triple-negative breast tumors and control	A total of 375 named metabolites were observed, with 117 metabolites whose levels were significantly different between African American and Caucasian American women (P < .05 and q < 0.10) and 78 that differed between breast cancer cases and healthy controls (P < .05 and q < 0.10).	UPLC/MS/MS2;GC-MS	Plasma	case vs.control group	24466379
METAC_275	74	breast cancer	ER+/PR+, Triple negative breast cancer	1612	ER+/PR+ breast cancer		F	30	Control		F	60	Comparison of metabolites between ER+/PR+ breast tumours and control	A total of 375 named metabolites were observed, with 117 metabolites whose levels were significantly different between African American and Caucasian American women (P < .05 and q < 0.10) and 78 that differed between breast cancer cases and healthy controls (P < .05 and q < 0.10).	UPLC/MS/MS2;GC-MS	Plasma	case vs.control group	24466379
METAC_276	210	breast cancer	ER+/PR+, Triple negative breast cancer	1612	A-3N: AA(African Americans) breast cancer patients with triple-negative breast tumors		F	15	A-C: AA(African Americans) control subjects		F	24	Comparison of metabolites between AA (African Americans) breast cancer patients with triple-negative breast tumors and   AA (African Americans) control subjects	A total of 375 named metabolites were observed, with 117 metabolites whose levels were significantly different between African American and Caucasian American women (P < .05 and q < 0.10) and 78 that differed between breast cancer cases and healthy controls (P < .05 and q < 0.10).	UPLC/MS/MS2;GC-MS	Plasma	case vs.control group	24466379
METAC_277	210	breast cancer	ER+/PR+, Triple negative breast cancer	1612	C-3N: CA(Caucasian Americans) breast cancer patients with triple-negative breast tumors		F	15	C-C: CA(Caucasian Americans) control subjects		F	36	Comparison of metabolites between CA (Caucasian Americans) breast cancer patients with triple-negative breast tumors and CA (Caucasian Americans) control subjects	A total of 375 named metabolites were observed, with 117 metabolites whose levels were significantly different between African American and Caucasian American women (P < .05 and q < 0.10) and 78 that differed between breast cancer cases and healthy controls (P < .05 and q < 0.10).	UPLC/MS/MS2;GC-MS	Plasma	case vs.control group	24466379
METAC_278	210	breast cancer	ER+/PR+, Triple negative breast cancer	1612	Triple negative breast cancer		F	30	Control		F	60	Comparison of metabolites between Triple negative breast tumours and controls	A total of 375 named metabolites were observed, with 117 metabolites whose levels were significantly different between African American and Caucasian American women (P < .05 and q < 0.10) and 78 that differed between breast cancer cases and healthy controls (P < .05 and q < 0.10).	UPLC/MS/MS2;GC-MS	Plasma	case vs.control group	24466379
METAC_279	75	breast cancer	ER+/PR+, Triple negative breast cancer	1612	A-P: AA(African Americans) breast cancer patients with ER+/PR+ breast tumors		F	14	A-3N: AA(African Americans) breast cancer patients with triple-negative breast tumors		F	15	Comparison of metabolites between AA (African Americans) breast cancer patients with ER+/PR+ breast tumors and  AA (African Americans) breast cancer patients with triple-negative breast tumors	A total of 375 named metabolites were observed, with 117 metabolites whose levels were significantly different between African American and Caucasian American women (P < .05 and q < 0.10) and 78 that differed between breast cancer cases and healthy controls (P < .05 and q < 0.10).	UPLC/MS/MS2;GC-MS	Plasma	case vs.control group	24466379
METAC_280	75	breast cancer	ER+/PR+, Triple negative breast cancer	1612	C-P: CA(Caucasian Americans) breast cancer patients with ER+/PR+ breast tumors		F	15	C-3N: CA(Caucasian Americans) breast cancer patients with triple-negative breast tumors		F	15	Comparison of metabolites between CA (Caucasian Americans) breast cancer patients with ER+/PR+ breast tumors and  CA (Caucasian Americans) breast cancer patients with triple-negative breast tumors	A total of 375 named metabolites were observed, with 117 metabolites whose levels were significantly different between African American and Caucasian American women (P < .05 and q < 0.10) and 78 that differed between breast cancer cases and healthy controls (P < .05 and q < 0.10).	UPLC/MS/MS2;GC-MS	Plasma	case vs.control group	24466379
METAC_281	75	breast cancer	ER+/PR+, Triple negative breast cancer	1612	ER+/PR+ breast cancer		F	30	Triple negative breast cancer		F	30	Comparison of metabolites between ER+/PR+ and Triple negative breast tumours	A total of 375 named metabolites were observed, with 117 metabolites whose levels were significantly different between African American and Caucasian American women (P < .05 and q < 0.10) and 78 that differed between breast cancer cases and healthy controls (P < .05 and q < 0.10).	UPLC/MS/MS2;GC-MS	Plasma	case vs.control group	24466379
METAC_282	80	breast cancer	nan	1612	FIT breast cancer patients		F	49					Serum concentrations of metabolites found significantly deregulated in Fit breast cancer patients	ANOVA was applied to identify the metabolites differing significantly among Fit, Unfit, and Frail patients. In patients carrying the frail phenotype, the amino acid perturbations involve serine, tryptophan, hydroxyproline, histidine, its derivate 3-methyl-hystidine, cystine, and β-aminoisobutyric acid.	LC-MS/MS	Blood	profiling group	24659054
METAC_283	80	breast cancer	nan	1612	UNFIT breast cancer patients		F	23					Serum concentrations of metabolites found significantly deregulated in Unfit breast cancer patients	ANOVA was applied to identify the metabolites differing significantly among Fit, Unfit, and Frail patients. In patients carrying the frail phenotype, the amino acid perturbations involve serine, tryptophan, hydroxyproline, histidine, its derivate 3-methyl-hystidine, cystine, and β-aminoisobutyric acid.	LC-MS/MS	Blood	profiling group	24659054
METAC_284	80	breast cancer	nan	1612	FRAIL breast cancer patients		F	17					Serum concentrations of metabolites found significantly deregulated in Frail breast cancer patients	ANOVA was applied to identify the metabolites differing significantly among Fit, Unfit, and Frail patients. In patients carrying the frail phenotype, the amino acid perturbations involve serine, tryptophan, hydroxyproline, histidine, its derivate 3-methyl-hystidine, cystine, and β-aminoisobutyric acid.	LC-MS/MS	Blood	profiling group	24659054
METAC_285	27	breast cancer	nan	1612	Breast cancer		F	85	healthy controls		F	45	Breast cancer compared with healthy controls	Three volatile organic metabolites in the exhaled air, 2,5,6-trimethyloctane, 1,4-dimethoxy-2,3-butanediol, and cyclohexanone, distinguished breast cancer patients from healthy individuals, mammary gland fibroma patients, and patients with cyclomastopathy (P < 0.05).	GC-MS	Breath sample	case vs.control group	24947160
METAC_286	27	breast cancer	nan	1612	Breast cancer		F	85	cyclomastopathy		F	25	Breast cancer compared with cyclomastopathy	Three volatile organic metabolites in the exhaled air, 2,5,6-trimethyloctane, 1,4-dimethoxy-2,3-butanediol, and cyclohexanone, distinguished breast cancer patients from healthy individuals, mammary gland fibroma patients, and patients with cyclomastopathy (P < 0.05).	GC-MS	Breath sample	case vs.control group	24947160
METAC_287	27	breast cancer	nan	1612	Breast cancer		F	85	mammary gland fibroma		F	21	Breast cancer compared with mammary gland fibroma	Three volatile organic metabolites in the exhaled air, 2,5,6-trimethyloctane, 1,4-dimethoxy-2,3-butanediol, and cyclohexanone, distinguished breast cancer patients from healthy individuals, mammary gland fibroma patients, and patients with cyclomastopathy (P < 0.05).	GC-MS	Breath sample	case vs.control group	24947160
METAC_288	27	breast cancer	nan	1612	breast cancer tumor		F	65	non-tumour		F	65	Differentially abundant metabolites in breast cancer	specific biochemical alterations distinguish liver, pancreatic and breast cancer and could be applied as cancer classification tools to differentiate tumors based on tissue of origin.	LC/MS;GC/MS	Breast tissue	case vs.control group	25210494
METAC_289	110	liver cancer	nan	3571	breast cancer tumor		F&M	30	non-tumour		F	30	Differentially abundant metabolites in liver cancer	specific biochemical alterations distinguish liver, pancreatic and breast cancer and could be applied as cancer classification tools to differentiate tumors based on tissue of origin.	LC/MS;GC/MS	Liver tissue	case vs.control group	25210494
METAC_290	157	pancreatic cancer	nan	1793	breast cancer tumor		F&M	38	non-tumour		F	39	Differentially abundant metabolites in pancreas cancer	specific biochemical alterations distinguish liver, pancreatic and breast cancer and could be applied as cancer classification tools to differentiate tumors based on tissue of origin.	LC/MS;GC/MS	Pancreatic tissue	case vs.control group	25210494
METAC_291	27	breast cancer	nan	1612	Premenopausal cases	44.0 ± 6.3	F	41	Premenopausal controls	40.5 ± 9.0	F	211	Absolute values (lg/mg creatinine) of the estradiol metabolites 2-hydroxyestrone (2-OHE1) and 16a-hydroxyestrone (16-OHE1) in premenopausal women with and without breast cancer	In premenopausal patients, log ratio of 2-OHE1/ 16-OHE1 was 0.25 (CI 0.20;0.29) and 0.21 (CI 0.11;0.31) for controls and cases without significant difference.	ELISA	Urine	case vs.control group	25318606
METAC_292	27	breast cancer	nan	1612	Postmenopausal cases	62.7 ± 8.5	F	207	Postmenopausal controls	59.5 ± 8.1	F	206	Absolute values (lg/mg creatinine) of the estradiol metabolites 2-hydroxyestrone (2-OHE1) and 16a-hydroxyestrone (16-OHE1) in postmenopausal women with and without breast cancer	In postmenopausal patients, log ratio was 0.22 (CI 0.17;0.26) and 0.11 (CI 0.07;0.15) in controls and cases, respectively, and was statistically significantly lower (p = 0.0002).	ELISA	Urine	case vs.control group	25318606
METAC_293	109	breast cancer	early-stage breast cancer	1612	post-intervention		F	38	pre-intervention		F	38	Metabolites that changed after 2-6 weeks daily limonene intervention	Of the 397 named metabolites identified, 72 changed significantly with limonene intervention.	UPLC;GC-MS	Plasma	case vs.control group	25388013
METAC_294	210	breast cancer	ER+, Triple negative breast cancer	1612	triple-negative breast cancer	53	F	15	ER+ breast cancer	56	F	15	Table of all identified biochemicals for the specific comparison TNBC vs. ER+.	TNBC tumors have metabolic signatures that distinguish them from ER+ tumors and suggest that distinctive metabolic characteristics of these tumors might offer new targets for treatment.	UHPLC/MS/MS;GC/MS	Breast tissue	case vs.control group	25422359
METAC_295	28	breast cancer	ER+, Triple negative breast cancer	1612	Breast cancer patients death		F		Breast cancer patients survial		F		Table of all identified biochemicals and their correlation with death vs. survival	nan	UHPLC/MS/MS;GC/MS	Breast tissue	case vs.control group	25422359
METAC_296	33	breast cancer	ER breast cancer	1612	Lymph nodes		F						Concentrations of Tamoxifen (T), Desmethyltamoxifen (d-T), and 4-Hydroxytamoxifen (4-OH-T) After Single 20 mg Oral Dose, 5 Hours Before Surgery in Lymph nodes	nan	HPLC	Lymph node	profiling group	17529893
METAC_297	33	breast cancer	ER breast cancer	1612	breast cancer tissue		F						Concentrations of Tamoxifen (T), Desmethyltamoxifen (d-T), and 4-Hydroxytamoxifen (4-OH-T) After Single 20 mg Oral Dose, 5 Hours Before Surgery in breast tissue	nan	HPLC	Breast tissue	profiling group	17529893
METAC_298	33	breast cancer	ER breast cancer	1612	Muscle		F						Concentrations of Tamoxifen (T), Desmethyltamoxifen (d-T), and 4-Hydroxytamoxifen (4-OH-T) After Single 20 mg Oral Dose, 5 Hours Before Surgery in Muscle	nan	HPLC	Muscle	profiling group	17529893
METAC_299	33	breast cancer	ER breast cancer	1612	Skin		F						Concentrations of Tamoxifen (T), Desmethyltamoxifen (d-T), and 4-Hydroxytamoxifen (4-OH-T) After Single 20 mg Oral Dose, 5 Hours Before Surgery in Skin	nan	HPLC	Skin	profiling group	17529893
METAC_300	33	breast cancer	ER breast cancer	1612	Fat		F						Concentrations of Tamoxifen (T), Desmethyltamoxifen (d-T), and 4-Hydroxytamoxifen (4-OH-T) After Single 20 mg Oral Dose, 5 Hours Before Surgery in Fat	nan	HPLC	Fat	profiling group	17529893
METAC_301	33	breast cancer	ER breast cancer	1612	Normal gland		F						Concentrations of Tamoxifen (T), Desmethyltamoxifen (d-T), and 4-Hydroxytamoxifen (4-OH-T) After Single 20 mg Oral Dose, 5 Hours Before Surgery in Normal gland	nan	HPLC	Gland	profiling group	17529893
METAC_302	33	breast cancer	ER breast cancer	1612	Serum		F						Concentrations of Tamoxifen (T), Desmethyltamoxifen (d-T), and 4-Hydroxytamoxifen (4-OH-T) After Single 20 mg Oral Dose, 5 Hours Before Surgery in Serum	nan	HPLC	Serum	profiling group	17529893
METAC_303	27	breast cancer	invasive breast cancer	1612	Breast cancer patients		F	141	Health female volunteers		F	141	Simultaneous determination of phytoestrogens and key metabolites in breast cancer patients’ and healthy control's urine	Mean concentrations of equol, daidzein, genistein, naringenin, biochanin A and enterolactone in the breast cancer patients’ urine are higher than those of cancer-free controls. The mean concentration of enterodiol in patients’ urine, on the contrary, is lower than that of cancer-free controls.	LC-MS/MS	Urine	case vs.control group	19595530
METAC_304	27	breast cancer	nan	1612	breast cancer	47.8 ± 9.0	F	20	control group		F	18	potential biomarkers for breast cancer	The study identified 12 metabolites as potential biomarkers including amino acids, organic acids, and nucleosides. They revealed elevated tryptophan and nucleoside metabolism as well as protein degradation in breast cancer patients.	RRLC-MS/MS	Urine	profiling group	19768207
METAC_305	27	breast cancer	ductal carcinoma, lobular carcinoma	1612	breast cancer	56 (30-86)	F	48	healthy controls	56 (19-83)	F	62	Metabolite changes in human urine with breast cancer when compared with a healthy group	urinary metabolomics may be useful for detecting early-stage breast and ovarian cancer	NMR	Urine	case vs.control group	20956617
METAC_306	153	ovarian cancer	nan	2394	Ovarian cancer	56 (21-83)	F	50	healthy controls	56 (19-83)	F	62	Metabolite changes in human urine with ovarian cancer when compared with a healthy group	urinary metabolomics may be useful for detecting early-stage breast and ovarian cancer	NMR	Urine	case vs.control group	20956617
METAC_307	5	breast cancer	advanced metastatic breast cancer	1612	metastatic breast cancer	57.2 ± 11.5	F	37	localized breast cancer	56.1 ± 10.0	F	46	Significant metabolites derived from the model differentiating  patients with metastatic and localized breast cancer.	a robust serum metabolic signature of  metastatic breast cancer as compared to patients with localized breast tumors	¹H NMR	Serum	case vs.control group	24041867
METAC_308	5	breast cancer	advanced metastatic breast cancer	1612	metastatic breast cancer	56.2 ± 11.1	F	49	localized breast cancer	58.5 ± 12.2	F	58	Significant metabolites derived from the model differentiating  patients with metastatic and localized breast cancer.	a robust serum metabolic signature of  metastatic breast cancer as compared to patients with localized breast tumors	¹H NMR	Serum	case vs.control group	24041867
METAC_309	72	breast cancer	ER− and ER + breast cancer.	1612	ER- breast cacer		F	67	ER+ breast cancer		F	204	metabolites differentially regulated between ER- and ER+ breast cancer.	demonstrates for the first time that the metabolism in breast cancer cells strongly depends on ER status	GC-TOF-MS	Breast tissue	case vs.control group	24125731
METAC_311	27	breast cancer	nan	1612	breast cancer	57 (29-77)	F	30	controls	43 (20-75)	F&M	87	metabolites between breast cancer and controls	nan	CE-TOF-MS	Saliva	case vs.control group	20300169
METAC_312	158	pancreatic cancer	nan	1793	pancreatic cancer	67 (11-87)		18	controls	43 (20-75)	F&M	87	metabolites between pancreatic cancer and controls	nan	CE-TOF-MS	Saliva	case vs.control group	20300169
METAC_316	27	breast cancer	nan	1612	breast cancer	57 (29-77)	F	30	pancreatic cancer	67 (11-87)		18	metabolites between breast cancer and pancreatic cancer	nan	CE-TOF-MS	Saliva	case vs.control group	20300169
METAC_317	27	breast cancer	nan	1612	breast cancer	57 (29-77)	F	30	periodontal disease	60 (23-76)		11	metabolites between breast cancer and periodontal disease	nan	CE-TOF-MS	Saliva	case vs.control group	20300169
METAC_318	158	pancreatic cancer	nan	1793	pancreatic cancer	67 (11-87)		18	periodontal disease	60 (23-76)		11	metabolites between pancreatic cancer and periodontal disease	nan	CE-TOF-MS	Saliva	case vs.control group	20300169
METAC_319	34	breast cancer	nan	1612	Within and Post recurrence		F	49	No evidence of disease (NED) 	53 (37-75) 	F	141	11 markers identified Within and Post recurrence vs. No evidence of disease (NED)	Eleven metabolite markers (seven from NMR and four from GC×GC-MS) were shortlisted from an analysis of all patient samples by using logistic regression and 5-fold cross-validation.	¹H NMR;GCxGC-MS	Serum	case vs.control group	20959483
METAC_320	34	breast cancer	nan	1612	Pre-recurrence		F	67	No evidence of disease (NED) 	53 (37-75) 	F	141	11 markers identified Pre recurrence vs. No evidence of disease (NED)	Eleven metabolite markers (seven from NMR and four from GC×GC-MS) were shortlisted from an analysis of all patient samples by using logistic regression and 5-fold cross-validation.	¹H NMR;GCxGC-MS	Serum	case vs.control group	20959483
METAC_321	58	breast cancer	nan	1612	Ultra-rapid metabolizer (UM)		F	27					Tamoxifen and tamoxifen metabolite concentrations (ng/mL) by CYP2D6 phenotype Ultra-rapid metabolizer (UM)	nan	HPLC	Serum	profiling group	21430657
METAC_322	58	breast cancer	nan	1612	Extensive metabolizer (EM) 		F	1097					Tamoxifen and tamoxifen metabolite concentrations (ng/mL) by CYP2D6 phenotype Extensive metabolizer (EM)	nan	HPLC	Serum	profiling group	21430657
METAC_323	58	breast cancer	nan	1612	Intermediate metabolizer (IM)		F	164					Tamoxifen and tamoxifen metabolite concentrations (ng/mL) by CYP2D6 phenotype Intermediate metabolizer (IM)	nan	HPLC	Serum	profiling group	21430657
METAC_324	58	breast cancer	nan	1612	Poor metabolizer (PM)		F	82					Tamoxifen and tamoxifen metabolite concentrations (ng/mL) by CYP2D6 phenotype Poor metabolizer (PM)	nan	HPLC	Serum	profiling group	21430657
METAC_325	212	bladder cancer	non-muscle-invasive bladder cancer(NMIBC)	11054	After transurethral resection of bladder tumor (TURBT)	69.6 ±5.6	F&M	10	Before transurethral resection of bladder tumor (TURBT)	69.6 ±5.6	F&M	10	the significance of differences in annotated metabolite levels (before TURBT(collected on the morning of TURBT.) vs. after TURBT (2 weeks after TURBT))	the implementation of longitudinal data in metabolomics analysis is of great importance and provides valuable information.	HPLC-TOF/MS;GC-QqQ/MS	Urine	case vs.control group	35267519
METAC_327	20	bladder cancer	nan	11054	bladder cancer	68.9 (43-87)	F&M	53	cancer-free controls	51.9 (45-66)	F&M	56	Volatile metabolites differences between BC patients and cancer-free controls.	List of twenty-three volatile metabolites found altered in urine of BC patients compared with cancer-free controls.	HS-SPME-GC-MS	Urine	case vs.control group	33810601
METAC_329	20	bladder cancer	nan	11054	bladder cancer	64.21 ± 14.18	F&M	42	renal cell carcinoma	56.96 ± 15.09	F&M	53	Differential metabolites for distinction of bladder cancer and renal cell carcinoma.	we also found eight metabolites that showed good predictive ability for BC, RCC and control discrimination. This study indicated that plasma metabolomics and lipidomics may be effective for BC, RCC and control discrimination, and combined plasma metabolomics and lipidomics showed better predictive performance.	LC-MS	Serum	case vs.control group	32500026
METAC_331	20	bladder cancer	nan	11054	bladder cancer distinction		F&M	122	renal cell carcinoma		F&M	85	Differential metabolites for cancer(bladder cancer and renal cell carcinoma) distinction.	nan	UPLC-MS	Urine	case vs.control group	31805976
METAC_332	20	bladder cancer	nan	11054	bladder cancer without hematuria	62 (33-87)	F&M	53	renal cell carcinoma without hematuria	53 (14-82)	F&M	64	Differential metabolites between bladder cancer and renal cell carcinoma without hematuria	nan	UPLC-MS	Urine	case vs.control group	31805976
METAC_333	20	bladder cancer	nan	11054	bladder cancer with hematuria	67 (40-90)	F&M	69	renal cell carcinoma with hematuria	52 (32-78)	F&M	21	Differential metabolites between bladder cancer and renal cell carcinoma with hematuria	nan	UPLC-MS	Urine	case vs.control group	31805976
METAC_334	79	bladder cancer	nan	11054	Pre-gemcitabine bladder cancer (Bca)	55-85	F&M	12	normal tissues	55-85	F&M	12	Differential metabolites in the comparison between pre-gemcitabine bladder cancer and normal tissues.	nan	LC-HRMS	Bladder tissue	case vs.control group	31545404
METAC_335	79	bladder cancer	nan	11054	Post-gemcitabine bladder cancer (Bca)	55-85	F&M	12	pre-gemcitabine normal tissues	55-85	F&M	12	Differential metabolites in the comparison between post-gemcitabine bladder cancer and pre-gemcitabine normal tissues.	nan	LC-HRMS	Bladder tissue	case vs.control group	31545404
METAC_336	79	bladder cancer	nan	11054	Pre-gemcitabine bladder cancer (Bca)	55-85	F&M	12	normal tissues	55-85	F&M	12	Differential metabolites in the comparison between pre-gemcitabine bladder cancer and normal tissues.	nan	LC-HRMS	Bladder tissue	case vs.control group	31545404
METAC_337	79	bladder cancer	nan	11054	Post-gemcitabine bladder cancer (Bca)	55-85	F&M	12	pre-gemcitabine normal tissues	55-85	F&M	12	Differential metabolites in the comparison between post-gemcitabine normal tissues and pre-gemcitabine normal tissues.	nan	LC-HRMS	Bladder tissue	case vs.control group	31545404
METAC_338	142	bladder cancer	non-muscle-invasive bladder cancer(NMIBC)	11054	Non-Muscle-Invasive Bladder Cancer	62.2 ± 13.2	F&M	54	control group	59.5 ± 11.2	F&M	78	Differential metabolites between Non-Muscle-Invasive Bladder Cancer (NMIBC) and control group.	nan	LC-HRMS	Urine	case vs.control group	30450336
METAC_339	142	bladder cancer	non-muscle-invasive bladder cancer(NMIBC)	11054	low-grade Non-Muscle-Invasive Bladder Cancer	59.7 ± 13.5	F&M	43	control group	59.8 ± 12.8	F&M	43	Differential metabolites between low-grade Non-Muscle-Invasive Bladder Cancer (NMIBC) and control group	nan	LC-HRMS	Urine	case vs.control group	30450336
METAC_340	143	bladder cancer	non-muscle-invasive bladder cancer(NMIBC)	11054	low-grade Non-Muscle-Invasive Bladder Cancer with hematuria	65.4 ± 10.7	F&M	18	high-grade Non-Muscle-Invasive Bladder Cancer with hematuria	68.9 ± 10.8	F&M	69	Differential metabolites between high and low grade Non-Muscle-Invasive Bladder Cancer (NMIBC) without hematuria	metabolites involved in tryptophan metabolism were upregulated in the urine of high-grade NMIBC patients when compared with low-grade NMIBC patients with the presence or absence of hematuria.	LC-HRMS	Urine	case vs.control group	30450336
METAC_341	143	bladder cancer	non-muscle-invasive bladder cancer(NMIBC)	11054	low-grade Non-Muscle-Invasive Bladder Cancer without hematuria	59.7 ± 13.5	F&M	43	high-grade Non-Muscle-Invasive Bladder Cancer without hematuria	66.5 ± 10.4	F&M	37	Differential metabolites between high and low grade Non-Muscle-Invasive Bladder Cancer (NMIBC) with hematuria	metabolites involved in tryptophan metabolism were upregulated in the urine of high-grade NMIBC patients when compared with low-grade NMIBC patients with the presence or absence of hematuria.	LC-HRMS	Urine	case vs.control group	30450336
METAC_342	20	bladder cancer	nan	11054	bladder cancer	65 ± 12.0	F&M	24	healthy volunteers	64 ± 10.4	F&M	24	Information on metabolites significantly differentiating urinary profiles from bladder cancer patients and healthy volunteers.	amino acid metabolism is particularly affected in BCa patients.	LC-MS;GC-MS;¹H NMR	Urine	case vs.control group	31171223
METAC_343	68	bladder cancer	early-stage bladder cancer	11054	bladder cancer	65.14 ± 13.27	F&M	23	healthy volunteers	53.76 ± 19.47	F&M	21	Differential metabolites between early stage bladder cancer patients and healthy volunteers.	three BCa-upregulated metabolites: nicotinuric acid, trehalose, AspAspGlyTrp, and three BCa-downregulated metabolites: inosinic acid, ureidosuccinic acid, GlyCysAlaLys.	LC-MS	Urine	case vs.control group	25562196
METAC_344	20	bladder cancer	nan	11054	bladder cancer	56 (42-71)	F&M	27	healthy controls	53 (46-67)	F&M	32	Differential metabolites between bladder cancer patients and healthy controls.	potential specific biomarkers in urine as a noninvasive bladder cancer.	HPLC-MS	Urine	case vs.control group	21799048
METAC_345	20	bladder cancer	nan	11054	bladder cancer(BC)	67.2 ± 12.3	F&M	24	Non-BC Subjects	61.3 ± 12.4	F&M	51	Marker Metabolites Differentiating Bladder Cancer (BC) and Non-BC Subjects	Marker metabolites of bladdercancer.	GC/TOFMS	Urine	case vs.control group	20337499
METAC_346	21	bladder cancer	low-grade bladder cancer	11054	low-grade bladder cancer	23.1 (17.1-27.6)	F&M	34	healthy controls	23.5 (17.5-27.7)	F&M	30	Differential serum metabolites among LG (low-grade) bladder cancer patients as well as healthy controls.	The serum samples of BC patients exhibited higher levels of 5-aminoimidazole ribonucleotide (AIR), 5-methylcytidine, hypoxanthine, inosine, kynurenine, AFMK, indolelactic acid, indoleacetic acid, glycocholic acid, PS(O-18:0/0:0), phytosphingosine, sphinganine, acylcarnitines and LysoPCs in combination with lower levels of citric acid, hippuric acid and LysoPE(22:6/0:0).	UHPLC-Q-TOFMS	Serum	case vs.control group	28382976
METAC_347	21	bladder cancer	high-grade bladder cancer	11054	high-grade bladder cancer	22.3 (16.6-28.2)	F&M	34	healthy controls	23.5 (17.5-27.7)	F&M	30	Differential serum metabolites among HG (high-grade) bladder cancer patients as well as healthy controls.	The serum samples of BC patients exhibited higher levels of 5-aminoimidazole ribonucleotide (AIR), 5-methylcytidine, hypoxanthine, inosine, kynurenine, AFMK, indolelactic acid, indoleacetic acid, glycocholic acid, PS(O-18:0/0:0), phytosphingosine, sphinganine, acylcarnitines and LysoPCs in combination with lower levels of citric acid, hippuric acid and LysoPE(22:6/0:0).	UHPLC-Q-TOFMS	Serum	case vs.control group	28382976
METAC_348	21	bladder cancer	high-grade bladder cancer; low-grade bladder cancer	11054	high-grade bladder cancer	22.3 (16.6-28.2)	F&M	34	low-grade bladder cancer	23.1 (17.1-27.6)	F&M	34	Differential metabolites for discrimination between HG (high-grade) bladder cancer patients and LG (low-grade) bladder cancer patients.	The serum samples of BC patients exhibited higher levels of 5-aminoimidazole ribonucleotide (AIR), 5-methylcytidine, hypoxanthine, inosine, kynurenine, AFMK, indolelactic acid, indoleacetic acid, glycocholic acid, PS(O-18:0/0:0), phytosphingosine, sphinganine, acylcarnitines and LysoPCs in combination with lower levels of citric acid, hippuric acid and LysoPE(22:6/0:0).	UHPLC-Q-TOFMS	Serum	case vs.control group	28382976
METAC_349	77	bladder cancer	nan	11054	high FAVL Expressed Cells				low FAVL Expressed Cells				Differentially Expressed GC-MS Platform Metabolites between low and high FAVL Expressed Cells	nan	UPLC-MS	HTB-4 cell line	case vs.control group	26956768
METAC_350	71	ovarian cancer	clear cell ovarian carcinoma; endometrioid ovarian carcinoma	2394	clear cell ovarian carcinoma(CCC)		F	10	endometrioid ovarian carcinoma (EC)		F	10	Differential metabolites between clear cell ovarian carcinoma and endometrioid ovarian carcinoma.	significant features of EOC subtypes	LC/MS	Serum	case vs.control group	34789766
METAC_351	71	ovarian cancer	clear cell ovarian carcinoma;mucinous ovarian carcinoma	2394	clear cell ovarian carcinoma(CCC)		F	10	mucinous ovarian carcinoma (MC)		F	9	Differential metabolites between clear cell ovarian carcinoma and mucinous ovarian carcinoma.	significant features of EOC subtypes	LC/MS	Serum	case vs.control group	34789766
METAC_352	71	ovarian cancer	endometrioid ovarian carcinoma; mucinous ovarian carcinoma	2394	endometrioid ovarian carcinoma (EC)		F	10	mucinous ovarian carcinoma (MC)		F	9	Differential metabolites between endometrioid ovarian carcinoma and mucinous ovarian carcinoma.	significant features of EOC subtypes	LC/MS	Serum	case vs.control group	34789766
METAC_353	71	ovarian cancer	non-serous ovarian carcinoma; serous ovarian carcinoma	2394	non-serous ovarian carcinoma (NSeC)		F	9	serous ovarian carcinoma (SeC)		F	11	Differential metabolites between non-serous ovarian carcinoma and serous ovarian carcinoma .	significant features of EOC subtypes	LC/MS	Serum	case vs.control group	34789766
METAC_354	71	ovarian cancer	epithelial ovarian cancer	2394	epithelial ovarian cancer	58 ± 13	F	80	healthy controls	59 ± 12	F	80	Differential metabolites between epithelial ovarian cancer and healthy controls.	77 significantly increased and 114 significantly decreased metabolites in EOC patients compared with healthy controls.	UHPLC-MS	Serum	case vs.control group	34209281
METAC_355	71	ovarian cancer	epithelial ovarian cancer	2394	primary ovarian cancer	62	F	5	omental metastatic cancer	62	F	5	Differential metabolites between primary ovarian cancer and omental metastatic cancer.	HGSOC samples contained more amino acids and GSH than non-serous carcinoma samples.	CE-TOF-MS; CE-QqQMS	Ovarian tissue	case vs.control group	34134729
METAC_356	71	ovarian cancer	epithelial ovarian cancer	2394	epithelial ovarian cancer	47.1 ± 4.5	F	39	healthy controls	46.1 ± 5.8	F	31	Differential metabolites between epithelial ovarian cancer and healthy controls.	The levels of 14 metabolites were significantly altered in the EOC group compared to healthy controls	UPLC-MS	Serum	case vs.control group	33746017
METAC_357	153	ovarian cancer	nan	2394	A2780cis cells				A2780 cells				Metabolites with significant differences in expression between A2780 and A2780cis cells	Levels of glutamine, glutamate, and glutathione (GSH), a key drug resistance mediator synthesized from glutamate, were significantly elevated in A2780cis cells than those in A2780 cells. Furthermore, glutamine starvation decreased the GSH levels and CDDP resistance in A2780cis cells.	CE-TOF-MS	A2780 cells	case vs.control group	33596851
METAC_358	153	ovarian cancer	nan	2394	A2780cis cells				A2780 cells				Metabolites with significant differences in expression between A2780 and A2780cis cells in the presence of glutamine	Levels of glutamine, glutamate, and glutathione (GSH), a key drug resistance mediator synthesized from glutamate, were significantly elevated in A2780cis cells than those in A2780 cells. Furthermore, glutamine starvation decreased the GSH levels and CDDP resistance in A2780cis cells.	CE-TOF-MS	A2780 cells	case vs.control group	33596851
METAC_359	153	ovarian cancer	nan	2394	A2780cis cells				A2780 cells				Metabolites with significant differences in expression between A2780 and A2780cis cells under glutamine starvation	Levels of glutamine, glutamate, and glutathione (GSH), a key drug resistance mediator synthesized from glutamate, were significantly elevated in A2780cis cells than those in A2780 cells. Furthermore, glutamine starvation decreased the GSH levels and CDDP resistance in A2780cis cells.	CE-TOF-MS	A2780 cells	case vs.control group	33596851
METAC_360	88	ovarian cancer	nan	2394	A2780 cells without glutamine				A2780 cells with glutamine				Metabolites significantly changed under glutamine starvation in A2780 cells	Levels of glutamine, glutamate, and glutathione (GSH), a key drug resistance mediator synthesized from glutamate, were significantly elevated in A2780cis cells than those in A2780 cells. Furthermore, glutamine starvation decreased the GSH levels and CDDP resistance in A2780cis cells.	CE-TOF-MS	A2780 cells	case vs.control group	33596851
METAC_361	88	ovarian cancer	nan	2394	A2780cis cells without glutamine				A2780cis cells with glutamine				Metabolites significantly changed under glutamine starvation in A2780cis cells	Levels of glutamine, glutamate, and glutathione (GSH), a key drug resistance mediator synthesized from glutamate, were significantly elevated in A2780cis cells than those in A2780 cells. Furthermore, glutamine starvation decreased the GSH levels and CDDP resistance in A2780cis cells.	CE-TOF-MS	A2780 cells	case vs.control group	33596851
METAC_362	153	ovarian cancer	high-grade serous carcinoma	2394	primary ascites	55	F	6	tumor tissue	55	F	6	Differential metabolites between the primary ascites and tumor tissue in ovarian cancer	nan	LC-MS	Ascites and ovarian tissue	case vs.control group	33523930
METAC_363	153	ovarian cancer	nan	2394	ovarian cancer	59.7 ± 15.4	F	10	healthy controls	55.5 ± 12.5	F	10	Differential metabolites between ovarian carcinoma and healthy controls.	nan	ESI-LC-MS	Serum	case vs.control group	33228226
METAC_364	20	bladder cancer	nan	11054	bladder cancer patients	68.2 (48-92)	F&M	29	healthy controls	68.2 (48-92)	F&M	15	Differential metabolites between bladder cancer patients and healthy controls annotated in KEGG or HMDB database	An obvious discrimination was obtained by OPLS-DA analysis based on the identi-fied metabolites between bladder cancer patients and healthy controls.	UPLC-MS	Urine	case vs.control group	35220945
METAC_365	155	ovarian cancer	nan	2394	recurrence ovarian cancer	54.26 ± 9.80	F	23	non-recurrence ovarian cancer	52.54 ± 7.66	F	12	Differential metabolites between recurrence and non-recurrence ovarian cancer before surgery.	five biomarkers decrease in recurrence groups compared to non-recurrence groups, i.e. creatinine, lysine, phosphohydroxypyruvic acid, carnitine, l-beta-aspartyl-l-glutamic acid. Whereas other five biomarkers increase, i.e. hydroxyphenyllactic acid, uric acid, 3-(3,5-diiodo-4-hydroxyphenyl) lactate, coproporphyrinogen and 24,25-hydroxyvitamin D3	RRLC/MS	Plasma	case vs.control group	30830339
METAC_366	155	ovarian cancer	nan	2394	recurrence ovarian cancer	54.26 ± 9.80	F	23	non-recurrence ovarian cancer	52.54 ± 7.66	F	12	Differential metabolites between recurrence and non-recurrence ovarian cancer after surgery.	five biomarkers decrease in recurrence groups compared to non-recurrence groups, i.e. creatinine, lysine, phosphohydroxypyruvic acid, carnitine, l-beta-aspartyl-l-glutamic acid. Whereas other five biomarkers increase, i.e. hydroxyphenyllactic acid, uric acid, 3-(3,5-diiodo-4-hydroxyphenyl) lactate, coproporphyrinogen and 24,25-hydroxyvitamin D3	RRLC/MS	Plasma	case vs.control group	30830339
METAC_367	153	ovarian cancer	nan	2394	ovarian cancer	54.7 ± 11.54	F	30	control groups	55.82 ± 10.94	F	30	Differential metabolites between the ovarian cancer and control groups.	Relative contents of 18 differential metabolites between patients with ovarian cancer and healthy controls in discovery	UPLC-QTOF-MS	Serum	case vs.control group	30476914
METAC_368	153	ovarian cancer	epithelial ovarian cancer	2394	epithelial ovarian cancer	59.6 (41-83)	F	15	control samples	56.3 (34-82)	F	21	Differential metabolites between the ovarian cancer and control samples.	nan	HPLC-TQ/MS	Serum	case vs.control group	29904684
METAC_326	20	bladder cancer	nan	11054	bladder cancer patients	65.8 ± 3.5	F&M	57	cancer-free controls	61 ± 4.1	F&M	38	Metabolites found changed in the urine of bladder cancer patients (n=57) compared with cancer-free controls (n=38).	It is possible to perform non-invasive clinical diagnoses of bladder cancer through these candidate biomarkers	UPLC-MS	Urine	case vs.control group	34850327
METAC_369	162	ovarian cancer	epithelial ovarian cancer	2394	platinum‑resistant		F		platinum‑sensitive		F		Differential metabolites between platinum‑resistant samples and platinum‑sensitive samples.	PTR exhibit a specific metabolic trait characterized by decreased levels of calycanthidine and increased levels of 1-monopalmitin, ricinoleic acid methl ester, polyoxyethylene (600)mono-ricinoleate/glycidyl stearate. Furthermore, the concentration of dodemorph was higher and of C16 sphinganine was lower in the EOC compared to NC	HPLC-MS	Serum	case vs.control group	27511453
METAC_370	162	ovarian cancer	epithelial ovarian cancer	2394	platinum‑resistant		F		platinum‑sensitive		F		Differential metabolites between platinum‑resistant samples and normal control.	PTR exhibit a specific metabolic trait characterized by decreased levels of calycanthidine and increased levels of 1-monopalmitin, ricinoleic acid methl ester, polyoxyethylene (600)mono-ricinoleate/glycidyl stearate. Furthermore, the concentration of dodemorph was higher and of C16 sphinganine was lower in the EOC compared to NC	HPLC-MS	Serum	case vs.control group	27511453
METAC_371	69	ovarian cancer	epithelial ovarian cancer	2394	early-stage epithelial ovarian cancer	53.09 (30.90-72.10)	F	21	controls	53.75 (28.00-74.30)	F	31	Differential metabolites in plasma to discriminate the early-stage epithelial ovarian cancer (EOC) patients and controls.	52 metabolites were used for differentiating early stage EOC patients from normal controls.18 metabolites were obtained and identified as candidate biomarkers	UPLC-QTOF-MS	Plasma	case vs.control group	27390602
METAC_372	167	ovarian cancer	epithelial ovarian cancer	2394	primary epithelial ovarian cancer patients	53.67 ± 9.04	F	35	controls	53.22 ± 8.30	F	35	The detailed information about 37 potential biomarkers that are differential between primary epithelial ovarian cancer (EOC) patients and controls.	In the primary EOC patients, these markers included elevated l-kynurenine, hypoxanthine, and hydroxyphenyllactic acid, and decreased lysophosphatidylcholines (LPCs), fatty acids, amino acids, and bile acids	RRLC-MS	Plasma	case vs.control group	26996990
METAC_373	154	ovarian cancer	epithelial ovarian cancer	2394	preoperative patients	53.67 ± 9.04	F	35	postoperative EOC patients	53.76 ± 9.05	F	35	The detailed information about 30 potential biomarkers that are differential between pre- and postoperative epithelial ovarian cancer (EOC) patients	Post-operative EOC patients were characterized by increased fatty acids, amino acids, and uric acid, and decreased LPCs, l-kynurenine, and indoxylsulfuric acid	RRLC-MS	Plasma	case vs.control group	26996990
METAC_374	154	ovarian cancer	epithelial ovarian cancer	2394	postoperative patients	53.76 ± 9.05	F	35	relapsed EOC patients	54.31 ± 7.28	F	35	The detailed information about 42 potential biomarkers that are differential between postoperative epithelial ovarian cancer (EOC) patients and relapsed epithelial ovarian cancer (EOC) patients	Compared with post-operative EOC patients, recurrent EOC patients showed increased LPCs, lysophosphatidylethanolamines (LPEs) and amino acids, and decreased 2-octenoic acid and creatine	RRLC-MS	Plasma	case vs.control group	26996990
METAC_375	167	ovarian cancer	epithelial ovarian cancer	2394	primary epithelial ovarian cancer patients	53.67 ± 9.04	F	35	relapsed EOC patients	54.31 ± 7.28	F	35	The detailed information about 26 potential biomarkers that are differential between primary epithelial ovarian cancer (EOC) patients and relapsed epithelial ovarian cancer (EOC) patients	Compared with primary EOC patients, the levels of a series of lipids, amino acids and their related metabolites were remarkably increased in recurrent EOC patients	RRLC-MS	Plasma	case vs.control group	26996990
METAC_376	167	ovarian cancer	epithelial ovarian cancer	2394	primary epithelial ovarian cancer	58.41 ± 8.51	F	56	health volunteers	57.36 ± 7.82	F	15	Differential metabolites between primary epithelial ovarian cancer patients and health volunteers.	8 metabolites reflecting different metabolic states between healthy people and ovarian cancer patients at different clinical stages were identified	UPLC-QTOF-MS	Urine	case vs.control group	26770415
METAC_377	97	ovarian cancer	high-grade serous ovarian cancer	2394	malignant high-grade serous ovarian cancer		F	158	control		F	100	Malignant vs control group t-test results for the main identified metabolite peaks.	The study represents the first comprehensive metabolomics analysis in HGSOC and propose metabolites of hydroxybutyric acid can serve as diagnostic and prognostic biomarkers of ovarian high-grade serous carcinomas.	GCxGC-TOF-MS	Serum	case vs.control group	26685161
METAC_378	153	ovarian cancer	nan	2394	ovarian cancer	50 (33-70)	F	21	healthy controls	46 (25-66)	F	20	Differential metabolites between ovarian cancer and healthy controls.	eight carbohydrates were significantly differentiated (P-value < 0.05, Student's t-test) from the ovarian cancer versus healthy control, the ovarian cancer versus the ovarian benign tumor	UHPLC-MS	Serum	case vs.control group	26549419
METAC_379	153	ovarian cancer	nan	2394	ovarian cancer	50 (33-70)	F	21	ovarian benign tumor	42 (25-55)	F	17	Differential metabolites between ovarian cancer and ovarian benign tumor.	eight carbohydrates were significantly differentiated (P-value < 0.05, Student's t-test) from the ovarian cancer versus healthy control, the ovarian cancer versus the ovarian benign tumor	UHPLC-MS	Serum	case vs.control group	26549419
METAC_380	152	ovarian cancer	nan	2394	ovarian benign tumor	42 (25-55)	F	17	healthy controls	46 (25-66)	F	20	Differential metabolites between ovarian benign tumor and healthy controls.	eight carbohydrates were significantly differentiated (P-value < 0.05, Student's t-test) from the ovarian cancer versus healthy control, the ovarian cancer versus the ovarian benign tumor	UHPLC-MS	Serum	case vs.control group	26549419
METAC_381	155	ovarian cancer	epithelial ovarian cancer	2394	patients with recurrent epithelial ovarian cancer (EOC)		F	26	patients without recurrent epithelial ovarian cancer (EOC)		F	12	Identified metabolites showing statistically significant changes between patients with and without recurrent epithelial ovarian cancer (EOC)	L-tryptophan, LysoPC (14 : 0) and LysoPE (18 : 2) decreased in EOC patients with recurrence, whereas kynurenine and bilirubin increased	UPLC-QTOF-MS	Serum	case vs.control group	25424060
METAC_382	71	ovarian cancer	epithelial ovarian cancer	2394	epithelial ovarian cancer	53.9 (33.4−68.2)	F	40	healthy controls	45.0 (26.2−57.5)	F	54	Differential metabolites between epithelial ovarian cancer (EOC) and healthy controls.	22 ascertained urinary metabolic biomarkers were highly possible to be associated with EOC	UPLC-QTOF-MS	Urine	case vs.control group	23163809
METAC_383	71	ovarian cancer	epithelial ovarian cancer	2394	epithelial ovarian cancer	53.9 (33.4−68.2)	F	40	benign ovarian tumor	41.1 (19.6−67.4)	F	62	Differential metabolites between epithelial ovarian cancer (EOC) and benign ovarian tumor (BOT).	22 ascertained urinary metabolic biomarkers were highly possible to be associated with EOC	UPLC-QTOF-MS	Urine	case vs.control group	23163809
METAC_384	154	ovarian cancer	epithelial ovarian cancer	2394	preoperative epithelial ovarian cancer	53.9 (33.4−68.2)	F	40	postoperative epithelial ovarian cancer	51.8 (40.0−68.2)	F	18	Differential metabolites between preoperative epithelial ovarian cancer(EOC) patients and postoperative epithelial ovarian cancer(EOC) patients	22 ascertained urinary metabolic biomarkers were highly possible to be associated with EOC	UPLC-QTOF-MS	Urine	case vs.control group	23163809
METAC_385	153	ovarian cancer	nan	2394	ovarian cancer		F	22	healthy controls		F	25	Differential metabolites between ovarian cancer and healthy controls.	Five metabolites were found to be specific to ovarian cancer and ten metabolites were considered commonly related to ovarian cancer and benign ovarian tumor	RRLC-MS; HILIC-MS	Urine	case vs.control group	23109122
METAC_386	153	ovarian cancer	nan	2394	ovarian cancer		F	22	benign ovarian tumor		F	29	Differential metabolites between ovarian cancer and benign ovarian tumor.	Five metabolites were found to be specific to ovarian cancer and ten metabolites were considered commonly related to ovarian cancer and benign ovarian tumor	RRLC-MS; HILIC-MS	Urine	case vs.control group	23109122
METAC_387	71	ovarian cancer	epithelial ovarian cancer	2394	epithelial ovarian cancer	53.48	F	42	healthy controls	45.34	F	58	Differential metabolites between epithelial ovarian cancer and healthy controls.	The eight metabolites are significantly associated with EOC.	UPLC-QTOF-MS	Urine	case vs.control group	22283470
METAC_388	71	ovarian cancer	epithelial ovarian cancer	2394	epithelial ovarian cancer	56 (21-83)	F	50	healthy controls	56 (19-83)	F	62	Differential metabolites between ovarian cancer and healthy controls.	nan	NMR	Urine	case vs.control group	20956617
METAC_389	71	ovarian cancer	epithelial ovarian cancer	2394	epithelial ovarian cancer	56 (21-83)	F	50	breast cancer	56 (30-86)	F	48	Differential metabolites between ovarian cancer and breast cancer.	nan	NMR	Urine	case vs.control group	20956617
METAC_390	110	liver cancer	nan	3571	liver cancer population	58 (11-88 )	F&M	274	health population	44 (22-91)	F&M	100	Odds of liver cancer diagnosis by blood concentrations of neonicotinoid insecticides (NEOs) and their metabolites presented in a liver cancer population (n = 274)-health population (n = 100) study from South China.	nan	HPLC-MS	Blood	case vs.control group	35016862
METAC_391	91	liver cancer	hepatocellular carcinoma	3571	hepatocellular carcinoma	60.6 ± 8.97	F&M	25	liver liver cirrhosis	51.62 ± 9.5	F&M	29	The different metabolites between hepatocellular carcinoma and liver cancer in positive mode	nan	LC-MS	Plasma	case vs.control group	33490775
METAC_392	91	liver cancer	hepatocellular carcinoma	3571	hepatocellular carcinoma	60.6 ± 8.97	F&M	25	liver liver cirrhosis	51.62 ± 9.5	F&M	29	The different metabolites between hepatocellular carcinoma and liver cancer in negative mode	nan	LC-MS	Plasma	case vs.control group	33490775
METAC_393	91	liver cancer	hepatocellular carcinoma	3571	hepatocellular carcinoma	60.6 ± 8.97	F&M	25	Chronic hepatitis B virus	41.67 ± 10.99	F&M	27	The different metabolites between hepatocellular carcinoma and chronic hepatitis B virus (CHB) in positive mode	nan	LC-MS	Plasma	case vs.control group	33490775
METAC_394	91	liver cancer	hepatocellular carcinoma	3571	hepatocellular carcinoma	60.6 ± 8.97	F&M	25	Chronic hepatitis B virus	41.67 ± 10.99	F&M	27	The different metabolites between hepatocellular carcinoma and chronic hepatitis B virus (CHB) in negative mode	nan	LC-MS	Plasma	case vs.control group	33490775
METAC_399	185	kidney cancer	renal cell carcinoma	263	Renal cell carcinoma (RCC) patients	64.4 (32-87)	F&M	50	Control group			50	Differential metabolites between Controls and Renal cell carcinoma (RCC) patients.	Among the most significantly changed metabolites we found lactate, N-acetylated compounds (NAC2 δ = 2.05 ppm), threonine, and histidine, followed by ketones and choline	¹H NMR	Serum	case vs.control group	34822425
METAC_401	208	pancreatic cancer	Pancreatic ductal adenocarcinoma	1793	PANC-1 cells treated with TGFβ				PANC-1 cells treated with DMSO				significantly dysregulated metabolites of PANC-1 cells treated with TGFβ (compared to DMSO)	nan	UPLC-ESI-QTOF-MS/MS	PANC-1 cells	case vs.control group	34944824
METAC_402	208	pancreatic cancer	Pancreatic ductal adenocarcinoma	1793	PANC-1 cells treated with TGFβ				PANC-1 cells treated with DMSO				significantly dysregulated amino acids of PANC-1 cells treated with TGFβ (compared to DMSO)	nan	UPLC-TQS	PANC-1 cells	case vs.control group	34944824
METAC_403	208	pancreatic cancer	Pancreatic ductal adenocarcinoma	1793	PANC-1 cells treated with TGFβ				PANC-1 cells treated with DMSO				significantly dysregulated metabolites of PANC-1 cells treated with TGFβ (compared to DMSO)	nan	LC-MS/MS	PANC-1 cells	case vs.control group	34944824
METAC_404	158	pancreatic cancer	nan	1793	pancreatic cancer patients	64.74 ± 7.93	F&M	26	type 2 diabetic patients	56.93 ± 9.93	F&M	27	Differential Metabolites between pancreatic cancer patients and type 2 diabetic patients	Results from the nonparametric test show significant differences in the content of 4 metabolite ions between the PC group and the DM group	UPLC-MS	Plasma	case vs.control group	34868309
METAC_405	158	pancreatic cancer	nan	1793	pancreatic cancer patients	64.74 ± 7.93	F&M	26	healthy volunteers	60.22 ± 6.65	F&M	23	Differential Metabolites between pancreatic cancer patients and healthy volunteers	Compared to the normal group, the levels of lysoPC (20 : 4), deoxyadenosine, asparaginyl-histidine, and vaccenyl carnitine in the PC group and DM group were significantly increased, while the levels of phytal, 2 (R)-hydroxydocosanoic acid, behenic acid, catelaidic acid, 2-hydroxyphytanic acid, phytosphingosine, cerebronic acid, docosanamide, and eicosenoic acid in the PC group and DM group were significantly reduced	UPLC-MS	Plasma	case vs.control group	34868309
METAC_406	158	pancreatic cancer	nan	1793	pancreatic cancer patients	62.7 ± 12.1	F&M	58	normal pancreas	62.7 ± 12.1	F&M	58	Differential MRS Metabolites between pancreatic pancreatic cancer and normal pancreas	pancreatic cancer had significantly decreased Glx (p= 0.009), NAA (p= 0.001), Lipid_2 (p= 0.042), and Lipid_1 (p< 0.001) levels. Additionally, the Cr_1 level was decreased in pancreatic cancer (p= 0.051)	single-voxel MRS	Pancreatic tissue	case vs.control group	34573881
METAC_407	159	pancreatic cancer	nan	1793	Well- and Moderately		F&M	11	Poorly Differentiated		F&M	9	Differences in MRS metabolites relative to pancreatic Cancer pathological grades	No differences were found in the MRS metabolite levels between well-moderately and poorly differentiated tumors	single-voxel MRS	Pancreatic tissue	case vs.control group	34573881
METAC_408	211	pancreatic cancer	nan	1793	T4 Pancreatic Cancer		F&M	32	T1-3 Pancreatic Cancer		F&M	26	Differences in MRS metabolites relative to Pancreatic Cancer T stage	lower lipid_1 level was found in T4 patients	single-voxel MRS	Pancreatic tissue	case vs.control group	34573881
METAC_409	211	pancreatic cancer	nan	1793	N1 Pancreatic Cancer		F&M	44	N0 Pancreatic Cancer		F&M	14	Differences in MRS metabolites relative to Pancreatic Cancer N stage	lower Cr_2 level was found in N1 patients	single-voxel MRS	Pancreatic tissue	case vs.control group	34573881
METAC_410	211	pancreatic cancer	nan	1793	M1 Pancreatic Cancer		F&M	33	M0 Pancreatic Cancer		F&M	25	Differences in MRS metabolites relative to Pancreatic Cancer M stage	metabolic signatures of RCC progression are present, however, the degree with which these changes occur could be dependent on gender.	single-voxel MRS	Pancreatic tissue	case vs.control group	34573881
METAC_414	15	bladder cancer	basal and luminal MIBC subtypes	11054	basal subtype				luminal subtype				lipid differences in Muscle Invasive Bladder Cancer (MIBC) tissues in patients of basal and luminal MIBC subtypes	free fatty acids (FFAs) and sulfatides (SLs), which are closely associated with immune and stromal cell types, can contribute to the diagnosis of basal and luminal subtypes of MIBC	UPLC-Triple TOF-MS	Bladder tissue	case vs.control group	34484294
METAC_415	15	bladder cancer	basal and luminal MIBC subtypes	11054	basal subtype				luminal subtype				metabolite differences in Muscle Invasive Bladder Cancer (MIBC) tissues in patients of basal and luminal MIBC subtypes	the GCP/imidazoles and nucleosides/imidazoles ratios have potential clinical applications as biomarkers, while GCP, nucleosides, and imidazoles may be the targets of MIBC precision therapy.	UPLC-QTRAP-MS	Bladder tissue	case vs.control group	34484294
METAC_426	41	liver cancer	child Pugh A hepatocellular carcinoma; child Pugh B hepatocellular carcinoma	3571	child Pugh B hepatocellular carcinoma		F&M	9	child Pugh A hepatocellular carcinoma		F&M	38	Annotated plasma metabolites that were differentially expressed (all three p-values ≤0⋅05) at higher or lower levels in Child Pugh B (CP B) vs. Child Pugh A (CP A) HCC patients.	69 metabolites of interest were differentially expressed (all three p-values ≤0⋅05) in HCC patients and strongly separated the CP B patients from the CP A patients	GC-MS;LC-MS	Plasma	case vs.control group	32891936
METAC_427	41	liver cancer	child Pugh A hepatocellular carcinoma; child Pugh B hepatocellular carcinoma	3571	child Pugh B hepatocellular carcinoma		F&M	9	child Pugh A hepatocellular carcinoma		F&M	38	Annotated plasma metabolites that were differentially expressed (all three p-values ≤0⋅05) at higher or lower levels in Child Pugh B (CP B) vs. Child Pugh A (CP A) HCC patients after one to two fractions of liver SBRT.	After one to two fractions of SBRT, 62 metabolites of interest were differentially expressed (all three p-values ≤0.05) and strongly separated the CP B patients from the CP A patients	GC-MS;LC-MS	Plasma	case vs.control group	32891936
METAC_428	91	liver cancer	hepatocellular carcinoma	3571	hepatocellular carcinoma	66.7 (25‐95)	F&M	112	healthy controls	58.8 (36‐80)	F&M	54	Differential metabolites between hepatocellular carcinoma patients and healthy controls.	Interestingly, 18 of the 22 identified metabolites were significantly increased in patients with HCC compared to healthy control subjects (FDR P < 0.1). Of these 18 metabolites, (E)‐2‐nonene (FDR P = 3.03 × 10−5), ethane (FDR P = 1.08 × 10−4), and benzene (FDR P = 1.08 × 10−4) were the most significantly increased	SIFT‐MS	Breath sample	case vs.control group	32626836
METAC_429	91	liver cancer	hepatocellular carcinoma	3571	hepatocellular carcinoma	66.7 (25‐95)	F&M	112	liver cirrhosis patients	59.6 (37‐79)	F&M	30	Differential metabolites between hepatocellular carcinoma patients and liver cirrhosis patients.	Acetone (FDR P = 6.7 × 10−4), acetaldehyde (FDR P = 6.7 × 10−4), and dimethyl sulfide (FDR P = 6.7 × 10−4) were the three most significantly enriched in patients with cirrhosis. Ethanol (FDR P = 0.089) was the only metabolite that was significantly enriched in patients with HCC compared to those with cirrhosis.	SIFT‐MS	Breath sample	case vs.control group	32626836
METAC_430	91	liver cancer	hepatocellular carcinoma	3571	hepatocellular carcinoma	66.7 (25‐95)	F&M	112	colorectal cancer liver metastases patients	55.9 (26‐82)	F&M	51	Differential metabolites between hepatocellular carcinoma patients and colorectal cancer liver metastases patients.	The three most significant metabolite were displayed.	SIFT‐MS	Breath sample	case vs.control group	32626836
METAC_431	20	bladder cancer	nan	11054	bladder cancer	65 ± 12.0	F&M	24	healthy control	64 ± 10.4	F&M	24	Differential metabolites between bladder cancer patients and healthy controls	This profiling has not only identified a group of metabolites that may contribute to bladder cancer development, but also compounds that show potential in the prevention of cancer.	SPME-LC-MS	Urine	case vs.control group	33920347
METAC_432	158	pancreatic cancer	Pancreatic ductal adenocarcinoma	1793	pancreatic cancer patients before anesthesia induction	71 (50-81)	F&M	10	pancreatic cancer patients during the anesthetic surgical andobservation period	71 (50-81)	F&M	10	significantly changing metabolites of patients diagnosed with pancreatic malignancies during the perioperative period	nan	FIA-MS/MS;LC-MS/MS	Plasma	case vs.control group	34012512
METAC_433	158	pancreatic cancer	Pancreatic ductal adenocarcinoma	1793	pancreatic cancer patients before anesthesia induction	71 (50-81)	F&M	10	pancreatic cancer patients during the anesthetic period	71 (50-81)	F&M	10	significantly changing metabolites of patients diagnosed with pancreatic malignancies which mainly changed during the anesthetic period	nan	FIA-MS/MS;LC-MS/MS	Plasma	case vs.control group	34012512
METAC_434	158	pancreatic cancer	Pancreatic ductal adenocarcinoma	1793	pancreatic cancer patients before anesthesia induction	71 (50-81)	F&M	10	pancreatic cancer patients after the anesthetic period	71 (50-81)	F&M	10	significantly changing metabolites of patients diagnosed with pancreatic malignancies which mainly changed after the anesthetic period	nan	FIA-MS/MS;LC-MS/MS	Plasma	case vs.control group	34012512
METAC_435	158	pancreatic cancer	nan	1793	pancreatic cancer patients			36	healthy cohort			70	Differential Metabolites between pancreatic cancer patients and healthy controls	Glycolysis-related metabolite concentrations showed upregulation of glucose and lactic acid and downregulation of pyruvic acid and citric acid in cancer patients	NMR	Plasma	case vs.control group	33708985
METAC_436	110	liver cancer	nan	3571	liver cancer patients	46 ± 15	F&M	9	healthy controls	43 ± 12	F&M	9	Differential metabolites between liver cancer patients and healthy controls before the operative.	Thirty-three differential endogenous metabolites were screened	UPLC-MS/MS	Plasma	case vs.control group	32572018
METAC_437	111	liver cancer	nan	3571	1-day postoperative patients	46 ± 15	F&M	9	preoperative patients	46 ± 15	F&M	9	Differential metabolites between 1-day postoperative patients and preoperative patients.	The average metabolite intensities of taurocholic acid and taurochenodesoxycholic acid on the first day after liver transplantation were lower than those observed pre-transplantation.The average metabolite intensities of glycocholic acid and chenodeoxycholic acid glycine conjugate showed an increasing trend	UPLC-MS/MS	Plasma	case vs.control group	32572018
METAC_438	111	liver cancer	nan	3571	7-day postoperative patients	46 ± 15	F&M	9	preoperative patients	46 ± 15	F&M	9	Differential metabolites between 7-day postoperative patients and preoperative patients.	The average metabolite intensities of taurocholic acid and taurochenodesoxycholic acid on the first day after liver transplantation were lower than those observed pre-transplantation. The average metabolite intensities on day 3 after liver transplantation showed a sudden increase and then decreased after 7 postoperative days. The average metabolite intensities of glycocholic acid and chenodeoxycholic acid glycine conjugate showed an increasing trend	UPLC-MS/MS	Serum	case vs.control group	32572018
METAC_439	111	liver cancer	nan	3571	3-day postoperative patients	46 ± 15	F&M	9	1-day postoperative patients	46 ± 15	F&M	9	Differential metabolites between 3-day postoperative patients and 1-day postoperative patients.	The average metabolite intensities of taurocholic acid and taurochenodesoxycholic acid on the first day after liver transplantation were lower than those observed pre-transplantation. The average metabolite intensities on day 3 after liver transplantation showed a sudden increase and then decreased after 7 postoperative days. The average metabolite intensities of glycocholic acid and chenodeoxycholic acid glycine conjugate showed an increasing trend	UPLC-MS/MS	Serum	case vs.control group	32572018
METAC_440	111	liver cancer	nan	3571	7-day postoperative patients	46 ± 15	F&M	9	3-day postoperative patients	46 ± 15	F&M	9	Differential metabolites between 7-day postoperative patients and 3-day postoperative patients.	The average metabolite intensities of taurocholic acid and taurochenodesoxycholic acid on the first day after liver transplantation were lower than those observed pre-transplantation. The average metabolite intensities on day 3 after liver transplantation showed a sudden increase and then decreased after 7 postoperative days. The average metabolite intensities of glycocholic acid and chenodeoxycholic acid glycine conjugate showed an increasing trend	UPLC-MS/MS	Serum	case vs.control group	32572018
METAC_442	10	liver cancer	hepatocellular carcinoma	3571	hepatocellular carcinoma with abnormal AFP levels		F&M	21	hepatocellular carcinoma with normal AFP levels		F&M	14	Nuclear magnetic resonance (NMR) observed serum metabolites with intensity differences associated with different AFP for hepatocellular carcinoma in Investigation cohort.	Serum metabolites with intensity differences associated with different AFP for hepatocellular carcinoma	NMR	Plasma	case vs.control group	32493393
METAC_443	10	liver cancer	hepatocellular carcinoma	3571	hepatocellular carcinoma with abnormal AFP levels		F&M	10	hepatocellular carcinoma with normal AFP levels		F&M	12	Nuclear magnetic resonance (NMR) observed serum metabolites with intensity differences associated with different AFP for hepatocellular carcinoma in validation cohort.	Serum metabolites with intensity differences associated with different AFP for hepatocellular carcinoma	NMR	Plasma	case vs.control group	32493393
METAC_444	91	liver cancer	hepatocellular carcinoma	3571	hepatocellular carcinoma patients	60.09 ± 5.06	F&M	22	liver cirrhosis patients	58.59 ± 7.83	F&M	22	Differential metabolites between hepatocellular carcinoma patients and liver cirrhosis patients.	34 known metabolites were detected, of which five metabolites were identified to have the strongest discriminatory power for separation between HCC and cirrhosis groups	GC-MS	Plasma	case vs.control group	31893244
METAC_445	91	liver cancer	hepatocellular carcinoma	3571	hepatocellular carcinoma patients	52.2 (30-69)	F&M	122	healthy controls		F&M	52	Differential metabolites between hepatocellular carcinoma patients and healthy controls.	All five metabolites were significantly altered between the HC and HCC groups	UPLC-MS	Plasma	case vs.control group	31331801
METAC_446	91	liver cancer	hepatocellular carcinoma	3571	hepatocellular carcinoma patients	52.2 (30-69)	F&M	122	liver cirrhosis patients		F&M	25	Differential metabolites between hepatocellular carcinoma patients and liver cirrhosis patients.	PC(o-16:0/20:4), nutriacholic acid, and 2-oxo-4-methylthiobutanoic acid were decreased, while PC(18:2/OH-16:0) was elevated in the HCC group compared with the LC group	UPLC-MS	Plasma	case vs.control group	31331801
METAC_447	91	liver cancer	hepatocellular carcinoma	3571	hepatocellular carcinoma (HCC) liver tissues		F&M	40	adjacent liver tissues		F&M	40	Significant metabolites identified by GC-MS and LC-MS in hepatocellular carcinoma (HCC) vs. adjacent liver tissues.	hypoxanthine, adenosine monophosphate, PC (34:2), and glycerylphosphorylethanolamine showed statistically significant alteration only in the whole population	GC-MS; LC-MS	Liver tissue	case vs.control group	31188000
METAC_448	91	liver cancer	hepatocellular carcinoma	3571	hepatocellular carcinoma (HCC) liver tissues	56.8 (11.4)	M	10	adjacent liver tissues	56.8 (11.4)	M	10	Significant metabolites identified by GC-MS and LC-MS in hepatocellular carcinoma (HCC) vs. adjacent liver tissues (African-American).	Among the three metabolites found significant for AS, only one overlaps with those selected for AA, the other two are unique to AS	GC-MS; LC-MS	Liver tissue	case vs.control group	31188000
METAC_449	91	liver cancer	hepatocellular carcinoma	3571	hepatocellular carcinoma (HCC) liver tissues	59.4 (12.8)	F&M	14	adjacent liver tissues	59.4 (12.8)	F&M	14	Significant metabolites identified by GC-MS and LC-MS in hepatocellular carcinoma (HCC) vs. adjacent liver tissues (Asian-American).	among the 18 metabolites selected in this study, the majority (thirteen out of 18) showed statistically significant changes (FDR < 10%) in AA	GC-MS; LC-MS	Liver tissue	case vs.control group	31188000
METAC_450	91	liver cancer	hepatocellular carcinoma	3571	hepatocellular carcinoma (HCC) liver tissues	65.6 (11.9)	F&M	16	adjacent liver tissues	65.6 (11.9)	F&M	16	Significant metabolites identified by GC-MS and LC-MS in hepatocellular carcinoma (HCC) vs. adjacent liver tissues (European-American).	All seven metabolites that were found statistically significant in EA are a subset of the fourteen significant metabolites selected for AA	GC-MS; LC-MS	Liver tissue	case vs.control group	31188000
METAC_451	166	brain cancer	nan	1319	PCNSL(primary central nervous system lymphoma)	53.6 (21-76)	F&M	59	NT (nontumorous brain lesions)	49 (17-86)	F&M	36	Identifed metabolites from the comparison of PCNSL (primary central nervous system lymphoma) vs. NT (nontumorous brain lesions)	nan	LC-Q/TOF-MS	Cerebrospinal fuid	case vs.control group	31822990
METAC_452	131	brain cancer	nan	1319	MBT(metastatic brain tumors)	57 (27-75)	F&M	34	NT (nontumorous brain lesions)	49 (17-86)	F&M	36	Identifed metabolites from the comparison of MBT (metastatic brain tumors) vs. NT (nontumorous brain lesions)	nan	LC-Q/TOF-MS	Cerebrospinal fuid	case vs.control group	31822990
METAC_453	166	brain cancer	nan	1319	PCNSL(primary central nervous system lymphoma)	53.6 (21-76)	F&M	59	SCNSL (second?ary central nervous system involvement of systemic lymphoma)	57.5 (20-76)	F&M	11	Identifed metabolites from the comparison of PCNSL (primary central nervous system lymphoma) vs. SCNSL (second?ary central nervous system involvement of systemic lymphoma)	nan	LC-Q/TOF-MS	Cerebrospinal fuid	case vs.control group	31822990
METAC_454	166	brain cancer	nan	1319	PCNSL(primary central nervous system lymphoma)	53.6 (21-76)	F&M	59	MBT (metastatic brain tumors)	57 (27-75)	F&M	34	Identifed metabolites from the comparison of PCNSL(primary central nervous system lymphoma) vs. MBT (metastatic brain tumors)	nan	LC-Q/TOF-MS	Cerebrospinal fuid	case vs.control group	31822990
METAC_455	195	brain cancer	nan	1319	SCNSL(secondary central nervous system involvement of systemic lymphoma)	57.5 (20-76)	F&M	11	MBT (metastatic brain tumors)	57 (27-75)	F&M	34	Identifed metabolites from the comparison of SCNSL(secondary central nervous system involvement of systemic lymphoma) vs. MBT (metastatic brain tumors)	nan	LC-Q/TOF-MS	Cerebrospinal fuid	case vs.control group	31822990
METAC_456	131	brain cancer	nan	1319	MBT(metastatic brain tumors)	57 (27-75)	F&M	34	NMBT (non-metastatic brain tumors)	53.5 (37-73)	F&M	23	Identifed metabolites from the comparison of MBT(metastatic brain tumors) vs. NMBT (non-metastatic brain tumors)	nan	LC-Q/TOF-MS	Cerebrospinal fuid	case vs.control group	31822990
METAC_457	61	pancreatic cancer	Pancreatic ductal adenocarcinoma	1793	pancreatic neuroendocrine tumor group	64 (58-68)	F&M	10	intraductal papillary mucinous neoplasm group	66 (54-72)	F&M	10	Differential metabolites between pancreatic neuroendocrine tumor (PNET) and intraductal papillary mucinous neoplasm (IPMN)	The number of metabolites that differed between group decreased with progressive disease	UHPLC-MS	Plasma	case vs.control group	31514959
METAC_458	61	pancreatic cancer	Pancreatic ductal adenocarcinoma	1793	intraductal papillary mucinous neoplasm group	66 (54-72)	F&M	10	localized Pancreatic ductal adenocarcinoma	63 (58-74)	F&M	10	Differential metabolites between intraductal papillary mucinous neoplasm (IPMN) and localized Pancreatic ductal adenocarcinoma	The number of metabolites that differed between group decreased with progressive disease	UHPLC-MS	Plasma	case vs.control group	31514959
METAC_459	61	pancreatic cancer	Pancreatic ductal adenocarcinoma	1793	localized Pancreatic ductal adenocarcinoma	63 (58-74)	F&M	10	locally advanced Pancreatic ductal adenocarcinoma	70 (67-73)	F&M	10	Differential metabolites between localized Pancreatic ductal adenocarcinoma and locally advanced Pancreatic ductal adenocarcinoma	The number of metabolites that differed between group decreased with progressive disease	UHPLC-MS	Plasma	case vs.control group	31514959
METAC_460	61	pancreatic cancer	Pancreatic ductal adenocarcinoma	1793	locally advanced Pancreatic ductal adenocarcinoma	70 (67-73)	F&M	10	metastatic Pancreatic ductal adenocarcinoma	64 (61-71)	F&M	10	Differential metabolites between locally advanced Pancreatic ductal adenocarcinoma and intraductal metastatic Pancreatic ductal adenocarcinoma	The number of metabolites that differed between group decreased with progressive disease	UHPLC-MS	Plasma	case vs.control group	31514959
METAC_461	158	pancreatic cancer	intraductal papillary mucinous neoplasm	1793	intraductal papillary mucinous neoplasm	69 (46-83)	F&M	26	serous cystic neoplasm	48 (34-58)	F	5	Differential metabolites between intraductal papillary mucinous neoplasm (IPMN) and serous cystic neoplasm (SCN)	nan	UPLC-MS/MS	Pancreatic cyst fluid	case vs.control group	31308419
METAC_462	158	pancreatic cancer	intraductal papillary mucinous neoplasm	1793	intraductal papillary mucinous neoplasm	69 (56-83)	F&M	16	serous cystic neoplasm	53 (34-68)	F	5	Differential metabolites between intraductal papillary mucinous neoplasm (IPMN) and serous cystic neoplasm (SCN)	nan	UPLC-MS/MS	Plasma	case vs.control group	31308419
METAC_463	158	pancreatic cancer	intraductal papillary mucinous neoplasm	1793	intraductal papillary mucinous neoplasm(IPMN) with low-grade dysplasia	66 (56-81)	F&M	8	serous cystic neoplasm	48 (34-58)	F	5	Differential metabolites between intraductal papillary mucinous neoplasm (IPMN) with low-grade dysplasia and serous cystic neoplasm (SCN)	nan	UPLC-MS/MS	Pancreatic cyst fluid	case vs.control group	31308419
METAC_464	158	pancreatic cancer	intraductal papillary mucinous neoplasm	1793	intraductal papillary mucinous neoplasm(IPMN) with low-grade dysplasia	65 (56-76)	F&M	5	serous cystic neoplasm	53 (34-68)	F	5	Differential metabolites between intraductal papillary mucinous neoplasm (IPMN) with low-grade dysplasia and serous cystic neoplasm (SCN)	nan	UPLC-MS/MS	Plasma	case vs.control group	31308419
METAC_465	158	pancreatic cancer	intraductal papillary mucinous neoplasm	1793	intraductal papillary mucinous neoplasm(IPMN) with high-grade dysplasia	72 (66-75)	F&M	7	serous cystic neoplasm	48 (34-58)	F	5	Differential metabolites between intraductal papillary mucinous neoplasm (IPMN) with high-grade dysplasia and serous cystic neoplasm (SCN)	nan	UPLC-MS/MS	Pancreatic cyst fluid	case vs.control group	31308419
METAC_466	158	pancreatic cancer	intraductal papillary mucinous neoplasm	1793	intraductal papillary mucinous neoplasm(IPMN) with high-grade dysplasia	72.5 (66-75)	F&M	6	serous cystic neoplasm	53 (34-68)	F	5	Differential metabolites between intraductal papillary mucinous neoplasm (IPMN) with high-grade dysplasia and serous cystic neoplasm (SCN)	nan	UPLC-MS/MS	Plasma	case vs.control group	31308419
METAC_467	158	pancreatic cancer	intraductal papillary mucinous neoplasm	1793	invasive intraductal papillary mucinous neoplasm(cancer)	69 (46-83)	F&M	11	serous cystic neoplasm	48 (34-58)	F	5	Differential metabolites between invasive intraductal papillary mucinous neoplasm and serous cystic neoplasm (SCN)	nan	UPLC-MS/MS	Pancreatic cyst fluid	case vs.control group	31308419
METAC_468	158	pancreatic cancer	intraductal papillary mucinous neoplasm	1793	invasive intraductal papillary mucinous neoplasm(cancer)	69 (65-83)	F&M	5	serous cystic neoplasm	53 (34-68)	F	5	Differential metabolites between invasive intraductal papillary mucinous neoplasm and serous cystic neoplasm (SCN)	nan	UPLC-MS/MS	Plasma	case vs.control group	31308419
METAC_469	158	pancreatic cancer	intraductal papillary mucinous neoplasm	1793	invasive intraductal papillary mucinous neoplasm(cancer) and intraductal papillary mucinous neoplasm with high-grade dysplasia	70 (46-83)	F&M	18	serous cystic neoplasm	48 (34-58)	F	5	Differential metabolites between (invasive intraductal papillary mucinous neoplasm or intraductal papillary mucinous neoplasm with high grade dysplasia)  and serous cystic neoplasm (SCN)	nan	UPLC-MS/MS	Pancreatic cyst fluid	case vs.control group	31308419
METAC_470	158	pancreatic cancer	intraductal papillary mucinous neoplasm	1793	invasive intraductal papillary mucinous neoplasm(cancer) and intraductal papillary mucinous neoplasm with high-grade dysplasia	71 (65-83)	F&M	11	serous cystic neoplasm	53 (34-68)	F	5	Differential metabolites between (invasive intraductal papillary mucinous neoplasm or intraductal papillary mucinous neoplasm with high grade dysplasia)  and serous cystic neoplasm (SCN)	nan	UPLC-MS/MS	Plasma	case vs.control group	31308419
METAC_471	168	pancreatic cancer	intraductal papillary mucinous neoplasm	1793	intraductal papillary mucinous neoplasm(IPMN) with high-grade dysplasia	72 (66-75)	F&M	7	intraductal papillary mucinous neoplasm (IPMN) with low-grade dysplasia	66 (56-81)	F&M	8	Differential metabolites between intraductal papillary mucinous neoplasm(IPMN) with high-grade dysplasia and IPMN with low-grade dysplasia	nan	UPLC-MS/MS	Pancreatic cyst fluid	case vs.control group	31308419
METAC_472	168	pancreatic cancer	intraductal papillary mucinous neoplasm	1793	intraductal papillary mucinous neoplasm(IPMN) with high-grade dysplasia	72.5 (66-75)	F&M	6	intraductal papillary mucinous neoplasm (IPMN) with low-grade dysplasia	65 (56-76)	F&M	5	Differential metabolites between intraductal papillary mucinous neoplasm(IPMN) with high-grade dysplasia and IPMN with low-grade dysplasia	nan	UPLC-MS/MS	Plasma	case vs.control group	31308419
METAC_473	168	pancreatic cancer	intraductal papillary mucinous neoplasm	1793	invasive intraductal papillary mucinous neoplasm(cancer)	69 (46-83)	F&M	11	intraductal papillary mucinous neoplasm (IPMN) with low-grade dysplasia	66 (56-81)	F&M	8	Differential metabolites between invasive intraductal papillary mucinous neoplasm and  intraductal papillary mucinous neoplasm with low-grade dysplasia	nan	UPLC-MS/MS	Pancreatic cyst fluid	case vs.control group	31308419
METAC_474	168	pancreatic cancer	intraductal papillary mucinous neoplasm	1793	invasive intraductal papillary mucinous neoplasm(cancer) and intraductal papillary mucinous neoplasm with high-grade dysplasia	70 (46-83)	F&M	18	intraductal papillary mucinous neoplasm (IPMN) with low-grade dysplasia	66 (56-81)	F&M	8	Differential metabolites between (invasive intraductal papillary mucinous neoplasm or intraductal papillary mucinous neoplasm with high grade dysplasia) and  intraductal papillary mucinous neoplasm with low-grade dysplasia	nan	UPLC-MS/MS	Pancreatic cyst fluid	case vs.control group	31308419
METAC_475	168	pancreatic cancer	intraductal papillary mucinous neoplasm	1793	invasive intraductal papillary mucinous neoplasm(cancer)	69 (65-83)	F&M	5	intraductal papillary mucinous neoplasm (IPMN) with high-grade dysplasia	72.5 (66-75)	F&M	6	Differential metabolites between invasive intraductal papillary mucinous neoplasm and  intraductal papillary mucinous neoplasm with high-grade dysplasia	nan	UPLC-MS/MS	Plasma	case vs.control group	31308419
METAC_476	91	liver cancer	hepatocellular carcinoma	3571	hepatocellular carcinoma patients 	60	F&M	63	liver cirrhosis patients	58.6	F&M	65	Differential metabolites between hepatocellular carcinoma patients and liver cirrhosis patients.	selected eleven metabolites whose expression levels jointly differentiate HCC cases from cirrhotic controls.	GC-MS	Plasma	case vs.control group	27913395
METAC_477	110	liver cancer	nan	3571	liver cancer patients			50	Heathy Volunteers			50	Amounts of polyamine metabolome in plasma from liver cancer patients.	nan	UHPLC-MS/MS	Plasma	case vs.control group	27517900
METAC_478	110	liver cancer	nan	3571	liver cancer patients			50	Heathy Volunteers			50	Amounts of polyamine metabolome in urine from liver cancer patients.	nan	UHPLC-MS/MS	Urine	case vs.control group	27517900
METAC_479	91	liver cancer	hepatocellular carcinoma	3571	hepatocellular carcinoma patients		F&M	30	liver colorectal patients		F&M	39	Differential metabolites between hepatocellular carcinoma patients and liver colorectal patients (African-Americans and European-Americans).	the majority of the metabolites selected in this study showed better AUC in one or all three groups (AA and EA, AA, EA) than AFP.	GC-SIM-MS	Plasma	case vs.control group	29538406
METAC_480	91	liver cancer	hepatocellular carcinoma	3571	hepatocellular carcinoma patients	60.6±4.4	F&M	11	liver colorectal patients	59.8±5.2	F&M	8	Differential metabolites between hepatocellular carcinoma patients and liver colorectal patients (African-Americans).	The AUC for valine and alpha tocopherol are the highest in AA only group whereas phenylalanine and glycine in EA	GC-SIM-MS	Plasma	case vs.control group	29538406
METAC_481	91	liver cancer	hepatocellular carcinoma	3571	hepatocellular carcinoma patients	57.7±6.1	F&M	19	liver colorectal patients	57.8±6.7	F&M	31	Differential metabolites between hepatocellular carcinoma patients and liver colorectal patients (European-Americans).	The AUC for valine and alpha tocopherol are the highest in AA only group whereas phenylalanine and glycine in EA	GC-SIM-MS	Plasma	case vs.control group	29538406
METAC_483	91	liver cancer	hepatocellular carcinoma	3571	hepatocellular carcinoma patients	49.0 ± 9.8	F&M	28	liver colorectal patients	48.1 ± 14.5	F&M	26	Differential metabolites between hepatocellular carcinoma patients and liver cirrhosis patients.	nan	¹H NMR	Serum	case vs.control group	24382646
METAC_484	91	liver cancer	hepatocellular carcinoma	3571	hepatocellular carcinoma patients	49.0 ± 9.8	F&M	28	healthy volunteers	40.5 ± 4.1	F&M	9	Differential metabolites between hepatocellular carcinoma patients and healthy volunteers.	nan	¹H NMR	Serum	case vs.control group	24382646
METAC_485	24	brain cancer	glioblastoma,oligodendroglioma(,glial tumour,astroglioma,non-glial meningioma	1319	Brain tumours		F&M	60	controls	56 (39-78)	F&M	28	Different palsma metabolite between Brain tumours and controls	In blood plasma of primary brain tumour patients, we found significantly increased levels of glycolytic metabolites glucose and pyruvate, and significantly decreased level of glutamine and also metabolites participating in tricarboxylic acid (TCA) cycle, citrate and succinate, when compared with controls.	NMR	Plasma	case vs.control group	31419008
METAC_486	83	brain cancer	glioblastoma	1319	glioblastoma(GBM)		F&M	28	controls	56 (39-78)	F&M	28	Different palsma metabolite between glioblastoma (GBM) and controls	plasma metabolites levels: tyrosine, phenylalanine, glucose, creatine and creatinine correlated significantly with tumour grade.	NMR	Plasma	case vs.control group	31419008
METAC_487	151	brain cancer	oligodendroglioma	1319	oligodendroglioma(OLGD)		F&M	10	controls	56 (39-78)	F&M	28	Different palsma metabolite between oligodendroglioma (OLGD) and controls	plasma metabolites levels: tyrosine, phenylalanine, glucose, creatine and creatinine correlated significantly with tumour grade.	NMR	Plasma	case vs.control group	31419008
METAC_488	82	brain cancer	glial tumour	1319	glial tumour(GT)		F&M	6	controls	56 (39-78)	F&M	28	Different palsma metabolite between glial tumour (GT) and controls	plasma metabolites levels: tyrosine, phenylalanine, glucose, creatine and creatinine correlated significantly with tumour grade.	NMR	Plasma	case vs.control group	31419008
METAC_489	14	brain cancer	astroglioma	1319	astroglioma(ATSR)		F&M	5	controls	56 (39-78)	F&M	28	Different palsma metabolite between astroglioma (ATSR) and controls	plasma metabolites levels: tyrosine, phenylalanine, glucose, creatine and creatinine correlated significantly with tumour grade.	NMR	Plasma	case vs.control group	31419008
METAC_490	138	brain cancer	non-glial meningioma	1319	non-glial meningioma(MNG)		F&M	11	controls	56 (39-78)	F&M	28	Different palsma metabolite between non-glial meningioma (MNG) and controls	plasma metabolites levels: tyrosine, phenylalanine, glucose, creatine and creatinine correlated significantly with tumour grade.	NMR	Plasma	case vs.control group	31419008
METAC_491	85	brain cancer	glioblastoma	1319	glioblastoma(GBM) IV stage		F&M	28	low grade(I,II,III)		F&M	31	Different palsma metabolite between glioblastoma (GBM) IV stage and low grade (I,II,III)	Only two plasma metabolites tyrosine and phenylalanine were increased exclusively in blood plasma of patients with glioblastoma.	NMR	Plasma	case vs.control group	31419008
METAC_492	91	liver cancer	hepatocellular carcinoma	3571	hepatocellular carcinoma adjacent tumor tissue	54.2 ± 9.2	F&M	10	hepatocellular carcinoma normal tissue	54.2 ± 9.2	F&M	10	Differential metabolites between adjacent tumor tissue and normal tissue.	14 of these were further identified as characteristic metabolites that showed significant differences in levels between the central tumor tissue group and distant tumor tissue group	UPLC-LTQ-Orbitrap-XL-MS	Liver tissue	case vs.control group	23801834
METAC_493	91	liver cancer	hepatocellular carcinoma	3571	hepatocellular carcinoma adjacent tumor tissue	54.2 ± 9.2	F&M	10	hepatocellular carcinoma normal tissue	54.2 ± 9.2	F&M	10	Differential metabolites between adjacent tumor tissue and tumor tissue.	14 of these were further identified as characteristic metabolites that showed significant differences in levels between the central tumor tissue group and distant tumor tissue group	UPLC-LTQ-Orbitrap-XL-MS	Liver tissue	case vs.control group	23801834
METAC_494	91	liver cancer	hepatocellular carcinoma	3571	hepatocellular carcinoma tumor tissue	54.2 ± 9.2	F&M	10	hepatocellular carcinoma normal tissue	54.2 ± 9.2	F&M	10	Differential metabolites between normal tissue and tumor tissue.	14 of these were further identified as characteristic metabolites that showed significant differences in levels between the central tumor tissue group and distant tumor tissue group	UPLC-LTQ-Orbitrap-XL-MS	Liver tissue	case vs.control group	23801834
METAC_495	91	liver cancer	hepatocellular carcinoma	3571	hepatocellular carcinoma patients			23	healthy controls			23	Differential metabolites between hepatocellular carcinoma (HCC) patients and healthy controls.	nan	UPLC-QTOF-MS	Stool	case vs.control group	21458633
METAC_496	91	liver cancer	hepatocellular carcinoma	3571	liver cancer group 			21	healthy controls			24	Differential metabolites between the liver cancer group and the healthy controls.	16 + 8 metabolites are summarized	LC-MS	Urine	case vs.control group	19720165
METAC_497	91	liver cancer	hepatocellular carcinoma	3571	hepatocellular carcinoma (HCC)	51 (21−70)	F&M	59	healthy controls	42.5 (31−56)	F&M	20	Differential metabolites between hepatocellular carcinoma (HCC) and healthy controls.	13 potential biomarkers suggested disturbances in organic acids, phospholipids, fatty acid, bile acids, and gut flora metabolism in HCC patients	UPLC-MS/MS	Serum	case vs.control group	22200553
METAC_498	91	liver cancer	hepatocellular carcinoma	3571	hepatocellular carcinoma (HCC)	51 (21−70)	F&M	59	liver cirrhosis (LC)	46.5 (30−59)	F&M	20	Differential metabolites between hepatocellular carcinoma (HCC) and liver cirrhosis (LC).	13 potential biomarkers suggested disturbances in organic acids, phospholipids, fatty acid, bile acids, and gut flora metabolism in HCC patients	UPLC-MS/MS	Serum	case vs.control group	22200553
METAC_501	91	liver cancer	hepatocellular carcinoma	3571	hepatocellular carcinoma (HCC) patients			39	healthy controls			63	Summary of the 1H nuclear magnetic resonance (NMR) detected statistically significant changes in relative levels of serum metabolites for hepatocellular carcinoma (HCC) patients compared to healthy humans	statistically significant changes in relative levels of serum metabolites for HCC patients compared to healthy humans.	¹H NMR	Serum	case vs.control group	19469021
METAC_502	91	liver cancer	hepatocellular carcinoma	3571	hepatocellular carcinoma (HCC) patients			60	cirrhosis patients			129	Differential metabolites between hepatocellular carcinoma (HCC) patients and cirrhosis patients.	Bile acid related and liver-specific metabolites down-regulated in HCC vs. cirrhosis; and Metabolites such as S-1-P and LysoPC 17:0 up-regulated in HCC vs. cirrhosis.	LC-MS	Serum	case vs.control group	22882828
METAC_503	91	liver cancer	hepatocellular carcinoma	3571	hepatocellular carcinoma (HCC) patients			13	cirrhosis patients			50	Differential metabolites between hepatocellular carcinoma (HCC) patients and cirrhosis patients.	Bile acid related and liver-specific metabolites down-regulated in HCC vs. cirrhosis; and Metabolites such as S-1-P and LysoPC 17:0 up-regulated in HCC vs. cirrhosis.	LC-MS	Serum	case vs.control group	22882828
METAC_504	91	liver cancer	hepatocellular carcinoma	3571	hepatocellular carcinoma (HCC) patients			5	cirrhosis patients			5	Differential metabolites between hepatocellular carcinoma (HCC) patients and cirrhosis patients.	Bile acid related and liver-specific metabolites down-regulated in HCC vs. cirrhosis; and Metabolites such as S-1-P and LysoPC 17:0 up-regulated in HCC vs. cirrhosis.	LC-MS	Serum	case vs.control group	22882828
METAC_505	87	brain cancer	glioma	1319	glioma patients( discovery cohorts)		F&M	42	controls		F&M	24	Significant metabolites in glioma patients( discovery cohorts)	Five metabolites, namely uracil, arginine, lactate, cystamine, and ornithine, significantly differed between high- and low-grade glioma patients in both the discovery and validation cohorts. When the discovery and validation cohorts were combined, we identified 29 significant metabolites with 18 remaining significant after adjusting for multiple comparisons.	LC-QQQ-MS	Plasma	case vs.control group	26967252
METAC_506	87	brain cancer	glioma	1319	glioma patients( validation cohorts)		F&M	47	controls		F&M	24	Significant metabolites in glioma patients( validation cohorts)	Five metabolites, namely uracil, arginine, lactate, cystamine, and ornithine, significantly differed between high- and low-grade glioma patients in both the discovery and validation cohorts. When the discovery and validation cohorts were combined, we identified 29 significant metabolites with 18 remaining significant after adjusting for multiple comparisons.	LC-QQQ-MS	Plasma	case vs.control group	26967252
METAC_507	87	brain cancer	glioma	1319	glioma patients(discovery and validation cohorts)		F&M	89	controls		F&M	24	Significant metabolites in glioma patients( discovery and validation cohorts)	Five metabolites, namely uracil, arginine, lactate, cystamine, and ornithine, significantly differed between high- and low-grade glioma patients in both the discovery and validation cohorts. When the discovery and validation cohorts were combined, we identified 29 significant metabolites with 18 remaining significant after adjusting for multiple comparisons.	LC-QQQ-MS	Plasma	case vs.control group	26967252
METAC_508	100	brain cancer	glioma	1319	IDH positive patients		F&M	24	IDH negative patients		F&M	12	Significant metabolites differentiating IDH mutation status	6 metabolites that significantly differed between IDH mutation positive and negative patients after multiple comparison adjusting.	LC-QQQ-MS	Plasma	case vs.control group	26967252
METAC_509	83	brain cancer	glioblastoma,oligodendroglioma	1319	glioblastoma			57	oligodendroglioma			20	Significant tissue metabolites in distinguishing glioblastoma and oligodendroglioma	nan	GC-TOF-MS	Brain tissue	case vs.control group	26389964
METAC_510	149	brain cancer	oligodendroglioma	1319	oligodendroglioma grade III				oligodendroglioma grade II				Significant tissue metabolites in  distinguishing oligodendroglioma grade III and grade II	nan	GC-TOF-MS	Brain tissue	case vs.control group	26389964
METAC_511	84	brain cancer	glioblastoma	1319	glioblastoma grade III				glioblastoma grade II				Significant tissue metabolites in  distinguishing glioblastoma grade III and grade III	nan	GC-TOF-MS	Brain tissue	case vs.control group	26389964
METAC_512	150	brain cancer	oligodendroglioma	1319	oligodendroglioma long survival				oligodendroglioma short survival				Significant tissue metabolites in  distinguishing oligodendroglioma long survival and short survival	nan	GC-TOF-MS	Brain tissue	case vs.control group	26389964
METAC_513	83	brain cancer	glioblastoma,oligodendroglioma	1319	glioblastoma			57	oligodendroglioma			20	Significant serum metabolites in distinguishing glioblastoma and oligodendroglioma	nan	GC-TOF-MS	Serum	case vs.control group	26389964
METAC_514	149	brain cancer	oligodendroglioma	1319	oligodendroglioma grade III				oligodendroglioma grade II				Significant serum metabolites in  distinguishing oligodendroglioma grade III and grade II	nan	GC-TOF-MS	Serum	case vs.control group	26389964
METAC_516	150	brain cancer	oligodendroglioma	1319	oligodendroglioma long survival				oligodendroglioma short survival				Significant serum metabolites in  distinguishing oligodendroglioma long survival and short survival	nan	GC-TOF-MS	Serum	case vs.control group	26389964
METAC_517	49	colorectal cancer	nan	9256	preoperative colorectal cancer (CRC) patients			83	postoperative colorectal cancer (CRC) patients			83	Differential metabolites between preoperative colorectal cancer (CRC) patients and postoperative colorectal cancer (CRC) patients.	nan	CE-TOF-MS	Stool	case vs.control group	35311577
METAC_518	49	colorectal cancer	nan	9256	preoperative colorectal cancer (CRC) patients			83	postoperative colorectal cancer (CRC) patients			83	Differential metabolites between preoperative colorectal cancer (CRC) patients and postoperative colorectal cancer (CRC) patients.	nan	CE-TOF-MS	Stool	case vs.control group	35311577
METAC_519	49	colorectal cancer	nan	9256	preoperative colorectal cancer (CRC) patients			83	postoperative colorectal cancer (CRC) patients			83	Differential metabolites between preoperative colorectal cancer (CRC) patients and postoperative colorectal cancer (CRC) patients.	nan	CE-TOF-MS	Stool	case vs.control group	35311577
METAC_520	49	colorectal cancer	nan	9256	right-preoperative colorectal cancer (CRC) patients			19	right-postoperative colorectal cancer (CRC) patients			19	Differential metabolites between right-preoperative colorectal cancer (CRC) patients and right-postoperative colorectal cancer (CRC) patients.	nan	CE-TOF-MS	Stool	case vs.control group	35311577
METAC_521	49	colorectal cancer	nan	9256	right-preoperative colorectal cancer (CRC) patients			19	right-postoperative colorectal cancer (CRC) patients			19	Differential metabolites between right-preoperative colorectal cancer (CRC) patients and right-postoperative colorectal cancer (CRC) patients.	nan	CE-TOF-MS	Stool	case vs.control group	35311577
METAC_522	49	colorectal cancer	nan	9256	right-preoperative colorectal cancer (CRC) patients			19	right-postoperative colorectal cancer (CRC) patients			19	Differential metabolites between right-preoperative colorectal cancer (CRC) patients and right-postoperative colorectal cancer (CRC) patients.	nan	CE-TOF-MS	Stool	case vs.control group	35311577
METAC_523	49	colorectal cancer	nan	9256	left-preoperative colorectal cancer (CRC) patients			64	left-postoperative colorectal cancer (CRC) patients			64	Differential metabolites between left-preoperative colorectal cancer (CRC) patients and left-postoperative colorectal cancer (CRC) patients.	nan	CE-TOF-MS	Stool	case vs.control group	35311577
METAC_524	49	colorectal cancer	nan	9256	left-preoperative colorectal cancer (CRC) patients			64	left-postoperative colorectal cancer (CRC) patients			64	Differential metabolites between left-preoperative colorectal cancer (CRC) patients and left-postoperative colorectal cancer (CRC) patients.	nan	CE-TOF-MS	Stool	case vs.control group	35311577
METAC_525	49	colorectal cancer	nan	9256	left-preoperative colorectal cancer (CRC) patients			64	left-postoperative colorectal cancer (CRC) patients			64	Differential metabolites between left-preoperative colorectal cancer (CRC) patients and left-postoperative colorectal cancer (CRC) patients.	nan	CE-TOF-MS	Stool	case vs.control group	35311577
METAC_526	49	colorectal cancer	nan	9256	left-preoperative colorectal cancer (CRC) patients			64	right-preoperative colorectal cancer (CRC) patients			19	Differential metabolites between left-preoperative colorectal cancer (CRC) patients and right-preoperative colorectal cancer (CRC) patients.	nan	CE-TOF-MS	Stool	case vs.control group	35311577
METAC_527	49	colorectal cancer	nan	9256	left-preoperative colorectal cancer (CRC) patients			64	right-preoperative colorectal cancer (CRC) patients			19	Differential metabolites between left-preoperative colorectal cancer (CRC) patients and right-preoperative colorectal cancer (CRC) patients.	nan	CE-TOF-MS	Stool	case vs.control group	35311577
METAC_528	49	colorectal cancer	nan	9256	left-preoperative colorectal cancer (CRC) patients			64	right-preoperative colorectal cancer (CRC) patients			19	Differential metabolites between left-preoperative colorectal cancer (CRC) patients and right-preoperative colorectal cancer (CRC) patients.	nan	CE-TOF-MS	Stool	case vs.control group	35311577
METAC_529	49	colorectal cancer	nan	9256	left-postoperative colorectal cancer (CRC) patients			64	right-postoperative colorectal cancer (CRC) patients			19	Differential metabolites between left-postoperative colorectal cancer (CRC) patients and right-postoperative colorectal cancer (CRC) patients.	nan	CE-TOF-MS	Stool	case vs.control group	35311577
METAC_530	49	colorectal cancer	nan	9256	left-postoperative colorectal cancer (CRC) patients			64	right-postoperative colorectal cancer (CRC) patients			19	Differential metabolites between left-postoperative colorectal cancer (CRC) patients and right-postoperative colorectal cancer (CRC) patients.	nan	CE-TOF-MS	Stool	case vs.control group	35311577
METAC_531	49	colorectal cancer	nan	9256	left-postoperative colorectal cancer (CRC) patients			64	right-postoperative colorectal cancer (CRC) patients			19	Differential metabolites between left-postoperative colorectal cancer (CRC) patients and right-postoperative colorectal cancer (CRC) patients.	nan	CE-TOF-MS	Stool	case vs.control group	35311577
METAC_532	49	colorectal cancer	nan	9256	preoperative without chemotherapy colorectal cancer (CRC) patients			61	postoperative without chemotherapy colorectal cancer (CRC) patients			61	Differential metabolites between preoperative without chemotherapy colorectal cancer (CRC) patients and postoperative without chemotherapy colorectal cancer (CRC) patients.	nan	CE-TOF-MS	Stool	case vs.control group	35311577
METAC_533	49	colorectal cancer	nan	9256	preoperative without chemotherapy colorectal cancer (CRC) patients			61	postoperative without chemotherapy colorectal cancer (CRC) patients			61	Differential metabolites between preoperative without chemotherapy colorectal cancer (CRC) patients and postoperative without chemotherapy colorectal cancer (CRC) patients.	nan	CE-TOF-MS	Stool	case vs.control group	35311577
METAC_534	49	colorectal cancer	nan	9256	preoperative without chemotherapy colorectal cancer (CRC) patients			61	postoperative without chemotherapy colorectal cancer (CRC) patients			61	Differential metabolites between preoperative without chemotherapy colorectal cancer (CRC) patients and postoperative without chemotherapy colorectal cancer (CRC) patients.	nan	CE-TOF-MS	Stool	case vs.control group	35311577
METAC_535	52	colorectal cancer	stage 0 colorectal cancer	9256	stage 0 colorectal cancer (CRC) patients			68	healthy controls			245	Differential metabolites between stage 0 colorectal cancer (CRC) patients and healthy controls.	nan	CE-TOF-MS	Stool	case vs.control group	35311577
METAC_536	52	colorectal cancer	stage I/II colorectal cancer	9256	stage I/II colorectal cancer (CRC) patients			140	healthy controls			245	Differential metabolites between stage I/II colorectal cancer (CRC) patients and healthy controls.	nan	CE-TOF-MS	Stool	case vs.control group	35311577
METAC_537	52	colorectal cancer	stage III/IV colorectal cancer	9256	stage III/IV colorectal cancer (CRC) patients			85	healthy controls			245	Differential metabolites between stage III/IV colorectal cancer (CRC) patients and healthy controls.	nan	CE-TOF-MS	Stool	case vs.control group	35311577
METAC_538	101	brain cancer	childhood brain tumours	1319	in vivo MRS (magic angle spinning)				ex vivo 1 H HR-MAS (magic angle spinning)				Comparison of metabolite signals as detected by in vivo MRS with ex vivo 1 H HR-MAS for childhood brain tumours	Linear regression was performed on the metabolite quantities to asses the agreement between MRS and HR-MAS. Eight of the 12 metabolite quantities were found to correlate significantly (P < 0.05).	HR-MAS	Brain tissue	case vs.control group	19067434
METAC_539	124	brain cancer	glioma	1319	malignant glioma samples		F&M	13	brain adjacent to tumour (BAT) samples		F&M	13	Metabolites in 13 malignant glioma samples and brain adjacent to tumour (BAT) samples	the levels of lactate, glutamate and glycerol were shown to be higher in tumour tissue compared to BAT, although not statistically significant.	FDG-PET	Brain tissue	case vs.control group	18563297
METAC_540	49	colorectal cancer	nan	9256	postoperative colorectal cancer (CRC) patients	58.5 ± 12.9	F&M	25	healthy controls	52.3 ± 11.4	F&M	21	Differential metabolites between postoperative colorectal cancer (CRC) patients and healthy controls.	metabolic profiles of healthy volunteers were distinct from those of CRC patients in the remaining three groups	NMR	Urine	case vs.control group	35186705
METAC_541	163	colorectal cancer	nan	9256	postchemotherapy colorectal cancer (CRC) patients	52.3 ± 13.7	F&M	25	healthy controls	52.3 ± 11.4	F&M	21	Differential metabolites between postchemotherapy colorectal cancer (CRC) patients and healthy controls.	metabolic profiles of healthy volunteers were distinct from those of CRC patients in the remaining three groups	NMR	Urine	case vs.control group	35186705
METAC_542	46	colorectal cancer	nan	9256	colorectal cancer (CRC) patients 	56.5 ± 14.1	F&M	25	healthy controls	52.3 ± 11.4	F&M	21	Differential metabolites between colorectal cancer (CRC) patients and healthy controls.	metabolic profiles of healthy volunteers were distinct from those of CRC patients in the remaining three groups	NMR	Urine	case vs.control group	35186705
METAC_543	49	colorectal cancer	nan	9256	postoperative colorectal cancer (CRC) patients	58.5 ± 12.9	F&M	25	presurgery colorectal cancer (CRC patients	56.5 ± 14.1	F&M	25	Differential metabolites between postoperative colorectal cancer (CRC) patients and presurgery colorectal cancer (CRC) patients.	postoperative patients were more diverse in their metabolic profiles than the CRC patients in the other two groups	NMR	Urine	case vs.control group	35186705
METAC_544	163	colorectal cancer	nan	9256	postchemotherapy colorectal cancer (CRC) patients	52.3 ± 13.7	F&M	25	postoperative colorectal cancer (CRC patients	58.5 ± 12.9	F&M	25	Differential metabolites between postchemotherapy colorectal cancer (CRC) patients and postoperative colorectal cancer (CRC) patients.	postoperative patients were more diverse in their metabolic profiles than the CRC patients in the other two groups	NMR	Urine	case vs.control group	35186705
METAC_545	13	brain cancer	Astrocytomas	1319	Primary astrocytomas tumors	39 ± 11		22	Recurring astrocytomas tumors	39 ± 11		22	Metabolite concentrations of primary and recurrent human astrocytomas tumors	nan	¹H NMR	Brain tissue	case vs.control group	15959923
METAC_546	86	brain cancer	Glioblastomas	1319	Primary astrocytomas tumors	58 ± 9		11	Recurring astrocytomas tumors	58 ± 9		11	Metabolite concentrations of primary and recurrent human glioblastomas tumors	nan	¹H NMR	Brain tissue	case vs.control group	15959923
METAC_547	127	brain cancer	Meningiomas	1319	Primary astrocytomas tumors	55 ± 19		13	Recurring astrocytomas tumors	55 ± 19		13	Metabolite concentrations of primary and recurrent human meningiomas tumors	nan	¹H NMR	Brain tissue	case vs.control group	15959923
METAC_548	4	colorectal cancer	nan	9256	advanced colorectal cancer (CRC) patients		F&M	34	healthy persons		F&M	92	Differential metabolites between advanced colorectal cancer (CRC) patients and healthy persons.	lipid metabolism, amino acid metabolism, nucleotide metabolism, and glucose metabolism in CRC patients were all different than that in healthy controls.	GC-MS; LC-MS	Plasma	case vs.control group	35174409
METAC_549	46	colorectal cancer	nan	9256	colorectal cancer	67 ± 12	F&M	18	controls	53 ± 8	F&M	36	Differential metabolites between colorectal cancer (CRC) patients and controls.	Groups mainly differed by lipids, including monoacyl-glycerophosphocholines (lysoPC), acylcarnitines (AC), diacyl-glycerophosphocholines (PC aa), alkyl-acyl-glycerophosphocholines (PC ae) and derived parameters.	FIA-MS/MS	Serum	case vs.control group	35160173
METAC_550	46	colorectal cancer	nan	9256	colorectal cancer	67 ± 12	F&M	18	advanced adenoma	60 ± 10	F&M	28	Differential metabolites between colorectal cancer (CRC) patients and advanced adenoma.	Groups mainly differed by lipids, including monoacyl-glycerophosphocholines (lysoPC), acylcarnitines (AC), diacyl-glycerophosphocholines (PC aa), alkyl-acyl-glycerophosphocholines (PC ae) and derived parameters.	LC-MS/MS	Serum	case vs.control group	35160173
METAC_551	46	colorectal cancer	nan	9256	colorectal cancer	68.8 ± 11.8	F&M	214	adenoma 	65.9 ± 14.0	F&M	34	Multiple logistic regression model to discriminate colorectal cancer (CRC) from adenoma (AD).	nan	CE-TOF-MS	Urine	case vs.control group	35050180
METAC_552	106	kidney cancer	clear cell renal cell carcinomas (ccRCC), oncocytomas, angiomyolipomas (AML), chromophobe renal cell carcinomas (chRCC), papillary renal cell carcinomas (pRCC), collecting duct carcinoma(CDC), simple renal cyst (SRC) and tubulocystic renal cell carcinoma (TCRC)	263	kidney cancer tumor	69 (36-87)	F&M	50	control		F&M		Urine metabolites as potential biomarkers of kidney cancer	nan	¹H NMR	Urine	case vs.control group	33197834
METAC_553	51	colorectal cancer	nan	9256	colorectal cancer (CRC) patients with recurrence				CCR patients without recurrence				Differential metabolites between colorectal cancer (CRC) patients with or without recurrence.	11 metabolites presented significantly high prognosis predictivity	CE-TOF-MS	Urine	case vs.control group	35050180
METAC_554	46	colorectal cancer	nan	9256	colorectal cancer (CRC) group	61.61 ± 9.86	F&M	98	healthy control	61.52 ± 6.81	F&M	50	The identified differential metabolites between the colorectal cancer (CRC) group and the healthy control.	9 metabolites were identified as the potential biomarkers	LC-MS/MS	Serum	case vs.control group	34917201
METAC_555	46	colorectal cancer	nan	9256	colorectal cancer cancer tissue	65 ± 12	F&M	48	paracarcinoma tissue	65 ± 12	F&M	48	The identification of potential biomarkers in tissue level based on GC-MS between cancer tissue and paracarcinoma tissue.	the trends of stearic acid and cholesterol are consistent, which were the most promising biomarkers	GC-MS	Colorectal tissue	case vs.control group	34804922
METAC_556	49	colorectal cancer	nan	9256	Preoperative serum	65 ± 12	F&M	48	postoperative serum	65 ± 12	F&M	48	The identification of potential biomarkers in tissue level based on GC-MS between Preoperative and postoperative serum.	the trends of stearic acid and cholesterol are consistent, which were the most promising biomarkers	GC-MS	Serum	case vs.control group	34804922
METAC_557	46	colorectal cancer	nan	9256	colorectal cancer (CRC) patients		F&M	49	normal healthy population	53.45 ± 5.59	F&M	31	Differential metabolites between colorectal cancer (CRC) patients and normal healthy population.	Based on these metabolites, a clear division between abnormal colorectal patients (C and A) and the normal individuals could also be achieved	RPLC-MS/MS	Serum	case vs.control group	34462336
METAC_558	46	colorectal cancer	nan	9256	colorectal cancer (CRC) patients		F&M	49	adenoma patients		F&M	12	Differential metabolites between colorectal cancer (CRC) patients and adenoma patients.	Based on these metabolites, a clear division between abnormal colorectal patients (C and A) and the normal individuals could also be achieved	RPLC-MS/MS	Serum	case vs.control group	34462336
METAC_559	185	kidney cancer	Renal Cell Carcinoma	263	Renal Cell Carcinoma	53.3 ± 13.3	F&M	143	health control	48.2 ± 13.1	F&M	204	Differential metabolites and lipids between Renal Cell Carcinoma (RCC) and health control groups	nan	LC-MS	Plasma	case vs.control group	33014794
METAC_560	185	kidney cancer	Renal Cell Carcinoma	263	Renal Cell Carcinoma	53.3 ± 13.3	F&M	143	benign groups	45.3 ± 11.2	F&M	34	Differential metabolites and lipids between Renal Cell Carcinoma (RCC) and benign groups	nan	LC-MS	Plasma	case vs.control group	33014794
METAC_561	185	kidney cancer	Renal Cell Carcinoma	263	Renal Cell Carcinoma	62 (35-89)	F&M	50	health control		F&M	50	Differential metabolites between Renal Cell Carcinoma (RCC) and health control groups	A database search enabled the assignment of signals for the most promising 15 features among them: serine, heptanol, 3-methylene-indolenine, 2-methyl-3-hydroxy-5-formylpyridine-4-carboxylate, phosphodimethylethanolamine, 4-methoxyphenylacetic acid, N-acetylglutamine, 3,5-dihydroxyphenylvaleric acid, hydroxyhexanoylglycine, valyl-leucine, leucyl-histidine, oleamide, 9,12,13-trihydroxyoctadecenoic acid, stearidonyl carnitine and squalene.	gold nanoparticle-enhanced target (AuNPET) LDI MS	Urine	case vs.control group	32830161
METAC_562	106	kidney cancer	clear cell renal cell carcinomas (ccRCC), oncocytomas, angiomyolipomas (AML), chromophobe renal cell carcinomas (chRCC), papillary renal cell carcinomas (pRCC), collecting duct carcinoma (CDC), simple renal cyst (SRC), tubulocystic renal cell carcinoma (TCRC)	263	kidney cancer	69 (36-87)	F&M	50	health control		F&M	49	Mean metabolite concentrations (mM) for controls vs. kidney cancer serum extracts on 1H NMR data set.	Compared with healthy human serum, kidney cancer serum had higher levels of glucose and lower levels of choline, glycerol, glycine, lactate, leucine, myo-inositol, and 1-methylhistidine.	¹H NMR	Serum	case vs.control group	32661677
METAC_563	43	kidney cancer	clear cell renal cell carcinoma	263	clear cell renal cell carcinoma	63.3 ± 11.2	F&M	87	Control	63.4 ± 9.1	F&M	60	Urinary metabolites compared in the clear cell renal cell carcinoma (ccRCC) group and control group	nan	LC-MS/MS	Urine	case vs.control group	32350988
METAC_564	185	kidney cancer	Renal cell carcinoma (RCC)	263	Renal cell carcinoma (RCC)	65 (42-85)	F&M	23	healthy controls	64 (44-85)	F&M	23	Identiﬁcation of the most discriminant metabolomic variables between renal cell carcinoma (RCC) patients before surgery and healthy controls.	Our untargeted metabolomic analysis carried out in urine samples from RCC patients and healthy individual reveals p-cresol glucuronide as potential diagnostic marker for RCC	UPLC-QTOF-MS	Urine	case vs.control group	32126320
METAC_565	188	kidney cancer	Renal cell carcinoma (RCC)	263	Renal cell carcinoma (RCC) patients before surgery.		F&M	23	Renal cell carcinoma (RCC) patients 1 year after surgery.		F&M	23	Identiﬁcation of the most discriminant metabolomic variables between renal cell carcinoma (RCC) patients before and 1 year after surgery.	The analysis of RCC urine samples one year post-nephrectomy reveals isobutyryl-L-carnitine and L-proline betaine as potential prognostic markers.	UPLC-QTOF-MS	Urine	case vs.control group	32126320
METAC_566	189	kidney cancer	Renal cell carcinoma (RCC)	263	renal tumor	52.1 ± 12.9	F&M	61	controls	56.8 ± 11.0	F&M	68	Differential metabolites between renal tumor and control	A metabolite panel consisting of cortolone, testosterone and L-2-aminoadipate adenylate was discovered to have good ability of distinguishing RCC from benign tumors, with an AUC of 0.868 for tenfold cross-validation and 0.873 for the validation group. In addition, the panel of aminoadipic acid, 2-(formamido)-N1-(5-phospho-D-ribosyl) acetamidine and alpha-N-phenylacetyl-L-glutamine could distinguish the RCC group from the healthy control group, with an AUC of 0.841 for tenfold cross-validation and 0.894 for the validation group.	LC-MS	Urine	case vs.control group	31732842
METAC_567	19	kidney cancer	Renal cell carcinoma (RCC)	263	benign renal tumor 	46.1 ± 12.5	F&M	22	Renal cell carcinoma (RCC	55.4 ± 12.1	F&M	39	Differential metabolites between benign renal tumor and renal cell carcinoma (RCC)	A metabolite panel consisting of cortolone, testosterone and L-2-aminoadipate adenylate was discovered to have good ability of distinguishing RCC from benign tumors, with an AUC of 0.868 for tenfold cross-validation and 0.873 for the validation group. In addition, the panel of aminoadipic acid, 2-(formamido)-N1-(5-phospho-D-ribosyl) acetamidine and alpha-N-phenylacetyl-L-glutamine could distinguish the RCC group from the healthy control group, with an AUC of 0.841 for tenfold cross-validation and 0.894 for the validation group.	LC-MS	Urine	case vs.control group	31732842
METAC_568	185	kidney cancer	Renal cell carcinoma (RCC)	263	Renal cell carcinoma (RCC)	55.4 ± 12.1	F&M	39	controls	56.8 ± 11.0	F&M	68	Differential metabolites between renal cell carcinoma (RCC) and control	A metabolite panel consisting of cortolone, testosterone and L-2-aminoadipate adenylate was discovered to have good ability of distinguishing RCC from benign tumors, with an AUC of 0.868 for tenfold cross-validation and 0.873 for the validation group. In addition, the panel of aminoadipic acid, 2-(formamido)-N1-(5-phospho-D-ribosyl) acetamidine and alpha-N-phenylacetyl-L-glutamine could distinguish the RCC group from the healthy control group, with an AUC of 0.841 for tenfold cross-validation and 0.894 for the validation group.	LC-MS	Urine	case vs.control group	31732842
METAC_569	43	kidney cancer	clear cell renal cell carcinoma	263	clear cell renal cell carcinoma	68 (57-82)	F&M	4	controls	58 (41-78)	F&M	15	List of putatively identified metabolites in tissue between clear cell renal carcinoma and healthy controls	Hydroxybutyrylcarnitine, decanoylcarnitine, propanoylcarnitine, carnitine, dodecanoylcarnitine, and norepinephrine sulfate were found in much higher concentrations in both cancer tissues (compared with the paired normal tissue) and in urine of cancer patients (compared with control urine). In contrast, riboflavin and acetylaspartylglutamate (NAAG) were present at significantly higher concentrations both in normal kidney tissue as well as in urine samples of healthy persons. This preliminary study resulted in the identification of several compounds that may be considered potential clear cell renal carcinoma biomarkers.	LC-HRMS	Kidney tissue	case vs.control group	29658093
METAC_570	43	kidney cancer	clear cell renal cell carcinoma	263	clear cell renal cell carcinoma	68 (57-82)	F&M	4	controls	58 (41-78)	F&M	15	List of putatively identified metabolites in urine samples between clear cell renal carcinoma and healthy controls	Hydroxybutyrylcarnitine, decanoylcarnitine, propanoylcarnitine, carnitine, dodecanoylcarnitine, and norepinephrine sulfate were found in much higher concentrations in both cancer tissues (compared with the paired normal tissue) and in urine of cancer patients (compared with control urine). In contrast, riboflavin and acetylaspartylglutamate (NAAG) were present at significantly higher concentrations both in normal kidney tissue as well as in urine samples of healthy persons. This preliminary study resulted in the identification of several compounds that may be considered potential clear cell renal carcinoma biomarkers.	LC-HRMS	Urine	case vs.control group	29658093
METAC_571	43	kidney cancer	clear cell renal cell carcinoma (ccRCC)	263	clear cell renal cell carcinoma (ccRCC)		F&M	21	adjacent non-tumor tissue		F&M	21	Metabolites/lipids with significantly different levels between 31 clear cell renal cell carcinoma (ccRCC) and paired adjacent non-tumor tissue	nan	LC-HRMS	Kidney tissue	case vs.control group	29452772
METAC_572	42	kidney cancer	chromophobe renal cell carcinoma (chRCC)	263	chromophobe renal cell carcinoma (chRCC)		F&M	11	adjacent non-tumor tissue		F&M	35	Metabolites/lipids with significantly different levels between chromophobe renal cell carcinoma (chRCC) (n=11) and adjacent non-tumor tissue (n=35)	nan	LC-HRMS	Kidney tissue	case vs.control group	29452772
METAC_573	43	kidney cancer	clear cell renal cell carcinoma (ccRCC), chromophobe renal cell carcinoma (chRCC)	263	clear cell renal cell carcinoma (ccRCC)		F&M	32	chromophobe renal cell carcinoma (chRCC)		F&M	11	Metabolites/lipids with significantly different levels between clear cell renal cell carcinoma (ccRCC) (n=32) and chromophobe renal cell carcinoma (chRCC) (n=11)	In addition to differences in certain lipids (lysophosphatidylcholines and sphingomyelins), the coregulation network of lipids differed between ccRCC and chRCC	LC-HRMS	Kidney tissue	case vs.control group	29452772
METAC_574	185	kidney cancer	Renal cell carcinoma (RCC)	263	Renal cell carcinoma (RCC)	59.95 ± 12.44	F&M	30	controls	69.08 ± 12.04	F&M	37	List of VOCs extracted from urine and varying in the renal cell carcinoma (RCC) group compared to controls	Two VOCs were found consistently and significantly altered between RCC and controls (2-oxopropanal and, according to identification using NIST14, 2,5,8-trimethyl-1,2,3,4-tetrahydronaphthalene-1-ol), strongly suggesting enhanced potential as RCC biomarkers.	GC-MS	Urine	case vs.control group	28378454
METAC_575	182	kidney cancer	Renal cell carcinoma (RCC)	263	RCC patients with DMT2		F&M	7	controls	69.08 ± 12.04	F&M	37	List of statistically significant varying metabolites in renal cell carcinoma (RCC) patients with DMT2 (n = 7) compared to controls (n = 37)	nan	GC-MS	Urine	case vs.control group	28378454
METAC_576	185	kidney cancer	Renal cell carcinoma (RCC)	263	Renal cell carcinoma (RCC)	61.89 (36-84)	F&M	40	benign samples	53.67 (39-69)	F&M	13	Differential metabolites linked to cancer in 1H NMR and GCMS analysis of serum samples	urine and serum metabolomics may be useful in differentiating benign renal tumors from RCC and for staging RCC	GC-MS;¹H NMR	Serum	case vs.control group	28165361
METAC_577	185	kidney cancer	Renal cell carcinoma (RCC)	263	Renal cell carcinoma (RCC)	61.89 (36-84)	F&M	40	benign samples	53.67 (39-69)	F&M	13	Differential metabolites linked to cancer in 1H NMR and GCMS analysis of urine sample	urine and serum metabolomics may be useful in differentiating benign renal tumors from RCC and for staging RCC	GC-MS;¹H NMR	Urine	case vs.control group	28165361
METAC_578	200	kidney cancer	Renal cell carcinoma (RCC)	263	smoker+ex-smoker Renal cell carcinoma (RCC) patients	57.67 ± 12.40	F&M	12	non-smoker Renal cell carcinoma (RCC) patients	61.69 ± 10.96	F&M	26	Metabolite variations in smoker+ex-smoker renal cell carcinoma (RCC) patients (n=12) vs. non-smokers (n=26)	nan	NMR	Urine	case vs.control group	27857216
METAC_579	22	kidney cancer	Renal cell carcinoma (RCC)	263	Renal cell carcinoma (RCC) patients with BMI≥25	61.33 ± 11.45	F&M	24	Renal cell carcinoma (RCC) patients with BM<25	59.50 ± 11.77	F&M	12	Metabolite variations in renal cell carcinoma (RCC) patients with BMI≥25 (n=24) vs. BM<25 (n=12)	nan	NMR	Urine	case vs.control group	27857216
METAC_580	43	kidney cancer	Renal cell carcinoma (RCC)	263	clear cell renal cell carcinoma (ccRCC)	61.88 ± 11.53	F&M	24	other Renal cell carcinoma (RCC) type		F&M	15	Metabolite variations in renal cell carcinoma (RCC) patients with clear cell renal cell carcinoma (ccRCC) (n=24) vs other subtypes (n=15)	nan	NMR	Urine	case vs.control group	27857216
METAC_581	207	kidney cancer	Renal cell carcinoma (RCC)	263	treatment (W5–6)	59.5 ± 10.7	F&M	64	baseline (W0)	59.5 ± 10.7	F&M	64	Metabolites identified as significant for  5-6 weeks after beginning of treatment (W5-6) compared with baseline (W0) armA (Intraveinous temsirolimus (25 mg weekly) and Intraveinous bevacizumab (10 mg kg-1 every 2 weeks))	nan	NMR	Serum	case vs.control group	26372698
METAC_582	102	kidney cancer	Renal cell carcinoma (RCC)	263	treatment (W5–6)	59.4 ± 8.8	F&M	30	baseline (W0)	59.4 ± 8.8	F&M	30	Metabolites identified as significant for  5-6 weeks after beginning of treatment (W5-6) compared with baseline (W0) armC (Intraveinous bevacizumab (10 mg kg-1 every 2 weeks) Subcateneous interferon α (9 mlU 3 times per week))	nan	NMR	Serum	case vs.control group	26372698
METAC_583	133	colorectal cancer	nan	9256	metastatic colorectal cancer	77 (70-86)	F&M	75	early stage colorectal cancer	78 (70-89)		94	Metabolite univariate analysis for the comparison between early stage colorectal cancer and metastatic colorectal cancer.	Significantly lower levels of glutamine and histidine were observed in patients with mCRC	NMR	Serum	case vs.control group	34199435
METAC_584	46	colorectal cancer	nan	9256	colorectal cancer patients		F&M	163	healthy control group		F&M	111	Important features identified by statistical analysis from urine samples of patients with colorectal cancer.	The GC-TOF/MS-derived models showed clear discriminations in metabolic profiles between the CRC group and healthy control group.	GC-TOF/MS	Urine	case vs.control group	34164923
METAC_585	46	colorectal cancer	nan	9256	colorectal cancer (CRC)	70.0 (60.0-76.0)	F&M	88	low-risk (LR) adenomas	66.0 (55.3-72.9)	F&M	200	statistically significant metabolites between colorectal cancer (CRC) and low-risk (LR) adenomas.	detected in total 442 statistically significant metabolic features in this untargeted metabolomics profiling	UHPLC-QTOF-MS	Serum	case vs.control group	33669644
METAC_586	46	colorectal cancer	nan	9256	colorectal cancer (CRC)	70.0 (60.0-76.0)	F&M	88	high-risk (LR) adenomas	65.4 (56.4-72.6)	F&M	200	Metabolites that were differentially expressed in colorectal cancer (CRC) versus healthy controls	detected in total 442 statistically significant metabolic features in this untargeted metabolomics profiling	UHPLC-QTOF-MS	Serum	case vs.control group	33669644
METAC_587	46	colorectal cancer	nan	9256	colorectal cancer (CRC)	64 ± 9	F&M	50	healthy controls	63 ± 6	F&M	50	Metabolites that were differentially expressed in colorectal cancer (CRC) versus healthy controls	The metabolites identified to be differently expressed between the healthy volunteers and CRC patients include acetylcarnitine, hypoxanthine, xanthine, uric acid (UA), methionine, tyrosine, citric acid, 5-oxoproline, pipecolic acid, lysoPC, and lysoPE	LCMS-QTOF-MS	Serum	case vs.control group	33469506
METAC_588	49	colorectal cancer	nan	9256	patients with pre-operative colorectal cancer	57.52 ± 9.71	F&M	68	patients with post-operative colorectal cancer	57.52 ± 9.71	F&M	68	Differentially regulated metabolites between samples from patients with pre- and post-operative colorectal cancer.	nan	UPLC-MS	Serum	case vs.control group	33260822
METAC_589	49	colorectal cancer	nan	9256	patients with pre-operative colorectal cancer	57.52 ± 9.71	F&M	68	patients with post-operative colorectal cancer	57.52 ± 9.71	F&M	68	Concentrations of nine polyamines in serum samples from pre- and post-operative patients with colorectal cancer.	the concentration of putrescine (PUT) was significantly decreased after surgery	UPLC-MS	Serum	case vs.control group	33260822
METAC_590	46	colorectal cancer	nan	9256	colorectal cancer (CRC) patients	36-87	F&M	139	controls	47-89 	F&M	50	Differential metabolites between colorectal cancer (CRC) patients and controls.	nan	UHPLC-Q-TOF-MS	Urine	case vs.control group	33123283
METAC_591	89	colorectal cancer	nan	9256	colorectal cancer (CRC) patients with hand foot syndrome 	58 (37-74)	F&M	32	colorectal cancer (CRC) patients without hand foot syndrome 	57 (36-81)	F&M	10	Differential metabolites between colorectal cancer (CRC) patients with adverse effects and colorectal cancer (CRC) patients without adverse effects (hand foot syndrome).	nan	UHPLC-Q-TOF-MS	Urine	case vs.control group	33123283
METAC_592	12	colorectal cancer	nan	9256	colorectal cancer (CRC) patients with anemia 	59 (49-74)	F&M	12	colorectal cancer (CRC) patients without anemia	57 (38-81)	F&M	23	Differential metabolites between colorectal cancer (CRC) patients with adverse effects and colorectal cancer (CRC) patients without adverse effects (anemia).	nan	UHPLC-Q-TOF-MS	Urine	case vs.control group	33123283
METAC_593	137	colorectal cancer	nan	9256	colorectal cancer (CRC) patients with neutropenia	59 (37-74)	F&M	18	colorectal cancer (CRC) patients without neutropenia	57 (38-81)	F&M	17	Differential metabolites between colorectal cancer (CRC) patients with adverse effects and colorectal cancer (CRC) patients without adverse effects (neutropenia).	nan	UHPLC-Q-TOF-MS	Urine	case vs.control group	33123283
METAC_594	209	colorectal cancer	nan	9256	colorectal cancer (CRC) patients with thrombocytopenia	59 (37-81)	F&M	20	colorectal cancer (CRC) patients without thrombocytopenia	56 (38-68)	F&M	15	Differential metabolites between colorectal cancer (CRC) patients with adverse effects and colorectal cancer (CRC) patients without adverse effects (thrombocytopenia).	nan	UHPLC-Q-TOF-MS	Urine	case vs.control group	33123283
METAC_595	23	colorectal cancer	nan	9256	colorectal cancer (CRC) patients with bone marrow suppression	60 (37-81)	F&M	24	colorectal cancer (CRC) patients without bone marrow suppression	54 (38-69)	F&M	11	Differential metabolites between colorectal cancer (CRC) patients with adverse effects and colorectal cancer (CRC) patients without adverse effects (bone marrow suppression).	nan	UHPLC-Q-TOF-MS	Urine	case vs.control group	33123283
METAC_596	123	colorectal cancer	nan	9256	Lymph Node Metastasis Group	65.79 ± 11.57	F&M	43	Lymph Node Non-Metastasis Group	61.3	F&M	163	Metabolites Between Lymph Node Metastasis Group and Lymph Node Non-Metastasis Group	nan	LC-MS/MS	Serum	case vs.control group	33123283
METAC_597	46	colorectal cancer	nan	9256	colorectal cancer (CRC) patients	49.7 ± 5.4	F&M	32	healthy controls	57.1	F&M	60	Differential metabolites between colorectal cancer (CRC) patients and healthy controls in Training cohort	The AUC values, cut-off values, sensitivity, and specificity of significantly changed carboxylic acids between CRC patients and healthy controls.	UHPLC-Q-TOF/MS	Serum	case vs.control group	32825913
METAC_598	46	colorectal cancer	nan	9256	colorectal cancer (CRC) patients	47 ± 8.4	F&M	15	healthy controls	47.6 ± 6.9	F&M	15	Differential metabolites between colorectal cancer (CRC) patients and healthy controls in Validation cohort	The AUC values, cut-off values, sensitivity, and specificity of significantly changed carboxylic acids between CRC patients and healthy controls.	UHPLC-Q-TOF/MS	Serum	case vs.control group	32825913
METAC_599	46	colorectal cancer	nan	9256	colorectal cancer (CRC) patients	63.6 ± 10.9	F&M	137	controls	60.5 ± 13	F&M	54	Differential metabolites between colorectal cancer (CRC) patients and controls.	CRC patients had a significantly higher arginine, ADMA, and SDMA and lower citrulline than healthy controls.	LC-MS/MS	Serum	case vs.control group	32521714
METAC_600	46	colorectal cancer	nan	9256	colorectal cancer (CRC) patients	63.6 ± 10.10	F&M	137	adenomas	58.5 ± 12.2	F&M	8	Differential metabolites between colorectal cancer (CRC) patients and adenomas.	The difference in DMA did not reach statistical significance but the metabolite was significantly elevated in patients with adenomas	LC-MS/MS	Serum	case vs.control group	32521714
METAC_601	46	colorectal cancer	nan	9256	colorectal cancer (CRC) patients	63.6 ± 10.11	F&M	137	non-malignant conditions		F&M	126	Differential metabolites between colorectal cancer (CRC) patients and non-malignant conditions.	CRC was characterized by a significantly lower systemic citrulline and DMA but higher SDMA	LC-MS/MS	Serum	case vs.control group	32521714
METAC_602	202	colorectal cancer	stage T3 colon cancer	9256	T3Nx			52	T3N0			52	Differential serum metabolites from patients with stage T3 colon cancer and different lymph node status.	17 serum metabolites could potentially distinguish the patients with lymph node metastasis from patients	LC-MS	Serum	case vs.control group	32391103
METAC_603	183	colorectal cancer	rectal cancer	9256	rectal cancer	68.48	F&M	23	healthy controls	66.49	F&M	45	Differential metabolites between healthy controls and rectal cancer (RC) patients.	RC patients exhibited more changes in metabolites than CC patients	GC-MS	Serum	case vs.control group	32281150
METAC_604	45	colorectal cancer	colon cancer	9256	colon cancer	64.41	F&M	22	healthy controls	66.49	F&M	45	Differential metabolites between healthy controls and colon cancer (CC) patients.	RC patients exhibited more changes in metabolites than CC patients	GC-MS	Serum	case vs.control group	32281150
METAC_605	183	colorectal cancer	rectal cancer; colon cancer	9256	rectal cancer	68.48	F&M	23	colon cancer	64.41	F&M	22	Differential metabolites between rectal cancer (RC) and colon cancer(CC) patients.	nine metabolites differed significantly between CC and RC patients	GC-MS	Serum	case vs.control group	32281150
METAC_606	185	kidney cancer	Renal cell carcinoma (RCC)	263	Renal cell carcinoma (RCC) tumours	54.87 ± 13.66	F&M	31	Renal cell carcinoma (RCC) adjacent tissues	54.87 ± 13.66	F&M	31	Quantitative comparison of metabolites found in tumors and paired adjacent tissues of Renal cell carcinoma (RCC) patients	Compared to the adjacent tissues, RCC tumors had elevated levels of lactate, glutamate, pyruvate, glutamine, and creatine, but decreased levels of acetate, malate, and amino acids including valine, alanine, and aspartate	¹H NMR	Kidney tissue	case vs.control group	22258851
METAC_607	186	kidney cancer	Renal cell carcinoma (RCC)	263	Advanced Renal cell carcinoma (RCC) (T3-4, with metastases)	55.82 ± 13.24	F&M	11	Low-grade Renal cell carcinoma (RCC) (T1-2, without metastases)	54.35 ± 14.20	F&M	20	Quantitative comparison of metabolites found in Renal cell carcinoma (RCC) tumors between Advanced RCC (T3-4, with metastases) and Low-grade RCC (T1-2, without metastases)	nan	¹H NMR	Kidney tissue	case vs.control group	22258851
METAC_608	186	kidney cancer	Renal cell carcinoma (RCC)	263	Advanced RCC (T3-4, with metastases)	55.82 ± 13.24	F&M	11	Low-grade Renal cell carcinoma (RCC) (T1-2, without metastases)	54.35 ± 14.20	F&M	20	Quantitative comparison of metabolites found in Renal cell carcinoma (RCC) adjacent tissues between Advanced RCC (T3-4, with metastases) and Low-grade RCC (T1-2, without metastases)	nan	¹H NMR	Kidney tissue	case vs.control group	22258851
METAC_609	106	kidney cancer	nan	263	kidney cancer patients			29	control			33	metabolites between 29 kidney cancer patients and 33 control patients.	nan	UHLC/MS/MS2;GC/MS	Urine	case vs.control group	21348635
METAC_610	186	kidney cancer	Renal cell carcinoma (RCC)	263	Low-grade Renal cell carcinoma (RCC) (T1-2, without metastases)		F&M	12	control	53 (43-71)	F&M	25	Potential Biomarkers identified between Low-grade renal cell carcinoma (RCC) (T1-2, without metastases) and controls	nan	LC-MS	Blood	case vs.control group	21186845
METAC_611	186	kidney cancer	Renal cell carcinoma (RCC)	263	Advanced Renal cell carcinoma (RCC) (T3-4, with metastases)		F&M	21	control	53 (43-71)	F&M	25	Potential Biomarkers identified between Advanced renal cell carcinoma (RCC) (T3-4, with metastases) and controls	nan	LC-MS	Blood	case vs.control group	21186845
METAC_612	106	kidney cancer	nan	263	kidney cancer patients	56 (40-72)	F&M	31	healthy controls	52 (43-71)	F&M	20	Potential biomarkers identified from LC-MS between kidney cancer patients and healthy controls	DIMS is recommended to be a fast diagnostic method for kidney cancer, while LC-MS is necessary when comprehensive screening of biomarkers is required.	LC-MS	Serum	case vs.control group	20856980
METAC_613	106	kidney cancer	nan	263	kidney cancer patients	56 (40-72)	F&M	31	healthy controls	52 (43-71)	F&M	20	Potential biomarkers identified from DIMS between kidney cancer patients and healthy controls	DIMS is recommended to be a fast diagnostic method for kidney cancer, while LC-MS is necessary when comprehensive screening of biomarkers is required.	DIMS	Serum	case vs.control group	20856980
METAC_614	46	colorectal cancer	nan	9256	model group		F&M	60	healthy group	51.9 ± 8.03	F&M	30	Differential metabolites between model group and healthy group.	This suggested that WD may induce metabolomic changes when administered in conjunction with laparoscopic surgery and basic postoperative treatment. The ability to regulate the level of twenty metabolites simultaneously to approach the HG that the WDG was more effective than the FTG, which may have contributed to the advantages of the multicomponent, multitarget, and multilevel actions of TCM.	UPLC/Q-TOF-MS/MS	Serum	case vs.control group	32104193
METAC_615	213	colorectal cancer	nan	9256	fundamental rental treatment group	60.77 ± 9.58	F&M	30	model group		F&M	60	Differential metabolites between fundamental rental treatment group and model group.	This suggested that WD may induce metabolomic changes when administered in conjunction with laparoscopic surgery and basic postoperative treatment. The ability to regulate the level of twenty metabolites simultaneously to approach the HG that the WDG was more effective than the FTG, which may have contributed to the advantages of the multicomponent, multitarget, and multilevel actions of TCM.	UPLC/Q-TOF-MS/MS	Serum	case vs.control group	32104193
METAC_616	213	colorectal cancer	nan	9256	wuda granule group	61.53 ± 10.02	F&M	30	model group		F&M	60	Differential metabolites between wuda granule group and model group.	This suggested that WD may induce metabolomic changes when administered in conjunction with laparoscopic surgery and basic postoperative treatment. The ability to regulate the level of twenty metabolites simultaneously to approach the HG that the WDG was more effective than the FTG, which may have contributed to the advantages of the multicomponent, multitarget, and multilevel actions of TCM.	UPLC/Q-TOF-MS/MS	Serum	case vs.control group	32104193
METAC_618	133	colorectal cancer	metastatic colorectal cancer	9256	metastatic colorectal cancer	59.9	F&M	65	controls	56.1	F&M	60	Differential metabolites between metastatic colorectal cancer and controls.	Five variables met the criteria established for potential biomarkers of metastatic CRC	LC-HRMS	Serum	case vs.control group	31882610
METAC_619	37	colorectal cancer	nan	9256	cachectic patients	58.38 ±10.33	F&M	16	non-cachectic patients	62.74 ±12.22	F&M	23	Comparison of mean level of metabolites in cachectic and non-cachectic patients.	eight metabolites had differing mean levels, with four being lower in cachectic patients	GC-MS	Urine	case vs.control group	31500101
METAC_620	37	colorectal cancer	nan	9256	cachectic patients	58.38 ±10.33	F&M	16	non-cachectic patients	62.74 ±12.22	F&M	23	Comparison of mean level of metabolites in cachectic and non-cachectic patients.	eight metabolites had differing mean levels, with four being lower in cachectic patients	¹H NMR	Urine	case vs.control group	31500101
METAC_621	185	kidney cancer	Renal cell carcinoma (RCC)	263	All Renal cell carcinoma (RCC)		F&M	74	controls	51.5 ± 13.1	F&M	55	metabolites between renal cell carcinoma (RCC) kidney cancer patients and controls	Compared to healthy human serum, RCC serum had higher levels of lipid (mainly very low-density lipoproteins), isoleucine, leucine, lactate, alanine, N-acetylglycoproteins, pyruvate, glycerol, and unsaturated lipid, together with lower levels of acetoacetate, glutamine, phosphatidylcholine/choline, trimethylamine-N-oxide, and glucose.	¹H NMR	Serum	case vs.control group	18706333
METAC_622	186	kidney cancer	Renal cell carcinoma (RCC)	263	T1a Renal cell carcinoma (RCC)	52.0 ± 12.5	F&M	49	controls	51.5 ± 13.1	F&M	55	metabolites between T1a kidney cancer patients(<4 cm, limited to the kidney) and controls	nan	¹H NMR	Serum	case vs.control group	18706333
METAC_623	186	kidney cancer	Renal cell carcinoma (RCC)	263	Advanced Renal cell carcinoma (RCC)		F&M	25	low grade Renal cell carcinoma (RCC)		F&M	49	metabolites between advanced renal cell carcinoma (RCC) patients(<4 cm, limited to the kidney) and low grade renal cell carcinoma (RCC)	nan	¹H NMR	Serum	case vs.control group	18706333
METAC_624	136	kidney cancer	Renal cell carcinoma (RCC)	263	After nephrectomy	54.7 ± 11.1	F&M	28	before nephrectomy	54.7 ± 11.1	F&M	28	metabolites between after and before nephrectomy	nan	¹H NMR	Serum	case vs.control group	18706333
METAC_625	185	kidney cancer	Renal cell carcinoma (RCC)	263	Renal cell carcinoma (RCC)		F&M	96	control renal tissue		F&M	84	Metabolites displaying relative concentration differences in renal cell carcinoma (RCC) and control renal tissue samples	α-tocopherol, hippuric acid, myoinositol, fructose-1-phosphate and glucose-1-phosphate contributed most to the tumour/normal discrimination and all showed pronounced concentration changes in RCC.	GC-TOF-MS	Kidney tissue	case vs.control group	19845817
METAC_626	187	kidney cancer	Renal cell carcinoma (RCC)	263	metastasized Renal cell carcinoma (RCC)		F&M	21	localized tumours		F&M	36	Metabolites with relative concentration differences in localized and metastasized renal cell carcinoma (RCC) samples	Data on metastasized tumours suggested a key role for metabolic pathways involving arachidonic acid, free fatty acids, proline, uracil and the tricarboxylic acid cycle.	GC-TOF-MS	Kidney tissue	case vs.control group	19845817
METAC_627	43	kidney cancer	clear cell renal cell carcinoma (ccRCC)	263	clear cell renal cell carcinoma (ccRCC)	63 (55-70)	F&M	138	adjacent normal kidney tissues	63 (55-70)	F&M	138	metabolic changes upon comparing primary clear cell renal cell carcinoma (ccRCC) to adjacent normal kidney tissues	nan	Mass spectrometry	Kidney tissue	case vs.control group	26766592
METAC_628	44	kidney cancer	clear cell renal cell carcinoma (ccRCC)	263	Stage III/IV tumors		F&M	90	Stage I/II tumors		F&M	48	metabolites significantly higher or lower in clear cell renal cell carcinoma (ccRCC) Stage III/IV tumors, compared to Stage I/II	nan	Mass spectrometry	Kidney tissue	case vs.control group	26766592
METAC_629	39	kidney cancer	clear cell renal cell carcinoma (ccRCC)	263	tumors developing metastases		F&M	19	tumour not developing metastases		F&M	119	Comparison of metabolite abundances in tumors developing metastases versus those not developing metastases at preparation of this report.	nan	Mass spectrometry	Kidney tissue	case vs.control group	26766592
METAC_630	43	kidney cancer	clear cell renal cell carcinoma (ccRCC)	263	clear cell renal cell carcinoma (ccRCC)		F&M	5	control		F&M	5	Primary metabolites differentially expressed in urine of clear cell renal cell carcinoma (ccRCC) and normal control patients	nan	gas chromatography	Urine	case vs.control group	17123452
METAC_631	185	kidney cancer	Renal cell carcinoma (RCC)	263	Renal cell carcinoma (RCC) tumours	60.9 ± 13.1	F&M	82	healthy controls	54.4 ± 10.32	F&M	176	Renal cell carcinoma (RCC) staging markers that are statistically significant when RCC (n=82) was compared with the healthy controls (n=176).	nan	NMR;LC-MS	Urine	case vs.control group	34944874
METAC_632	67	kidney cancer	Renal cell carcinoma (RCC)	263	early stage Renal cell carcinoma (RCC)		F&M	41	healthy controls	54.4 ± 10.32	F&M	176	Metabolomic features identified as statistically significant when healthy controls (n=176) were compared with early stage renal cell carcinoma (RCC) (n=41).	nan	NMR;LC-MS	Urine	case vs.control group	34944874
METAC_633	67	kidney cancer	Renal cell carcinoma (RCC)	263	early stage Renal cell carcinoma (RCC)		F&M	41	healthy controls	54.4 ± 10.32	F&M	176	Comparison of Renal cell carcinoma (RCC) staging markers in early staged RCC (n=41) vs. healthy controls (n =176).	nan	NMR;LC-MS	Urine	case vs.control group	34944874
METAC_634	7	kidney cancer	Renal cell carcinoma (RCC)	263	advanced stage Renal cell carcinoma (RCC)		F&M	29	healthy controls	54.4 ± 10.32	F&M	176	Metabolomic features identified as statistically significant when healthy controls (n=176) were compared with advanced stage renal cell carcinoma (RCC) (n=29).	nan	NMR;LC-MS	Urine	case vs.control group	34944874
METAC_635	7	kidney cancer	Renal cell carcinoma (RCC)	263	advanced stage Renal cell carcinoma (RCC)		F&M	41	healthy controls	54.4 ± 10.32	F&M	176	Comparison of renal cell carcinoma (RCC) staging markers in advanced staged RCC (n = 41) vs. healthy controls (n = 176).	nan	NMR;LC-MS	Urine	case vs.control group	34944874
METAC_636	43	kidney cancer	clear cell renal cell carcinoma (ccRCC)	263	clear cell renal cell carcinoma (ccRCC)	69 (35-89)	F&M	33	controls		F&M	50	compounds found by clear cell renal cell carcinoma (ccRCC) vs. Control	Four potential biomarkers were found in urine and serum samples to distinguish clear cell renal cell carcinoma (ccRCC) from controls, 4 for the ccRCC with and without metastases, and 6 metabolites to distinguish low and high stages or grades.	SALDI MS	Serum	case vs.control group	34273747
METAC_637	39	kidney cancer	clear cell renal cell carcinoma (ccRCC)	263	ccRCC with metastases		F&M	4	ccRCC without metastases		F&M	29	compounds found by clear cell renal cell carcinoma (ccRCC) without metastases vs. clear cell renal cell carcinoma (ccRCC) with metastases	Four potential biomarkers were found in urine and serum samples to distinguish clear cell renal cell carcinoma (ccRCC) from controls, 4 for the ccRCC with and without metastases, and 6 metabolites to distinguish low and high stages or grades.	SALDI MS	Serum	case vs.control group	34273747
METAC_638	44	kidney cancer	clear cell renal cell carcinoma (ccRCC)	263	High stages (T3 and T4) ccRCC		F&M	11	Low stages (T1 and T2) ccRCC		F&M	22	compounds found by Low stages (T1 and T2) clear cell renal cell carcinoma (ccRCC) vs. High stages (T3 and T4) clear cell renal cell carcinoma (ccRCC)	Four potential biomarkers were found in urine and serum samples to distinguish clear cell renal cell carcinoma (ccRCC) from controls, 4 for the ccRCC with and without metastases, and 6 metabolites to distinguish low and high stages or grades.	SALDI MS	Serum	case vs.control group	34273747
METAC_639	95	kidney cancer	clear cell renal cell carcinoma (ccRCC)	263	High grade (Fuhrman III and IV) ccRCC		F&M	12	Low grade (Fuhrman I and II) ccRCC		F&M	21	compounds found by Low grade (Fuhrman I and II) clear cell renal cell carcinoma (ccRCC) vs. High grade (Fuhrman III and IV) clear cell renal cell carcinoma (ccRCC)	Four potential biomarkers were found in urine and serum samples to distinguish clear cell renal cell carcinoma (ccRCC) from controls, 4 for the ccRCC with and without metastases, and 6 metabolites to distinguish low and high stages or grades.	SALDI MS	Serum	case vs.control group	34273747
METAC_640	43	kidney cancer	clear cell renal cell carcinoma (ccRCC)	263	clear cell renal cell carcinoma (ccRCC)	69 (35-89)	F&M	33	controls		F&M	50	compounds found by clear cell renal cell carcinoma (ccRCC) vs. Control	Four potential biomarkers were found in urine and serum samples to distinguish clear cell renal cell carcinoma (ccRCC) from controls, 4 for the ccRCC with and without metastases, and 6 metabolites to distinguish low and high stages or grades.	SALDI MS	Urine	case vs.control group	34273747
METAC_641	39	kidney cancer	clear cell renal cell carcinoma (ccRCC)	263	ccRCC with metastases		F&M	4	ccRCC without metastases		F&M	29	compounds found by clear cell renal cell carcinoma (ccRCC) without metastases vs. ccRCC with metastases	Four potential biomarkers were found in urine and serum samples to distinguish clear cell renal cell carcinoma (ccRCC) from controls, 4 for the ccRCC with and without metastases, and 6 metabolites to distinguish low and high stages or grades.	SALDI MS	Urine	case vs.control group	34273747
METAC_642	44	kidney cancer	clear cell renal cell carcinoma (ccRCC)	263	High stages (T3 and T4) ccRCC		F&M	11	Low stages (T1 and T2) ccRCC		F&M	22	compounds found by Low stages (T1 and T2) clear cell renal cell carcinoma (ccRCC) vs. High stages (T3 and T4) ccRCC	Four potential biomarkers were found in urine and serum samples to distinguish clear cell renal cell carcinoma (ccRCC) from controls, 4 for the ccRCC with and without metastases, and 6 metabolites to distinguish low and high stages or grades.	SALDI MS	Urine	case vs.control group	34273747
METAC_643	95	kidney cancer	clear cell renal cell carcinoma (ccRCC)	263	High grade (Fuhrman III and IV) ccRCC		F&M	12	Low grade (Fuhrman I and II) ccRCC		F&M	21	compounds found by Low grade (Fuhrman I and II) ccRCC vs. High grade (Fuhrman III and IV) ccRCC	Four potential biomarkers were found in urine and serum samples to distinguish clear cell renal cell carcinoma (ccRCC) from controls, 4 for the ccRCC with and without metastases, and 6 metabolites to distinguish low and high stages or grades.	SALDI MS	Urine	case vs.control group	34273747
METAC_644	106	kidney cancer	AML – angiomyolipoma; ccRCC - clear cell RCC; CDC - collecting duct carcinoma chRCC - chromophobe renal cell carcinoma	263	kidney cancer		F&M	49	controls		F&M	49	Mean metabolite concentrations (nmol/g of tissue) for controls vs. kidney cancer tissue extracts on 1H NMR data set	nan	¹H NMR	Kidney tissue	case vs.control group	33661419
METAC_645	160	lung cancer	lung adenocarcinoma	1324	Responders	54.4 ± 11.2 	F&M	24	Non-responders 	57.8 ± 10.8	F&M	84	Diagnostic ability of plasma endogenous compounds on chemotherapeutic efficacy of pemetrexed.	A panel of Phosphatidylserine 20:4/20:1, Sphingomyelin d18:1/18:0, and Phosphatidic Acid 18:1/20:0 could predict pemetrexed and platinum chemotherapy response with an Area Under the Receiver Operating Characteristic curve (AUROC) of 0.7968.	LC-MS/MS	Serum	case vs.control group	35290920
METAC_646	90	lung cancer	lung adenocarcinoma	1324	Blood adverse drug reaction (ADR) Group 	55.6 ± 9.8	F&M	76	Normal blood Group 	57.5 ± 8.3 	F&M	37	Diagnostic ability of plasma endogenous compounds on the occurrence of blood adverse drug reaction (ADR) after pemetrexed treatment.	A panel incorporating triglyceride 14:0/22:3/22:5, 3-(3-Hydroxyphenyl) Propionate Acid, and Carnitine C18:0 was the best predictive ability of hematological toxicity with an AUROC of 0.7954.	LC-MS/MS	Serum	case vs.control group	35290920
METAC_647	92	lung cancer	lung adenocarcinoma	1324	Liver adverse drug reaction (ADR) Group	51.7 ± 8.3	F&M	23	Normal Liver Group	57.3 ± 9.2	F&M	90	Diagnostic ability of plasma endogenous compounds on the occurrence of hepatotoxicity after pemetrexed treatment.	A model incorporating stearidonic acid, Thromboxane B3, l-Homocitrulline, and phosphoinositide 20:3/18:0 showed the best predictive ability of hepatotoxicity with an AUROC of 0.8186.	LC-MS/MS	Serum	case vs.control group	35290920
METAC_648	145	lung cancer	non-small-cell lung cancer	1324	non-small-cell lung cancer (NSCLC)	62 ± 9	F&M	69	healthy control (HC)	60 ± 13 	F&M	76	The differential metabolites between non-small-cell lung cancer (NSCLC) and healthy control (HC)	13(S)-HODE and arachidonic acid may be potential biomarkers of NSCLC.	LC-MS	Plasma	case vs.control group	35245482
METAC_649	113	lung cancer	adenocarcinoma(ADC), squamous cell lung carcinoma (SqCC), small cell lung carcinoma	1324	lung cancer(LC)	54.13 ± 10.96	F&M	39	healthy control(HC)	48.98 ± 7.27	F&M	42	Diagnostic Potential of Serum Metabolites Differentiating lung cancer(LC) from healthy control(HC)	Among various circulatory metabolites, six metabolites, including histidine, glutamine, glycine, threonine, alanine, and valine, were found to be of apposite diagnostic potential for clinical implications. These metabolic alterations indicated altered glucose metabolism, aberrant fatty acid synthesis, and augmented utilization of various amino acids including active glutaminolysis in LC.	NMR	Serum	case vs.control group	35187366
METAC_650	145	lung cancer	non-small-cell lung cancer	1324	non-small-cell lung cancer	55±10	F&M	55	healthy controls (HC	43±10	F&M	55	Metabolic profiles of preoperative NSCLC patients and healthy controls (PRE vs. HC)	Compared with healthy controls and postoperative NSCLC patients, increased branched-chain amino acid (BCAA) and decreased citrate were identified in the serum of preoperative NSCLC patients.	NMR	Serum	case vs.control group	35070754
METAC_651	122	lung cancer	non-small-cell lung cancer	1324	preoperative NSCLC	55±10	F&M	55	postoperative NSCLC	55±10	F&M	55	Metabolic profile of preoperative and postoperative NSCLC patients (PRE vs. POST)	Compared with healthy controls and postoperative NSCLC patients, increased branched-chain amino acid (BCAA) and decreased citrate were identified in the serum of preoperative NSCLC patients.	NMR	Serum	case vs.control group	35070754
METAC_652	113	lung cancer	nan	1324	lung cancer (LC)	63 (39-86)	F&M	42	benign lung lesion (BLL)	62 (43-86 )	F&M	21	identify salivary biomarkers for distinguishing lung cancer (LC) from benign lung lesion (BLL)	The profiles of 10 salivary metabolites were remarkably different between the LC and BLL samples. Among them, the concentration of salivary tryptophan was significantly lower in the samples from patients with LC than in those from patients with BLL, and the area under the curve (AUC) for discriminating patients with LC from those with BLL was 0.663 (95% confidence interval [CI] = 0.516-0.810, p = 0.036).	CE-TOF-MS	Saliva	case vs.control group	34918488
METAC_653	37	colorectal cancer	nan	9256	cachectic patients	58.38 ± 10.33	F&M	16	pre-cachectic patients	55.84 ± 11.67	F&M	13	Comparison of mean level of metabolites in cachectic and pre-cachectic patients.	nan	GC-MS	Urine	case vs.control group	31500101
METAC_654	37	colorectal cancer	nan	9256	cachectic patients	58.38 ± 10.33	F&M	16	pre-cachectic patients	55.84 ± 11.67	F&M	13	Comparison of mean level of metabolites in cachectic and pre-cachectic patients.	nan	¹H NMR	Urine	case vs.control group	31500101
METAC_655	165	colorectal cancer	nan	9256	pre-cachectic patients	55.84 ± 11.67	F&M	13	non-cachectic patients	62.74 ± 12.22	F&M	23	Comparison of mean level of metabolites in pre-cachectic and non-cachectic patients.	nan	GC-MS	Urine	case vs.control group	31500101
METAC_656	165	colorectal cancer	nan	9256	pre-cachectic patients	55.84 ± 11.67	F&M	13	non-cachectic patients	62.74 ± 12.22	F&M	23	Comparison of mean level of metabolites in pre-cachectic and non-cachectic patients.	nan	¹H NMR	Urine	case vs.control group	31500101
METAC_658	145	lung cancer	non-small cell lung cancer	1324	non-small cell lung cancer (NSCLC)	60.6 ± 9.5	F&M	43	control groups	62.8 ± 9.9	F&M	43	Differential metabolites between non-small cell lung cancer (NSCLC) and control groups screened out by GC-MS and LC-MS analyses.	An integrated mass spectrometry-based untargeted metabolomics was used to profle the plasma samples from 43 NSCLC patients and 43 healthy controls. We found that a series of 39 metabolites were altered signifcantly.	GC-MS;LC-MS	Plasma	case vs.control group	34617154
METAC_659	46	colorectal cancer	nan	9256	colorectal cancer	59.1	F&M	10	normal tissues	59.1	F&M	10	List of lipids with the significant differences between colorectal cancer and normal tissues determined by LC/MS-based lipid analysis.	The levels of 26 of the 31 FA were significantly increased in the CRC tissue samples. The levels of 5 AC were significantly increased in the CRC tissue samples. The levels of 27 and 3 PC were significantly increased and decreased in the CRC tissue samples, respectively. The levels of 15 and 6 PE were significantly increased and decreased in the CRC tissue samples, respectively. The levels of 35 LPC were significantly increased in the CRC tissue samples. The levels of 18 LPE were significantly increased in the CRC tissue samples.	LC-MS	Colorectal tissue	case vs.control group	31341153
METAC_660	46	colorectal cancer	nan	9256	colorectal cancer (CRC) groups		F&M	50	healthy controls		F&M	50	Fold changes (FC) for GC-MS-based metabolomics datasets for healthy controls and colorectal cancer (CRC) groups.	In the H group, the abundant metabolites were mainly sugars (maltose, fructose), sugar alcohols, amines (galactosamine) and a large set of organic and fatty acids (glycerol, octadecanoic acid, hexanedioic acid, benezenepropanoic acid, linoleic acid, and oleic acid). In contrast, the CRC group showed a higher abundance of polyamines (cadaverine, 1,4-Butanediamine), amino acids (Pro, Glu) and urea, suggesting that the H group is better able to maintain carbohydrate metabolism and a more reductive environment in the gut than in the CRC group	GC-MS	Stool	case vs.control group	31281534
METAC_661	145	lung cancer	non-small cell lung cancer	1324	non-small cell lung cancer (NSCLC)	65 ± 9	F&M	30	healthy controls	63 ± 3 	F&M	25	Metabolic signatures significantly altered in non-small cell lung cancer (NSCLC) patients at the time of diagnosis compared to healthy controls	Several metabolites were identified to be altered in the pre-treatment serum samples of small-cell lung cancer patients compared to healthy individuals.	NMR	Serum	case vs.control group	34585134
METAC_662	46	colorectal cancer	nan	9256	colorectal cancer (CRC) patients	66.4	F&M	171	healthy controls	58.9	F&M	171	Differential metabolites between healthy controls and colorectal cancer (CRC) patients.	A total of 17 metabolites were identified	LC-MS	Urine	case vs.control group	31151939
METAC_663	46	colorectal cancer	nan	9256	colorectal cancer (CRC) patients	60 (25-82)	F&M	40	healthy controls	55 (35-77)	F&M	38	Changes in relative levels of metabolites in the serum samples from colorectal cancer (CRC) patients and healthy controls.	the levels of isoleucine, 3-hydroxybutyrate, lactate, acetate, glutamate, choline, glycine, serine, and glucose were increased in the CRC group, and the levels of lipid, leucine, valine, alanine, glutamine, succinate, citrate, aspartate, proline, and tyrosine were decreased in the CRC group	¹H NMR	Serum	case vs.control group	31089393
METAC_664	46	colorectal cancer	nan	9256	colorectal cancer (CRC) patients	60 (25-82)	F&M	40	colorectal polyp patients	57 (26-86)	F&M	32	Changes in relative levels of metabolites in the serum samples from colorectal cancer (CRC) patients and colorectal polyp patients.	The metabolites of lysine, N-acetyl glycoproteins, glutamine, glycerol, serine, and glucose were elevated in the CRC group. The metabolites of lipid, leucine, valine, alanine, glutamate citrate, PUFA, proline, and tyrosine were reduced in the CRC group	¹H NMR	Serum	case vs.control group	31089393
METAC_665	53	colorectal cancer	colorectal cancer; advanced adenoma	9256	colorectal neoplasia	60 (32-85)	F&M	92	control	52 (22-76)	F&M	156	Marker identification for early detection of colorectal neoplasia.	relative amounts of taurine, alanine, 3-aminoisobutyrate, and valine were greater in CRN samples than in healthy controls, where relative amounts of threonine, glycerol, hippurate, ascorbate, creatinine and citrate were greater in healthy controls than in CRN groups	NMR	Urine	case vs.control group	30886205
METAC_666	32	colorectal cancer	nan	9256	NACT responsive CRC patients	53.66 ± 7.45	F&M	27	NACT non‑responsive CRC patients	56.16 ± 10.04	F&M	30	Differential metabolites between NACT responsive and non‑responsive colorectal cancer (CRC) patients.	two metabolites in Amide mode and seven metabolites in T3 mode were confirmed as independent predictive biomarkers	UHPLC-QTOF/MS	Plasma	case vs.control group	30830371
METAC_667	113	lung cancer	nan	1324	lung cancer (LC)		F&M	39	healthy group(HC)		F&M	40	Fold changes (FC) and Variable importance in projection (VIP) score for LC-MS-based metabolomics datasets for the healthy control (HC) and lung cancer (LC) groups.	serum levels of glycerophospholipids (LysoPE 18:3, LysoPC 14:0, LysoPC 18:3), Imidazopyrimidines (Hypoxanthine), AcylGlcADG 66:18; AcylGlcADG (22:6/22:6/22:6) and Acylcarnitine 11:0 were substantially different between HC and LC groups.	LC-MS	Serum	case vs.control group	34527604
METAC_668	46	colorectal cancer	nan	9256	colorectal cancer (CRC) patients	66.0 (58.0-73.0)	F&M	180	controls	51.0 (42.0-63.0)	F&M	153	Differential metabolites between controls and colorectal cancer (CRC) patients.	15 identified metabolites exhibited significant differences between colorectal cancer patients and controls	UHPLC-QTOF-MS	Serum	case vs.control group	30665271
METAC_669	46	colorectal cancer	nan	9256	colorectal cancer (CRC) patients	70.0 (60.0-76.0)	F&M	88	controls	64.0 (57.0-74.0)	F&M	200	Differential metabolites between controls and colorectal cancer (CRC) patients.	15 identified metabolites exhibited significant differences between colorectal cancer patients and controls	UHPLC-QTOF-MS	Serum	case vs.control group	30665271
METAC_670	66	lung cancer	Squemous Cell Carcinoma (SCC)	1324	early stage Squemous Cell Carcinoma (SCC)		F&M		Control group	61.5 ± 12.06		20	Differential tissue metabolites identificed from early stage Squemous Cell Carcinoma (SCC) and control groups	Based on the early stage tissue analysis, more than 200 metabolites differentiating adenocarcinoma (ADC) and squamous cell lung carcinoma (SCC) subtypes as well as normal tissue, were identified. Most of the identified metabolites were amino acids, fatty acids, carnitines, lysoglycerophospholipids, sphingomyelins, plasmalogens and glycerophospholipids.	LC-MS	Lung tissue	case vs.control group	34282765
METAC_671	63	lung cancer	Adenocarcinoma (ADC)	1324	early stage Adenocarcinoma (ADC)		F&M		Control group	61.5 ± 12.06		20	Differential tissue metabolites identificed from early stage Adenocarcinoma (ADC) and control groups	Based on the early stage tissue analysis, more than 200 metabolites differentiating adenocarcinoma (ADC) and squamous cell lung carcinoma (SCC) subtypes as well as normal tissue, were identified. Most of the identified metabolites were amino acids, fatty acids, carnitines, lysoglycerophospholipids, sphingomyelins, plasmalogens and glycerophospholipids.	LC-MS	Lung tissue	case vs.control group	34282765
METAC_672	66	lung cancer	Squemous Cell Carcinoma (SCC), Adenocarcinoma (ADC)	1324	early stage Squemous Cell Carcinoma (SCC)		F&M		early stage Adenocarcinoma (ADC)				Differential tissue metabolites identificed from early stage Squemous Cell Carcinoma (SCC) and Adenocarcinoma (ADC)	Based on the early stage tissue analysis, more than 200 metabolites differentiating adenocarcinoma (ADC) and squamous cell lung carcinoma (SCC) subtypes as well as normal tissue, were identified. Most of the identified metabolites were amino acids, fatty acids, carnitines, lysoglycerophospholipids, sphingomyelins, plasmalogens and glycerophospholipids.	LC-MS	Lung tissue	case vs.control group	34282765
METAC_673	66	lung cancer	Squemous Cell Carcinoma (SCC)	1324	early stage Squemous Cell Carcinoma (SCC)		F&M		Control group	61.5 ± 12.06		20	Differential plasma metabolites identificed from early stage Squemous Cell Carcinoma (SCC) and control groups	Based on the early stage tissue analysis, more than 200 metabolites differentiating adenocarcinoma (ADC) and squamous cell lung carcinoma (SCC) subtypes as well as normal tissue, were identified. Most of the identified metabolites were amino acids, fatty acids, carnitines, lysoglycerophospholipids, sphingomyelins, plasmalogens and glycerophospholipids.	LC-MS	Plasma	case vs.control group	34282765
METAC_674	63	lung cancer	Adenocarcinoma (ADC)	1324	early stage Adenocarcinoma (ADC)		F&M		Control group	61.5 ± 12.06		20	Differential plasma metabolites identificed from early stage Adenocarcinoma (ADC) and control groups	Based on the early stage tissue analysis, more than 200 metabolites differentiating adenocarcinoma (ADC) and squamous cell lung carcinoma (SCC) subtypes as well as normal tissue, were identified. Most of the identified metabolites were amino acids, fatty acids, carnitines, lysoglycerophospholipids, sphingomyelins, plasmalogens and glycerophospholipids.	LC-MS	Plasma	case vs.control group	34282765
METAC_676	46	colorectal cancer	nan	9256	colorectal cancer tumor tissues	62.5 ± 12.7	F&M	17	colorectal cancer normal tissues	62.5 ± 12.7	F&M	17	Differential metabolites between paired normal and tumor tissues.	Metabolites found to be significantly different in paired normal and tumor tissues by Wilcoxon signed rank test.	LC-MS	Colorectal tissue	case vs.control group	30576312
METAC_677	56	colorectal cancer	nan	9256	MET (metachronously metastasized) groups	73 (45-87)	F&M	42	NON (non-metastasized) groups	68 (52-86)	F&M	50	Significant metabolites between NON (non-metastasized) and MET (metachronously metastasized) groups.	nan	LC-MS	Plasma	case vs.control group	30560999
METAC_678	193	colorectal cancer	colon cancer	9256	left-sided colon cancer	61	F&M	147	right-sided colon cancer	62	F&M	105	Significant metabolites between left-sided colon cancer (LCC) and right-sided colon cancer (RCC).	six metabolites, five in Amide mode and one in T3 mode, were selected and confirmed as discriminatory metabolites	UHPLC-QTOF/MS	Plasma	case vs.control group	30296444
METAC_679	46	colorectal cancer	colon cancer	9256	colorectal cancer (CRC) patients		F&M	50	controls		F&M	50	The ratio of metabolite concentrations between colorectal cancer (CRC) patients and controls	twenty metabolites had FDR-adjusted p-value lower than 0.05 when values were compared between cancer patients and controls.	¹H NMR	Stool	case vs.control group	30279959
METAC_680	147	lung cancer	Non–Small Cell Lung Cancer	1324	Early-Stage Non–Small Cell Lung Cancer post-surgery	63.8 ± 7.0	F&M	29	Early-Stage Non–Small Cell Lung Cancer pre-surgery	63.8 ± 7.0	F&M	29	altered urine metabolites in Early-Stage Non-Small Cell Lung Cancer after surgery	We identified a profile of 48 metabolites that were significantly different pre- and post-surgery: 17 in urine and 31 in serum. A higher proportion of metabolites were upregulated than downregulated post-surgery (p < 0.01); however, the median fold change (FC) was higher for downregulated than upregulated metabolites (p < 0.05). Purines/pyrimidines and proteins had a larger dysregulation than other classes of metabo?lites (p < 0.05 for each class). Several of the dysregulated metabolites have been previously associated with cancer, including leucyl proline, asymmetric dimethylarginine, isopentenyladenine, fumaric acid (all downregulated post-surgery), as well as N6-methyladenosine and several deoxycholic acid moieties, which were upregulated post-surgery.	NMR;QTOF	Urine	case vs.control group	34208545
METAC_681	147	lung cancer	Non–Small Cell Lung Cancer	1324	Early-Stage Non–Small Cell Lung Cancer post-surgery	64.6 ±7.5	F&M	32	Early-Stage Non–Small Cell Lung Cancer pre-surgery	64.6 ±7.5	F&M	32	altered serum metabolites in Early-Stage Non-Small Cell Lung Cancer after surgery	We identified a profile of 48 metabolites that were significantly different pre- and post-surgery: 17 in urine and 31 in serum. A higher proportion of metabolites were upregulated than downregulated post-surgery (p < 0.01); however, the median fold change (FC) was higher for downregulated than upregulated metabolites (p < 0.05). Purines/pyrimidines and proteins had a larger dysregulation than other classes of metabo?lites (p < 0.05 for each class). Several of the dysregulated metabolites have been previously associated with cancer, including leucyl proline, asymmetric dimethylarginine, isopentenyladenine, fumaric acid (all downregulated post-surgery), as well as N6-methyladenosine and several deoxycholic acid moieties, which were upregulated post-surgery.	NMR;QTOF	Serum	case vs.control group	34208545
METAC_682	113	lung cancer	Squamous cell carcinoma, Adenocarcinoma, Small cell lung cancer	1324	Lung cancer	65.7 ± 12.4	F&M	38	Non-malignant control	77.5 ± 13.1	F&M	30	Te selected metabolites that were signifcantly diferent between the lung cancer patients and patients with nonmalignant disease as controls	Volatile metabolites of pleural efusion might be used in patients with cytology-negative pleural efusion to rule out malignancy.	GC-MS	Pleural effusion	case vs.control group	34193905
METAC_683	113	lung cancer	NSCLC, squamous cell carcinomas, adenocarcinomas	1324	lung cancer	59.1 (38-75)	F&M	48	healthy controls		F&M	30	The diagnostic efficacy of various metabolites in lung cancer.	10 different metabolites were identified through analysis, which may have potential clinical application value in the diagnosis of CTC-positive early-stage lung cancer	UPLC-Triple TOF-MS	Serum	case vs.control group	34136379
METAC_684	113	lung cancer	Adenocarcinoma, Squamous cell carcinoma, NSCLC, SCLC	1324	Lung Cancer Cases	67 (53-79)	F&M	123	Healthy Controls	67 (53-79)	F&M	123	Serum metabolites detect differences between groups of lung cancer and healthy controls	Despite several specific compounds showing significant differences between cancer patients and healthy controls within each study, only a few cancer-related features were common when both cohorts were compared, which included a reduced concentration of lysophosphatidylcholine LPC (18:0). Moreover, serum metabolome profiles in both noncancer groups were similar, and differences between cancer patients and both groups of healthy participants were comparable.	LC-HRMS	Serum	case vs.control group	34072693
METAC_685	113	lung cancer	Adenocarcinoma, Squamous cell carcinoma, NSCLC, SCLC	1324	Lung Cancer Cases	67 (53-79)	F&M	123	Benign Lung Nodules	67 (53-79)	F&M	123	Serum metabolites detect differences between groups of lung cancer and benign lung nodules	Despite several specific compounds showing significant differences between cancer patients and healthy controls within each study, only a few cancer-related features were common when both cohorts were compared, which included a reduced concentration of lysophosphatidylcholine LPC (18:0). Moreover, serum metabolome profiles in both noncancer groups were similar, and differences between cancer patients and both groups of healthy participants were comparable.	LC-HRMS	Serum	case vs.control group	34072693
METAC_686	18	lung cancer	benign lung nodules	1324	Healthy Controls	67 (53-79)	F&M	123	Healthy Controls	67 (53-79)	F&M	123	Serum metabolites detect differences between groups of benign lung nodules and healthy controls	Despite several specific compounds showing significant differences between cancer patients and healthy controls within each study, only a few cancer-related features were common when both cohorts were compared, which included a reduced concentration of lysophosphatidylcholine LPC (18:0). Moreover, serum metabolome profiles in both noncancer groups were similar, and differences between cancer patients and both groups of healthy participants were comparable.	LC-HRMS	Serum	case vs.control group	34072693
METAC_687	113	lung cancer	Adenocarcinoma, Spinocellular, Neuroendocrine, Adenosquamous	1324	Lung Cancer Cases	65.6	F&M	132	controls	55.0 ± 6.6	F&M	77	Plasma metabolites significantly changed (p-value <0.0023 after Bonferroni correction) between patients with lung cancer against controls	When comparing with healthy controls, significantly increased glucose, citrate, acetate, 3-hydroxybutyrate, and creatinine balanced with decreased pyruvate, lactate, alanine, tyrosine, and tryptophan were found as a common feature of both groups. Metabolomic analysis of blood plasma showed considerable proximity of patients with primary and secondary lung cancer.	NMR	Plasma	case vs.control group	33904314
METAC_688	120	lung cancer	lung metastasis	1324	lung metastasis of other origin	63.09	F&M	47	controls	55.0 ± 6.6	F&M	77	Plasma metabolites significantly changed (p-value <0.0023 after Bonferroni correction) between patients with lung metastasis of other origin against controls	When comparing with healthy controls, significantly increased glucose, citrate, acetate, 3-hydroxybutyrate, and creatinine balanced with decreased pyruvate, lactate, alanine, tyrosine, and tryptophan were found as a common feature of both groups. Metabolomic analysis of blood plasma showed considerable proximity of patients with primary and secondary lung cancer.	NMR	Plasma	case vs.control group	33904314
METAC_689	1	lung cancer	Acinar Cell Adenocarcinoma (ACA)	1324	Acinar Cell Adenocarcinoma (ACA) 			7	benign tumours			3	Compounds significantly affected by lung cancer type (Acinar Cell Adenocarcinoma (ACA) vs. Benign).	Several metabolites were found at higher concentrations in cancer patients such as lactic acid in Squamous Cell Carcinoma, and lysoPCs in Adenocarcinoma and Acinar Cell Carcinoma, which may be used to detect early onset and/or to monitor the progress of the cancer patients	LC-QTOF/MS	Blood	case vs.control group	33891605
METAC_690	2	lung cancer	Adenocarcinoma (AC)	1324	Adenocarcinoma (AC) 			7	benign tumours			3	Compounds significantly affected by lung cancer type (Adenocarcinoma (AC) vs. Benign).	Several metabolites were found at higher concentrations in cancer patients such as lactic acid in Squamous Cell Carcinoma, and lysoPCs in Adenocarcinoma and Acinar Cell Carcinoma, which may be used to detect early onset and/or to monitor the progress of the cancer patients	LC-QTOF/MS	Blood	case vs.control group	33891605
METAC_691	121	lung cancer	Squamous Cell Carcinoma (SCC)	1324	Squamous Cell Carcinoma (SCC)			11	benign tumours			3	Compounds significantly affected by lung cancer type (Squamous Cell Carcinoma (SCC) vs. Benign).	Several metabolites were found at higher concentrations in cancer patients such as lactic acid in Squamous Cell Carcinoma, and lysoPCs in Adenocarcinoma and Acinar Cell Carcinoma, which may be used to detect early onset and/or to monitor the progress of the cancer patients	LC-QTOF/MS	Blood	case vs.control group	33891605
METAC_692	194	lung cancer	nan	1324	second primary lung cancer (SPLC)		F&M	82	initial primary lung cancer (IPLC)		F&M	82	The top-ranking metabolites associated with second primary lung cancer (SPLC) based on univariable logistic regression analyses	Metabolites that were significantly associated with SPLC (False Discovery Rate q-value < 0.2) included 5-methylthioadenosine (odds ratio [OR]=2.04, 95% confidence interval [CI] 1.39–3.01; P=2.8×10−4) and phenylacetylglutamine (OR=2.65, 95% CI 1.56–4.51; P=3.2×10−4), each exhibiting approximately 1.5-fold increased levels among SPLC cases versus IPLC controls.	UPLC-MS/MS	Serum	case vs.control group	33743383
METAC_693	118	lung cancer	nan	1324	lung cancer(LC) patients with chronic bronchitis(CB)	53.89 ± 9.11	F&M	9	LC patients without COPD(con)	53.00 ± 6.19	F&M	10	Differential metabolites in the lung paracancer tissues in lung cancer (LC) patients with chronic bronchitis (CB) vs LC patients without COPD (con)	Overall, 60, 55, 33 and 63 differential metabolites (DM) were identified in comparisons between CB vs CON, E vs CON, CB vs E, and CB + E vs CON, respectively, and of these, 8 DM were shared in all comparisons. Among the high altered metabolites, E samples showed higher 'acetol' than CON samples, and lower 'azelaic acid', '3-methylglutaric acid' and 'allose'. CB samples showed higher 'turanose' and 'o-phosphoserine' and lower 'anandamide' than CON and E samples. In CB and E samples, 'galactonic acid', '2-mercaptoethanesulfonic acid', 'D-alanyl-D-alanine' '3-methylglutaric acid', 'glycine', 'L-4-Hydroxyphenylglycine' and 'O-phosphonothreonine' had common alteration trends compared with those of CON samples. 'Glycine', 'L-4-Hydroxyphenylglycine' and 'O-phosphonothreonine' were significantly enriched in glycine, serine and threonine metabolism pathways. The total differential metabolites detected were remarkably altered in pyrimidine, beta-alanine and purine metabolism.	GC-MS	Lung tissue	case vs.control group	32795777
METAC_694	215	lung cancer	nan	1324	lung cancer(LC) patients with emphysema(E) 	65.40 ± 8.94	F&M	10	LC patients without COPD(con)	53.00 ± 6.19	F&M	10	Differential metabolites in the lung paracancer tissues in lung cancer (LC) patients with emphysema (E) vs LC patients without COPD (con)	Overall, 60, 55, 33 and 63 differential metabolites (DM) were identified in comparisons between CB vs CON, E vs CON, CB vs E, and CB + E vs CON, respectively, and of these, 8 DM were shared in all comparisons. Among the high altered metabolites, E samples showed higher 'acetol' than CON samples, and lower 'azelaic acid', '3-methylglutaric acid' and 'allose'. CB samples showed higher 'turanose' and 'o-phosphoserine' and lower 'anandamide' than CON and E samples. In CB and E samples, 'galactonic acid', '2-mercaptoethanesulfonic acid', 'D-alanyl-D-alanine' '3-methylglutaric acid', 'glycine', 'L-4-Hydroxyphenylglycine' and 'O-phosphonothreonine' had common alteration trends compared with those of CON samples. 'Glycine', 'L-4-Hydroxyphenylglycine' and 'O-phosphonothreonine' were significantly enriched in glycine, serine and threonine metabolism pathways. The total differential metabolites detected were remarkably altered in pyrimidine, beta-alanine and purine metabolism.	GC-MS	Lung tissue	case vs.control group	32795777
METAC_695	118	lung cancer	nan	1324	lung cancer(LC) patients with chronic bronchitis(CB)	53.89 ± 9.11	F&M	9	LC patients with emphysema(E)	65.40 ± 8.94	F&M	10	Differential metabolites in the lung paracancer tissues in lung cancer (LC) patients with chronic bronchitis (CB) vs LC patients with emphysema (E)	Overall, 60, 55, 33 and 63 differential metabolites (DM) were identified in comparisons between CB vs CON, E vs CON, CB vs E, and CB + E vs CON, respectively, and of these, 8 DM were shared in all comparisons. Among the high altered metabolites, E samples showed higher 'acetol' than CON samples, and lower 'azelaic acid', '3-methylglutaric acid' and 'allose'. CB samples showed higher 'turanose' and 'o-phosphoserine' and lower 'anandamide' than CON and E samples. In CB and E samples, 'galactonic acid', '2-mercaptoethanesulfonic acid', 'D-alanyl-D-alanine' '3-methylglutaric acid', 'glycine', 'L-4-Hydroxyphenylglycine' and 'O-phosphonothreonine' had common alteration trends compared with those of CON samples. 'Glycine', 'L-4-Hydroxyphenylglycine' and 'O-phosphonothreonine' were significantly enriched in glycine, serine and threonine metabolism pathways. The total differential metabolites detected were remarkably altered in pyrimidine, beta-alanine and purine metabolism.	GC-MS	Lung tissue	case vs.control group	32795777
METAC_696	115	lung cancer	nan	1324	lung cancer(LC) patients with chronic bronchitis(CB) + LC patients with emphysema(E)		F&M	10	LC patients without COPD(con)	53.00 ± 6.19	F&M	10	Differential metabolites in the lung paracancer tissues in lung cancer (LC) patients with chronic bronchitis (CB) + LC patients with emphysema (E) vs LC patients without COPD(con)	Overall, 60, 55, 33 and 63 differential metabolites (DM) were identified in comparisons between CB vs CON, E vs CON, CB vs E, and CB + E vs CON, respectively, and of these, 8 DM were shared in all comparisons. Among the high altered metabolites, E samples showed higher 'acetol' than CON samples, and lower 'azelaic acid', '3-methylglutaric acid' and 'allose'. CB samples showed higher 'turanose' and 'o-phosphoserine' and lower 'anandamide' than CON and E samples. In CB and E samples, 'galactonic acid', '2-mercaptoethanesulfonic acid', 'D-alanyl-D-alanine' '3-methylglutaric acid', 'glycine', 'L-4-Hydroxyphenylglycine' and 'O-phosphonothreonine' had common alteration trends compared with those of CON samples. 'Glycine', 'L-4-Hydroxyphenylglycine' and 'O-phosphonothreonine' were significantly enriched in glycine, serine and threonine metabolism pathways. The total differential metabolites detected were remarkably altered in pyrimidine, beta-alanine and purine metabolism.	GC-MS	Lung tissue	case vs.control group	32795777
METAC_697	145	lung cancer	Non-small cell lung cancer (NSCLC)	1324	Non-small cell lung cancer (NSCLC)	55.5 (39-67)	F&M	99	healthy controls	44 (35-69)	F&M	109	List of significant metabolites of serum samples for non-small cell lung cancer (NSCLC) patients compared with healthy people in both ESI+ and ESI- modes.	nan	UPLC/Q-TOF MS	Serum	case vs.control group	32374740
METAC_698	113	lung cancer	nan	1324	Lung cancer patients	61 (50-74)	F&M	10	control group				potential lung cancer biomarkers in a comparison of the cancer and control groups	Receiver operating characteristic curve analysis revealed that adenosine 3′-monophosphate, creatine, glycerol, and 14 other differential metabolites were potential sensitive and specific biomarkers for the diagnosis and prognosis of lung adenocarcinoma.	LC-MS/MS	Lung tissue	case vs.control group	32316791
METAC_699	119	lung cancer	nan	1324	Benign lung tumors patients	54 (48-62)	F&M	10	control group				potential lung cancer biomarkers in a comparison of the lump (Benign lung tumors patients) and control groups	Receiver operating characteristic curve analysis revealed that adenosine 3′-monophosphate, creatine, glycerol, and 14 other differential metabolites were potential sensitive and specific biomarkers for the diagnosis and prognosis of lung adenocarcinoma.	LC-MS/MS	Lung tissue	case vs.control group	32316791
METAC_700	113	lung cancer	nan	1324	Lung cancer patients	61 (50-74)	F&M	10	Benign lung tumors patients	54 (48-62)	F&M	10	potential lung cancer biomarkers in a comparison of the cancer and lump groups	nan	LC-MS/MS	Lung tissue	case vs.control group	32316791
METAC_701	145	lung cancer	Non-small cell lung cancer (NSCLC)	1324	Non-small cell lung cancer (NSCLC)		F&M	156	healthy controls		F&M	60	Metabolites with significant different between normal cases and non-small cell lung cancer (NSCLC) patients	nan	LC/MS	Plasma	case vs.control group	32156060
METAC_702	125	lung cancer	nan	1324	malignant pleural effusion (MPE) 	63 ± 12	F&M	46	benign pleural effusion (BPE) 	49 ± 19	F&M	32	perturbed metabolites identified by lung cancer with malignant pleural effusion (MPE) and benign pleural effusion (BPE) cases	A total of 25 ether lipids, including phosphatidylcholines (PC), lysophosphatidylcholines (LPC) and phosphatidylethanolamines (PE), were observed to be significantly downregulated in MPE with excellent diagnostic potential. Plasmalogen PC(40:3p) showed highest AUC value of 0.953 in receiver operating characteristic (ROC) model. Oxidized polyunsaturated fatty acids (PUFA) were upregulated in MPE.	LC-MS/MS	Pleural effusion	case vs.control group	31884394
METAC_703	113	lung cancer	non-small cell LC	1324	lung cancer pre-radiotherapy	72 (65-79)	F&M	33	control group	42 (35-47)	F&M	50	selected metabolites in pre-radiotherapy lung cancer patients and the control group.	nan	GC-MS	Plasma	case vs.control group	31841666
METAC_704	116	lung cancer	non-small cell LC	1324	lung cancer patients post-radiotherapy	72 (65-79)	F&M	33	lung cancer patients pre-radiotherapy	72 (65-79)	F&M	33	selected metabolites in lung cancer patients pre- and post-radiotherapy	nan	GC-MS	Plasma	case vs.control group	31841666
METAC_705	116	lung cancer	non-small cell LC	1324	lung cancer post-radiotherapy	72 (65-79)	F&M	33	control group	42 (35-47)	F&M	50	selected metabolites in post-radiotherapy lung cancer patients and the control group.	nan	GC-MS	Plasma	case vs.control group	31841666
METAC_706	113	lung cancer	Adenomatous hyperplasia, Adenocarcinoma, Minimally invasive adenocarcinoma	1324	Lung cancer cases	67.6 ± 13.2	F&M	34	Controls	68.9 ± 14.5	F&M	39	serum potential diagnostic biomarkers for lung cancer	In total, we identified 9 metabolites in electron spray ionization (ESI)(+) mode and 7 metabolites in ESI(-) mode. L-(+)-gulose, phosphatidylethanolamine (PE)(22:2(13Z,16Z)/15:0), cysteinyl-glutamine, S-japonin, threoninyl-glutamine, chlorate, 3-oxoadipic acid, dukunolide A, and malonic semialdehyde levels were observed to be elevated in serum samples of lung cancer cases when compared to those of healthy controls. By contrast, 1-(2-furanylmethyl)-1H-pyrrole, 2,4-dihydroxybenzoic acid, monoethyl carbonate, guanidinosuccinic acid, pseudouridine, DIMBOA-Glc, and 4-feruloyl-1,5-quinolactone levels were lower in serum samples of lung cancer cases compared with those of healthy controls.	LC-Q-TOF-MS	Serum	case vs.control group	31555521
METAC_707	113	lung cancer	Adenocarcinoma, Squamous, Non Squamous, Small cell	1324	Lung Cancer	50.7 (27-75)	F&M	31	Normal	43.7 (27 -56)	F&M	15	Metabolite identified in training lung cancer cohort	A panel consisting of 14 metabolites, which included 6 metabolites in the polyamine pathway, was identified that correctly discriminated lung cancer patients from controls with an area under the curve of 0.97 (95% CI: 0.875-1.0)	LC-MS/MS	Plasma	case vs.control group	31362354
METAC_708	113	lung cancer	Adenocarcinoma, Squamous, Non Squamous, Small cell	1324	Lung Cancer	55.7 (27-70)	F&M	26	Normal	43.7 (27 -56)	F&M	15	Metabolite identified in validation lung cancer cohort	A panel consisting of 14 metabolites, which included 6 metabolites in the polyamine pathway, was identified that correctly discriminated lung cancer patients from controls with an area under the curve of 0.97 (95% CI: 0.875-1.0)	LC-MS/MS	Plasma	case vs.control group	31362354
METAC_709	113	lung cancer	nan	1324	Lung Cancer	66.7 (49-83)	F&M	10	Controls	64.1 (41-90)	F&M	100	Quantified amino acids and acylcarnitine in serum samples in 2015 lung cancer and control data set.	Six metabolites (glycine, valine, methionine, citrulline, arginine and C16-carnitine) were indicated to be involved in distinguishing patients with lung cancer from healthy controls.	LC‑MS/MS	Serum	case vs.control group	31258653
METAC_710	113	lung cancer	Adenocarcinoma,Squamous cell carcinoma,Small cell lung cancer,Other types of NSCLC	1324	Lung Cancer	66.3 (53-77)	F&M	17	Controls	62.8 (34-85)	F&M	30	Quantified amino acids and acylcarnitine in serum samples in the 2017 lung cancer and control data set.	Six metabolites (glycine, valine, methionine, citrulline, arginine and C16-carnitine) were indicated to be involved in distinguishing patients with lung cancer from healthy controls.	LC‑MS/MS	Serum	case vs.control group	31258653
METAC_711	113	lung cancer	non-small cell lung cancer	1324	Non-Small Cell Lung Cancer group	54.7 ± 14.3	F	30	controls		F	36	significantly different metabolites in nonsmoking female patients with non-small cell lung cancer group in the discovery set	A total of 56 annotated metabolites were found and verified to be significantly different in nonsmoking females with NSCLC compared with the control.	GC-MS	Serum	case vs.control group	30892048
METAC_712	121	lung cancer	Lung Squamous Cell Carcinoma	1324	Lung Squamous Cell Carcinoma	55 (39-71)	F&M	8	Lung Squamous Cell Carcinoma adjacent tissue	55 (39-71)	F&M	8	Defining Metabolite in Lung Squamous Cell Carcinoma	nan	FIE-HRMS	Lung tissue	case vs.control group	30866469
METAC_713	113	lung cancer	nan	1324	Lung Cancer	54.1 ± 9.9	F&M	31	Normal	52.1 ± 14.6	F&M	29	Significant different metabolites between patient and control group	GC-MS analysis showed that 23 of the 169 metabolites identified were significantly different.	GC-MS	Serum	case vs.control group	30805978
METAC_714	113	lung cancer	Non-small cell lung cancer, small cell lung cancer	1324	Lung Cancer	67 ± 12	F&M	30	Healthy control	56 ± 14	F&M	30	Altered metabolites in serum from lung cancer (LC) patients compared to healthy controls	nan	DI-ESI-QTOF-MS	Serum	case vs.control group	30439409
METAC_715	113	lung cancer	Non-small cell lung cancer, small cell lung cancer	1324	Lung Cancer	67 ± 12	F&M	30	Chronic Obstructive Pulmonary Disease	66 ± 9	F&M	30	Altered metabolites in serum from lung cancer (LC) patients compared to Chronic Obstructive Pulmonary Disease (COPD)	A total of 35 altered and common metabolites between LC and COPD, including amino acids, fatty acids, lysophospholipids, phospholipids and triacylglycerides were identified, being alanine, aspartate and glutamate metabolism the most altered	DI-ESI-QTOF-MS	Serum	case vs.control group	30439409
METAC_716	49	colorectal cancer	nan	9256	PCRC		F&M		HC		F&M		Plasma differently altered metabolites in postoperative colorectal cancer (PCRC) compared to healthy control (HC)	Eight identified endogenous metabolites were differently altered in PCRC	GC-MS	Plasma	case vs.control group	29458921
METAC_717	46	colorectal cancer	nan	9256	colorectal cancer (CRC) patients	60.5	F&M	53	controls		F&M	81	Differential metabolites between controls and colorectal cancer (CRC) patients.	48 metabolites were employed in the metabolomic model, which resulted in an encouraging model	FIA-MS/MS	Serum	case vs.control group	29301511
METAC_718	52	colorectal cancer	stage I/II colorectal cancer	9256	colorectal cancer (CRC) patients	61 (27-84)	F&M	23	controls	59 (28-78)	F&M	40	Marker metabolites found in OPLS-DA models of 1H NMR-based urine metabolic profiling between I/II stage of colorectal cancer (CRC) and healthy controls	Urinary metabolites contributing to CRC early detection	NMR	Serum	case vs.control group	29285295
METAC_719	52	colorectal cancer	stage I/II colorectal cancer	9256	colorectal cancer (CRC) patients	61 (27-84)	F&M	23	esophageal cancers (EC) patients	59 (28-78)	F&M	40	Marker metabolites found in OPLS-DA models of 1H NMR-based urine metabolic profiling between stage I/II colorectal cancer (CRC) patients and esophageal cancers (EC) patients	nan	NMR	Serum	case vs.control group	29285295
METAC_720	113	lung cancer	Adenocarcinoma, Squamous cell cancer, Undifferentiated non small cell lung cancer, Small cell lung cancer	1324	lung caner	66 ± 12	F&M	32	healthy controls	56 ± 13	F&M	29	Altered metabolites in serum from lung cancer and healthy controls	Twenty six and thirty one perturbed metabolites in the LC were annotated in the comparison of serum and urine samples	GC-MS	Serum	case vs.control group	30292984
METAC_721	113	lung cancer	Adenocarcinoma, Squamous cell cancer, Undifferentiated non small cell lung cancer, Small cell lung cancer	1324	lung caner	66 ± 12	F&M	32	healthy controls	56 ± 13	F&M	29	Altered metabolites in urine from lung cancer and healthy controls	Twenty six and thirty one perturbed metabolites in the LC were annotated in the comparison of serum and urine samples	GC-MS	Urine	case vs.control group	30292984
METAC_722	113	lung cancer	Adenocarcinoma, Squamous cell cancer, Undifferentiated non small cell lung cancer, Small cell lung cancer	1324	lung caner	65 ± 12	F&M	24	Non-cancerous control	55 ± 15	F&M	30	Altered metabolites in bronchoalveolar lavage fluid (BALF) from lung cancer and Non-cancerous control	Sixteen metabolites were altered in BALF of LC patients compared to NCC.	GC-MS	Bronchoalveolar lavage fluid	case vs.control group	30292984
METAC_723	2	lung cancer	adenocarcinoma	1324	adenocarcinoma	62.11 ± 9.73	F&M	33	adjacent normal lung tissue	62.11 ± 9.73	F&M	33	Significant different metabolites between adenocarcinoma and adjacent normal lung tissue	nan	UPLC/MS/MS;GC/MS	Lung tissue	case vs.control group	30099851
METAC_724	121	lung cancer	squamouscell lung carcinoma	1324	"squamous
cell lung carcinoma"	68.71 ± 7.46	F&M	35	adjacent normal lung tissue	68.71 ± 7.46	F&M	35	Significant different metabolites between squamous cell lung carcinom and adjacent normal lung tissue	nan	UPLC/MS/MS;GC/MS	Lung tissue	case vs.control group	30099851
METAC_725	162	lung cancer	SCLC, NSCLC	1324	partial response		F&M	26	progressive disease		F&M	27	potential biomarkers for predicting platinum chemotherapy efficacy	Interestingly, 2-hydroxyglutaric acid (2-HG) as an oncometabolite accumulated in lung cancer was remarkably elevated in the partial response (PR) patients. Collectively, our findings implicated that metabolomics can serve as a potential tool to select lung cancer patients that are more likely to benefit from the platinum-based treatment.	LC-MS	Plasma	case vs.control group	29544107
METAC_726	145	lung cancer	non-small cell lung cancer (NSCLC)	1324	non-small cell lung cancer (NSCLC)		F&M	38	healthy controls		F&M	43	Potential serum biomarkers identified by 1H NMR and their variations among non-small cell lung cancer (NSCLC) patients, microwave ablation (MWA) treated patients and healthy controls	Compared with healthy controls, NSCLC patients showed significantly elevated serum levels of lactate, alanine, glutamate, proline, glycoprotein, phenylalanine, tyrosine and tryptophan, and markedly decreased serum levels of glucose, taurine, glutamine, glycine, phosphocreatine and threonine (p < 0.05).	¹H NMR	Serum	case vs.control group	29530051
METAC_727	135	lung cancer	non-small cell lung cancer (NSCLC)	1324	MWA(microwave ablation) treated patients		F&M	39	non-small cell lung cancer (NSCLC)		F&M	38	Potential serum biomarkers identified by 1H NMR and their variations among MWA(microwave ablation) treated patients and NSCLC patients	MWA treatment reversed the metabolic profiles of NSCLC patients towards the control group.	¹H NMR	Serum	case vs.control group	29530051
METAC_728	135	lung cancer	non-small cell lung cancer (NSCLC)	1324	MWA(microwave ablation) treated patients		F&M	39	healthy controls		F&M	43	Potential serum biomarkers identified by 1H NMR and their variations among MWA(microwave ablation) treated patients and healthy controls	MWA treatment reversed the metabolic profiles of NSCLC patients towards the control group.	¹H NMR	Serum	case vs.control group	29530051
METAC_729	46	colorectal cancer	nan	9256	colorectal cancer (CRC) patients	31-80	F&M	25	healthy controls	18-22	F&M	10	Differential metabolites between controls and colorectal cancer (CRC) patients.	8 lipid species, including PG (34:0), SM (42:2), Cer (44:5), LPC (18:3), LPC (18:2), PE (O-36:3), PE (O-38:3) and SM (38:8), having the AUC more than 0.900	LC-QTOF-MS	Plasma	case vs.control group	29028617
METAC_730	46	colorectal cancer	nan	9256	tumour mucosal tissue	76 (55-85)	F&M	18	normal mucosal tissue	76 (55-85)	F&M	18	Differential metabolites between tumour or normal mucosal tissue.	Colonic mucosal metabolites are highly diagnostic of cancer .	¹H NMR	Mucosa	case vs.control group	28827587
METAC_731	177	colorectal cancer	Qi deficiency colorectal cancer	9256	Qi deficiency (QD)		F&M	30	Nondeficiency (ND)		F&M	30	Differential metabolites in the plasmas of colorectal cancer (colorectal cancer (CRC)) patients with Qi deficiency (QD) compared with those with Nondeficiency (ND).	twenty-five metabolites displayed differences between QD and ND	GC-MS	Serum	case vs.control group	28811829
METAC_732	218	colorectal cancer	Yin deficiency colorectal cancer	9256	Yin deficiency (YD)		F&M	30	Nondeficiency (ND)		F&M	30	Differential metabolites in the plasmas of colorectal cancer (CRC) patients with Yin deficiency (YD) compared with those with Nondeficiency (ND).	twenty-eight metabolites displayed differences between YD and ND	GC-MS	Serum	case vs.control group	28811829
METAC_733	177	colorectal cancer	Qi deficiency colorectal cancer	9256	Qi deficiency (QD)		F&M	30	Yin deficiency (YD)		F&M	30	Differential metabolites in the plasmas of colorectal cancer (CRC) patients with Qi deficiency (QD) compared with those with Yin deficiency (YD).	26 discriminating metabolites were identified	GC-MS	Serum	case vs.control group	28811829
METAC_734	46	colorectal cancer	nan	9256	colorectal cancer (CRC) patients	53.97	F&M	30	controls	55.23	F&M	30	Differential metabolites between controls and colorectal cancer (CRC) patients.	Twenty metabolites showed increasing levels in CRC and PLP patients comparing with controls and 30 metabolites with decreasing levels.	LC-MS/MS	Serum	case vs.control group	28640361
METAC_735	46	colorectal cancer	nan	9256	colorectal cancer (CRC) patients	53.97	F&M	30	colorectal adenoma polyps patients	51.87	F&M	30	Differential metabolites between colorectal adenoma polyps and colorectal cancer (CRC) patients.	Twenty metabolites showed increasing levels in CRC and PLP patients comparing with controls and 30 metabolites with decreasing levels.	LC-MS/MS	Serum	case vs.control group	28640361
METAC_736	46	colorectal cancer	nan	9256	colorectal cancer (CRC) patients	60.1 ± 9.8	F&M	25	controls	62.3 ± 14.0	F&M	10	Differential metabolites between controls and colorectal cancer (CRC) patients.	abnormal change of 2, 3-dinor-8-iso-PGF2α, 19-HETE and 12-keto-LTB4 from arachidonic acid were observed in colorectal cancer patients. Meanwhile, 9-HODE and 13-HODE from linoleic acid were significant lower	UPLC-MS/MS	Serum	case vs.control group	28515019
METAC_737	133	colorectal cancer	metastatic colorectal cancer	9256	metastatic colorectal cancer patients	51	F&M	52	controls	56.8	F&M	41	Differential metabolites between controls and metastatic colorectal cancer patients.	30 and 39 distinguishing metabolites were identified for the non-metastatic and metastatic CRC cases	¹H NMR	Colorectal tissue	case vs.control group	27748865
METAC_738	141	colorectal cancer	non‑metastatic colorectal cancer	9256	non‑metastatic colorectal cancer patients	57.8	F&M	73	controls	56.8	F&M	41	Differential metabolites between controls and non‑metastatic colorectal cancer patients.	30 and 39 distinguishing metabolites were identified for the non-metastatic and metastatic CRC cases	¹H NMR	Colorectal tissue	case vs.control group	27748865
METAC_739	55	colorectal cancer	metastatic colorectal cancer; non‑metastatic colorectal cancer	9256	metastatic colorectal cancer patients	51	F&M	52	non‑metastatic colorectal cancer patients	57.8	F&M	73	Differential metabolites between non‑metastatic colorectal cancer patients and metastatic colorectal cancer patients.	10 tissue metabolites (VIP >1 and p<0.05) were identified as potential biomarkers for use in discriminating between non-metastatic and metastatic CRC cases	¹H NMR	Colorectal tissue	case vs.control group	27748865
METAC_740	146	lung cancer	Non-Small Cell Lung Cancer	1324	progressive disease (PD) group		F&M	53	disease control (DC) group (including the PR and SD groups) 		F&M	198	Metabolites identified in the discovery disease control (DC) group (including the PR and SD groups) and the progressive disease (PD) group	nan	LC/MS-MS	Serum	case vs.control group	29437793
METAC_741	148	lung cancer	Non-Small Cell Lung Cancer	1324	NSCLC patients with poor survival		F&M	55	NSCLC patients with good survival		F&M	55	significant metabolites showing differential levels between non-small cell lung cancer (NSCLC) patients with poor and good survival in discovery phase	We found levels of 4 metabolites, caffeine, paraxanthine, stachydrine, and methyl glucopyranoside (alpha + beta), differed significantly between NSCLC patients with poor and good survival in both discovery and validation phases (P<0.05)	LC-MS/MS	Serum	case vs.control group	29173770
METAC_742	148	lung cancer	Non-Small Cell Lung Cancer	1324	NSCLC patients with poor survival		F&M	55	NSCLC patients with good survival		F&M	55	significant metabolites showing differential levels between non-small cell lung cancer (NSCLC) patients with poor and good survival in validation phase	We found levels of 4 metabolites, caffeine, paraxanthine, stachydrine, and methyl glucopyranoside (alpha + beta), differed significantly between NSCLC patients with poor and good survival in both discovery and validation phases (P<0.05)	LC-MS/MS	Serum	case vs.control group	29173770
METAC_743	64	lung cancer	adenocarcinoma, squamous cell carcinoma, otherwise specified NSCLC	1324	Cancer cases	60 (52-72)	F&M	31	controls	59 (52-73)	F&M	92	Compounds with differential abundance between early lung cancer and control samples	There were several metabolites detected in the sera whose abundances discriminated patients with lung cancer from controls. Majority of the differentiating components were downregulated in cancer samples, including amino acids, carboxylic acids and tocopherols, whereas benzaldehyde was the only compound significantly upregulated.	GC/MS	Serum	case vs.control group	28803255
METAC_744	65	lung cancer	Non-small-cell lung cancer	1324	Non-small-cell lung cancer	65 (53-86)	F&M	50	Control group	64 (50-78)	F&M	25	Compounds with differential abundance between early stage non-small-cell lung cancer and control	36 features were found significantly changed between NSCLC group and controls after FDR adjustment and 19 were identified using various metabolite databases (in-house library, HMDB, mzCloud).	LC-HRMS	Serum	case vs.control group	28168355
METAC_745	145	lung cancer	non-small cell lung cancer	1324	non-small cell lung cancer	68.3 ± 10	F&M	10	benign respiratory conditions	63.0 ± 13.3	F&M	10	Metabolites identified in exhaled breath condensate (EBC) samples between non-small cell lung cancer and patients with benign respiratory conditions	In the EBC samples, median concentrations of propionate, ethanol, acetate, and acetone were higher in lung cancer patients compared to the patients with benign conditions. Median concentration of methanol was lower in lung cancer patients (0.028 mM) than in patients with benign conditions (0.067 mM; P = 0.028).	¹H NMR	Breath sample	case vs.control group	27891048
METAC_746	145	lung cancer	non-small cell lung cancer	1324	non-small cell lung cancer 	68.3 ± 10	F&M	8	benign respiratory conditions	63.0 ± 13.3	F&M	10	Metabolites identified in sputum samples between non-small cell lung cancer and patients with benign respiratory conditions	In the combined sputum and saliva and the cytologically confirmed sputum samples, median concentrations of N-acetyl sugars, glycoprotein, propionate, lysine, acetate, and formate were lower in the lung cancer patients than in patients with benign conditions.	¹H NMR	Sputum	case vs.control group	27891048
METAC_747	52	colorectal cancer	stage I colorectal cancer	9256	stage I colorectal cancer	70.4	F&M	14	normal	67.7	F&M	60	Differential metabolites between stage I colorectal cancer patients and normal.	7 metabolites were upregulated and 29 were down-regulated compared to normal control samples	CE-TOF-MS	Serum	case vs.control group	27650200
METAC_748	52	colorectal cancer	stage II colorectal cancer	9256	stage II colorectal cancer	69.3	F&M	14	normal	67.7	F&M	60	Differential metabolites between stage II colorectal cancer patients and normal.	11 metabolites were up-regulated and 19 were down-regulated	CE-TOF-MS	Serum	case vs.control group	27650200
METAC_749	52	colorectal cancer	stage III colorectal cancer	9256	stage III colorectal cancer	71.2	F&M	14	normal	67.7	F&M	60	Differential metabolites between stage III colorectal cancer patients and normal.	5 metabolites were up-regulated and 39 were down-regulated	CE-TOF-MS	Serum	case vs.control group	27650200
METAC_750	52	colorectal cancer	stage IV colorectal cancer	9256	stage IV colorectal cancer	70.7	F&M	14	normal	67.7	F&M	60	Differential metabolites between stage IV colorectal cancer patients and normal.	6 metabolites were up-regulated and 28 were down-regulated compared to normal controls	CE-TOF-MS	Serum	case vs.control group	27650200
METAC_751	113	lung cancer	adenosquamous carcinoma, Adenocarcinomas, small cell carcinomas	1324	lung cancer	51.2 ± 10.6	F&M	25	healthy controls	49.5 ± 8.2	F&M	25	Concentrations of 23 serum free amino acids in lung cancer patients and healthy controls	We identified 25 metabolites that were differentially regulated between the lung cancer patients and matched controls. Of those, 16 were detected using the non-targeted approach and 9 were identified using the targeted approach. Both groups of metabolites could differentiate between lung cancer patients and healthy controls with 100% sensitivity and specificity.	RRLC	Serum	case vs.control group	27566571
METAC_753	52	colorectal cancer	stage I/II colorectal cancer	9256	stage I/II colorectal cancer (CRC) patients		F&M	68	healthy controls		F&M	32	Differential metabolites between the stage I/II colorectal cancer (CRC) patients and healthy controls.	The fecal metabolic profiles in CRC patients at an early stage were distinct from those of healthy controls.	¹H NMR	Stool	case vs.control group	27107423
METAC_754	158	pancreatic cancer	nan	1793	Pancreatic Cancer			14	benign disease/negative control			20	Differential metabolites between pancreatic cancer (PC) and BD/NC(benign disease/normal control).	Bile acids (especially taurocholic acid) performed to be potential biomarkers in PC diagnosis. Other amino acids (such as L-glutamine, glutamic acid, L-phenylalanine, L-tryptophan, and L-arginine) in serum samples from PC patients might provide a sensitive, blood-borne diagnostic signature for the presence of PC or its precursor lesions.	RPLC/HILIC	Serum	case vs.control group	32243985
METAC_755	158	pancreatic cancer	nan	1793	Pancreatic Cancer			14	benign disease			10	Differential metabolites between pancreatic cancer (PC) and BD(benign disease).	Bile acids (especially taurocholic acid) performed to be potential biomarkers in PC diagnosis. Other amino acids (such as L-glutamine, glutamic acid, L-phenylalanine, L-tryptophan, and L-arginine) in serum samples from PC patients might provide a sensitive, blood-borne diagnostic signature for the presence of PC or its precursor lesions.	RPLC/HILIC	Serum	case vs.control group	32243985
METAC_756	50	colorectal cancer	nan	9256	DP (disease progression)				CR (complete remission) + SD(stable disease)				Summary of metabolites with low p values (p < 0.05) using sequential metabolite ratios in comparing DP (disease progression) vs. CR (complete remission) + SD(stable disease).	19 metabolites from different compound classes, such as monosaccharides, amino acids, carboxylic acids, and nucleosides, showed a significant statistical difference	LC-MS/MS	Serum	case vs.control group	26342311
METAC_757	49	colorectal cancer	nan	9256	post-surgery colorectal cancer (CRC) patients		F&M	9	pre-surgery colorectal cancer (CRC) patients		F&M	79	Significantly altered metabolites distinguishing pre- from post-surgery colorectal cancer (CRC) patients	39 metabolites detected by GC-MS remained significant after adjustment for covariables and multiple testing (FDR <0.05), whereas only 2-aminobutyrate was found to be significant in our 1H-NMR analysis	GC-MS	Urine	case vs.control group	29250455
METAC_758	49	colorectal cancer	nan	9256	post-surgery colorectal cancer (CRC) patients		F&M	10	pre-surgery colorectal cancer (CRC) patients		F&M	88	Significantly altered metabolites distinguishing pre- from post-surgery colorectal cancer (CRC) patients	39 metabolites detected by GC-MS remained significant after adjustment for covariables and multiple testing (FDR <0.05), whereas only 2-aminobutyrate was found to be significant in our 1H-NMR analysis	¹H NMR	Urine	case vs.control group	29250455
METAC_759	113	lung cancer	nan	1324	lung cancer	66 ± 11	F&M	24	controls	56 ± 13	F&M	31	Altered metabolites in lung cancer (LC) bronchoalveolar lavage fluid (BALF) samples detected with DI-ESI-QTOF-MS	two complementary metabolomics tech?niques based on direct infusion high resolution mass spectrometry (DI-ESI-QTOF-MS) and gas chromatography mass spectrometry (GC–MS) have been applied to compare statistically differences between lung cancer (LC) and control (C) BALF samples, using partial least square discriminant analysis (PLS-DA) in order to find and iden?tify potential biomarkers of the disease. A total of 42 altered metabolites were found in BALF from LC.	DI-ESI-QTOF-MS	Bronchoalveolar lavage fluid	case vs.control group	27255828
METAC_760	113	lung cancer	nan	1324	lung cancer	66 ± 11	F&M	24	controls	56 ± 13	F&M	31	Altered metabolites in lung cancer (LC) bronchoalveolar lavage fluid (BALF) samples detected with GC-MS	two complementary metabolomics tech?niques based on direct infusion high resolution mass spectrometry (DI-ESI-QTOF-MS) and gas chromatography mass spectrometry (GC–MS) have been applied to compare statistically differences between lung cancer (LC) and control (C) BALF samples, using partial least square discriminant analysis (PLS-DA) in order to find and iden?tify potential biomarkers of the disease. A total of 42 altered metabolites were found in BALF from LC.	GC-MS	Bronchoalveolar lavage fluid	case vs.control group	27255828
METAC_761	47	colorectal cancer	nan	9256	subcutaneous adipose tissue (VST)	62.9 ± 13.7	F&M	59	visceral adipose tissue (VAT)	62.9 ± 13.7	F&M	59	The most significantly different metabolites between subcutaneous adipose tissue (SAT) and subcutaneous visceral adipose tissue (VAT).	The most significantly different metabolites between SAT and VAT based on a PLS VIP value (component 1) >1.5 and an FDR <0.051.	GC-TOF-MS	Serum	case vs.control group	26156741
METAC_762	48	colorectal cancer	nan	9256	post-BRB (black raspberries) urine			28	pre-BRB (black raspberries) urine			28	List of metabolites significantly changed in post-BRB (black raspberries) urine.	34 urinary metabolites were significantly changed by BRBs, including 31 increased metabolites and 3 decreased metabolites.	GC/MS	Urine	case vs.control group	26054356
METAC_763	48	colorectal cancer	nan	9256	post-BRB (black raspberries) plasma			28	pre-BRB (black raspberries) plasma			28	List of metabolites significantly changed in post-BRB (black raspberries (BRBs) ) plasma.	BRBs significantly increased 6 plasma metabolites.	GC/MS	Serum	case vs.control group	26054356
METAC_764	46	colorectal cancer	nan	9256	colorectal cancer (CRC) patients			33	controls				Differentiating metabolites between colorectal cancer (CRC) patient and controls.	15 main metabolites were identified	¹H NMR	Serum	case vs.control group	25202454
METAC_765	145	lung cancer	non-small cell lung cancer	1324	non-small cell lung cancer 		F&M	182	healthy individuals		F&M	87	Mean intensities and variations of the most significant metabolites found in the comparison between healthy individuals and non-small cell lung cancer (NSCLC) patients	We found that the metabolic profile of NSCLC patients, compared with healthy individuals, is characterized by statistically significant changes in the concentration of 18 metabolites representing different amino acids, organic acids and alcohols, as well as different lipids and molecules involved in lipid metabolism.	¹H NMR	Serum	case vs.control group	26883203
METAC_766	8	lung cancer	non-small cell lung cancer	1324	advanced-stage NSCLC patients		F&M	90	early-stage NSCLC patients		F&M	92	Mean intensities and variations of the most significant metabolites found in the comparison between early-stage and advanced-stage non-small cell lung cancer (NSCLC) patients	The analysis of the differences between the metabolic profiles of NSCLC patients at different stages of the disease revealed the existence of 17 metabolites involved in metabolic changes associated with disease progression.	¹H NMR	Serum	case vs.control group	26883203
METAC_767	145	lung cancer	non-small cell lung cancer	1324	non-small cell lung cancer 		F&M	182	benign pulmonary diseases(BPD) patients		F&M	27	Variations of the mean intensities of the most relevant metabolites involved in the discrimination between benign pulmonary diseases(BPD) patients and non-small cell lung cancer (NSCLC) patients	nan	¹H NMR	Serum	case vs.control group	26883203
METAC_768	113	lung cancer	squamous cell carcinoma, adenocarcinoma , small cell carcinoma, large cell carcinoma, non-small cell lung cancer	1324	lung cancer patients	63 ± 7 	F&M	48	healthy controls	60 ± 9 	F&M	61	Differentiating metabolites between lung cancer patients and healthy controls	Tentative compounds that contribute to discrimination between the three groups were identified, and a relevant role for lipids such as monoacylglycerols and squalene was found. These results could support the ability of metabolomics to go inside the study of lung cancer.	GC-TOF/MS	Breath sample	case vs.control group	26866403
METAC_769	113	lung cancer	squamous cell carcinoma, adenocarcinoma , small cell carcinoma, large cell carcinoma, non-small cell lung cancer	1324	lung cancer patients	63 ± 7 	F&M	48	risk factor group	61 ± 8	F&M	130	Differentiating metabolites between lung cancer patients and risk factor group (130 individuals, all of them active smokers or ex-smokers)	Tentative compounds that contribute to discrimination between the three groups were identified, and a relevant role for lipids such as monoacylglycerols and squalene was found. These results could support the ability of metabolomics to go inside the study of lung cancer.	GC-TOF/MS	Breath sample	case vs.control group	26866403
METAC_770	113	lung cancer	nan	1324	Preoperative lung cancer group (PRLC)	61.58 ± 10.67	F&M	30	Control group	60.35 ± 12.48	F&M	30	LC-Q-TOF/MS identification of potential biomarker between Preoperative lung cancer group (PRLC) and Control group	nan	LC-QTOF-MS	Serum	case vs.control group	25961003
METAC_771	114	lung cancer	nan	1324	Postoperative lung cancer group (POLC)	61.58 ± 10.67	F&M	30	Control group	60.35 ± 12.48	F&M	30	LC-Q-TOF/MS identification of potential biomarker between Postoperative lung cancer group (POLC) and Control group	nan	LC-QTOF-MS	Serum	case vs.control group	25961003
METAC_772	114	lung cancer	nan	1324	Preoperative lung cancer group (PRLC)	61.58 ± 10.67	F&M	30	Postoperative lung cancer group (POLC)	61.58 ± 10.67	F&M	30	LC-Q-TOF/MS identification of potential biomarker between Preoperative lung cancer group (PRLC) and Postoperative lung cancer group (POLC)	nan	LC-QTOF-MS	Serum	case vs.control group	25961003
METAC_773	113	lung cancer	nan	1324	Preoperative lung cancer group (PRLC)	61.58 ± 10.67	F&M	30	Control group	60.35 ± 12.48	F&M	30	GC/MS identification of potential biomarker between Preoperative lung cancer group (PRLC) and Control group	nan	GC/MS	Serum	case vs.control group	25961003
METAC_774	114	lung cancer	nan	1324	Postoperative lung cancer group (POLC)	61.58 ± 10.67	F&M	30	Control group	60.35 ± 12.48	F&M	30	GC/MS identification of potential biomarker between Postoperative lung cancer group (POLC) and Control group	nan	GC/MS	Serum	case vs.control group	25961003
METAC_775	114	lung cancer	nan	1324	Preoperative lung cancer group (PRLC)	61.58 ± 10.67	F&M	30	Postoperative lung cancer group (POLC)	61.58 ± 10.67	F&M	30	GC/MS identification of potential biomarker between Preoperative lung cancer group (PRLC) and Postoperative lung cancer group (POLC)	nan	GC/MS	Serum	case vs.control group	25961003
METAC_776	113	lung cancer	nan	1324	lung cancer	63 (42-87)	F&M	41	control individuals		F&M	55	metabolites in sweat to discriminate between lung cancer patients and control individuals	nan	LC-QTOF MS/MS	Sweat	case vs.control group	25935675
METAC_777	113	lung cancer	NSCLC, adenocarcinoma	1324	Lung cancer		F&M	18	Control		F&M	20	Mean and fold change between cancer and control subjects in Study 1(FHCRC, 18 cancer patients and 20 controls)	Differential analysis identified 15 known metabolites in one study and 18 in a second study that were statistically different (p-values <0.05). Levels of maltose, palmitic acid, glycerol, ethanolamine, glutamic acid, and lactic acid were increased in cancer samples while amino acids tryptophan, lysine and histidine decreased.	GC-TOF-MS	Blood	case vs.control group	25859693
METAC_778	113	lung cancer	NSCLC, SCLC, Mesothelioma	1324	Lung cancer		F&M	11	Control		F&M	11	Mean and fold change between cancer and control subjects in Study 2 (UC Davis ,contained 11 subjects in each group)	Differential analysis identified 15 known metabolites in one study and 18 in a second study that were statistically different (p-values <0.05). Levels of maltose, palmitic acid, glycerol, ethanolamine, glutamic acid, and lactic acid were increased in cancer samples while amino acids tryptophan, lysine and histidine decreased.	GC-TOF-MS	Blood	case vs.control group	25859693
METAC_779	113	lung cancer	Squamous cell carcinoma, Adenocarcinoma, Small cell carcinoma, Non Small cell carcinoma	1324	lung cancer (LC)		F&M	100	healthy non-smokers (NS)		F&M	96	Metabolites between lung cancer (LC) and healthy non-smokers (NS)	nan	GC-MS	Plasma	case vs.control group	25712604
METAC_780	113	lung cancer	adenocarcinoma, squamous cell carcinoma, sarcomatoid carcinomas, large cell carcinomas, adenosquamous carcinomas, carcinoid tumours, small cell carcinomas	1324	lung cancer	62 ± 10	F&M	56	control tissues	62 ± 10	F&M	56	Metabolites showing statistically significant differences between lung tumours and control tissues	Notably, the magnitude of those differences were clearly distinct for AdC and SqCC: major alterations in AdC were related to phospholipid metabolism (increased phosphocholine, glycerophosphocholine and phosphoethanolamine, together with decreased acetate) and protein catabolism (increased peptide moieties), whereas SqCC had stronger glycolytic and glutaminolytic profiles (negatively correlated variations in glucose and lactate and positively correlated increases in glutamate and alanine). Other tumour metabolic features were increased creatine, glutathione, taurine and uridine nucleotides, the first two being especially prominent in SqCC and the latter in AdC.	NMR	Lung tissue	case vs.control group	25368033
METAC_781	2	lung cancer	Adenocarcinoma	1324	Adenocarcinoma 		F&M	19	control tissues		F&M	19	Metabolites showing statistically significant differences between Adenocarcinoma and control tissues	Notably, the magnitude of those differences were clearly distinct for AdC and SqCC: major alterations in AdC were related to phospholipid metabolism (increased phosphocholine, glycerophosphocholine and phosphoethanolamine, together with decreased acetate) and protein catabolism (increased peptide moieties), whereas SqCC had stronger glycolytic and glutaminolytic profiles (negatively correlated variations in glucose and lactate and positively correlated increases in glutamate and alanine). Other tumour metabolic features were increased creatine, glutathione, taurine and uridine nucleotides, the first two being especially prominent in SqCC and the latter in AdC.	NMR	Lung tissue	case vs.control group	25368033
METAC_782	121	lung cancer	Squamous cell lung tumours	1324	Squamous cell lung tumours		F&M	19	control tissues		F&M	19	Metabolites showing statistically significant differences between Squamous cell lung tumours and control tissues	Notably, the magnitude of those differences were clearly distinct for AdC and SqCC: major alterations in AdC were related to phospholipid metabolism (increased phosphocholine, glycerophosphocholine and phosphoethanolamine, together with decreased acetate) and protein catabolism (increased peptide moieties), whereas SqCC had stronger glycolytic and glutaminolytic profiles (negatively correlated variations in glucose and lactate and positively correlated increases in glutamate and alanine). Other tumour metabolic features were increased creatine, glutathione, taurine and uridine nucleotides, the first two being especially prominent in SqCC and the latter in AdC.	NMR	Lung tissue	case vs.control group	25368033
METAC_783	2	lung cancer	Adenocarcinoma , Squamous cell lung tumours	1324	Adenocarcinoma 		F&M	19	Squamous cell lung tumours		F&M	19	Metabolites showing statistically significant differences between Adenocarcinoma and Squamous cell lung cancer	Notably, the magnitude of those differences were clearly distinct for AdC and SqCC: major alterations in AdC were related to phospholipid metabolism (increased phosphocholine, glycerophosphocholine and phosphoethanolamine, together with decreased acetate) and protein catabolism (increased peptide moieties), whereas SqCC had stronger glycolytic and glutaminolytic profiles (negatively correlated variations in glucose and lactate and positively correlated increases in glutamate and alanine). Other tumour metabolic features were increased creatine, glutathione, taurine and uridine nucleotides, the first two being especially prominent in SqCC and the latter in AdC.	NMR	Lung tissue	case vs.control group	25368033
METAC_784	113	lung cancer	nan	1324	preoperative lung cancer	61.58 ± 10.67	F&M	30	control groups	60.35 ± 12.48	F&M	30	Potential biomarkers found by LC/MS analysis of preoperative lung cancer and control groups	Based on pattern recognition results and univariate analysis, we showed that levels of ten potential biomarkers in serum were significantly different in the preoperative lung cancer patients compared with healthy volunteers and/or the postoperative lung cancer patients. The levels of sphingosine, phosphorylcholine, glycerophospho-N-arachidonoyl ethanolamine, γ-linolenic acid, 9,12-octadecadienoic acid, oleic acid, and serine were significantly different in preoperative lung cancer patients compared to healthy volunteers and to postoperative lung cancer patients. For prasterone sulfate, α-hydroxyisobutyric acid, 2,3,4-trihydroxybutyric acid, the levels were statistically different in preoperative and postoperative lung cancer patients compared with the healthy volunteers.	LC/MS	Serum	case vs.control group	25293627
METAC_785	114	lung cancer	nan	1324	postoperative lung cancer	61.58 ± 10.67	F&M	30	preoperative lung cancer	61.58 ± 10.67	F&M	30	Potential biomarkers found by LC/MS analysis of preoperative lung cancer and postoperative lung cancer samples	Based on pattern recognition results and univariate analysis, we showed that levels of ten potential biomarkers in serum were significantly different in the preoperative lung cancer patients compared with healthy volunteers and/or the postoperative lung cancer patients. The levels of sphingosine, phosphorylcholine, glycerophospho-N-arachidonoyl ethanolamine, γ-linolenic acid, 9,12-octadecadienoic acid, oleic acid, and serine were significantly different in preoperative lung cancer patients compared to healthy volunteers and to postoperative lung cancer patients. For prasterone sulfate, α-hydroxyisobutyric acid, 2,3,4-trihydroxybutyric acid, the levels were statistically different in preoperative and postoperative lung cancer patients compared with the healthy volunteers.	LC/MS	Serum	case vs.control group	25293627
METAC_786	114	lung cancer	nan	1324	postoperative lung cancer	61.58 ± 10.67	F&M	30	control groups	60.35 ± 12.48	F&M	30	Potential biomarkers found by LC/MS analysis of postoperative lung cancer and control groups	Based on pattern recognition results and univariate analysis, we showed that levels of ten potential biomarkers in serum were significantly different in the preoperative lung cancer patients compared with healthy volunteers and/or the postoperative lung cancer patients. The levels of sphingosine, phosphorylcholine, glycerophospho-N-arachidonoyl ethanolamine, γ-linolenic acid, 9,12-octadecadienoic acid, oleic acid, and serine were significantly different in preoperative lung cancer patients compared to healthy volunteers and to postoperative lung cancer patients. For prasterone sulfate, α-hydroxyisobutyric acid, 2,3,4-trihydroxybutyric acid, the levels were statistically different in preoperative and postoperative lung cancer patients compared with the healthy volunteers.	LC/MS	Serum	case vs.control group	25293627
METAC_787	113	lung cancer	nan	1324	preoperative lung cancer	61.58 ± 10.67	F&M	30	control groups	60.35 ± 12.48	F&M	30	Potential biomarkers found by GC/MS analysis of preoperative lung cancer and control groups	Based on pattern recognition results and univariate analysis, we showed that levels of ten potential biomarkers in serum were significantly different in the preoperative lung cancer patients compared with healthy volunteers and/or the postoperative lung cancer patients. The levels of sphingosine, phosphorylcholine, glycerophospho-N-arachidonoyl ethanolamine, γ-linolenic acid, 9,12-octadecadienoic acid, oleic acid, and serine were significantly different in preoperative lung cancer patients compared to healthy volunteers and to postoperative lung cancer patients. For prasterone sulfate, α-hydroxyisobutyric acid, 2,3,4-trihydroxybutyric acid, the levels were statistically different in preoperative and postoperative lung cancer patients compared with the healthy volunteers.	GC/MS	Serum	case vs.control group	25293627
METAC_788	114	lung cancer	nan	1324	postoperative lung cancer	61.58 ± 10.67	F&M	30	preoperative lung cancer	61.58 ± 10.67	F&M	30	Potential biomarkers found by GC/MS analysis of preoperative lung cancer and postoperative lung cancer samples	Based on pattern recognition results and univariate analysis, we showed that levels of ten potential biomarkers in serum were significantly different in the preoperative lung cancer patients compared with healthy volunteers and/or the postoperative lung cancer patients. The levels of sphingosine, phosphorylcholine, glycerophospho-N-arachidonoyl ethanolamine, γ-linolenic acid, 9,12-octadecadienoic acid, oleic acid, and serine were significantly different in preoperative lung cancer patients compared to healthy volunteers and to postoperative lung cancer patients. For prasterone sulfate, α-hydroxyisobutyric acid, 2,3,4-trihydroxybutyric acid, the levels were statistically different in preoperative and postoperative lung cancer patients compared with the healthy volunteers.	GC/MS	Serum	case vs.control group	25293627
METAC_789	114	lung cancer	nan	1324	postoperative lung cancer	61.58 ± 10.67	F&M	30	control groups	60.35 ± 12.48	F&M	30	Potential biomarkers found by GC/MS analysis of postoperative lung cancer and control groups	Based on pattern recognition results and univariate analysis, we showed that levels of ten potential biomarkers in serum were significantly different in the preoperative lung cancer patients compared with healthy volunteers and/or the postoperative lung cancer patients. The levels of sphingosine, phosphorylcholine, glycerophospho-N-arachidonoyl ethanolamine, γ-linolenic acid, 9,12-octadecadienoic acid, oleic acid, and serine were significantly different in preoperative lung cancer patients compared to healthy volunteers and to postoperative lung cancer patients. For prasterone sulfate, α-hydroxyisobutyric acid, 2,3,4-trihydroxybutyric acid, the levels were statistically different in preoperative and postoperative lung cancer patients compared with the healthy volunteers.	GC/MS	Serum	case vs.control group	25293627
METAC_790	46	colorectal cancer	nan	9256	colorectal cancer (CRC) patients	58	F&M	66	healthy controls	57	F&M	92	Differential metabolites between colorectal cancer (CRC) patients and healthy controls.	42 of these metabolites showed statistical significance between CRC patients and healthy controls	LC-MS	Serum	case vs.control group	25126899
METAC_791	46	colorectal cancer	nan	9256	colorectal cancer (CRC) patients	58	F&M	66	polyp patients	56	F&M	76	Differential metabolites between colorectal cancer (CRC) patients and polyp patients.	48 showed statistically significant differences between CRC and polyp patients	LC-MS	Serum	case vs.control group	25126899
METAC_792	46	colorectal cancer	nan	9256	colorectal cancer (CRC) patients	57 (31-79)	F&M	85	adjacent normal controls	57 (31-79)	F&M	85	Identified differential metabolites between colorectal cancer (CRC) patients and adjacent normal controls.	nan	GC-TOF-MS	Colorectal tissue	case vs.control group	24526730
METAC_793	46	colorectal cancer	nan	9256	colorectal cancer (CRC) patients	61 (34-84)	F&M	65	adjacent normal controls	61 (34-84)	F&M	65	Identified differential metabolites between colorectal cancer (CRC) patients and adjacent normal controls.	nan	GC-TOF-MS	Colorectal tissue	case vs.control group	24526730
METAC_794	46	colorectal cancer	nan	9256	colorectal cancer (CRC) patients	61 (40-75)	F&M	23	adjacent normal controls	61 (40-75)	F&M	23	Identified differential metabolites between colorectal cancer (CRC) patients and adjacent normal controls.	nan	GC-TOF-MS	Colorectal tissue	case vs.control group	24526730
METAC_795	46	colorectal cancer	nan	9256	colorectal cancer (CRC) patients	59 (35-81)	F&M	20	adjacent normal controls	59 (35-81)	F&M	20	Identified differential metabolites between colorectal cancer (CRC) patients and adjacent normal controls.	nan	GC-TOF-MS	Colorectal tissue	case vs.control group	24526730
METAC_796	46	colorectal cancer	nan	9256	colorectal cancer (CRC) patients	64.5 ± 8.2	F&M	11	healthy subjects	57.4 ± 10.1	F&M	10	Fecal marker metabolites differentiating colorectal cancer (CRC) patients and healthy subjects.	All 3 identified metabolites were found at lower levels in the feces of CRC patients compared with healthy subjects.	GC-TOF-MS	Stool	case vs.control group	24424155
METAC_797	46	colorectal cancer	nan	9256	colorectal cancer (CRC) tumor mucosae	66.4 ± 8.7	F&M	8	colorectal cancer (CRC) normal mucosae	66.4 ± 8.7	F&M	8	Tissue marker metabolites differentiating colorectal cancer (CRC) tumor and matched normal mucosae.	Glucose, galactose, 3-phosphoglycerate, citric acid, inosine, and creatinine were reduced while uracil, uridine, and proline were elevated in the tumor tissue compared with matched normal mucosae	GC-TOF-MS	Mucosa	case vs.control group	24424155
METAC_798	46	colorectal cancer	nan	9256	colorectal cancer (CRC) patients	63.7 ± 17.7	F&M	11	healthy individuals	40.7 ± 14.6	F&M	10	Candidate stool metabolites identified from GC-MS chromatograms that differ between colorectal cancer (CRC) and healthy individuals.	acetic and valeric acids were significantly higher in stool samples from CRC patients (p<0.0001 and p = 0.024 respectively) while butyric acid was significantly higher in the feces of healthy individuals	GC/MS	Stool	case vs.control group	23940645
METAC_799	46	colorectal cancer	nan	9256	colorectal cancer (CRC) patients	60.1 (24-82)	F&M	62	healthy controls	59.4 (31-75)	F&M	62	Differential Serum Metabolites between colorectal cancer (CRC) Patients and Healthy Controls.	A panel of serum metabolite markers is of great potential as a noninvasive diagnostic method for the detection of CRC.	GC-TOF-MS	Serum	case vs.control group	23675754
METAC_800	46	colorectal cancer	nan	9256	colorectal cancer group	37-87	F&M	20	control group	50-86	F&M	14	Different metabolites identified in normal control group and colorectal cancer group.	Among the metabolites, the lactic acid, arginine, isoleucine, leucine, and valine were significantly upregulated, while the citric acid, histidine, methionine, serine, aspartate, malic acid, and succinate were remarkably downregulated in CRC compared to the normal control subjects (P < 0.01).	CE-ESI-MS	Urine	case vs.control group	23243419
METAC_801	52	colorectal cancer	nan	9256	advanced group	39-80	F&M	12	early stage group	37-87	F&M	8	Different metabolites identified in early stage group and advanced group.	The levels of valine and isoleucine were lower in advanced stage colorectal cancer group than the early colorectal cancer group.	CE-ESI-MS	Urine	case vs.control group	23243419
METAC_802	46	colorectal cancer	nan	9256	colorectal cancer (CRC) patients	67.7	F&M	60	healthy individuals	64.5	F&M	60	The sensitivity and specificity of the metabolites whose levels differed significantly between the colorectal cancer patients and healthy volunteers.	27 metabolites were selected as biomarker candidates	GC/MS	Serum	case vs.control group	22792336
METAC_803	46	colorectal cancer	nan	9256	colorectal cancer (CRC) Patient Group				Healthy Adult Group				Endogenous Serum Metabolites of the Healthy Adult Group and colorectal cancer (CRC) Patient Group as Measured by GC-MS.	6 metabolites were selected and confirmed as potential biomarkers	GC/MS	Serum	case vs.control group	22395091
METAC_804	46	colorectal cancer	nan	9256	Fetus Group				Healthy Adult Group				Endogenous Serum Metabolites of the Healthy Adult Group and Fetus Group as Measured by GC-MS.	the similar metabolic patterns between CRC and fetus serum represent shared metabolic regulatory pathways in tumorigenesis and embryogenesis	GC/MS	Serum	case vs.control group	22395091
METAC_805	46	colorectal cancer	nan	9256	colorectal cancer (CRC) patients	59 (24−83)	F&M	61	healthy controls	60 (31−75)	F&M	62	Representative Differential Metabolites Contributed for the Separation between the colorectal cancer (CRC) Patients and the Healthy Controls Derived from UPLC-QTOFMS and GC-TOFMS Analysis	A panel of 35 metabolites with VIP threshold (VIP > 1) from the training set and p-value (p < 0.001) were selected as metabolite markers	UPLC-QTOF-MS; GC-TOFMS	Urine	case vs.control group	22148915
METAC_806	113	lung cancer	nan	1324	Lung cancer		F&M	23	Healthy control		F&M	23	Potential biomarkers for lung cancer patients compare with healthy controls	In total, 27 differential metabolites were identified, which were mostly related to the perturbation of lipid metabolism, including choline, free fatty acids, lysophosphatidylcholines, etc.	UPLC/Q-TOF MS	Serum	case vs.control group	24856296
METAC_807	145	lung cancer	non-small cell lung cancer	1324	non-small cell lung cancer	38-74	F&M	20	healthy volunteers	35-66	F&M	20	Qualitative identification results of differential urine metabolites of non-small cell lung cancer (NSCLC)	Twenty differential metabolites were identified based on standard compounds or tandem mass spectrometry fragments. Among them, some medium-/long-chain acylcarnitines, for example, cis-3,4-methylene heptanoylcarnitine, were found to be downregulated while carnitine was upregulated in urine samples from the cancer group compared to the control group.	UHPLC-Q-TOF	Urine	case vs.control group	24771673
METAC_808	113	lung cancer	ADC, SCC, NSCLC	1324	Lung cancer	66.2	F&M	469	Healthy control	66.6	F&M	536	Association of top four metabolites with lung cancer diagnosis in the training set in all cases .	Creatine riboside was the strongest classifier of lung cancer status in all and stage I-II cases, important for early detection of lung cancer	UPLC-ESI-QTOFMS	Urine	case vs.control group	24736543
METAC_809	6	lung cancer	ADC, SCC, NSCLC	1324	stages I–II lung cancer		F&M	213	Healthy control	66.6	F&M	536	Association of top four metabolites with lung cancer diagnosis in the training set in cases of stages I-II.	Creatine riboside was the strongest classifier of lung cancer status in all and stage I-II cases, important for early detection of lung cancer	UPLC-ESI-QTOFMS	Urine	case vs.control group	24736543
METAC_810	113	lung cancer	non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC)	1324	Malignant group (NSCLC/SCLC)	73 (53-85)	F&M	20	Benign group (tuberculous pleurisy/pneumonia)	63.6 (44-86)	F&M	20	metabolites found in pleural effusions with significant difference between lung cancer and benign groups	5 compounds including cyclohexanone and 2-ethyl-1-hexanol were found to be statistically different (Student's t-test, P<0.05) between the two groups by statistical analysis based on the peak areas of all identified metabolites. Among them, cyclohexanone and 2-ethyl-1-hexanol might be considered as candidate biomarkers of lung cancer to differentiate malignant from benign effusions.	GC/MS	Pleural effusion	case vs.control group	24321761
METAC_811	113	lung cancer	small cell lung cancer (SCLC), non- small cell lung cancer (NSCLC)	1324	lung adenocarcinoma 	63 (40-81)	F&M	31	healthy persons	37 (29-50)	F&M	28	Plasma metabolites derived from GC-MS and LC-MS contributing to the discrimination between patients with lung adenocarcinoma and healthy persons	The OPLS-DA models derived from both GC-MS and LC-MS showed significant discriminations in metabolic profiles between cases and healthy controls. It was found that around 37 metabolites contributed to the differences. The alterations of these metabolites implied disturbances in amino acids, lipids, fatty acids and glutaminolysis metabolism in human lung adenocarcinoma.	GC-MS;LC-MS	Plasma	case vs.control group	23857124
METAC_812	113	lung cancer	nan	1324	lung cancer		F&M	19	patients with other lung diseases 		F&M	15	Significantly changed metabolites in serum of lung cancer and other lung diseases	The t-test results indicated a total of 13 metabolites in the serum and 7 metabolites in the urine with statistically significant differences.	GC/MS	Serum	case vs.control group	22510503
METAC_813	113	lung cancer	nan	1324	lung cancer		F&M	19	patients with other lung diseases 		F&M	15	Significantly changed metabolites in urine of lung cancer and other lung diseases	The t-test results indicated a total of 13 metabolites in the serum and 7 metabolites in the urine with statistically significant differences.	GC/MS	Urine	case vs.control group	22510503
METAC_814	113	lung cancer	adenocarcinoma, epidermoid carcinoma, carcinoid, sarcomatoid carcinoma, large cell carcinoma, small cell carcinoma, adenosquamous carcinoma	1324	Lung Cancer Patients 	63 (30-85)	F&M	85	Healthy Subjects	41 (22-60)	F&M	78	Main Metabolites Contributing to the Discrimina- tion between Plasma of Lung Cancer Patients and of Healthy Subjects	Relatively lower HDL and higher VLDL + LDL in the patients' plasma, together with increased lactate and pyruvate and decreased levels of glucose, citrate, formate, acetate, several amino acids (alanine, glutamine, histidine, tyrosine, valine), and methanol, could be detected.	NMR	Plasma	case vs.control group	21744875
METAC_815	192	colorectal cancer	nan	9256	proximal to left side tumor tissue	66.8 ± 17.2	F&M	20	proximal to right side tumor tissue	66.8 ± 17.2	F&M	20	Concentrations of resveratrol and its major metabolites in normal tissue (proximal or distal to the tumor) and tumor tissue, obtained from the right (cecum, ascending colon, hepatic flexure) or left side (splenic flexure, descending colon, sigmoid colon, rectum) of the colorectum, in patients who received resveratrol daily for 8 days at 0.5g.	Individual values varied substantially from each other, reflected by coefficients of variation in some cases exceeding 200%, both between specific tissue sites for each individual and for each site between patients.	HPLC/UV	Colorectal tissue	case vs.control group	20841478
METAC_816	192	colorectal cancer	nan	9256	left side tumor tissue	66.8 ± 17.2	F&M	20	right side tumor tissue	66.8 ± 17.2	F&M	20	Concentrations of resveratrol and its major metabolites in normal tissue (proximal or distal to the tumor) and tumor tissue, obtained from the right (cecum, ascending colon, hepatic flexure) or left side (splenic flexure, descending colon, sigmoid colon, rectum) of the colorectum, in patients who received resveratrol daily for 8 days at 0.5g.	Individual values varied substantially from each other, reflected by coefficients of variation in some cases exceeding 200%, both between specific tissue sites for each individual and for each site between patients.	HPLC/UV	Colorectal tissue	case vs.control group	20841478
METAC_817	192	colorectal cancer	nan	9256	distal to left side tumor tissue	66.8 ± 17.2	F&M	20	distal to right side tumor tissue	66.8 ± 17.2	F&M	20	Concentrations of resveratrol and its major metabolites in normal tissue (proximal or distal to the tumor) and tumor tissue, obtained from the right (cecum, ascending colon, hepatic flexure) or left side (splenic flexure, descending colon, sigmoid colon, rectum) of the colorectum, in patients who received resveratrol daily for 8 days at 0.5g.	Individual values varied substantially from each other, reflected by coefficients of variation in some cases exceeding 200%, both between specific tissue sites for each individual and for each site between patients.	HPLC/UV	Colorectal tissue	case vs.control group	20841478
METAC_818	192	colorectal cancer	nan	9256	proximal to left side tumor tissue	66.8 ± 17.2	F&M	20	proximal to right side tumor tissue	66.8 ± 17.2	F&M	20	Concentrations of resveratrol and its major metabolites in normal tissue (proximal or distal to the tumor) and tumor tissue, obtained from the right (cecum, ascending colon, hepatic flexure) or left side (splenic flexure, descending colon, sigmoid colon, rectum) of the colorectum, in patients who received resveratrol daily for 8 days at 1.0g.	Individual values varied substantially from each other, reflected by coefficients of variation in some cases exceeding 200%, both between specific tissue sites for each individual and for each site between patients.	HPLC/UV	Colorectal tissue	case vs.control group	20841478
METAC_819	192	colorectal cancer	nan	9256	left side tumor tissue	66.8 ± 17.2	F&M	20	right side tumor tissue	66.8 ± 17.2	F&M	20	Concentrations of resveratrol and its major metabolites in normal tissue (proximal or distal to the tumor) and tumor tissue, obtained from the right (cecum, ascending colon, hepatic flexure) or left side (splenic flexure, descending colon, sigmoid colon, rectum) of the colorectum, in patients who received resveratrol daily for 8 days at 1.0g.	Individual values varied substantially from each other, reflected by coefficients of variation in some cases exceeding 200%, both between specific tissue sites for each individual and for each site between patients.	HPLC/UV	Colorectal tissue	case vs.control group	20841478
METAC_820	192	colorectal cancer	nan	9256	distal to left side tumor tissue	66.8 ± 17.2	F&M	20	distal to right side tumor tissue	66.8 ± 17.2	F&M	20	Concentrations of resveratrol and its major metabolites in normal tissue (proximal or distal to the tumor) and tumor tissue, obtained from the right (cecum, ascending colon, hepatic flexure) or left side (splenic flexure, descending colon, sigmoid colon, rectum) of the colorectum, in patients who received resveratrol daily for 8 days at 1.0g.	Individual values varied substantially from each other, reflected by coefficients of variation in some cases exceeding 200%, both between specific tissue sites for each individual and for each site between patients.	HPLC/UV	Colorectal tissue	case vs.control group	20841478
METAC_821	117	lung cancer	Squamous cell carcinoma, Adenocarcinoma, Small cell lung carcinoma, Malignant mesothelioma	1324	CT (i.e.,centre tissue of tumor) 		F&M	17	AT (i.e., adjacent tissue of tumor)		F&M	17	Significantly changed metabolites CT (i.e.,centre tissue of tumor) and AT (i.e., adjacent tissue of tumor)	Compared with the adjacent noninvolved tissues, the lung cancer tissues had significantly high levels of aspartate, phosphocholine, glycerophosphocholine and lactate but significantly low levels of glucose and valine.	¹H NMR	Lung tissue	case vs.control group	21523825
METAC_822	117	lung cancer	Squamous cell carcinoma, Adenocarcinoma, Small cell lung carcinoma, Malignant mesothelioma	1324	CT (i.e.,centre tissue of tumor) 		F&M	17	PT (i.e., parenchyma tissue of tumor)		F&M	17	Significantly changed metabolites CT (i.e.,centre tissue of tumor) and PT (i.e., parenchyma tissue of tumor)	nan	¹H NMR	Lung tissue	case vs.control group	21523825
METAC_823	64	lung cancer	adenocarcinoma, squamous cell carcinoma, small cell lung carcinoma	1324	early stage lung cancer 		F&M	11	healthy volunteers	64 (34-78)	F&M	29	The list of significantly changed metabolites (p < 0.05) in serum of early stage lung cancer patients and healthy volunteers.	nan	GC/MS	Serum	case vs.control group	21411176
METAC_824	6	lung cancer	adenocarcinoma, squamous cell carcinoma, small cell lung carcinoma	1324	advanced stage lung cancer 		F&M	22	healthy volunteers	64 (34-78)	F&M	29	The list of significantly changed metabolites (p < 0.05) in serum of advanced stage lung cancer patients and healthy volunteers.	nan	GC/MS	Serum	case vs.control group	21411176
METAC_825	113	lung cancer	adenocarcinoma, squamous cell carcinoma, small cell lung carcinoma	1324	lung cancer	65 (55-81)	F&M	33	healthy volunteers	64 (34-78)	F&M	29	The list of significantly changed metabolites (p < 0.05) in serum of lung cancer patients and healthy volunteers.	The levels of 23 of the 58 serum metabolites were significantly changed in all lung cancer patients compared with healthy volunteers, and the levels of 48 of the 71 metabolites were significantly changed in the tumor tissue compared with the non-tumor tissue.	GC/MS	Serum	case vs.control group	21411176
METAC_826	113	lung cancer	adenocarcinoma, squamous cell carcinoma	1324	lung cancer tumour tissue	61 (53-82)	F&M	7	non-tumor lung tissues	61 (53-82)	F&M	7	The list of significantly changed metabolites (p < 0.05) in tumor and non-tumor lung tissues.	The levels of 23 of the 58 serum metabolites were significantly changed in all lung cancer patients compared with healthy volunteers, and the levels of 48 of the 71 metabolites were significantly changed in the tumor tissue compared with the non-tumor tissue.	GC/MS	Lung tissue	case vs.control group	21411176
METAC_827	113	lung cancer	adenocarcinomas, epidermoid carcinomas, carcinoids, sarcomatoid carcinomas, large cell carcinomas, small cell carcinomas, adenosquamous carcinoma	1324	lung cancer	64 (43-85)	F&M	71	Healthy Subjects	42 (25-57)	F&M	54	Main Metabolites Contributing for the Discrimination between Lung Cancer Patients and Healthy Subjects	The main metabolites contributing to this discrimination, as highlighted by multivariate analysis and confirmed by spectral integration, were hippurate and trigonelline (reduced in patients), and β-hydroxyisovalerate, α-hydroxyisobutyrate, N-acetylglutamine, and creatinine (elevated in patients relatively to controls).	¹H NMR	Urine	case vs.control group	21058631
METAC_828	46	colorectal cancer	nan	9256	colorectal cancer (CRC) patients			50	healthy controls			34	Significantly changed metabolites found from the OSC-PLS model of ‘global’ metabolic profiling.	Significantly changed metabolites found from the OSC-PLS model of ‘global’ metabolic profiling.	UPLC-MS	Urine	case vs.control group	20617254
METAC_829	46	colorectal cancer	nan	9256	colorectal cancer (CRC) patients			50	healthy controls			34	Significantly changed metabolites found from the OSC-PLS model of urinary nucleosides profiling.	Significantly changed metabolites found from the OSC-PLS model of urinary nucleosides profiling.	UPLC-MS	Urine	case vs.control group	20617254
METAC_830	113	lung cancer	Adenocarcinoma, squamous cell cancer	1324	lung ancer		F&M	35	healthy controls		F&M	32	Potential biomarkers of lung cancer identified from lung cancer and healthy controls	Eleven potential biomarkers, ten from HILIC column and one from the second RP column, were identified and all of these biomarkers were found upregulated in lung cancer patients	HILIC/RPLC-MS	Urine	case vs.control group	20309903
METAC_831	46	colorectal cancer	nan	9256	colorectal cancer (CRC) patients	58.8 (42-76)	F&M	60	healthy controls	55.5 (42-74)	F&M	63	List of Identified Differential Metabolites between Preoperative colorectal cancer (CRC) Patients and Healthy Controls	Using GC−MS spectral databases, we were able to identify 15 metabolites, of which 9 were verified by standard compounds	GC/MS	Serum	case vs.control group	20121166
METAC_832	46	colorectal cancer	nan	9256	colorectal cancer (CRC) patients	59 (42-74)	F&M	64	healthy controls	55 (42-69)	F&M	65	Differential Metabolites Derived from OPLS-DA Mode of GC-TOFMS Analysis with Wilcoxon-Mann-Whitney Test.	Twenty-two metabolites were identified using MS spectral databases and 14 were confirmed	GC-TOF-MS	Serum	case vs.control group	19678709
METAC_833	46	colorectal cancer	nan	9256	colorectal cancer (CRC) patients	59 (42-74)	F&M	64	healthy controls	55 (42-69)	F&M	65	Differential Metabolites Derived from OPLS-DA Mode of UPLC-QTOFMS Analysis with Wilcoxon-Mann-Whitney Test	A total of 16 metabolites identified from UPLC−QTOFMS positive ion mode and negative ion mode are demonstrated	UPLC-QTOF-MS	Serum	case vs.control group	19678709
METAC_834	46	colorectal cancer	nan	9256	colorectal cancer (CRC) colon mucosae	67 ± 13	F&M	31	normal colon mucosae	67 ± 13	F&M	31	1H Chemical Shifts of Marker Metabolites Found in HR-MAS NMR Spectra of Human CRC and Normal Colon Mucosae.	The percentage changes of these metabolites in cancer compared to the normal mucosae were also consistent in direction and order of magnitude between the two analytical platforms	HR-MAS NMR	Mucosa	case vs.control group	19063642
METAC_835	46	colorectal cancer	nan	9256	colorectal cancer (CRC) patients	63.2 ± 12.6	F&M	21	healthy controls	58.1 ± 11.9	F&M	11	Resonance intensity ratios, standard deviation and P values (analysis of variance) for the most relevant metabolites in differentiation of fecal water extracts from controls and patients with colorectal cancer	A low concentration of short-chain fatty acids, such as acetate and butyrate, previously associated with the development of colorectal cancer, appears to be the most effective marker. Concentrations of proline and cysteine, which are major components of most colonic epithelium mucus glycoproteins, also display significant changes in samples from colorectal cancer	NMR	Stool	case vs.control group	19006102
METAC_836	145	lung cancer	non-small-cell lung cancer (NSCLC)	1324	non-small-cell lung cancer (NSCLC) 	62.7 (34-83)	F&M	141	controls	61.1 (32-82)	F&M	423	Significantly changed metabolites in plasma of non-small-cell lung cancer (NSCLC) and controls	The plasma amino-acid profiles significantly differed between the NSCLC patients and the controls.	HPLC-ESI-MS	Plasma	case vs.control group	21176209
METAC_837	113	lung cancer	nan	1324	lung cancer		F&M	100	controls		F&M	100	Plasma sphingolipid concentrations in lung cancer cases (n=100) and matched controls (n=200)	nan	LC/MS/ MS	Plasma	case vs.control group	23749868
METAC_838	198	lung cancer	adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma	1324	preoperative ipsilateral lungs				preoperative ipsilateral lungs				Potential biomarkers in exhaled breath samples from preoperative contralateral and ipsilateral lungs	nan	GC/MS	Breath sample	case vs.control group	25482491
METAC_839	198	lung cancer	adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma	1324	postoperative contralateral lungs				postoperative ipsilateral lungs				Potential biomarkers in exhaled breath samples from postoperative contralateral and ipsilateral lungs	nan	GC/MS	Breath sample	case vs.control group	25482491
METAC_840	114	lung cancer	adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma	1324	Ipsilateral lung preoperative				Ipsilateral lung postoperative				Potential biomarkers in exhaled breath samples from Ipsilateral lung preoperative and postoperative	nan	GC/MS	Breath sample	case vs.control group	25482491
METAC_841	114	lung cancer	adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma	1324	postoperative group				preoperative group				Potential biomarkers in blood samples from preoperative and postoperative group	nan	GC/MS	Blood	case vs.control group	25482491
METAC_842	2	lung cancer	adenocarcinoma	1324	Lung Cancer	72.33 ± 8.78	F&M	39	non-malignant tissue	72.33 ± 8.78	F&M	39	Significantly altered metabolites and key discriminants of biochemical changes in adenocarcinoma compared to non-malignant tissue	Cancer-associated biochemical alterations were characterized by (i) decreased glucose levels, consistent with the Warburg effect, (ii) changes in cellular redox status highlighted by elevations in cysteine and antioxidants, alpha- and gamma-tocopherol, (iii) elevations in nucleotide metabolites 5,6-dihydrouracil and xanthine suggestive of increased dihydropyrimidine dehydrogenase and xanthine oxidoreductase activity, (iv) increased 5'-deoxy-5'-methylthioadenosine levels indicative of reduced purine salvage and increased de novo purine synthesis, and (v) coordinated elevations in glutamate and UDP-N-acetylglucosamine suggesting increased protein glycosylation. The present study revealed distinct metabolic perturbations associated with early stage lung adenocarcinoma, which may provide candidate molecular targets for personalizing therapeutic interventions and treatment efficacy monitoring.	GC-TOF-MS	Lung tissue	case vs.control group	25657018
METAC_843	2	lung cancer	adenocarcinoma	1324	Adenocarcinoma lung cancer	65.9 ± 9.87	F&M	49	Healthy controls	64.1 ± 8.97	F&M	31	Serum metabolites in Adenocarcinoma Lung Cancer ADC1 training sets.	nan	GC-TOF-MS	Serum	case vs.control group	26282632
METAC_844	2	lung cancer	adenocarcinoma	1324	Adenocarcinoma lung cancer	65.9 ± 8.05	F&M	43	Healthy controls	38.6 ± 26.46	F&M	43	Serum metabolites in Adenocarcinoma Lung Cancer ADC2 test sets.	nan	GC-TOF-MS	Serum	case vs.control group	26282632
METAC_845	2	lung cancer	adenocarcinoma	1324	Adenocarcinoma lung cancer	65.9 ± 9.66	F&M	52	Healthy controls	64.1 ± 8.97	F&M	31	Plasma metabolite in Adenocarcinoma Lung Cancer ADC1 training sets.	nan	GC-TOF-MS	Plasma	case vs.control group	26282632
METAC_846	2	lung cancer	adenocarcinoma	1324	Adenocarcinoma lung cancer	65.9 ± 8.05	F&M	43	Healthy controls	38.6 ± 26.46	F&M	43	Plasma metabolite in Adenocarcinoma Lung Cancer ADC2 test sets.	nan	GC-TOF-MS	Plasma	case vs.control group	26282632
METAC_847	113	lung cancer	nan	1324	lung tumor tissues			52	adjacent normal tissues			21	Potential biomarkers of lung tumors from lung cancer and adjacent tissues	In this study, we developed an in situ metabolomics method based on ambient mass spectrometry imaging using air flow-assisted desorption electrospray ionization (AFADESI), which can spatially explore the alteration of global metabolites in tissues with high sensitivity. Using this method, we discovered potential histopathological diagnosis biomarkers (including lipids, amino acids, choline, peptides, and carnitine) from 52 postoperative lung cancer tissue samples and then subsequently used these biomarkers to generate images for rapid and label-free histopathological diagnosis.	LC-MS/MS	Lung tissue	case vs.control group	26404114
METAC_848	144	lung cancer	Non–Small Cell cancer	1324	Non–Small Cell cancer	68.7	F&M	94	controls	66.2	F&M	190	Metabolite alterations in Non-Small Cell cancer patients than controls	Differences in the serum metabolite profile exist between patients with stage I through stage III non-small cell lung cancer and matched controls.	GC/MS;LC/MS	Serum	case vs.control group	26762741
METAC_849	113	lung cancer	nan	1324	lung cancer			40	healthy controls			100	Comparison of concentrations of amino acids and acylcarnitines between controls and lung cancer patients	The results showed that the serum concentration of lung cancer patients were significant from those of healthy controls.	LC-MS/MS	Serum	case vs.control group	27129889
METAC_850	145	lung cancer	non-small cell lung cancer (NSCLC)	1324	non-small cell lung cancer (NSCLC)		F&M	90	control group		F&M	60	Median values of the organic acid concentration levels determined in the serum from the patients with non-small cell lung cancer (NSCLC) and control subjects	nan	LC-MS/MS	Serum	case vs.control group	27454081
METAC_851	145	lung cancer	Non-small cell lung cancer patients	1324	non-small cell lung cancer (NSCLC)	64 ± 6.9	F&M	90	control group	62 ± 8.7	F&M	63	The determined concentration levels of free amino acids in the analyzed serum samples from the patients with non-small cell lung cancer (NSCLC) and control subjects	nan	LC-MS/MS	Serum	case vs.control group	27597283
METAC_852	145	lung cancer	Non-small cell lung cancer patients	1324	non-small cell lung cancer (NSCLC)	62.1 ± 6.7	F&M	30	healthy controls	51.7 ± 7.1	F&M	30	The average concentration of PCs by targeted metabolomics in non-small cell lung cancer (NSCLC) patients and healthy controls	The identified biomarker candidates were further externally validated via a targeted metabolomics analysis. The global metabolomics profiles could clearly distinguish NSCLC patients from HC. Phosphatidylcholine (PC) levels were found to be dysregulated in glycerophospholipid (GPL) metabolism, which was the top altered pathway in early-stage NSCLC. Compared with those in HC, significant increases in the levels of saturated and monounsaturated PCs such as PC (15:0/18:1), PC (18:0/16:0) and PC (18:0/20:1) were observed in NSCLC. Additionally, relative to those in HC, the levels of 9 polyunsaturated PCs, namely, PC (17:2/2:0), PC (18:4/3:0), and PC (15:0/18:2), and so on were significantly decreased in NSCLC patients.	UHPLC-Q-TOF/MS	Serum	case vs.control group	29740076
METAC_853	2	lung cancer	Adenocarcinoma	1324	Adenocarcinoma screening group	59 (44-80)	F&M	28	controls	58 (47-80)	F&M	56	Differential metabolites associated with Adenocarcinoma screening group	Orthogonal Projections to Latent Structures Discriminant Analysis (OPLS-DA) modeling indicated that 28 endogenous metabolites were present at significantly different levels in patients with NSCLC than healthy controls (variable importance in projection (VIP)>1 and P<0.001 (independent samples t-test) in both the screening group and the validation group). Significant associations between specific plasma metabolites and the pathological type or stage of NSCLC were also observed.	UPLC-MS	Plasma	case vs.control group	29896992
METAC_854	2	lung cancer	Adenocarcinoma	1324	Adenocarcinoma validation group	59 (43-71)	F&M	24	controls	59 (42-79)	F&M	56	Differential metabolites associated with Adenocarcinoma validation group	Orthogonal Projections to Latent Structures Discriminant Analysis (OPLS-DA) modeling indicated that 28 endogenous metabolites were present at significantly different levels in patients with NSCLC than healthy controls (variable importance in projection (VIP)>1 and P<0.001 (independent samples t-test) in both the screening group and the validation group). Significant associations between specific plasma metabolites and the pathological type or stage of NSCLC were also observed.	UPLC-MS	Plasma	case vs.control group	29896992
METAC_855	121	lung cancer	Squamous cell carcinoma	1324	Squamous cell carcinoma screening group	59.8 (43-83)	F&M	25	controls	58 (47-80)	F&M	56	Differential metabolites associated with Squamous cell carcinoma screening group	Orthogonal Projections to Latent Structures Discriminant Analysis (OPLS-DA) modeling indicated that 28 endogenous metabolites were present at significantly different levels in patients with NSCLC than healthy controls (variable importance in projection (VIP)>1 and P<0.001 (independent samples t-test) in both the screening group and the validation group). Significant associations between specific plasma metabolites and the pathological type or stage of NSCLC were also observed.	UPLC-MS	Plasma	case vs.control group	29896992
METAC_856	121	lung cancer	Squamous cell carcinoma	1324	Squamous cell carcinoma validation group	60.5 (42-73)	F&M	22	controls	59 (42-79)	F&M	56	Differential metabolites associated with Squamous cell carcinoma validation group	Orthogonal Projections to Latent Structures Discriminant Analysis (OPLS-DA) modeling indicated that 28 endogenous metabolites were present at significantly different levels in patients with NSCLC than healthy controls (variable importance in projection (VIP)>1 and P<0.001 (independent samples t-test) in both the screening group and the validation group). Significant associations between specific plasma metabolites and the pathological type or stage of NSCLC were also observed.	UPLC-MS	Plasma	case vs.control group	29896992
METAC_857	199	lung cancer	small-cell lung cancer (SCLC)	1324	small-cell lung cancer (SCLC)			20	controls			20	The discriminated metabolites between Control and small-cell lung cancer (SCLC) group obtained by LC- (±) MS/MS analysis.	The results showed that 43 metabolites were significantly changed, and arginine metabolism was apparently disturbed, which proved the proposed approach could be a powerful tool for discovering reliable disease biomarkers and aberrant metabolic pathways.	LC-MS/MS	Plasma	case vs.control group	30473010
METAC_859	8	lung cancer	non‑small cell lung cancer	1324	Lung cancer patients 	62 ± 5	F&M	20	Healthy controls	63 ± 6	F&M	20	List of differentiating metabolites with their serum concentrations determined in the studied groups	Among the assayed lipid species, the significant differences between NSCLC and non-cancer subjects were observed in the group of phosphatidylcholines (PC) and lysophosphatidylcholines (lysoPC), especially in the levels of lysoPC a C26:0; lysoPC a C26:1; PC aa C42:4; and PC aa C34:4.	Triple quadrupole tandem mass spectrometer 4000 QTRAP	Serum	case vs.control group	31264112
METAC_860	145	lung cancer	non‑small cell lung cancer	1324	non-small cell lung cancer		F	64	Healthy controls		F	63	Serum lipidomic biomarkers for non-small cell lung cancer in nonsmoking female patients	We observed that levels of unsaturated fatty acids clearly decreased, while saturated fatty acids and lysophosphatidylethanolamines pronouncedly increased in Lca patients, compared with the healthy controls, which revealed significant disturbance of lipid metabolism in NSCLC females.	UHPLC-Q-TOF/MS	Serum	case vs.control group	32145537
METAC_861	113	lung cancer	nan	1324	lung cancer	62 (56−69)	F&M	57	healthy controls	60 (59−62)	F&M	59	Differential putative metabolites between lung cancer and healthy control in discovery cohort	The results showed that 15 metabolites were significantly dysregulated between LC and HC, and a panel, comprising cholesterol, oleic acid, myo-inositol, 2-hydroxybutyric acid, and 4-hydroxybutyric acid, was demonstrated to have excellent differentiating capability for LC based on multiple classification modelings	GC-MS	Serum	case vs.control group	34056907
METAC_862	113	lung cancer	nan	1324	lung cancer		F&M	98	healthy controls		F&M	75	Qualitative identification results of differential plasma metabolites of lung cancer.	Metabolites with different polarities (amino acids, fatty acids, and acylcarnitines) can be detected and identified as differential metabolites of lung cancer in small volumes of plasma.	LC-MS	Plasma	case vs.control group	34083687
METAC_863	170	prostate cancer	nan	10283	prostate cancer(PC)	65.9 ± 6.5	M	41	benign prostatic hyperplasia (BPH)	65.2 ± 7.3	M	32	List of 12 compounds with VIP >1 relevant to differentiate prostate cancer (PC) from benign prostatic hyperplasia (BPH) patient samples.	nan	UHPLC-HRMS	Urine	case vs.control group	33863412
METAC_864	170	prostate cancer	nan	10283	prostate cancer(PC)	70 (46-84)	M	41	benign prostatic hyperplasia (BPH)	70 (46-87)	M	38	The differential metabolites between prostate cancer (PC) and benign prostatic hyperplasia (BPH)	The results showed that twelve metabolites were significantly dysregulated between PCa and BPH, three metabolites including L-serine, myo-inositol, and decanoic acid could be potential biomarkers for discriminating PCa from BPH	GC-MS	Plasma	case vs.control group	33831421
METAC_865	170	prostate cancer	nan	10283	prostate cancer(PC)		M	15	Non‐cancer epithelium (NCE)		M	15	The differential metabolites between prostate cancer (PC) and Non-cancer epithelium (NCE) in negative ion mode	nan	MALDI-TOF MS	Prostate tissue	case vs.control group	33514438
METAC_866	170	prostate cancer	nan	10283	prostate cancer(PC)		M	15	stroma		M	15	The differential metabolites between prostate cancer (PC) and stroma in negative ion mode	nan	MALDI-TOF MS	Prostate tissue	case vs.control group	33514438
METAC_867	170	prostate cancer	nan	10283	prostate cancer(PC)		M	15	Non‐cancer epithelium (NCE)		M	15	The differential metabolites between prostate cancer (PC) and Non-cancer epithelium (NCE) in positive ion mode	nan	MALDI-TOF MS	Prostate tissue	case vs.control group	33514438
METAC_868	170	prostate cancer	nan	10283	prostate cancer(PC)		M	15	stroma		M	15	The differential metabolites between prostate cancer (PC) and stroma in positive ion mode	nan	MALDI-TOF MS	Prostate tissue	case vs.control group	33514438
METAC_869	170	prostate cancer	nan	10283	prostate cancer	70.00 ± 8.98	M	50	controls	63.30 ± 9.61	M	50	Twenty identified metabolites between prostate cancer and control group	The present study highlights that guanidinoacetate, phenylacetylglycine, and glycine are potential candidate biomarkers of PC.	¹H NMR	Urine	case vs.control group	33498542
METAC_870	170	prostate cancer	nan	10283	prostate cancer		M	40	controls		M	43	Statistically significant plasma and urine metabolites in patients with prostate cancer compared to those in healthy controls.	Eleven urinary and three plasma metabolites were selected as statistically significant in patients with CaP as compared to those in healthy controls.	GC-QqQ/MS	Urine	case vs.control group	32969349
METAC_871	81	prostate cancer	nan	10283	high-GS(Gleason Score)	64.33 ± 11.60	M	30	low-GS(Gleason Score)	65.69 ± 6.61	M	36	Mean intensities and variations for the metabolites identified in the serum samples of low- and high-GS(Gleason Score) prostate cancer patients	Serum and urine samples were collected from 73 PCa patients. Samples were classified according to their Gleason score (GS) into low-GS (GS < 7) and high-GS PCa (GS ≥ 7) groups. A total of 36 metabolic pathways were found to be dysregulated in the comparison between different PCa grades. Particularly, the levels of glucose, glycine and 1-methlynicotinamide, metabolites involved in energy metabolism and nucleotide synthesis were significantly altered between both groups of patients. These results underscore the potential of targeted metabolomic profiling to characterize relevant metabolic changes involved in the progression of this neoplastic process.	NMR	Serum	case vs.control group	32924497
METAC_872	81	prostate cancer	nan	10283	high-GS(Gleason Score)	64.47 ± 11.23	M	32	low-GS(Gleason Score)	65.66 ± 6.95	M	41	Mean intensities and variations for the metabolites identified in the urine samples of low- and high-GS(Gleason Score) prostate cancer patients	Serum and urine samples were collected from 73 PCa patients. Samples were classified according to their Gleason score (GS) into low-GS (GS < 7) and high-GS PCa (GS ≥ 7) groups. A total of 36 metabolic pathways were found to be dysregulated in the comparison between different PCa grades. Particularly, the levels of glucose, glycine and 1-methlynicotinamide, metabolites involved in energy metabolism and nucleotide synthesis were significantly altered between both groups of patients. These results underscore the potential of targeted metabolomic profiling to characterize relevant metabolic changes involved in the progression of this neoplastic process.	NMR	Urine	case vs.control group	32924497
METAC_873	99	prostate cancer	nan	10283	Hormone-Sensitive Prostate Cancer (HSPC)	71.6 ± 2.8	M	39	Benign Prostatic Hyperplasia (BPH)	65.3 ± 2.7	M	39	Changes in Selected Metabolites and Their Diagnosis Values among Hormone-Sensitive Prostate Cancer (HSPC) and Benign Prostatic Hyperplasia (BPH)	Based on these metabolic changes, we identified potential biomarker panels for the discrimination between BPH vs HSPC, BPH vs CRPC, and HSPC vs CRPC with the AUC values of 0.995, 0.972, and 0.937, respectively. Collectively, tissue-based metabolomics analysis not only identifies the altered metabolic pathways during PCa progression but also has the potential to help the classification and diagnosis of PCa in clinical practice.	NMR	Prostate tissue	case vs.control group	32702989
METAC_874	38	prostate cancer	nan	10283	Castration-Resistant Prostate Cancer (CRPC)	70.8 ± 2.5	M	25	Benign Prostatic Hyperplasia (BPH)	65.3 ± 2.7	M	39	Changes in Selected Metabolites and Their Diagnosis Values among Castration-Resistant Prostate Cancer (CRPC) and Benign Prostatic Hyperplasia (BPH)	Based on these metabolic changes, we identified potential biomarker panels for the discrimination between BPH vs HSPC, BPH vs CRPC, and HSPC vs CRPC with the AUC values of 0.995, 0.972, and 0.937, respectively. Collectively, tissue-based metabolomics analysis not only identifies the altered metabolic pathways during PCa progression but also has the potential to help the classification and diagnosis of PCa in clinical practice.	NMR	Prostate tissue	case vs.control group	32702989
METAC_875	38	prostate cancer	nan	10283	Castration-Resistant Prostate Cancer (CRPC)	70.8 ± 2.5	M	25	Hormone-Sensitive Prostate Cancer (HSPC)	71.6 ± 2.8	M	39	Changes in Selected Metabolites and Their Diagnosis Values among Castration-Resistant Prostate Cancer (CRPC) and Hormone-Sensitive Prostate Cancer (HSPC)	Based on these metabolic changes, we identified potential biomarker panels for the discrimination between BPH vs HSPC, BPH vs CRPC, and HSPC vs CRPC with the AUC values of 0.995, 0.972, and 0.937, respectively. Collectively, tissue-based metabolomics analysis not only identifies the altered metabolic pathways during PCa progression but also has the potential to help the classification and diagnosis of PCa in clinical practice.	NMR	Prostate tissue	case vs.control group	32702989
METAC_876	170	prostate cancer	nan	10283	prostate cancer (PCa)	63 ± 7	M	13	adjacent benign tissue (ABT)	63 ± 7	M	13	Selected significant metabolites of mass spectrometry cohort(prostate cancer and adjacent benign tissue (ABT))	nan	CE-MS;LC-MS	Prostate tissue	case vs.control group	32640711
METAC_877	176	prostate cancer	prostatic intraepithelial neoplasia (PIN)	10283	prostatic intraepithelial neoplasia (PIN) 		M	16	controls		M	38	Discrimination of most predictive metabolites between prostatic intraepithelial neoplasia (PIN) and control	nan	GC-MS;LC-MS	Plasma	case vs.control group	32556743
METAC_878	170	prostate cancer	nan	10283	prostate cancer (PCa)		M	27	controls		M	38	Discrimination of most predictive metabolites between prostate cancer (PCa) and control	nan	GC-MS;LC-MS	Plasma	case vs.control group	32556743
METAC_879	81	prostate cancer	nan	10283	Gleason score ≥7		M	10	Gleason score <7		M	17	Signifcant comparisons of metabolites according to Gleason score in the prostate cancer (PCa) group	nan	GC-MS;LC-MS	Plasma	case vs.control group	32556743
METAC_880	96	prostate cancer	nan	10283	Lotus (Nelumbo nucifera) bee pollen (LBP) with High hydrostatic pressure (HHP) treatment				Lotus (Nelumbo nucifera) bee pollen (LBP) without High hydrostatic pressure (HHP) treatment				Metabolites positively identiﬁed in Lotus (Nelumbo nucifera) bee pollen (LBP) without High hydrostatic pressure (HHP) treatment (control) and treated with HHP.	HHP treatment enhanced anti-proliferative activities, cell apoptosis, cell cycle disruption, glutathione- depletion in prostate cancer PC-3 cells. The metabolomics analysis showed that some metabolites such as chaetoglobosin A, glutathione oxidized, cyanidin 3-rutinoside, brassicoside, sophoranone, curcumin II, soyasa- ponin II were signiﬁcantly increased (p < 0.05) after the HHP treatment	LC-MS	PC-3 cells	case vs.control group	32505838
METAC_881	170	prostate cancer	nan	10283	prostate cancer (PCa)		M	59	controls		M	60	List of metabolites signifcantly altered in urine from prostate cancer (PCa) patients compared to controls by GC-MS and 1H NMR spectroscopy	nan	GC-MS;¹H NMR	Urine	case vs.control group	32495062
METAC_882	170	prostate cancer	nan	10283	prostate cancer tissues		M	70	benign prostate tissues		M	59	Metabolic alterations in prostate cancer tissues compared to benign prostate tissues	nan	NMR;LC/MS	Prostate tissue	case vs.control group	32423389
METAC_883	81	prostate cancer	nan	10283	high Gleason score (GS ≥ 7) 		M	27	low Gleason score (GS = 6) prostate cancer		M	43	Metabolic alterations in high Gleason score (GS ≥ 7) to low Gleason score (GS = 6) prostate cancer	nan	NMR;LC/MS	Prostate tissue	case vs.control group	32423389
METAC_884	73	prostate cancer	nan	10283	ERG Rearrangement-positive prostate cancer(PC) 		M	46	ERG Rearrangement-negative PC		M	24	Metabolic alterations in ERG Rearrangement-positive prostate cancer(PC) versus ERG Rearrangement-negative PC	nan	NMR;LC/MS	Prostate tissue	case vs.control group	32423389
METAC_885	170	prostate cancer	nan	10283	prostate cancer (PCa)	64.4 ± 6.4	M	40	controls	59.3 ± 3.0	M	42	List of volatile organic compounds (VOCs) signiﬁcantly altered in prostate cancer (PCa) group compared to controls	nan	GC-MS	Urine	case vs.control group	31588123
METAC_886	170	prostate cancer	nan	10283	prostate cancer (PCa)	63.7 ± 6.5	M	40	controls	59.3 ± 2.8	M	40	List of volatile carbonyl compounds (VCCs) signiﬁcantly altered in prostate cancer (PCa) group compared to controls	nan	GC-MS	Urine	case vs.control group	31588123
METAC_887	170	prostate cancer	nan	10283	Malignant prostate cancer	65.21 ± 5.68	M	39	Benign prostate disease	63.79 ± 5.27	M	39	plasma arginine level and its downstream metabolites in diagnosing prostate cancer	Plasma arginine, ornithine, AOR and urinary diacetylspermine levels may be used as molecular markers to predict prostate biopsy outcomes in patients with PSA 4–10 ng/ml.	LC-MS/MS	Plasma	case vs.control group	31444697
METAC_888	184	prostate cancer	nan	10283	PC patients with rectal proctitis		M	6	PC patients without rectal proctitis		M	93	Predictive biomarkers of rectal proctitis post-prostate Radiation therapy (SBRT)	nan	UPLC-QQQ-MS	Plasma	case vs.control group	31576546
METAC_889	216	prostate cancer	nan	10283	PC patients with urinary late effects (flare)		M	16	PC patients without urinary late effects (flare)		M	83	Table showing a 9 metabolites panel predictive of urinary flare patients treated with prostate Radiation therapy (SBRT)	nan	UPLC-QQQ-MS	Plasma	case vs.control group	31576546
METAC_890	170	prostate cancer	nan	10283	prostate cancer (PCa)	59 ± 4	M	61	controls	58 ± 7	M	42	Chemical Identities of Prostate Cancer Compounds Involved in the oPLS-DA ModelA	nan	FI-TWIM-MS/MS	Serum	case vs.control group	30379062
METAC_891	170	prostate cancer	nan	10283	prostate cancer (PCa)	59 ± 4	M	61	controls	58 ± 7	M	42	Chemical Identities of Prostate Cancer Compounds Involved in the oPLS-DA ModelB	nan	FI-TWIM-MS/MS	Serum	case vs.control group	30379062
METAC_892	170	prostate cancer	nan	10283	prostate cancer (PCa)	68.1 ± 8.4	M	103	participants without prostate cancer	64.1 ± 8.1	M	78	Descriptive statistics for hormonal and biochemical profiles in prostate cancer and non-prostate cancer	nan	electrochemiluminescent assay (ECLIA)	Blood	case vs.control group	30354924
METAC_893	170	prostate cancer	nan	10283	prostate cancer (PCa)	64 ± 4.41)	M	31	benign prostate hyperplasia (BPH)	70 ± 5.71	M	14	metabolites identified between prostate cancer (PCa) and benign prostate hyperplasia (BPH)	We detected 248 metabolites belonging to different chemical families including amino acids and various lipid species. Among these metabolites, 76 exhibited significant differential abundance between PCa and BPH.	UHPLC-MS	Urine	case vs.control group	29760869
METAC_894	174	prostate cancer	nan	10283	prostate cancer (PCa) stage3	64.5 ± 4.68	M	15	prostate cancer (PCa) stage2	64 ± 4.12	M	16	metabolites identified between prostate cancer (PCa) stage3 and stage 2	nan	UHPLC-MS	Urine	case vs.control group	29760869
METAC_895	172	prostate cancer	nan	10283	prostate cancer (PCa) Perineural invasion(P1) 	64 ± 3.47	M	10	prostate cancer (PCa) Perineural non-invasion(P0)	65.5 ± 5.02	M	6	metabolites identified between prostate cancer (PCa) Perineural invasion(P1) and non-invasion(P0)	nan	UHPLC-MS	Urine	case vs.control group	29760869
METAC_896	201	prostate cancer	nan	10283	SPOP-mutated PCa tumor (PCT)		M	11	adjacent non-tumor (ANT) tissues		M	11	Differential metabolites in SPOP-mutated cohort	nan	GC-MS;LC-MS	Prostate tissue	case vs.control group	29262542
METAC_898	170	prostate cancer	nan	10283	prostate cancer	71 (64-80)	M	62	healthy control	62.5 (57.8-69)	M	42	Differential metabolites in urine between prostate cancer patients and healthy control	The research provided 28 significant metabolites tentatively identified in urine, used to develop a partial least squares discriminant analysis (PLS-DA) model.	LC-QTOF	Urine	case vs.control group	27910903
METAC_899	169	prostate cancer	nan	10283	peripheral zone		M	18	transitional zone		M	18	Significant differences in metabolite concentrations between peripheral zone and transitional zone	nan	GC-MS;LC-MS	Prostate tissue	case vs.control group	29156692
METAC_900	175	prostate cancer	nan	10283	recurrent prostate cancers	62.5 ± 5	M	50	non-recurrent prostate cancers	61.7 ± 6	M	60	Metabolite concentrations and ratio levels in non-recurrent and recurrent prostate cancers following radical prostatectomy	Spermine concentration and tChoCre/Spm ratio in prostatectomy specimens were independent prognostic markers of recurrence.	HR-MAS MRS	Prostate tissue	case vs.control group	28972967
METAC_902	170	prostate cancer	nan	10283	prostate cancer (PCa)	66.2 (50.0-86.3)	M	64	benign prostatic hyperplasia (BPH)	62.1 (41.4-74.5)	M	51	Signifcant metabolites between individuals diagnosed with prostate cancer (PCa) and benign prostatic hyperplasia (BPH)	The urine metabolomic profile of PCa patients is characterised by increased concentrations of branched-chain amino acids (BCAA), glutamate and pseudouridine, and decreased concentrations of glycine, dimethylglycine, fumarate and 4-imidazole-acetate compared with individuals diagnosed with BPH.	¹H NMR	Urine	case vs.control group	28804274
METAC_903	170	prostate cancer	nan	10283	prostate cancer (PCa)	66.6 ±8.2	M	34	benign prostatic hyperplasia (BPH)	63.6 ±7.5	M	25	The concentrations of different metabolites between prostate cancer (PCa) and benign prostatic hyperplasia (BPH) in the prediction score group	nan	HPLC-(QTOF)-MS	Blood	case vs.control group	28776421
METAC_904	180	prostate cancer	nan	10283	before radical prostatectomy (rPX)	68.5 (50.0−88.0)	M	34	after radical prostatectomy (rPX)	68.5 (50.0−88.0)	M	34	List of 23 annotated metabolites showing significant changes in urine levels 8 weeks after radical prostatectomy (rPX)	We annotated 23 metabolites showing significant changes eight weeks after rPX. While the levels of uridine and six acylcarnitines in urine were increased before surgery, lower levels were detected for 16 metabolites, like e.g. citrate, phenyl-lactic acid, choline, myo-inositol, emphasizing a relevant pathophysiological role of these biomarkers and the associated metabolic pathways. These results have important implications for potential use of metabolome analyses for detection of prostate cancer and related pathologic and molecular features.	ACQUITY-UHPLC	Urine	case vs.control group	34371449
METAC_905	179	prostate cancer	nan	10283	2/3 weeks radiation therapy to the prostate and pelvic lymph nodes (PLNRT)	66 (63-72)	M	32	baseline	66 (63-72)	M	32	Plasma metabolite between 2/3 weeks radiation therapy to the prostate and pelvic lymph nodes (PLNRT) and baseline	nan	LC-MS/MS;¹H NMR	Plasma	case vs.control group	34352290
METAC_416	179	prostate cancer	nan	10283	2/3 weeks radiation therapy to the prostate and pelvic lymph nodes (PLNRT)	66 (63-72)	M	32	baseline	66 (63-72)	M	32	Urine metabolite between 2/3 weeks radiation therapy to the prostate and pelvic lymph nodes (PLNRT) and baseline	nan	LC-MS/MS;¹H NMR	Urine	case vs.control group	34352290
METAC_417	179	prostate cancer	nan	10283	2/3 weeks radiation therapy to the prostate and pelvic lymph nodes (PLNRT)	66 (63-72)	M	32	baseline	66 (63-72)	M	32	Stool metabolite between 2/3 weeks radiation therapy to the prostate and pelvic lymph nodes (PLNRT) and baseline	nan	¹H NMR	Stool	case vs.control group	34352290
METAC_906	179	prostate cancer	nan	10283	4/5 weeks radiation therapy to the prostate and pelvic lymph nodes (PLNRT)	66 (63-72)	M	32	2/3 weeks radiation therapy to the prostate and pelvic lymph nodes (PLNRT)	66 (63-72)	M	32	Plasma metabolite between 4/5 weeks and 2/3 weeks radiation therapy to the prostate and pelvic lymph nodes (PLNRT)	nan	LC-MS/MS;¹H NMR	Plasma	case vs.control group	34352290
METAC_418	179	prostate cancer	nan	10283	4/5 weeks radiation therapy to the prostate and pelvic lymph nodes (PLNRT)	66 (63-72)	M	32	2/3 weeks radiation therapy to the prostate and pelvic lymph nodes (PLNRT)	66 (63-72)	M	32	Urine metabolite between 4/5 weeks and 2/3 weeks radiation therapy to the prostate and pelvic lymph nodes (PLNRT)	nan	LC-MS/MS;¹H NMR	Urine	case vs.control group	34352290
METAC_419	179	prostate cancer	nan	10283	4/5 weeks radiation therapy to the prostate and pelvic lymph nodes (PLNRT)	66 (63-72)	M	32	2/3 weeks radiation therapy to the prostate and pelvic lymph nodes (PLNRT)	66 (63-72)	M	32	Stool metabolite between 4/5 weeks and 2/3 weeks radiation therapy to the prostate and pelvic lymph nodes (PLNRT)	nan	¹H NMR	Stool	case vs.control group	34352290
METAC_907	179	prostate cancer	nan	10283	12 weeks radiation therapy to the prostate and pelvic lymph nodes (PLNRT)	66 (63-72)	M	32	4/5 weeks radiation therapy to the prostate and pelvic lymph nodes (PLNRT)	66 (63-72)	M	32	Plasma metabolite between 12 weeks and 4/5 weeks radiation therapy to the prostate and pelvic lymph nodes (PLNRT)	nan	LC-MS/MS;¹H NMR	Plasma	case vs.control group	34352290
METAC_420	179	prostate cancer	nan	10283	12 weeks radiation therapy to the prostate and pelvic lymph nodes (PLNRT)	66 (63-72)	M	32	4/5 weeks radiation therapy to the prostate and pelvic lymph nodes (PLNRT)	66 (63-72)	M	32	Urine metabolite between 12 weeks and 4/5 weeks radiation therapy to the prostate and pelvic lymph nodes (PLNRT)	nan	LC-MS/MS;¹H NMR	Urine	case vs.control group	34352290
METAC_421	179	prostate cancer	nan	10283	12 weeks radiation therapy to the prostate and pelvic lymph nodes (PLNRT)	66 (63-72)	M	32	4/5 weeks radiation therapy to the prostate and pelvic lymph nodes (PLNRT)	66 (63-72)	M	32	Stool metabolite between 12 weeks and 4/5 weeks radiation therapy to the prostate and pelvic lymph nodes (PLNRT)	nan	¹H NMR	Stool	case vs.control group	34352290
METAC_908	179	prostate cancer	nan	10283	6 months radiation therapy to the prostate and pelvic lymph nodes (PLNRT)	66 (63-72)	M	32	2 weeks radiation therapy to the prostate and pelvic lymph nodes (PLNRT)	66 (63-72)	M	32	Plasma metabolite between 6 months and 12 weeks radiation therapy to the prostate and pelvic lymph nodes (PLNRT)	nan	LC-MS/MS;¹H NMR	Plasma	case vs.control group	34352290
METAC_422	179	prostate cancer	nan	10283	6 months radiation therapy to the prostate and pelvic lymph nodes (PLNRT)	66 (63-72)	M	32	2 weeks radiation therapy to the prostate and pelvic lymph nodes (PLNRT)	66 (63-72)	M	32	Urine metabolite between 6 months and 12 weeks radiation therapy to the prostate and pelvic lymph nodes (PLNRT)	nan	LC-MS/MS;¹H NMR	Urine	case vs.control group	34352290
METAC_423	179	prostate cancer	nan	10283	6 months radiation therapy to the prostate and pelvic lymph nodes (PLNRT)	66 (63-72)	M	32	2 weeks radiation therapy to the prostate and pelvic lymph nodes (PLNRT)	66 (63-72)	M	32	Stool metabolite between 6 months and 12 weeks radiation therapy to the prostate and pelvic lymph nodes (PLNRT)	nan	¹H NMR	Stool	case vs.control group	34352290
METAC_909	179	prostate cancer	nan	10283	12 months radiation therapy to the prostate and pelvic lymph nodes (PLNRT)	66 (63-72)	M	32	6 months radiation therapy to the prostate and pelvic lymph nodes (PLNRT)	66 (63-72)	M	32	Plasma metabolite between 12 months and 6 months radiation therapy to the prostate and pelvic lymph nodes (PLNRT)	nan	LC-MS/MS;¹H NMR	Plasma	case vs.control group	34352290
METAC_424	179	prostate cancer	nan	10283	12 months radiation therapy to the prostate and pelvic lymph nodes (PLNRT)	66 (63-72)	M	32	6 months radiation therapy to the prostate and pelvic lymph nodes (PLNRT)	66 (63-72)	M	32	Urine metabolite between 12 months and 6 months radiation therapy to the prostate and pelvic lymph nodes (PLNRT)	nan	LC-MS/MS;¹H NMR	Urine	case vs.control group	34352290
METAC_425	179	prostate cancer	nan	10283	12 months radiation therapy to the prostate and pelvic lymph nodes (PLNRT)	66 (63-72)	M	32	6 months radiation therapy to the prostate and pelvic lymph nodes (PLNRT)	66 (63-72)	M	32	Stool metabolite between 12 months and 6 months radiation therapy to the prostate and pelvic lymph nodes (PLNRT)	nan	¹H NMR	Stool	case vs.control group	34352290
METAC_910	179	prostate cancer	nan	10283	4/5 weeks radiation therapy to the prostate and pelvic lymph nodes (PLNRT)	66 (63-72)	M	32	baseline	66 (63-72)	M	32	Plasma metabolite between 4/5 weeks radiation therapy to the prostate and pelvic lymph nodes (PLNRT) and baseline	nan	LC-MS/MS;¹H NMR	Plasma	case vs.control group	34352290
METAC_230	179	prostate cancer	nan	10283	4/5 weeks radiation therapy to the prostate and pelvic lymph nodes (PLNRT)	66 (63-72)	M	32	baseline	66 (63-72)	M	32	Urine metabolite between 4/5 weeks radiation therapy to the prostate and pelvic lymph nodes (PLNRT) and baseline	nan	LC-MS/MS;¹H NMR	Urine	case vs.control group	34352290
METAC_231	179	prostate cancer	nan	10283	4/5 weeks radiation therapy to the prostate and pelvic lymph nodes (PLNRT)	66 (63-72)	M	32	baseline	66 (63-72)	M	32	Stool metabolite between 4/5 weeks radiation therapy to the prostate and pelvic lymph nodes (PLNRT) and baseline	nan	¹H NMR	Stool	case vs.control group	34352290
METAC_911	179	prostate cancer	nan	10283	12 weeks radiation therapy to the prostate and pelvic lymph nodes (PLNRT)	66 (63-72)	M	32	baseline	66 (63-72)	M	32	Plasma metabolite between 12 weeks radiation therapy to the prostate and pelvic lymph nodes (PLNRT) and baseline	nan	LC-MS/MS;¹H NMR	Plasma	case vs.control group	34352290
METAC_232	179	prostate cancer	nan	10283	12 weeks radiation therapy to the prostate and pelvic lymph nodes (PLNRT)	66 (63-72)	M	32	baseline	66 (63-72)	M	32	Urine metabolite between 12 weeks radiation therapy to the prostate and pelvic lymph nodes (PLNRT) and baseline	nan	LC-MS/MS;¹H NMR	Urine	case vs.control group	34352290
METAC_233	179	prostate cancer	nan	10283	12 weeks radiation therapy to the prostate and pelvic lymph nodes (PLNRT)	66 (63-72)	M	32	baseline	66 (63-72)	M	32	Stool metabolite between 12 weeks radiation therapy to the prostate and pelvic lymph nodes (PLNRT) and baseline	nan	¹H NMR	Stool	case vs.control group	34352290
METAC_912	179	prostate cancer	nan	10283	6 months radiation therapy to the prostate and pelvic lymph nodes (PLNRT)	66 (63-72)	M	32	baseline	66 (63-72)	M	32	Plasma metabolite between 6 months radiation therapy to the prostate and pelvic lymph nodes (PLNRT) and baseline	nan	LC-MS/MS;¹H NMR	Plasma	case vs.control group	34352290
METAC_234	179	prostate cancer	nan	10283	6 months radiation therapy to the prostate and pelvic lymph nodes (PLNRT)	66 (63-72)	M	32	baseline	66 (63-72)	M	32	Urine metabolite between 6 months radiation therapy to the prostate and pelvic lymph nodes (PLNRT) and baseline	nan	LC-MS/MS;¹H NMR	Urine	case vs.control group	34352290
METAC_235	179	prostate cancer	nan	10283	6 months radiation therapy to the prostate and pelvic lymph nodes (PLNRT)	66 (63-72)	M	32	baseline	66 (63-72)	M	32	Stool metabolite between 6 months radiation therapy to the prostate and pelvic lymph nodes (PLNRT) and baseline	nan	¹H NMR	Stool	case vs.control group	34352290
METAC_913	179	prostate cancer	nan	10283	12 months radiation therapy to the prostate and pelvic lymph nodes (PLNRT)	66 (63-72)	M	32	baseline	66 (63-72)	M	32	Plasma metabolite between 12 months radiation therapy to the prostate and pelvic lymph nodes (PLNRT) and baseline	nan	LC-MS/MS;¹H NMR	Plasma	case vs.control group	34352290
METAC_236	179	prostate cancer	nan	10283	12 months radiation therapy to the prostate and pelvic lymph nodes (PLNRT)	66 (63-72)	M	32	baseline	66 (63-72)	M	32	Urine metabolite between 12 months radiation therapy to the prostate and pelvic lymph nodes (PLNRT) and baseline	nan	LC-MS/MS;¹H NMR	Urine	case vs.control group	34352290
METAC_237	179	prostate cancer	nan	10283	12 months radiation therapy to the prostate and pelvic lymph nodes (PLNRT)	66 (63-72)	M	32	baseline	66 (63-72)	M	32	Stool metabolite between 12 months radiation therapy to the prostate and pelvic lymph nodes (PLNRT) and baseline	nan	¹H NMR	Stool	case vs.control group	34352290
METAC_914	130	prostate cancer	nan	10283	Metabotype IV		M	7	others metabotype		M	27	Statistical comparison between the metabolic profiles of Metabotype IV versus the others	nan	¹H NMR	Plasma	case vs.control group	34344464
METAC_915	130	prostate cancer	nan	10283	Metabotype II 		M	10	Metabotype III		M	14	Statistical comparison between the metabolic profiles of Metabotype II versus Metabotype III.	nan	¹H NMR	Plasma	case vs.control group	34344464
METAC_916	170	prostate cancer	nan	10283	prostate cancer		M	39	benign prostate hyperplasia (BPH)		M	45	serum metabolites between prostate cancer patients and benign prostate hyperplasia (BPH)	nan	LC-MS	Serum	case vs.control group	34026644
METAC_917	11	prostate cancer	nan	10283	3 (M3) months postrandomization		M		baseline before ADT (BL)		M		Top metabolites affected by the androgen deprivation therapy (ADT) in the low-carbohydrate diets (LCD) arm at 3 (M3) months postrandomization	We found androsterone sulfate was most consistently reduced by ADT and was slightly further reduced in the LCD arm. Contrastingly, LCD intervention in?creased 3‐hydroxybutyric acid and various acyl‐carnitines, counteracting their re?duction during ADT. LCD also reversed the ADT‐reduced lactic acid, alanine, and S‐adenosyl methionine (SAM), elevating glycolysis metabolites and alanine. While the degree of androsterone reduction by ADT was strongly correlated with glucose and indole‐3‐carboxaldehyde, LCD disrupted such correlations.	GC/MS‐TOF;QqQ LC-HILIC-MS/MS,TripleTOF LC‐RP‐MS	Blood	case vs.control group	33949711
METAC_918	11	prostate cancer	nan	10283	6 (M6) months postrandomization		M		baseline before ADT (BL)		M		Top metabolites affected by the androgen deprivation therapy (ADT) in the low-carbohydrate diets (LCD) arm at 6 (M6) months postrandomization	We found androsterone sulfate was most consistently reduced by ADT and was slightly further reduced in the LCD arm. Contrastingly, LCD intervention in?creased 3‐hydroxybutyric acid and various acyl‐carnitines, counteracting their re?duction during ADT. LCD also reversed the ADT‐reduced lactic acid, alanine, and S‐adenosyl methionine (SAM), elevating glycolysis metabolites and alanine. While the degree of androsterone reduction by ADT was strongly correlated with glucose and indole‐3‐carboxaldehyde, LCD disrupted such correlations.	GC/MS‐TOF;QqQ LC-HILIC-MS/MS,TripleTOF LC‐RP‐MS	Blood	case vs.control group	33949711
METAC_919	158	pancreatic cancer	nan	1793	pancreatic cancer patients(peripheral blood)	31-84	F&M	22	healthy controls(peripheral blood)	27-85	F&M	40	dysregulated lipids in serum exosome between peripheral blood of pancreatic cancer patients and healthy control	signifcantly dysregulated lipids between groups were revealed by corresponding statistical analysis	LC-MRM-MS	Plasma	case vs.control group	31147790
METAC_920	158	pancreatic cancer	nan	1793	pancreatic cancer patients	69.1 ± 8.9	F&M	10	healthy control	59.0 ± 9.2	F&M	10	differential metabolites between pancreatic cancer patients and healthy controls	substantially increased levels in the patient group were found, e.g. for arginine, phenylalanine and acetoacetate, while the control samples primarily contained higher levels of hypoxanthine and isopropanol	¹H NMR	Plasma	case vs.control group	30270368
METAC_921	217	pancreatic cancer	nan	1793	patient-derived orthotopic xenograft	60.23 ± 8.51	F&M	17	pancreatic cancer patients	61.8 ± 8.2	F&M	25	Comparative analysis of metabolite profiling between original patient tumors and patient-derived heterotopic xenograft tumors	Thirteen of the total 23 metabolites were not significantly different from those of the original primary tumor for both PDOX and PDAX models, and five metabolites differed in both groups	LC-MS/MS	Pancreatic tissue	case vs.control group	29487698
METAC_922	217	pancreatic cancer	nan	1793	patient-derived heterotopic xenograft	62.17 ± 7.69	F&M	18	pancreatic cancer patients	61.8 ± 8.2	F&M	25	Comparative analysis of metabolite profiling between original patient tumors and patient-derived orthotopic xenograft tumors	Thirteen of the total 23 metabolites were not significantly different from those of the original primary tumor for both PDOX and PDAX models, and five metabolites differed in both groups	LC-MS/MS	Pancreatic tissue	case vs.control group	29487698
METAC_923	158	pancreatic cancer	nan	1793	pancreatic cancer/biliary tract cancer group	63.1 ± 10.9	F&M	90	ovarian cancer/colorectal cancer/healthy control group	58.3 ± 9.8	F&M	230	metabolites which can discriminate between pancreatic cancer/biliary tract cancer and ovarian cancer/colorectal cancer/healthy control	fourteen discriminative LMIs were identified, and each showed perfect discrimination between the PC and BTC groups and the control, CRC, and OVC group	LC-MS/MS	Serum	case vs.control group	30174764
METAC_924	158	pancreatic cancer	nan	1793	pancreatic cancer group	63.7 ± 10.6	F&M	51	biliary tract cancer group	62.3 ± 11.3	F&M	39	metabolites which can help discriminate between pancreatic cancer and biliary tract cancer	lysophosphatidylcholine (LysoPC) (16:0) and LysoPC(20:4(5Z,8Z,11Z,14Z)), identified according to their MS/MS patterns in the analyses of the sera of BTC patients, could discriminate between PC and BTC	LC-MS/MS	Serum	case vs.control group	30174764
METAC_925	158	pancreatic cancer	nan	1793	pancreatic cancer/biliary tract cancer patients		F&M	64	pancreatic cancer/biliary tract cancer high risk group		F&M	36	metabolites which can discriminate between pancreatic cancer/biliary tract cancer and pancreatic cancer/biliary tract cancer high risk group	nan	LC-MS/MS	Serum	case vs.control group	30174764
METAC_926	158	pancreatic cancer	nan	1793	normal control group	79	F&M	48	pancreatic cancer group	74.2	F&M	59	ten metabolite PC biomarker expression between Pancreatic Cancer group and Normal Control group	eight of the ten metabolites were down-regulated in PC, including lactate, LysoPC (18:2), alanine, choline, threonine, asparagine, tyrosine, and lysine. Palmitate and 3-hydroxybutyrate were upregulated in PC when compared to normal controls.	UPLC-MS	Serum	case vs.control group	28978166
METAC_927	158	pancreatic cancer	nan	1793	Type 2 diabetes mellitus group	55	F&M	19	pancreatic cancer group	74.2	F&M	59	ten metabolite PC biomarker expression between Pancreatic Cancer group and Type 2 diabetes mellitus group	eight of the ten metabolites were down-regulated in PC, including lactate, LysoPC (18:2), alanine, choline, threonine, asparagine, tyrosine, and lysine. Palmitate and 3-hydroxybutyrate were upregulated in PC when compared to normal controls.	UPLC-MS	Serum	case vs.control group	28978166
METAC_928	158	pancreatic cancer	nan	1793	colorectal cancer group	63.45	F&M	66	pancreatic cancer group	74.2	F&M	59	ten metabolite PC biomarker expression between Pancreatic Cancer group and colorectal cancer group	eight of the ten metabolites were down-regulated in PC, including lactate, LysoPC (18:2), alanine, choline, threonine, asparagine, tyrosine, and lysine. Palmitate and 3-hydroxybutyrate were upregulated in PC when compared to normal controls.	UPLC-MS	Serum	case vs.control group	28978166
METAC_929	217	pancreatic cancer	Pancreatic ductal adenocarcinoma	1793	Panc-1 cell subcutaneous xenograft				healthy control mice				The significantly differential metabolites in serum between Panc-1 cell subcutaneous xenograft and controls	SX and OX models both in BxPC-3 and Panc-1 cell groups demonstrated similar metabonomic characteristics in serum, where the differential metabolites from SX and OX share the same variation trends and no one showed contrary variation trend	¹H NMR	Serum	case vs.control group	28977862
METAC_930	217	pancreatic cancer	Pancreatic ductal adenocarcinoma	1793	Panc-1 cell orthotopic xenograft				healthy control mice				The significantly differential metabolites in serum between Panc-1 cell orthotopic xenograft and controls	SX and OX models both in BxPC-3 and Panc-1 cell groups demonstrated similar metabonomic characteristics in serum, where the differential metabolites from SX and OX share the same variation trends and no one showed contrary variation trend	¹H NMR	Serum	case vs.control group	28977862
METAC_931	217	pancreatic cancer	Pancreatic ductal adenocarcinoma	1793	BxPC-3 cell subcutaneous xenograft				healthy control mice				The significantly differential metabolites in serum between BxPC-3 cell subcutaneous xenograft and controls	SX and OX models both in BxPC-3 and Panc-1 cell groups demonstrated similar metabonomic characteristics in serum, where the differential metabolites from SX and OX share the same variation trends and no one showed contrary variation trend	¹H NMR	Serum	case vs.control group	28977862
METAC_932	217	pancreatic cancer	Pancreatic ductal adenocarcinoma	1793	BxPC-3 cell orthotopic xenograft				healthy control mice				The significantly differential metabolites in serum between BxPC-3 cell orthotopic  xenograft and controls	SX and OX models both in BxPC-3 and Panc-1 cell groups demonstrated similar metabonomic characteristics in serum, where the differential metabolites from SX and OX share the same variation trends and no one showed contrary variation trend	¹H NMR	Serum	case vs.control group	28977862
METAC_933	158	pancreatic cancer	nan	1793	pancreatic cancer with new-onset diabetic mellitus patients	62.85 ± 9.86	F&M	30	new-onset diabetic mellitus patients	52.76 ± 9.94	F&M	30	Differential plasma metabolites in pancreatic cancer with new-onset diabetic mellitus patients compared to controls (new-onset diabetic mellitus patients)	21 variables were identified between the two groups in the positive mode and 41 in the negative mode.	LC-MS	Plasma	case vs.control group	28418859
METAC_934	158	pancreatic cancer	nan	1793	Pancreatic adenocarcinomas from patients			44	pancreatic parenchyma from patients			9	Differential metabolites in Pancreatic adenocarcinomas tissue compared to pancreatic parenchyma(healthy tissue)	Choline (p = 0.0014), ethanolamine (p = 0.0226), glycerol (p = 0.0037), glycine (p = 0.0005), lactate (p = 0.0006), and taurine (p = 0.0021) were statistically significant between PP and PA (both without any neoadjuvant chemotherapy)	HR-MAS NMR	Pancreatic tissue	case vs.control group	28298227
METAC_935	158	pancreatic cancer	nan	1793	pancreatic parenchyma from patients who received neoadjuvant chemotherapy			8	pancreatic parenchyma from patients who did not received neoadjuvant chemotherapy			9	Differential metabolites in pancreatic parenchyma(healthy tissue) from patients who received neoadjuvant chemotherapy compared to pancreatic parenchyma from patients who did not	No discriminant metabolites were found using the Mann-WhitneyUtest	HR-MAS NMR	Pancreatic tissue	case vs.control group	28298227
METAC_936	158	pancreatic cancer	nan	1793	Pancreatic adenocarcinomas from patients who received neoadjuvant chemotherapy			62	Pancreatic adenocarcinomas from patients who did not received neoadjuvant chemotherapy			44	Differential metabolites in Pancreatic adenocarcinomas from patients who received neoadjuvant chemotherapy compared to Pancreatic adenocarcinomas from patients who did not	Aspartate (p = 0.0017) was statistically significant between PA samples from patients who received neoadjuvant chemotherapy and those who did not	HR-MAS NMR	Pancreatic tissue	case vs.control group	28298227
METAC_937	158	pancreatic cancer	nan	1793	pancreatic parenchyma(healthy tissue) from long-term survivors			8	pancreatic parenchyma(healthy tissue) from short-term survivors			9	Differential metabolites in pancreatic parenchyma(healthy tissue) from long-term survivors compared to pancreatic parenchyma from short-term survivors	Choline (p = 0.0150), ethanolamine (p = 0.0078), lactate (p = 0.0360), and phenylalanine (p = 0.0055) were statistically significant between long-term and short-term survival in patients with PA	HR-MAS NMR	Pancreatic tissue	case vs.control group	28298227
METAC_938	158	pancreatic cancer	Pancreatic ductal adenocarcinoma	1793	pancreatic cancer group			60	healthy controls			40	metabolites in pancreatic cancer patients and healthy controls	palmitic acid, 1,2-dioleoyl-sn-glycero-3-phospho-rac-glycerol, lanosterol, lignoceric acid, monooleoyl-rac-glycerol, cholesterol 5α,6α epoxide, erucic acid, T-LCA, oleoyl-L-carnitine, oleanolic acid clearly achieved the highest importance values than all other metabolites.	LC-MS/MS	Serum	case vs.control group	26735340
METAC_939	158	pancreatic cancer	nan	1793	pancreatic cancer patients from Connecticut	67.9 (44.2, 85.7)	F&M	100	healthy controls	67.8 (44.1, 84.3)	F&M	100	significantly altered plasma metabolites in both pancreatic cancer patients from Connecticut compared to healthy controls	65 differentially expressed metabolites in the CT set and 62 in the SH set were obtained, among which 31 metabolites were the same and were significantly altered in the same direction	LC/GC-MS	Plasma	case vs.control group	25429707
METAC_940	158	pancreatic cancer	nan	1793	pancreatic cancer patients from Shanghai	64.3 (40.5, 79.1)	F&M	100	healthy controls	64.4 (41.2, 79.2)	F&M	100	significantly altered plasma metabolites in both pancreatic cancer patients from Shanghai compared to healthy controls	65 differentially expressed metabolites in the CT set and 62 in the SH set were obtained, among which 31 metabolites were the same and were significantly altered in the same direction	LC/GC-MS	Plasma	case vs.control group	25429707
METAC_941	158	pancreatic cancer	nan	1793	pancreatic cancer patients with Cachexia	72 (39-76)	F&M	9	pancreatic cancer patients without Cachexia	64.5 (36-77)	F&M	12	significantly differed metabolites between pancreatic cancer patients with Cachexia and patients without Cachexia at 6:30 AM	at 6:30 AM, catechol (0.70, p = 0.04) and paraxanthine (0.21, p = 0.006); at 11:30 AM, valine (0.68, p = 0.01), proline (0.66, p = 0.049), p-hydroxybenzoic acid (0.79, p = 0.03), and paraxanthine (0.16, p = 0.006); and at 4:30 PM, valine (0.62, p = 0.02) and paraxanthine (0.13, p = 0.007). Although differences in levels of paraxanthine were not statistically significant (0.26, p = 0.08) at 9:30 PM, the levels were clearly lower in the cohort with cachexia at all time points	GC/MS	Serum	case vs.control group	25411961
METAC_942	158	pancreatic cancer	nan	1793	pancreatic cancer patients with Cachexia	72 (39-76)	F&M	9	pancreatic cancer patients without Cachexia	64.5 (36-77)	F&M	12	significantly differed metabolites between pancreatic cancer patients with Cachexia and patients without Cachexia at 11:30 AM	at 6:30 AM, catechol (0.70, p = 0.04) and paraxanthine (0.21, p = 0.006); at 11:30 AM, valine (0.68, p = 0.01), proline (0.66, p = 0.049), p-hydroxybenzoic acid (0.79, p = 0.03), and paraxanthine (0.16, p = 0.006); and at 4:30 PM, valine (0.62, p = 0.02) and paraxanthine (0.13, p = 0.007). Although differences in levels of paraxanthine were not statistically significant (0.26, p = 0.08) at 9:30 PM, the levels were clearly lower in the cohort with cachexia at all time points	GC/MS	Serum	case vs.control group	25411961
METAC_943	158	pancreatic cancer	nan	1793	pancreatic cancer patients with Cachexia	72 (39-76)	F&M	9	pancreatic cancer patients without Cachexia	64.5 (36-77)	F&M	12	significantly differed metabolites between pancreatic cancer patients with Cachexia and patients without Cachexia at 4:30 PM	at 6:30 AM, catechol (0.70, p = 0.04) and paraxanthine (0.21, p = 0.006); at 11:30 AM, valine (0.68, p = 0.01), proline (0.66, p = 0.049), p-hydroxybenzoic acid (0.79, p = 0.03), and paraxanthine (0.16, p = 0.006); and at 4:30 PM, valine (0.62, p = 0.02) and paraxanthine (0.13, p = 0.007). Although differences in levels of paraxanthine were not statistically significant (0.26, p = 0.08) at 9:30 PM, the levels were clearly lower in the cohort with cachexia at all time points	GC/MS	Serum	case vs.control group	25411961
METAC_944	158	pancreatic cancer	nan	1793	pancreatic cancer patients	65.2 (31-79)	F&M	40	healthy controls	63.8 (40-75)	F&M	50	significantly diffential metabolites in pancreatic cancer patients and healthy controls (discovery)	This approach identified 68 masses	FI-FTICR-MS	Serum	case vs.control group	24024929
METAC_945	158	pancreatic cancer	nan	1793	pancreatic cancer patients	65.2 (31-79)	F&M	40	healthy controls	63.8 (40-75)	F&M	50	significantly diffential metabolites in pancreatic cancer patients and healthy controls(validation)	The results of the FI-MS/MS analysis for each metabolic system were consistent with the FI-FTICR-MS results	FI-MS/MS	Serum	case vs.control group	24024929
METAC_946	158	pancreatic cancer	nan	1793	set A pancreatic cancer patients	59.0 (47.9-70.5)	F&M	20	set A healthy controls	51.0 (38.0-66.7)	F&M	20	differences in CA 19-9 and amino acid concentrations between set A pancreatic cancer patients and set A healthy controls	only four (arginine, glutamic acid, phenylalanine, and tryptophan) unaltered between the study groups	FIA-MS/MS	Serum	case vs.control group	23678345
METAC_947	158	pancreatic cancer	nan	1793	set A pancreatic cancer patients	59.0 (47.9-70.5)	F&M	20	set C healthy controls	53.5 (33.4-69.5)	F&M	20	differences in CA 19-9 and amino acid concentrations between set A pancreatic cancer patients and set C healthy controls	only four (arginine, glutamic acid, phenylalanine, and tryptophan) unaltered between the study groups	FIA-MS/MS	Serum	case vs.control group	23678345
METAC_948	158	pancreatic cancer	nan	1793	set A pancreatic cancer patients	59.0 (47.9-70.5)	F&M	20	set D patients with pancreatitis	43.5 (26.8-66.0)	F&M	20	differences in CA 19-9 and amino acid concentrations between set A pancreatic cancer patients and set D patients with pancreatitis	only four (arginine, glutamic acid, phenylalanine, and tryptophan) unaltered between the study groups	FIA-MS/MS	Serum	case vs.control group	23678345
METAC_949	158	pancreatic cancer	nan	1793	set C pancreatic cancer patients	66.0 (43.9-71.5)	F&M	20	set A healthy controls	51.0 (38.0-66.7)	F&M	20	differences in CA 19-9 and amino acid concentrations between set C pancreatic cancer patients and set A healthy controls	only four (arginine, glutamic acid, phenylalanine, and tryptophan) unaltered between the study groups	FIA-MS/MS	Serum	case vs.control group	23678345
METAC_950	158	pancreatic cancer	nan	1793	set C pancreatic cancer patients	66.0 (43.9-71.5)	F&M	20	set C healthy controls	53.5 (33.4-69.5)	F&M	20	differences in CA 19-9 and amino acid concentrations between set C pancreatic cancer patients and set C healthy controls	only four (arginine, glutamic acid, phenylalanine, and tryptophan) unaltered between the study groups	FIA-MS/MS	Serum	case vs.control group	23678345
METAC_951	158	pancreatic cancer	nan	1793	set C pancreatic cancer patients	66.0 (43.9-71.5)	F&M	20	set D patients with pancreatitis	43.5 (26.8-66.0)	F&M	20	differences in CA 19-9 and amino acid concentrations between set C pancreatic cancer patients and set D patients with pancreatitis	only four (arginine, glutamic acid, phenylalanine, and tryptophan) unaltered between the study groups	FIA-MS/MS	Serum	case vs.control group	23678345
METAC_952	158	pancreatic cancer	nan	1793	pancreatic cancer patients	66.2 (36-84)	F&M	43	healthy volunteers	63.2 (39-79)	F&M	42	significantly diffential metabolites in pancreatic cancer patients and healthy volunteers	18 of these metabolites displayed significantly altered levels in the pancreatic cancer compared with the healthy volunteers	GC/MS	Serum	case vs.control group	23542803
METAC_953	158	pancreatic cancer	Pancreatic ductal adenocarcinoma	1793	metastatic pancreatic cancer patients				patients with pancreatitis			5	differential ceramides and cerebrosides between metastatic pancreatic cancer patients and patients with pancreatitis	higher tissue levels of C16:0-ceramide (p < 0.05) and C24:1-ceramide (p < 0.005) were associated with positive regional lymph node metastasis	LC-MS/MS	Pancreatic tissue	case vs.control group	24970174
METAC_954	158	pancreatic cancer	Pancreatic ductal adenocarcinoma	1793	metastatic pancreatic cancer patients				patients with pancreatitis			5	differential ceramides and cerebrosides between metastatic pancreatic cancer patients and patients with pancreatitis	higher tissue levels of C16:0-ceramide (p < 0.05) and C24:1-ceramide (p < 0.005) were associated with positive regional lymph node metastasis	LC-MS/MS	Plasma	case vs.control group	24970174
METAC_955	158	pancreatic cancer	Pancreatic ductal adenocarcinoma	1793	non-metastatic pancreatic cancer patients				patients with pancreatitis			5	differential cerebrosides between non-metastatic pancreatic cancer patients and patients with pancreatitis	higher tissue levels of C16:0-ceramide (p < 0.05) and C24:1-ceramide (p < 0.005) were associated with positive regional lymph node metastasis	LC-MS/MS	Pancreatic tissue	case vs.control group	24970174
METAC_956	134	pancreatic cancer	Pancreatic ductal adenocarcinoma	1793	metastatic pancreatic cancer patients				non-metastatic pancreatic cancer patients				differential ceramides and cerebrosides between metastatic pancreatic cancer patients and non-metastatic pancreatic cancer patients	patients with positive lymph node metastasis have a markedly higher level of ceramide species (C16:0 and C24:1) in their tumor specimens compared to pancreatic cancer patients without nodal disease or to patients with pancreatitis	LC-MS/MS	Pancreatic tissue	case vs.control group	24970174
METAC_957	134	pancreatic cancer	Pancreatic ductal adenocarcinoma	1793	metastatic pancreatic cancer patients				non-metastatic pancreatic cancer patients				differential ceramides and cerebrosides between metastatic pancreatic cancer patients and non-metastatic pancreatic cancer patients	patients with positive lymph node metastasis have a markedly higher level of ceramide species (C16:0 and C24:1) in their tumor specimens compared to pancreatic cancer patients without nodal disease or to patients with pancreatitis	LC-MS/MS	Plasma	case vs.control group	24970174
METAC_958	158	pancreatic cancer	Pancreatic ductal adenocarcinoma	1793	Pancreatic ductal adenocarcinoma(PDAC) patients	64 (55-76)	F&M	5	controls without cancer	49.8 (32-71)	F&M	5	differential metabolites in Pancreatic ductal adenocarcinoma (PDAC) patients and controls without cancer	The candidate biomarkers included amino acids such as N-methylalanine, lysine, glutamine, phenylalanine, fatty acids such as arachidonic acid, lipids such as lysoPC (18:2), PC (34:2), PE (26:0), and bile acids such as tauroursodeoxycholic acid, taurocholic acid, deoxycholylglycine and cholylglycine.	GC-TOF-MS;HILIC-LC/MS;RP-LC/MS	Plasma	case vs.control group	20143319
METAC_959	170	prostate cancer	nan	10283	prostate cancer	64.2 ± 8.1	M	32	healthy group	52.9 ± 10.7	M	32	Statistically significant metabolites identified in urine samples from prostate cancer patients compared to healthy volunteers with LC-TOF/MS technique in positive (+) and negative (-) polarity	The selected pathways, like urea and tricarboxylic acid cycle, amino acid and purine metabolism, can play crucial role in pathogenesis of prostate cancer disease.	LC-TOF/MS	Urine	case vs.control group	25684700
METAC_960	170	prostate cancer	nan	10283	prostate cancer	64.2 ± 8.1	M	32	healthy group	52.9 ± 10.7	M	32	Statistically significant metabolites identified in urine samples from prostate cancer patients compared to healthy volunteers with GC-MS technique.	The selected pathways, like urea and tricarboxylic acid cycle, amino acid and purine metabolism, can play crucial role in pathogenesis of prostate cancer disease.	GC-MS	Urine	case vs.control group	25684700
METAC_961	170	prostate cancer	nan	10283	prostate cancer		M	30	healthy group		M	30	Identification of a potential biomarker between prostate cancer patients and controls	nan	LC-HRMS	Urine	case vs.control group	23823321
METAC_962	170	prostate cancer	nan	10283	malignant tissue samples from prostate cancer specimens	64 (62.5-65)	M	95	non-malignant tissue samples from prostate cancer specimens	64 (62.5-65)	M	95	List of the 172 known metabolites detected between malignant and non-malignant tissue samples from prostate cancer specimens	In matched malignant and nonmalignant prostatectomy samples from 95 PCa patients, aminoadipic acid, cerebronic acid, gluconic acid, glycerophosphoethanolamine, 2-hydroxybehenic acid, isopentenyl pyrophosphate, maltotriose, 7-methylguanine and tricosanoic acid were determined within a global metabolite profiling study using gas chromatography/liquid chromatography-mass spectrometry.	GC-MS;LC-MS/MS	Prostate tissue	case vs.control group	23737455
METAC_963	170	prostate cancer	nan	10283	Cancer samples		M	111	Normal adjacent samples		M	47	Metabolite concentrations (mmol/kg) in cancer and normal prostate tissue samples.	nan	HR-MAS MRS	Prostate tissue	case vs.control group	23626811
METAC_964	173	prostate cancer	nan	10283	high grade (GS≥7) prostate cancer		M	81	low grade (GS = 6) prostate cancer		M	30	Metabolite concentrations (mmol/kg) and ratios in low grade (GS = 6) and high grade (GS≥7) prostate cancer samples	nan	HR-MAS MRS	Prostate tissue	case vs.control group	23626811
METAC_965	11	prostate cancer	nan	10283	after androgen deprivation therapy (ADT)	64.8 ± 6.0	M	42	before androgen deprivation therapy (ADT)	64.8 ± 6.0	M	42	Comparison of 3a-diol G, PSA, androgens, and related hormones before and after androgen deprivation therapy (ADT)	nan	LC-MS/MS	Blood	case vs.control group	23524847
METAC_966	170	prostate cancer	nan	10283	prostate cancer	60-85	M		healthy group	30-60	M		Marker metabolites found in GC/MS chromatograms of the prostate cancer (PCa) group and the healthy male group	nan	GC/MS	Urine	case vs.control group	21626193
METAC_967	171	prostate cancer	nan	10283	prostate cancer (PCa) bone metastases 		M	20	normal bone (NB)		M	14	Significantly differentiating metabolites between prostate cancer (PCa) bone metastases and normal bone (NB) in test set.	Significant differences were found between PCa bone metastases, bone metastases of other cancers, and normal bone. Furthermore, we identified metabolites in primary tumor tissue and in plasma which were significantly associated with metastatic disease.	GC/TOFMS	Bone	case vs.control group	21151972
METAC_968	171	prostate cancer	nan	10283	prostate cancer patients diagnosed with bone metastases (M1) 		M	15	patients with benign disease.		M	13	Significantly differentiating metabolites between prostate tissue samples from prostate cancer patients diagnosed with bone metastases (M1) and patients with benign disease.	Significant differences were found between PCa bone metastases, bone metastases of other cancers, and normal bone. Furthermore, we identified metabolites in primary tumor tissue and in plasma which were significantly associated with metastatic disease.	GC/TOFMS	Prostate tissue	case vs.control group	21151972
METAC_969	171	prostate cancer	nan	10283	prostate cancer patients diagnosed with bone metastases (M1) 		M	15	patients with benign disease.		M	13	Significantly differentiating metabolites between blood plasma samples from prostate cancer patients diagnosed with bone metastases (M1) and patients with benign disease.	Significant differences were found between PCa bone metastases, bone metastases of other cancers, and normal bone. Furthermore, we identified metabolites in primary tumor tissue and in plasma which were significantly associated with metastatic disease.	GC/TOFMS	Plasma	case vs.control group	21151972
METAC_970	171	prostate cancer	nan	10283	high-risk prostate cancer patients with (M1)		M	13	prostate cancer without (M0) diagnosed bone metastases.		M	17	Significantly differentiating metabolites between prostate cancer tissue samples from high-risk patients with (M1) and without (M0) diagnosed bone metastases.	Significant differences were found between PCa bone metastases, bone metastases of other cancers, and normal bone. Furthermore, we identified metabolites in primary tumor tissue and in plasma which were significantly associated with metastatic disease.	GC/TOFMS	Prostate tissue	case vs.control group	21151972
METAC_971	171	prostate cancer	nan	10283	high-risk prostate cancer patients with (M1)		M	13	prostate cancer without (M0) diagnosed bone metastases.		M	17	Significant changed metabolites between blood plasma samples from high-risk prostate cancer patients with (M1) and without (M0) diagnosed bone metastases.	Significant differences were found between PCa bone metastases, bone metastases of other cancers, and normal bone. Furthermore, we identified metabolites in primary tumor tissue and in plasma which were significantly associated with metastatic disease.	GC/TOFMS	Plasma	case vs.control group	21151972
METAC_972	171	prostate cancer	nan	10283	prostate cancer (PCa) bone metastases		M	20	bone metastases from other cancers.		F&M	7	Significantly differentiating metabolites between prostate cancer (PCa) bone metastases and bone metastases from other cancers.	Significant differences were found between PCa bone metastases, bone metastases of other cancers, and normal bone. Furthermore, we identified metabolites in primary tumor tissue and in plasma which were significantly associated with metastatic disease.	GC/TOFMS	Bone	case vs.control group	21151972
METAC_973	219	prostate cancer	nan	10283	seminal fluid of prostate cancer patients	62 ± 13	M	7	urine of prostate cancer	62 ± 13	M	7	differential metabolites in prostate cancer patients between seminal fluid and urine	ejaculate comprises the metabolic signature of both matrices (polar compounds characteristic for urine, and non-polar ones present in plasma samples)	HPLC-TOF/MS	Seminal fluid;Urine	case vs.control group	35309505
METAC_974	219	prostate cancer	nan	10283	seminal fluid of prostate cancer patients	62 ± 13	M	7	plasma of prostate cancer	62 ± 13	M	7	differential metabolites in prostate cancer patients between seminal fluid and plasma	ejaculate comprises the metabolic signature of both matrices (polar compounds characteristic for urine, and non-polar ones present in plasma samples)	HPLC-TOF/MS	Seminal fluid;Plasma	case vs.control group	35309505
METAC_975	219	prostate cancer	nan	10283	urine of prostate cancer	62 ± 13	M	7	plasma of prostate cancer	62 ± 13	M	7	differential metabolites in prostate cancer patients between urine and plasma	ejaculate comprises the metabolic signature of both matrices (polar compounds characteristic for urine, and non-polar ones present in plasma samples)	HPLC-TOF/MS	Urine;Plasma	case vs.control group	35309505
METAC_976	219	prostate cancer	nan	10283	seminal fluid of prostate cancer patients	62 ± 13	M	7	urine of prostate cancer	62 ± 13	M	7	differential metabolites in prostate cancer patients between seminal fluid and urine	ejaculate comprises the metabolic signature of both matrices (polar compounds characteristic for urine, and non-polar ones present in plasma samples)	GC-QqQ/MS	Seminal fluid;Urine	case vs.control group	35309505
METAC_977	219	prostate cancer	nan	10283	seminal fluid of prostate cancer patients	62 ± 13	M	7	plasma of prostate cancer	62 ± 13	M	7	differential metabolites in prostate cancer patients between seminal fluid and plasma	ejaculate comprises the metabolic signature of both matrices (polar compounds characteristic for urine, and non-polar ones present in plasma samples)	GC-QqQ/MS	Seminal fluid;Plasma	case vs.control group	35309505
METAC_978	219	prostate cancer	nan	10283	urine of prostate cancer	62 ± 13	M	7	plasma of prostate cancer	62 ± 13	M	7	differential metabolites in prostate cancer patients between urine and plasma	ejaculate comprises the metabolic signature of both matrices (polar compounds characteristic for urine, and non-polar ones present in plasma samples)	GC-QqQ/MS	Urine;Plasma	case vs.control group	35309505
METAC_979	170	prostate cancer	nan	10283	prostate cancer patients	66 ± 7	M	20	benign prostatic hyperplasia patients	65 ± 6	M	20	differential metabolites between prostate cancer patients and benign prostatic hyperplasia patients	An unprecedented portfolio of prostate carcinoma biomarkers was tentatively identified including 22 and 47 alleged candidates from positive and negative ion electrospray (ESI+ and ESI-) datasets	UHPLC-HRMS	Urine	case vs.control group	35288652
METAC_980	170	prostate cancer	nan	10283	prostate cancer patients		M	66	normal individuals		M	43	differential amino acids between prostate cancer patients and normal individuals	Among the 15 common amino acids detected, only the levels of Gln and arginine (Arg) in the blood samples of patients with PCa were significantly lower compared with those in the samples from the normal individuals (P<0.05)	LC-MS/MS;GC/MS	Blood	case vs.control group	35191516
METAC_981	113	lung cancer	nan	1324	lung cancer	57.8 ± 13.4	F&M	45	healthy control	52.9 ± 12.3	F&M	25	Summary of feature peaks that could be used to distinguish early lung cancer patients from control subjects in discovery cohort	nan	TELDI-MS	Saliva	case vs.control group	34342461
METAC_982	113	lung cancer	nan	1324	lung cancer	55.3 ±10.9	F&M	44	healthy control	57.3 ±15.8	F&M	25	Summary of feature peaks that could be used to distinguish early lung cancer patients from control subjects in validation cohort	nan	TELDI-MS	Saliva	case vs.control group	34342461
METAC_983	2	lung cancer	adenocarcinoma, squamous cell lung carcinoma	1324	Adenocarcinoma (AC)		F&M	45	squamous cell lung carcinoma (SCC)		F&M	18	Differential metabolites between Adenocarcinoma (AC) and squamous cell lung carcinoma (SCC) after eliminating individual differences.	nan	LC-MS	Lung tissue	case vs.control group	32693607
METAC_984	113	lung cancer	adenocarcinoma, squamous cell lung carcinoma	1324	lung carcinoma tissue (LCT)		F&M	67	distal noncancerous tissue (DNT)		F&M	82	Pathway-related metabolites of lung cancer between lung carcinoma tissue (LCT) and distal noncancerous tissue (DNT) in discovery cohort	nan	LC-MS	Lung tissue	case vs.control group	32693607
METAC_985	113	lung cancer	adenocarcinoma, squamous cell lung carcinoma	1324	lung carcinoma tissue (LCT)		F&M	31	distal noncancerous tissue (DNT)		F&M	46	Pathway-related metabolites of lung cancer between lung carcinoma tissue (LCT) and distal noncancerous tissue (DNT) in validation cohort	nan	LC-MS	Lung tissue	case vs.control group	32693607
METAC_986	113	lung cancer	adenocarcinoma, squamous cell lung carcinoma	1324	lung carcinoma tissue (LCT)		F&M	67	benign lung tissue (BLT)		F&M	18	Differential metabolites between lung carcinoma tissue (LCT) and benign lung tissue (BLT)	nan	LC-MS	Lung tissue	case vs.control group	32693607
METAC_987	113	lung cancer	adenocarcinoma, squamous cell lung carcinoma	1324	lung cancer	59.6 ± 4.9	F&M	30	healthy control	27.7 ± 2.2	F&M	30	Analysis of differential metabolites in lung cancer patients based on metabolomics in didcovery cohort	A total of 35 potential mark?ers were identified, 11 of which overlapped	UPLC-Q-TOF/HRMS	Urine	case vs.control group	32356461
METAC_988	113	lung cancer	adenocarcinoma, squamous cell lung carcinoma	1324	lung cancer	70.2 ± 5.5	F&M	38	healthy control	28.0 ± 0.7	F&M	42	Analysis of differential metabolites in lung cancer patients based on metabolomics in validation cohort	A total of 35 potential mark?ers were identified, 11 of which overlapped	UPLC-Q-TOF/HRMS	Urine	case vs.control group	32356461
METAC_989	170	prostate cancer	nan	10283	prostate cancer patients after Carbon ion radiotherapy	73 (50-82)	M	15	prostate cancer patients before Carbon ion radiotherapy	73 (50-82)	M	15	differential metabolites between prostate cancer patients before Carbon ion radiotherapy and after Carbon ion radiotherapy	Thirty-five metabolites were significantly altered, with the majority of them being amino acids	UPLC-MS/MS	Urine	case vs.control group	34950631
METAC_990	170	prostate cancer	nan	10283	tumor tissues in prostate cancer patients	63.3  (5.5)	M	40	normal adjacent tissues	63.3  (5.5)	M	40	differential metabolites between tumor tissues in prostate cancer patients and normal adjacent tissues	significant alterations in the levels of 26 metabolites and 21 phospholipid species in PCa tissue compared with adjacent nonmalignant tissue	GC-MS	Prostate tissue	case vs.control group	34813334
METAC_991	170	prostate cancer	nan	10283	tumor tissues in prostate cancer patients	63.3  (5.5)	M	40	normal adjacent tissues	63.3  (5.5)	M	40	differential metabolites between tumor tissues in prostate cancer patients and normal adjacent tissues	significant alterations in the levels of 26 metabolites and 21 phospholipid species in PCa tissue compared with adjacent nonmalignant tissue	¹H NMR	Prostate tissue	case vs.control group	34813334
METAC_992	170	prostate cancer	nan	10283	tumor tissues in prostate cancer patients	63.3  (5.5)	M	40	normal adjacent tissues	63.3  (5.5)	M	40	differential metabolites between tumor tissues in prostate cancer patients and normal adjacent tissues	significant alterations in the levels of 26 metabolites and 21 phospholipid species in PCa tissue compared with adjacent nonmalignant tissue	HILIC-MS/MS	Prostate tissue	case vs.control group	34813334
METAC_993	170	prostate cancer	nan	10283	prostate cancer patients	64.1 ± 8.2	M	74	benign prostatic hyperplasia patients	62.2 ± 12.2	M	74	differential metabolites between prostate cancer patients and benign prostatic hyperplasia patients	The 18 lipid or lipid-associated metabolites identified in this study are potential diagnostic markers for differential diagnosis	LC-MS/MS	Serum	case vs.control group	34722271
METAC_994	170	prostate cancer	nan	10283	prostate cancer patients	70 (50-91)	M	89	healthy controls	65 (50-85)	M	70	differential amino acids between prostate cancer patients and healthy controls	metabolites from the plasma were more valuable than those from the urine	LC-MS/MS	Serum	case vs.control group	34590739
METAC_995	170	prostate cancer	nan	10283	prostate cancer patients	70 (50-91)	M	89	healthy controls	65 (50-85)	M	70	differential metabolites between prostate cancer patients and healthy controls	metabolites from the plasma were more valuable than those from the urine	GC-MS	Urine	case vs.control group	34590739
METAC_996	170	prostate cancer	nan	10283	prostate cancer patients	68.21 ± 5.54	M	24	bladder cancer patients	67.92 ± 10.42	M	29	differential metabolites between prostate cancer and bladder cancer	nan	¹H NMR	Urine	case vs.control group	34564407
METAC_997	170	prostate cancer	nan	10283	prostate cancer patients	68.21 ± 5.54	M	24	renal cell carcinoma	62.17 ± 11.76	M	12	differential metabolites between prostate cancer and renal cell carcinoma	nan	¹H NMR	Urine	case vs.control group	34564407
METAC_998	20	bladder cancer	nan	11054	bladder cancer patients	67.92 ± 10.42	M	29	renal cell carcinoma	62.17 ± 11.76	M	12	differential metabolites between bladder and renal cell carcinoma	nan	¹H NMR	Urine	case vs.control group	34564407
METAC_999	170	prostate cancer	nan	10283	patients before radical prostatectomy	64 ± 6	M	90	healthy controls	63 ± 7	M	70	differential metabolites between prostate cancer patients before radical prostatectomy and healthy controls	14 metabolites were statistically altered in knock-in PC compared to HC	¹H NMR	Blood	case vs.control group	34461489
METAC_1000	170	prostate cancer	nan	10283	patients before radical prostatectomy	64 ± 6	M	90	prostate cancer patients at the 15th day after radical prostatectomy	64 ± 6	M	90	differential metabolites between prostate cancer patients before radical prostatectomy and prostate cancer patients at the 15th day after radical prostatectomy	all these metabolites were playing a major role after removal of the prostate as therapeutic monitoring variables as well	¹H NMR	Blood	case vs.control group	34461489
METAC_1001	170	prostate cancer	nan	10283	patients before radical prostatectomy	64 ± 6	M	90	prostate cancer patients at the 30th day after radical prostatectomy	64 ± 6	M	90	differential metabolites between prostate cancer patients before radical prostatectomy and prostate cancer patients at the 30th day after radical prostatectomy	all these metabolites were playing a major role after removal of the prostate as therapeutic monitoring variables as well	¹H NMR	Blood	case vs.control group	34461489
METAC_1002	170	prostate cancer	nan	10283	prostate cancer patients at the 15th day after radical prostatectomy	64 ± 6	M	90	prostate cancer patients at the 30th day after radical prostatectomy	64 ± 6	M	90	differential metabolites between prostate cancer patients at the 15th day after radical prostatectomy and prostate cancer patients at the 30th day after radical prostatectomy	all these metabolites were playing a major role after removal of the prostate as therapeutic monitoring variables as well	¹H NMR	Blood	case vs.control group	34461489
METAC_1003	170	prostate cancer	nan	10283	prostate cancer tissues			23	Normal tissues				differential Sterol levels between prostate cancer tissues and healthy tissues	cholesterol precursor levels were significantly lower in tumour compared to normal tissues	GC-MS	Prostate tissue	case vs.control group	31017097
METAC_1004	170	prostate cancer	nan	10283	prostate cancer patients before radio therapy	68 (52-90)	M	55	prostate cancer patients after radio therapy	68 (52-90)	M	55	differential metabolites of prostate cancer patients before and after radiotherapy	only 15 of them were putatively identified through changes in peak intensity and database search	UPLC-ESI-QTOF-MS	Serum	case vs.control group	31009330
METAC_1005	170	prostate cancer	nan	10283	bladder cancer patients had recurrence	58 ± 6	M	40	bladder cancer patients had no recurrence	57 ± 6	M	40	differential metabolites bewteen prostate cancer patients had recurrence and patients had no recurrence	Over 600 metabolites were identified with different confidence levels as being altered in patients that recur	HILIC-MS/MS	Serum	case vs.control group	30758971
METAC_1006	170	prostate cancer	nan	10283	bladder cancer patients had recurrence	58 ± 6	M	40	bladder cancer patients had no recurrence	57 ± 6	M	40	differential metabolites bewteen prostate cancer patients had recurrence and patients had no recurrence	Over 600 metabolites were identified with different confidence levels as being altered in patients that recur	NMR	Serum	case vs.control group	30758971
METAC_1007	158	pancreatic cancer	nan	1793	(PDAC/Adenocarcinoma +IPMN)	71 (55-82)	F&M	15	serous cystic neoplasm	47 (30-68)	F	5	Differential metabolites(relative quantitation) between cancer(pancreatic ductal adenocarcinoma/Adenocarcinoma + intraductal papillary mucinous neoplasm) and serous cystic neoplasm (SCN)	nan	UPLC-MS/MS	Pancreatic cyst fluid	case vs.control group	33720736
METAC_1008	158	pancreatic cancer	nan	1793	(PDAC/Adenocarcinoma +IPMN)	76 (65-83)	F&M	10	serous cystic neoplasm	47 (30-69)	F	5	Differential metabolites(relative quantitation) between cancer(pancreatic ductal adenocarcinoma/Adenocarcinoma + intraductal papillary mucinous neoplasm) and serous cystic neoplasm (SCN)	nan	UPLC-MS/MS	Plasma	case vs.control group	33720736
METAC_1009	158	pancreatic cancer	nan	1793	(PDAC/Adenocarcinoma +IPMN)	71 (55-82)	F&M	15	serous cystic neoplasm	47 (30-68)	F	5	Differential metabolites(absolute quantitation) between cancer(pancreatic ductal adenocarcinoma/Adenocarcinoma + intraductal papillary mucinous neoplasm) and serous cystic neoplasm (SCN)	nan	UPLC-MS/MS	Pancreatic cyst fluid	case vs.control group	33720736
METAC_1010	158	pancreatic cancer	nan	1793	(PDAC/Adenocarcinoma +IPMN)	76 (65-83)	F&M	10	serous cystic neoplasm	47 (30-69)	F	5	Differential metabolites(absolute quantitation) between cancer(pancreatic ductal adenocarcinoma/Adenocarcinoma + intraductal papillary mucinous neoplasm) and serous cystic neoplasm (SCN)	nan	UPLC-MS/MS	Plasma	case vs.control group	33720736
METAC_1011	158	pancreatic cancer	nan	1793	intraductal papillary mucinous neoplasm with high-grade dysplasia(HGD)	76 (67-84)	F&M	8	serous cystic neoplasm	47 (30-68)	F	5	Differential metabolites(relative quantitation) between intraductal papillary mucinous neoplasm with high-grade dysplasia and serous cystic neoplasm (SCN)	nan	UPLC-MS/MS	Pancreatic cyst fluid	case vs.control group	33720736
METAC_1012	158	pancreatic cancer	nan	1793	intraductal papillary mucinous neoplasm with high-grade dysplasia(HGD)	74 (66-84)	F&M	10	serous cystic neoplasm	47 (30-69)	F	5	Differential metabolites(relative quantitation) between intraductal papillary mucinous neoplasm with high-grade dysplasia and serous cystic neoplasm (SCN)	nan	UPLC-MS/MS	Plasma	case vs.control group	33720736
METAC_1013	158	pancreatic cancer	nan	1793	intraductal papillary mucinous neoplasm with high-grade dysplasia(HGD)	76 (67-84)	F&M	8	serous cystic neoplasm	47 (30-68)	F	5	Differential metabolites(absolute quantitation) between intraductal papillary mucinous neoplasm with high-grade dysplasia and serous cystic neoplasm (SCN)	nan	UPLC-MS/MS	Pancreatic cyst fluid	case vs.control group	33720736
METAC_1014	158	pancreatic cancer	nan	1793	intraductal papillary mucinous neoplasm with high-grade dysplasia(HGD)	74 (66-84)	F&M	10	serous cystic neoplasm	47 (30-69)	F	5	Differential metabolites(absolute quantitation) between intraductal papillary mucinous neoplasm with high-grade dysplasia and serous cystic neoplasm (SCN)	nan	UPLC-MS/MS	Plasma	case vs.control group	33720736
METAC_1015	168	pancreatic cancer	intraductal papillary mucinous neoplasm	1793	(PDAC/Adenocarcinoma +IPMN)	71 (55-82)	F&M	15	intraductal papillary mucinous neoplasm with low-grade dysplasia (LGD)	70 (47-82)	F&M	29	Differential metabolites(relative quantitation) between cancer(pancreatic ductal adenocarcinoma/Adenocarcinoma + intraductal papillary mucinous neoplasm) and intraductal papillary mucinous neoplasm with low-grade dysplasia(LGD)	nan	UPLC-MS/MS	Pancreatic cyst fluid	case vs.control group	33720736
METAC_1016	168	pancreatic cancer	intraductal papillary mucinous neoplasm	1793	(PDAC/Adenocarcinoma +IPMN)	76 (65-83)	F&M	10	intraductal papillary mucinous neoplasm with low-grade dysplasia (LGD)	68 (55-79)	F&M	20	Differential metabolites(relative quantitation) between cancer(pancreatic ductal adenocarcinoma/Adenocarcinoma + intraductal papillary mucinous neoplasm) and intraductal papillary mucinous neoplasm with low-grade dysplasia(LGD)	nan	UPLC-MS/MS	Plasma	case vs.control group	33720736
METAC_1017	168	pancreatic cancer	intraductal papillary mucinous neoplasm	1793	(PDAC/Adenocarcinoma +IPMN)	71 (55-82)	F&M	15	intraductal papillary mucinous neoplasm with low-grade dysplasia (LGD)	70 (47-82)	F&M	29	Differential metabolites(absolute quantitation) between cancer(pancreatic ductal adenocarcinoma/Adenocarcinoma + intraductal papillary mucinous neoplasm) and intraductal papillary mucinous neoplasm with low-grade dysplasia(LGD)	nan	UPLC-MS/MS	Pancreatic cyst fluid	case vs.control group	33720736
METAC_1018	168	pancreatic cancer	intraductal papillary mucinous neoplasm	1793	(PDAC/Adenocarcinoma +IPMN)	76 (65-83)	F&M	10	intraductal papillary mucinous neoplasm with low-grade dysplasia (LGD)	68 (55-79)	F&M	20	Differential metabolites(absolute quantitation) between cancer(pancreatic ductal adenocarcinoma/Adenocarcinoma + intraductal papillary mucinous neoplasm) and intraductal papillary mucinous neoplasm with low-grade dysplasia(LGD)	nan	UPLC-MS/MS	Plasma	case vs.control group	33720736
METAC_1019	168	pancreatic cancer	intraductal papillary mucinous neoplasm	1793	intraductal papillary mucinous neoplasm with high-grade dysplasia(HGD)	76 (67-84)	F&M	8	intraductal papillary mucinous neoplasm with low-grade dysplasia (LGD)	70 (47-82)	F&M	29	Differential metabolites(relative quantitation) between intraductal papillary mucinous neoplasm with high-grade dysplasia(HGD) and intraductal papillary mucinous neoplasm with low-grade dysplasia(LGD)	nan	UPLC-MS/MS	Pancreatic cyst fluid	case vs.control group	33720736
METAC_1020	168	pancreatic cancer	intraductal papillary mucinous neoplasm	1793	intraductal papillary mucinous neoplasm with high-grade dysplasia(HGD)	74 (66-84)	F&M	10	intraductal papillary mucinous neoplasm with low-grade dysplasia (LGD)	68 (55-79)	F&M	20	Differential metabolites(relative quantitation) between intraductal papillary mucinous neoplasm with high-grade dysplasia(HGD) and intraductal papillary mucinous neoplasm with low-grade dysplasia(LGD)	nan	UPLC-MS/MS	Plasma	case vs.control group	33720736
METAC_1021	168	pancreatic cancer	intraductal papillary mucinous neoplasm	1793	intraductal papillary mucinous neoplasm with high-grade dysplasia(HGD)	76 (67-84)	F&M	8	intraductal papillary mucinous neoplasm with low-grade dysplasia (LGD)	70 (47-82)	F&M	29	Differential metabolites(absolute quantitation) between intraductal papillary mucinous neoplasm with high-grade dysplasia(HGD) and intraductal papillary mucinous neoplasm with low-grade dysplasia(LGD)	nan	UPLC-MS/MS	Pancreatic cyst fluid	case vs.control group	33720736
METAC_1022	168	pancreatic cancer	intraductal papillary mucinous neoplasm	1793	intraductal papillary mucinous neoplasm with high-grade dysplasia(HGD)	74 (66-84)	F&M	10	intraductal papillary mucinous neoplasm with low-grade dysplasia (LGD)	68 (55-79)	F&M	20	Differential metabolites(absolute quantitation) between intraductal papillary mucinous neoplasm with high-grade dysplasia(HGD) and intraductal papillary mucinous neoplasm with low-grade dysplasia(LGD)	nan	UPLC-MS/MS	Plasma	case vs.control group	33720736
METAC_1023	197	prostate cancer	nan	10283	SB200		M		control		M		Effect of silibinin feeding on endogenous metabolites in 22Rv1 xenograft tissues	Silibinin treatment led to a dramatic decrease in the tumor levels of total fatty acids, triacylglycerols, phospholipids, and cholesterol	¹H NMR	22Rv1 cells	case vs.control group	27533043
METAC_1024	170	prostate cancer	nan	10283	prostate cancer	65.8 (58-76)	M	29	benign prostatic hyperplasia	62.6 (52-69)	M	21	Differential metabolites between prostate cancer patients and benign prostatic hyperplasia controls.	Changes in fatty acid (acylcarnitines), choline (glycerophospholipids) and amino acid metabolism (arginine) as markers for PCa compared with BPH.	MS;MRS	Serum	case vs.control group	26633561
METAC_1025	27	breast cancer	ER positive and negative, Her2 positive and negative	1612	breast cancer		F	79	healthy control	46.4 (24-86)	F	96	Differential metabolites identifi ed between breast cancer and normal control plasma	We observed 64 differential metabolites between BC and normal group.	UPLC-Q/TOF-MS;GC-Q/MS	Plasma	case vs.control group	26848530
METAC_1026	113	lung cancer	nan	1324	lung cancer patients			50	Heathy Volunteers			50	Amounts of polyamine metabolome in plasma from lung cancer patients.	nan	UHPLC-MS/MS	Plasma	case vs.control group	27517900
METAC_1027	113	lung cancer	nan	1324	lung cancer patients			50	Heathy Volunteers			50	Amounts of polyamine metabolome in urine from lung cancer patients.	nan	UHPLC-MS/MS	Urine	case vs.control group	27517900
METAC_1028	113	lung cancer	adenosquamous carcinoma, Adenocarcinomas, small cell carcinomas	1324	lung cancer	51.2 ± 10.6	F&M	25	healthy controls	49.5 ± 8.2	F&M	25	Differentially regulated metabolites identified from 1H NMR-based non-targeted metabolic profiling	We identified 25 metabolites that were differentially regulated between the lung cancer patients and matched controls. Of those, 16 were detected using the non-targeted approach and 9 were identified using the targeted approach. Both groups of metabolites could differentiate between lung cancer patients and healthy controls with 100% sensitivity and specificity.	¹H NMR	Serum	case vs.control group	27566571
METAC_1029	123	colorectal cancer	nan	9256	Lymph Node Metastasis Group	57.1 (32-86)	F&M	60	Lymph Node Non-Metastasis Group	61.3 (32-83)	F&M	163	Metabolites Between Lymph Node Metastasis Group and Lymph Node Non-Metastasis Group.	There was a significant statistical difference in the concentration of most metabolites and the average concentration of these metabolites in the metastatic group was higher than that in the non-metastatic group.	LC-MS/MS	Serum	case vs.control group	33116609
METAC_1030	91	liver cancer	hepatocellular carcinoma	3571	hepatocellular carcinoma patients	49.0 ± 9.8	F&M	28	liver colorectal patients	48.1 ± 14.5	F&M	26	Differential metabolites between hepatocellular carcinoma patients and liver cirrhosis patients.	nan	LC-MS	Serum	case vs.control group	24382646
METAC_1031	91	liver cancer	hepatocellular carcinoma	3571	hepatocellular carcinoma patients	49.0 ± 9.8	F&M	28	healthy volunteers	40.5 ± 4.1	F&M	9	Differential metabolites between hepatocellular carcinoma patients and healthy volunteers.	nan	LC-MS	Serum	case vs.control group	24382646
METAC_1032	46	colorectal cancer	nan	9256	colorectal cancer (CRC) colon mucosae	67 ± 13	F&M	31	normal colon mucosae	67 ± 13	F&M	31	Marker Metabolites Found in GC/MS Chromatograms of Human colorectal cancer (CRC) and Normal Colon Mucosae	The percentage changes of these metabolites in cancer compared to the normal mucosae were also consistent in direction and order of magnitude between the two analytical platforms	GC/MS	Mucosa	case vs.control group	19063642
METAC_897	170	prostate cancer	nan	10283	prostate cancer		M	40	controls		M	43	Statistically significant plasma and urine metabolites in patients with prostate cancer compared to those in healthy controls.	Eleven urinary and three plasma metabolites were selected as statistically significant in patients with CaP as compared to those in healthy controls.	GC-QqQ/MS	Plasma	case vs.control group	32969349
METAC_1033	250	melanoma	malignant melanoma	1909	malignant melanoma			20	healthy controls			14	Potential biomarkers differentially expressed in MMP (malignant melanoma patients) compared with HC (healthy controls) serum-derived exosomes based on MS/MS fragmentation spectra and database search	nan	MS/MS	Serum	case vs.control group	33052601
METAC_1034	222	melanoma	advanced stage melanoma	1909	advanced stage melanoma		F&M	26	healthy controls		F&M	46	Univariate comparison of serum metabolites (NMR) between advanced stage melanoma and healthy controls	We accurately quantified 181 metabolites in serum using a combination of 1 H NMR and DI–LC–MS/MS. We observed significant separation between cases and controls in the PLS-DA scores plot (permutation test p-value=0.002).  Using the concentrations of PC-aa-C40:3, dl-carnitine, octanoyl-l-carnitine, ethanol, and methylmalonyl-l-carnitine we developed a diagnostic algorithm with an AUC (95% CI)=0.822 (0.665–0.979) with sensitivity and specificity of 100 and 56%, respectively. Furthermore, we identified arginine, proline, tryptophan, glutamine, glutamate, glutathione and ornithine metabolism to be significantly perturbed due to disease (p<0.05).	¹H NMR	Serum	case vs.control group	30830422
METAC_1035	222	melanoma	advanced stage melanoma	1909	advanced stage melanoma		F&M	28	healthy controls		F&M	54	Univariate comparison of serum metabolites (LC–MS) between advanced stage melanoma and healthy controls	We accurately quantified 181 metabolites in serum using a combination of 1 H NMR and DI–LC–MS/MS. We observed significant separation between cases and controls in the PLS-DA scores plot (permutation test p-value=0.002).  Using the concentrations of PC-aa-C40:3, dl-carnitine, octanoyl-l-carnitine, ethanol, and methylmalonyl-l-carnitine we developed a diagnostic algorithm with an AUC (95% CI)=0.822 (0.665–0.979) with sensitivity and specificity of 100 and 56%, respectively. Furthermore, we identified arginine, proline, tryptophan, glutamine, glutamate, glutathione and ornithine metabolism to be significantly perturbed due to disease (p<0.05).	DI-LC-MS/MS	Serum	case vs.control group	30830422
METAC_1036	236	cervical cancer	cervical squamous cell carcinoma (CSCC)	4362	post-CCRT (concurrent chemoradiotherapy (CCRT))		F	24	Primary cervical cancer	53.5±8.3	F	24	Detailed information on the 39 potential biomarkers found significant between Primary and post-CCRT (concurrent chemoradiotherapy (CCRT))	Metabolic profiles obtained were significantly different among primary, post-CCRT-treated,  and recurrent patients. Multivariate analyses showed that 37 metabolites differed significantly among the  three groups, of which the levels of 22 metabolites changed significantly after CCRT and recovered or even  exceeded the levels in primary patients when the tumor reappeared. These 22 metabolites were mainly  lipids involved in sphingolipid and glycerophospholipid metabolism.	UPLC-Q-TOF/MS	Plasma	case vs.control group	35117632
METAC_1037	229	cervical cancer	cervical squamous cell carcinoma (CSCC)	4362	recurrent cervical cancer	53.3±8.6	F	30	Primary cervical cancer	53.5±8.3	F	24	Detailed information on the 39 potential biomarkers found significant between Primary and recurrent	Metabolic profiles obtained were significantly different among primary, post-CCRT-treated,  and recurrent patients. Multivariate analyses showed that 37 metabolites differed significantly among the  three groups, of which the levels of 22 metabolites changed significantly after CCRT and recovered or even  exceeded the levels in primary patients when the tumor reappeared. These 22 metabolites were mainly  lipids involved in sphingolipid and glycerophospholipid metabolism.	UPLC-Q-TOF/MS	Plasma	case vs.control group	35117632
METAC_1038	236	cervical cancer	cervical squamous cell carcinoma (CSCC)	4362	post-CCRT (concurrent chemoradiotherapy (CCRT))		F		recurrent cervical cancer	53.3±8.6	F	30	Detailed information on the 39 potential biomarkers found significant between post-CCRT concurrent chemoradiotherapy (CCRT) and recurrent	Metabolic profiles obtained were significantly different among primary, post-CCRT-treated,  and recurrent patients. Multivariate analyses showed that 37 metabolites differed significantly among the  three groups, of which the levels of 22 metabolites changed significantly after CCRT and recovered or even  exceeded the levels in primary patients when the tumor reappeared. These 22 metabolites were mainly  lipids involved in sphingolipid and glycerophospholipid metabolism.	UPLC-Q-TOF/MS	Plasma	case vs.control group	35117632
METAC_1039	228	cervical cancer	cervical squamous cell carcinoma	4362	PP (cervical cancer patients with poor prognosis)	53.27±8.55	F	30	BT (primary cervical cancer patients before treatment)	52.20±7.99	F	30	Detailed information on the 31 potential biomarkers found significant between BT (primary cervical cancer patients before treatment) vs PP (cervical cancer patients with poor prognosis)	thirty plasma samples were collected from each group. Multivariate analyses showed that 31 metabolites were significantly different among the 3 groups studied. Of those, the 5 metabolites phosphatidyl choline (15:0/16:0), phosphatidyl glycerol (12:0/13:0), actosylceramide (d18:1/16:0), D-Maltose, and phthalic acid, with an area under the curve above 0.75, were identified as potential biomarkers. The present findings provide evidence for biomarkers to monitor prognosis of patients with CSCC, which may help in better managing the disease.	UPLC-Q-TOF/MS	Plasma	case vs.control group	31261558
METAC_1040	228	cervical cancer	cervical squamous cell carcinoma	4362	GP (cervical cancer patients with good prognosis)	52.40±8.02	F	30	BT (primary cervical cancer patients before treatment)	52.20±7.99	F	30	Detailed information on the 31 potential biomarkers found significant between BT (primary cervical cancer patients before treatment) vs GP (cervical cancer patients with good prognosis)	thirty plasma samples were collected from each group. Multivariate analyses showed that 31 metabolites were significantly different among the 3 groups studied. Of those, the 5 metabolites phosphatidyl choline (15:0/16:0), phosphatidyl glycerol (12:0/13:0), actosylceramide (d18:1/16:0), D-Maltose, and phthalic acid, with an area under the curve above 0.75, were identified as potential biomarkers. The present findings provide evidence for biomarkers to monitor prognosis of patients with CSCC, which may help in better managing the disease.	UPLC-Q-TOF/MS	Plasma	case vs.control group	31261558
METAC_1041	228	cervical cancer	cervical squamous cell carcinoma	4362	PP (cervical cancer patients with poor prognosis)	53.27±8.55	F	30	GP (cervical cancer patients with good prognosis)	52.40±8.02	F	30	Detailed information on the 31 potential biomarkers found significant between GP (cervical cancer patients with good prognosis) vs PP (cervical cancer patients with poor prognosis)	thirty plasma samples were collected from each group. Multivariate analyses showed that 31 metabolites were significantly different among the 3 groups studied. Of those, the 5 metabolites phosphatidyl choline (15:0/16:0), phosphatidyl glycerol (12:0/13:0), actosylceramide (d18:1/16:0), D-Maltose, and phthalic acid, with an area under the curve above 0.75, were identified as potential biomarkers. The present findings provide evidence for biomarkers to monitor prognosis of patients with CSCC, which may help in better managing the disease.	UPLC-Q-TOF/MS	Plasma	case vs.control group	31261558
METAC_1042	232	cervical cancer	squamous cell carcinoma (SCC)	4362	pCR (pathological complete response)	50.66 ± 10.99	F	15	SD ( stable disease)	46.44 ± 9.80	F	9	The differential metabolites in the prediction of chemotherapy response bewteen pCR (pathological complete response) vs. SD ( stable disease)	The metabolic profiles of plasma from 38 cervical cancer patients with a complete, partial and non-response to NACT were studied using a combination of liquid chromatography coupled with mass spectrometry (LC/MS) and multivariate analysis methods. L-Valine and L-tryptophan were finally identified and verified as the potential biomarkers.	UPLC-QTOF/MS	Plasma	case vs.control group	24865370
METAC_1043	232	cervical cancer	squamous cell carcinoma (SCC)	4362	pCR + PR (pathological complete response + partial response)		F	29	PR (partial response) 	50.66 ± 10.99	F	15	The differential metabolites in the prediction of chemotherapy response bewteen pCR + PR (pathological complete response + partial response) vs. PR (partial response)	The metabolic profiles of plasma from 38 cervical cancer patients with a complete, partial and non-response to NACT were studied using a combination of liquid chromatography coupled with mass spectrometry (LC/MS) and multivariate analysis methods. L-Valine and L-tryptophan were finally identified and verified as the potential biomarkers.	UPLC-QTOF/MS	Plasma	case vs.control group	24865370
METAC_1044	231	cervical cancer	cervical squamous cell carcinoma	4362	cervical squamous cell carcinoma	45.6±0.3	F	38	healthy controls	41.6±0.3	F	38	Differential plasma metabolites of patients with CSCC (cervical squamous cell carcinoma) and healthy controls.	Plasma from patients with CSCC had higher levels of acetate and formate, together with lower levels of creatine, lactate, isoleucine, leucine, valine, alanine, glutamine, histidine and tyrosine compared with the plasma of the healthy controls	¹H NMR	Plasma	case vs.control group	22969997
METAC_1045	230	cervical cancer	cervical intraepithelial neoplasia	4362	cervical intraepithelial neoplasia	39.6±0.7	F	38	healthy controls	41.6±0.3	F	38	Differential plasma metabolites of patients with CIN (cervical intraepithelial neoplasia) and healthy controls.	Compared with plasma obtained from the healthy controls,  plasma from patients with CIN had higher levels of very?low density lipoprotein (VLDL), acetone, unsaturated lipid and carnitine, together with lower levels of creatine, lactate, isoleucine, leucine, valine, alanine, glutamine, histidine, glycine, acetylcysteine, myo-inositol, choline and glycoprotein.	¹H NMR	Plasma	case vs.control group	22969997
METAC_1046	271	thyroid cancer	nan	1781	Thyroid cancer	42.54 ± 14.38	F&M	50	healthy controls	42.40 ± 13.80	F&M	58	Detailed information on differential metabolites between  thyroid cancer (TC) and  healthy controls (HCs)	nan	LC-MS/MS	Stool	case vs.control group	35721748
METAC_1047	251	thyroid cancer	medullary thyroid carcinoma	1781	medullary thyroid carcinoma	45.75±13.841	F&M	20	healthy controls	38.25±13.21	F&M	20	Substantially altered metabolites between MTC (medullary thyroid carcinoma) and healthy groups	13 metabolites were selected to be diferentially expressed in MTC patients compared to controls (P< 0.05).	GC-MS	Plasma	case vs.control group	35590091
METAC_1048	270	thyroid cancer	papillary thyroid carcinoma	1781	papillary thyroid carcinoma	44 ± 11	F&M	61	healthy controls	47 ± 19	F&M	61	Differential saliva metabolites between papillary thyroid carcinoma and healthy controls	We developed an ultra-high performance liquid chromatography-high resolution mass spectrometry (UPLC-HRMS) method to simultaneously determine the metabolic levels of 10 amino acids in saliva, aiming to study the amino acid metabolism profile to promote early diagnosis of thyroid cancer.	HILIC-UPLC-HRMS	Saliva	case vs.control group	34517597
METAC_1049	270	thyroid cancer	papillary thyroid cancer	1781	papillary thyroid cancer		F&M	65	paracancerous papillary thyroid cancer		F&M	65	Identified differential metabolites between PTC-tissue (papillary thyroid cancer) and para-PTC (paracancerous papillary thyroid cancer) in the positive and negative ion modes (ESI+ and ESI−)	Good separations were obtained for PTC tissue vs. paracancerous tissue, and 15 metabolites, including L-octa?noylcarnitine, N-arachidonoylglycine, and others were found to be disturbed in PTC tissue.	UPLC/Q-Tof/MS	Thyroid tissue	case vs.control group	34075541
METAC_1050	247	thyroid cancer	papillary thyroid cancer	1781	cancer tissues from an iodine excess area	47.95 ± 9.86	F&M	33	PTC tissues from an iodine adequate area	48.37 ± 10.44	F&M	32	Identified differential metabolites between APTC-tissue (PTC tissues from an iodine adequate area) and HPTC-tissue (cancer tissues from an iodine excess area) in the positive and negative ion modes (ESI+ and ESI−)	the metabolic profile presented considerable separation between PTC tissue from different iodine areas, and 15 metabolomic biomarkers were found to be differentially expressed. Among them, 10 metabolites, including arachidonoylcarnitine and LysoPCs, were related to thyroid cancer and excess iodine.	UPLC/Q-Tof/MS	Thyroid tissue	case vs.control group	34075541
METAC_1051	247	thyroid cancer	papillary thyroid cancer	1781	paracancerous tissues from an iodine excess area 	47.95 ± 9.86	F&M	33	paracancerous tissues from an iodine excess area	48.37 ± 10.44	F&M	32	Identified differential metabolites between para-APTC (paracancerous tissues from an iodine excess area (para-HPTC)) and para-HPTC (paracancerous tissues from an iodine excess area (para-HPTC)) in the positive and negative ion modes	nan	UPLC/Q-Tof/MS	Thyroid tissue	case vs.control group	34075541
METAC_1052	270	thyroid cancer	papillary thyroid cancer	1781	papillary thyroid cancer	41.63 ± 11.213	F&M	80	healthy subjects	43.44 ± 8.378	F&M	80	Differential metabolites in the serum of papillary thyroid cancer patients and healthy subjects with positive and negative ion patterns.	Among them, 22 metabolites, including proline betaine, taurocholic acid, L-phenylalanine, retinyl beta-glucuronide, alpha-tocotrienol, and threonine acid were upregulated in the PTC group; meanwhile, L-tyrosine, L-tryptophan, 2-arachidonylglycerol, citric acid, and other 42 metabolites were downregulated in this group.	HPLC-Q-TOF-MS/MS	Serum	case vs.control group	33598460
METAC_1053	270	thyroid cancer	papillary thyroid carcinoma	1781	papillary thyroid carcinoma	48.24 ± 11.34	F&M	49	normal controls	51.23 ± 10.22	F&M	48	OH-PAHs in urine samples assessed by GC-MS/MS between papillary thyroid carcinoma (PTC) and normal controls	2-hydroxynaphthalene (2-OH-NAP), 2-OH-DBF, and 1-OH-PHE in the PTC group were significantly higher than those in controls.	GC-MS/MS	Urine	case vs.control group	33310200
METAC_1054	270	thyroid cancer	papillary thyroid carcinoma	1781	papillary thyroid carcinoma	35.37 ± 10.80	F&M	19	healthy controls	43.4 ± 14.33	F&M	20	Significantly altered metabolites between papillary thyroid carcinoma(PTC) and Healthy	nan	GC-MS	Plasma	case vs.control group	32612989
METAC_1055	270	thyroid cancer	papillary thyroid carcinoma	1781	papillary thyroid carcinoma	35.37 ± 10.80	F&M	19	multinodular goiter	52.06 ± 10.96	F&M	16	Significantly altered metabolites between papillary thyroid carcinoma(PTC) and multinodular goiter (MNG)	nan	GC-MS	Plasma	case vs.control group	32612989
METAC_1056	270	thyroid cancer	papillary thyroid carcinoma	1781	papillary thyroid carcinoma	14.32 ± 2.31	F&M	41	healthy control	14.18 ± 2.32	F&M	40	metabolites in serum obtained  from the healthy control group and  patient groups	A total of 17 metabolites were identified. Compared with those from benign thyroid adenoma patients and healthy controls, the metabolites from papillary thyroid carcinoma patients, including leucine, lactate, alanine, glycine, acetate, lysine and choline, were increased, while glucose was decreased.	¹H NMR	Plasma	case vs.control group	31576470
METAC_1057	270	thyroid cancer	papillary thyroid carcinoma	1781	papillary thyroid carcinoma	14.32 ± 2.31	F&M	41	benign control	14.27 ± 2.33	F&M	55	metabolites in serum obtained  from the benign control group and  patient groups	A total of 17 metabolites were identified. Compared with those from benign thyroid adenoma patients and healthy controls, the metabolites from papillary thyroid carcinoma patients, including leucine, lactate, alanine, glycine, acetate, lysine and choline, were increased, while glucose was decreased.	¹H NMR	Plasma	case vs.control group	31576470
METAC_1058	271	thyroid cancer	thyroid carcinoma	1781	thyroid carcinoma	49.06 ± 6.49	F&M	15	healthy control	45.53 ± 6.97	F&M	15	Detailed information of significantly different metabolites between thyroid carcinoma and healthy control	72 significantly changed metabolites (VIP > 1.0 and p < 0.05) were observed and correlated to each other	UPLC-Q-TOF/MS	Stool	case vs.control group	30565661
METAC_1059	270	thyroid cancer	papillary thyroid carcinoma	1781	papillary thyroid carcinoma		F&M	17	multinodular goiter		F&M	17	The significant discriminating serum metabolites between papillary thyroid carcinoma and multinodular goiter	nan	¹H NMR	Serum	case vs.control group	30483387
METAC_1060	270	thyroid cancer	papillary thyroid carcinoma	1781	papillary thyroid carcinoma		F&M	17	healthy control		F&M	20	The significant discriminating serum metabolites between papillary thyroid carcinoma and healthy control	The significant metabolites in the PTC group  compared to healthy subjects also included scyllo- and myo-inositol, tryptophan, propionate, lactate,  homocysteine, 3-methyl glutaric acid, asparagine, aspartate, choline, and acetamide.	¹H NMR	Serum	case vs.control group	30483387
METAC_1061	270	thyroid cancer	papillary thyroid carcinoma	1781	papillary thyroid carcinoma	41.9 (16-68)	F&M	141	healthy control	42.3 (23–70)	F&M	100	Statistical analysis of 17 differential metabolites in serum from the comparison of healthy versus papillary thyroid carcinoma in the discovery phase	nan	LC-Q/TOF-MS	Serum	case vs.control group	30318614
METAC_1062	270	thyroid cancer	papillary thyroid carcinoma	1781	papillary thyroid carcinoma	41.9 (16-68)	F&M	141	healthy control	42.3 (23–70)	F&M	100	Statistical analysis of 42 differential metabolites in plasma from the comparison of healthy versus papillary thyroid carcinoma in the discovery phase	nan	LC-Q/TOF-MS	Plasma	case vs.control group	30318614
METAC_1063	270	thyroid cancer	papillary thyroid carcinoma	1781	papillary thyroid carcinoma		F&M	16	normal tissue		F&M	16	VIP value derived from the NMR data of metabolites in thyroid obtained from PTC and normal tissue	nan	¹H NMR	Thyroid tissue	case vs.control group	29484373
METAC_1064	252	thyroid cancer	papillary thyroid carcinoma	1781	metastatic papillary thyroid carcinoma	37.27  ± 13.89	F&M	37	ablation group	40.88 ± 11.08	F&M	40	A distinct serum metabolic signature of distant metastatic papillary thyroid carcinoma	A total of 31  metabolites were identified which are related to amino acid, lipid, glucose, vitamin metabolism and  diet/gut microbiota interaction.	GC-TOF-MS	Serum	case vs.control group	28755525
METAC_1065	262	thyroid cancer	papillary thyroid microcarcinoma	1781	papillary thyroid microcarcinoma		F&M	26	healthy groups		F&M	17	nine metabolites in plasma were considered different papillary thyroid microcarcinoma (PTMC)between and healthy gtoup	(ROC) curve model for PTMC prediction was able to classify cases with good sensitivity and specificity using 9 significant changed metabolites in plasma.	¹H NMR	Plasma	case vs.control group	27835583
METAC_1066	270	thyroid cancer	papillary thyroid carcinoma	1781	papillary thyroid carcinoma	45.3 ± 9.7	F&M	20	healthy groups	44.5 ± 10.9	F&M	20	Metabolites among the differences between papillary thyroid carcinoma and healthy controls	The content of metabolites in the serum of team T increased including valine, leucine, isoleucine, lactic acid, alanine, glutamic acid, lysine, glycine, while the lipids, choline, tyrosine decreased.	NMR	Serum	case vs.control group	26770396
METAC_1067	270	thyroid cancer	papillary thyroid carcinoma	1781	papillary thyroid carcinoma		F&M	16	normal tissue		F&M	16	Metabolomic alterations in matched PTC (papillary thyroid microcarcinoma) and normal thyroid tissues	Metabolites in carbohydrate metabolism, including glucose, fructose, galactose, mannose, 2-keto-D-gluconic acid and rhamnose, consistently decreased, while metabolites in nucleotide metabolism, including malonic acid and inosine, and lipid metabolism, including cholesterol and arachidonic acid, significantly altered in PTC.	GC-MS	Thyroid tissue	case vs.control group	26459747
METAC_1068	270	thyroid cancer	papillary thyroid carcinoma	1781	papillary thyroid carcinoma	44.5 ± 14.4	F&M	57	normal tissue	44.5 ± 14.4	F&M	57	Identities of 54 differential metabolites between PTC (papillary thyroid carcinoma and adjacent normal controls from each of the tissue samples	nan	GC-TOFMS;UPLC-QTOFMS	Thyroid tissue	case vs.control group	26130307
METAC_1069	244	thyroid cancer	papillary thyroid carcinoma	1781	male adjacent non-tumor tissues from PTC samples		F&M	14	female adjacent non-tumor tissues from PTC samples		F&M	43	Identities of 21 differential metabolites between male and female adjacent non-tumor tissues from PTC (papillary thyroid carcinoma) samples	nan	GC-TOFMS;UPLC-QTOFMS	Thyroid tissue	case vs.control group	26130307
METAC_1070	270	thyroid cancer	papillary thyroid carcinoma	1781	Papillary Thyroid Carcinomas		F	18	benign tumors	59.2 ± 5.8	F	9	Urinary estrogen concentrations associated with benign tumors and malignant Papillary Thyroid Carcinomas	nan	GC-SIM/MS	Urine	case vs.control group	24156385
METAC_1071	268	thyroid cancer	papillary thyroid carcinoma	1781	Stage I malignant Papillary Thyroid Carcinomas	56.1 ± 3.7	F	11	benign tumors	59.2 ± 5.8	F	9	Urinary estrogen concentrations associated with benign tumors and Stage I malignant Papillary Thyroid Carcinomas	nan	GC-SIM/MS	Urine	case vs.control group	24156385
METAC_1072	268	thyroid cancer	papillary thyroid carcinoma	1781	Stage III/IV malignant Papillary Thyroid Carcinomas	59.6 ± 10.9	F	7	benign tumors	59.2 ± 5.8	F	9	Urinary estrogen concentrations associated with benign tumors and Stage III/IV malignant Papillary Thyroid Carcinomas	nan	GC-SIM/MS	Urine	case vs.control group	24156385
METAC_1073	268	thyroid cancer	papillary thyroid carcinoma	1781	Stage III/IV malignant Papillary Thyroid Carcinomas	59.6 ± 10.9	F	7	Stage I malignant Papillary Thyroid Carcinomas	56.1 ± 3.7	F	11	Urinary estrogen concentrations associated with Stage I malignant Papillary Thyroid Carcinomas and Stage III/IV malignant Papillary Thyroid Carcinomas	nan	GC-SIM/MS	Urine	case vs.control group	24156385
METAC_1074	128	thyroid cancer	papillary thyroid carcinoma	1781	pre-menopausal PTC (papillary thyroid carcinoma) women	36.95 ± 7.19	F	21	controls	33.21 ± 10.48	F	24	Concentrations of urinary steroids in pre-menopausal PTC (papillary thyroid carcinoma) women and control	Among them, the levels of three active androgens, androstenedione, androstenediol and 16α-hydroxy DHEA, were significantly higher in the pre-menopausal women and men with PTC.	GC-MS	Urine	case vs.control group	21824401
METAC_1075	128	thyroid cancer	papillary thyroid carcinoma	1781	post-menopausal PTC (papillary thyroid carcinoma) women	52.79 ± 7.66	F	19	controls	49.67 ± 8.94	F	16	Concentrations of urinary steroids in post-menopausal PTC (papillary thyroid carcinoma) women and control	The corticoid levels were increased slightly in the PTC men, while progestins were not altered in the post-menopausal PTC women.	GC-MS	Urine	case vs.control group	21824401
METAC_1076	264	thyroid cancer	papillary thyroid carcinoma	1781	PTC (papillary thyroid carcinoma) men	41.88 ± 8.48	M	16	controls	42.75 ± 4.22	M	20	Concentrations of urinary steroids in the PTC (papillary thyroid carcinoma) men and control	nan	GC-MS	Urine	case vs.control group	21824401
METAC_1077	241	esophagus cancer	esophageal cancer	5041	esophageal cancer	63 (40-86)	F&M	44	controls	62 (41-84)	F&M	44	Key metabolite differences between esophageal cancer and healthy controls.	Urinary metabolomics identified discrete metabolic signatures that clearly distinguished both Barrett's esophagus and esophageal cancer from controls.	¹H NMR	Urine	case vs.control group	23241138
METAC_1078	226	esophagus cancer	Barrett’s esophagus cancer	5041	Barrett’s esophagus cancer	64.5 (38-81)	F&M	31	controls	64.5 (36-80)	F&M	31	Key metabolite differences between Barrett’s esophagus and healthy controls.	Urinary metabolomics identified discrete metabolic signatures that clearly distinguished both Barrett's esophagus and esophageal cancer from controls.	¹H NMR	Urine	case vs.control group	23241138
METAC_1079	267	oral cancer	oral squamous cell carcinoma	8618	Male oral squamous cell carcinoma		M	20	Female oral squamous cell carcinoma		F	15	Comparison of salivary metabolites between sex in the training group.	nan	CE-TOF-MS	Saliva	case vs.control group	35070995
METAC_1080	267	oral cancer	oral squamous cell carcinoma	8618	Male oral squamous cell carcinoma		M	18	Female oral squamous cell carcinoma		F	19	Comparison of salivary metabolites between sex in the validation group	nan	CE-TOF-MS	Saliva	case vs.control group	35070995
METAC_1081	259	oral cancer	oral squamous cell carcinoma	8618	oral squamous cell carcinoma	66 ± 12	F&M	72	oral erosive lichen planu	61 ± 7	F&M	75	Metabolites different between OSCC (oral squamous cell carcinoma) and OELP (oral erosive lichen planus)	A total of 20 kinds of endogenous metabolites were identified from plasma samples of OSCC patients and OELP patients.	UHPLC/Q-Orbitrap HRMS	Plasma	case vs.control group	34976172
METAC_1082	259	oral cancer	oral squamous cell carcinoma	8618	oral squamous cell carcinoma	66 ± 12	F&M	72	healthy controls	65 ± 9	F&M	47	Metabolites different between OSCC (oral squamous cell carcinoma) and HC (healthy control)	nan	UHPLC/Q-Orbitrap HRMS	Plasma	case vs.control group	34976172
METAC_1083	260	oral cancer	oral squamous cell carcinoma	8618	oral squamous cell carcinoma preoperative	58.5 (28-75)	F&M	73	oral squamous cell carcinoma postoperative	58.5 (28-75)	F&M	73	Statistical analysis of potential metabolic biomarkers for Oral Squamous Cell Carcinoma before and after the operation	In total, 14 differential metabolites and five disturbed pathways were identified between the preoperative group and postoperative group	UHPLC-Q-Orbitrap HRMS	Serum	case vs.control group	34692531
METAC_1084	259	oral cancer	Oral Squamous Cell Carcinoma	8618	Oral Squamous Cell Carcinoma	57 ± 13.87	F&M	27	CONTROL	57.34 ± 11.66	F&M	41	Set of metabolites up- and down-regulated in OSCC (Oral Squamous Cell Carcinoma) samples according to PCA analyses.	Twenty-four metabolites were identified with AUC > 0.8. Using the threshold of AUC = 0.9 we find malic acid, maltose, protocatechuic acid, lactose, 2-ketoadipic, and catechol metabolites expressed.	GC-MS	Saliva	case vs.control group	34677365
METAC_1085	257	oral cancer	nan	8618	Oral cancer	73 (29–94)	F&M	26	control	68 (21–90)	F&M	44	Salivary metabolites between oral cancer and controls	nan	CE-TOF-MS	Saliva	case vs.control group	33297326
METAC_1086	259	oral cancer	oral squamous cell carcinoma	8618	oral squamous cell carcinoma		F&M	125	healthy contrast		F&M	124	Top 10 metabolites with marked up-regulation or down-regulation compared healthy contrast to OSCC ( oral squamous cell carcinoma)	nan	CPSI-MS	Saliva	case vs.control group	32601197
METAC_1087	259	oral cancer	oral squamous cell carcinoma	8618	oral squamous cell carcinoma		F&M	125	premalignant lesion		F&M	124	Top 10 metabolites with marked up-regulation or down-regulation compared premalignant lesion (PML) to OSCC ( oral squamous cell carcinoma)	nan	CPSI-MS	Saliva	case vs.control group	32601197
METAC_1088	259	oral cancer	oral squamous cell carcinoma	8618	oral squamous cell carcinoma			10	Healthy Tissue			10	Metabolites between OSCC (oral squamous cell carcinoma) and Healthy Tissue	Cholesterol and the GPLs phosphatidylcho?lines, phosphatidylethanolamines, and phosphatidylinositols were most significantly increased in OSCC tissue (FC 1.8, 2.0, 2.1, and 2.3 and, P = .003, P = .005, P = .002, P = .007).	LC-MS	Mucosa	case vs.control group	32559714
METAC_1089	259	oral cancer	oral squamous cell carcinoma	8618	oral squamous cell carcinoma			8	normal tissues			8	Differential metabolites identified between oral squamous cell carcinoma (OSCC) tumor and normal tissues.	nan	GC-MS	Oral tissue	case vs.control group	32351881
METAC_1090	259	oral cancer	oral squamous cell carcinoma	8618	oral squamous cell carcinoma			10	normal tissues			10	AUC values of potential OSCC (oral squamous cell carcinoma) biomarkers by ROC curve analysis in validation group.	nan	UHPLC-MS/MS	Oral tissue	case vs.control group	32351881
METAC_1091	261	oral cancer	oral squamous cell carcinoma	8618	oral squamous cell carcinoma with extranodal extension			12	normal tissues			13	Altered metabolites between tumor and adjacent normal tissue at stage IV oral squamous cell carcinoma tumors with extranodal extension	nan	NMR	Oral tissue	case vs.control group	32235493
METAC_1092	261	oral cancer	oral squamous cell carcinoma	8618	oral squamous cell carcinoma without extranodal extension			17	normal tissues			15	Altered metabolites between tumor and adjacent normal tissue at stage IV oral squamous cell carcinoma tumors without extranodal extension	nan	NMR	Oral tissue	case vs.control group	32235493
METAC_1093	259	oral cancer	oral squamous cell carcinoma	8618	oral squamous cell carcinoma 	20.5 (29-87)	F&M	34	oral lichen planus	67.5 (34-98)	F&M	16	Significant salivary metabolites between oral lichen planus (OLP) and oral squamous cell carcinoma (OSCC) and AUC values for the discrimination of OSCC from OLP (μmol/L)	Fourteen metabolites were found to be significantly different between the OSCC and OLP groups.	CE-MS	Saliva	case vs.control group	31602722
METAC_1094	259	oral cancer	oral squamous cell carcinoma	8618	oral squamous cell carcinoma 	43 (39.5-54)	F&M	22	normal controls	32 (27.5-45.5)	F&M	18	Metabolites in the saliva samples between oral squamous cell carcinoma and normal saliva	nan	UPLC-QTOF-MS	Saliva	case vs.control group	30714209
METAC_1095	258	oral cancer	Oral cavity squamous cell carcinoma	8618	Oral cavity squamous cell carcinoma	51.7 (31-67)	F&M	31	normal tissues	51.7 (31-67)	F&M	31	List of the verified metabolites which are differentially expressed in OSCC (Oral cavity squamous cell carcinoma)	nan	LC-FT-MS	Oral tissue	case vs.control group	30661578
METAC_1096	257	oral cancer	Squamous cell carcinoma, Melanoma, Adenocarcinoma, Lymphoma	8618	Oral cancer		F&M	45	healthy controls		F&M	24	List of metabolites (29 entities) that are distinguished between healthy controls and oral cancer	nan	GC-MS	Plasma	case vs.control group	30548891
METAC_1097	257	oral cancer	Squamous cell carcinoma, Melanoma, Adenocarcinoma, Lymphoma	8618	Oral cancer		F&M	45	snuff dippers		F&M	32	List of metabolites (29 entities) that are distinguished between snuff dippers and oral cancer	nan	GC-MS	Plasma	case vs.control group	30548891
METAC_1098	257	oral cancer	Squamous cell carcinoma	8618	Oral cancer		F&M	50	healthy control		F&M	24	Significant differences between samples from healthy controls and oral cancer patients	Among them, twenty-seven VOCs (ten were decreased, seven disappeared, and ten were newly produced in the oral cancer group) depict significant differences between both the sample groups, and they have relevance as candidate biomarkers for OSCC.	GC-MS	Saliva	case vs.control group	30445287
METAC_1099	259	oral cancer	oral squamous cell carcinoma	8618	oral squamous cell carcinoma	66.3	F&M	48	oral diseases	60.3	F&M	29	Metabolites that were significantly different (P < 0.05) between patients with OSCC (oral squamous cell carcinoma) and OD (oral diseases)	nan	GC/MS	Plasma	case vs.control group	30282895
METAC_1100	257	oral cancer	oral cancer	8618	oral cancer	59.5 (34-87)	F&M	69	controls	43 (20-75)	F&M	87	metabolites between oral cancer and controls	nan	CE-TOF-MS	Saliva	case vs.control group	20300169
METAC_1101	257	oral cancer	oral cancer	8618	oral cancer	59.5 (34-87)	F&M	69	breast cancer	57 (29-77)	F	30	metabolites between oral cancer and breast cancer	nan	CE-TOF-MS	Saliva	case vs.control group	20300169
METAC_1102	257	oral cancer	oral cancer	8618	oral cancer	59.5 (34-87)	F&M	69	pancreatic cancer	67 (11-87)		18	metabolites between oral cancer and pancreatic cancer	nan	CE-TOF-MS	Saliva	case vs.control group	20300169
METAC_1103	257	oral cancer	oral cancer	8618	oral cancer	59.5 (34-87)	F&M	69	periodontal disease	60 (23-76)		11	metabolites between oral cancer and periodontal disease	nan	CE-TOF-MS	Saliva	case vs.control group	20300169
METAC_1104	257	oral cancer	nan	8618	oral cancer	56 ± 11	F&M	37	oral leukoplakia 	60 ± 13	F&M	32	Salivary metabolite signatures of oral cancer and oral leukoplakia (OLK)	The OSCC, OLK and healthy control groups demonstrate characteristic salivary metabolic signatures.	HPLC-MS	Saliva	case vs.control group	21190195
METAC_1105	257	oral cancer	nan	8618	oral cancer	56 ± 11	F&M	37	healthy control	43 ± 14		34	Salivary metabolite signatures of oral cancer and healthy control	The OSCC, OLK and healthy control groups demonstrate characteristic salivary metabolic signatures.	HPLC-MS	Saliva	case vs.control group	21190195
METAC_1106	257	oral cancer	nan	8618	oral cancer	72 (23–94)	F&M	24	normal tissue	68 (21–90) 	F&M	44	Metabolites of matched control and oral tumor tissue sets showing significantly different concentrations	In total, 85 and 45 metabolites showed significant differences between tumor and matched control samples, and between salivary samples from oral cancer and controls, respectively (P < 0.05 correlated by false discovery rate); 17 metabolites showed consistent differences in both saliva and tissue-based comparisons.	CE-TOF-MS	Oral tissue	case vs.control group	27539254
METAC_1107	257	oral cancer	nan	8618	oral cancer	72 (23–94)	F&M	24	normal tissue	68 (21–90) 	F&M	44	Metabolites of matched control and oral cancer saliva sample showing significantly different concentrations	In total, 85 and 45 metabolites showed significant differences between tumor and matched control samples, and between salivary samples from oral cancer and controls, respectively (P < 0.05 correlated by false discovery rate); 17 metabolites showed consistent differences in both saliva and tissue-based comparisons.	CE-TOF-MS	Saliva	case vs.control group	27539254
METAC_1108	259	oral cancer	Oral squamous cell carcinoma	8618	Oral squamous cell carcinoma	68 ± 13	F&M	22	healthy controls	56 ± 8	F&M	21	Significance of candidate metabolomes as biomarkers of OSCC (oral squamous cell carcinoma)	A total of 25 metabolites were revealed as potential markers to discriminate between patients with OSCC and healthy controls: Choline, p-hydroxyphenylacetic acid, and 2-hydroxy-4-methylvaleric acid (P<0.001); valine, 3-phenyl?lactic acid, leucine, hexanoic acid, octanoic acid, terephthalic acid, γ-butyrobetaine, and 3-(4-hydroxyphenyl)propionic acid (P<0.01); and isoleucine, tryptophan, 3-phenylpropi?onic acid, 2-hydroxyvaleric acid, butyric acid, cadaverine, 2-oxoisovaleric acid, N6,N6,N6-trimethyllysine, taurine, glycolic acid, 3-hydroxybutyric acid, heptanoic acid, alanine, and urea (P<0.05, according to the Wilcoxon rank sum test).	CE-MS	Saliva	case vs.control group	28393236
METAC_1109	258	oral cancer	Oral cavity squamous cell carcinoma	8618	Oral cavity squamous cell carcinoma		F&M	79	Control		F&M	20	Metabolites differentiating between OCC (Oral cavity squamous cell carcinoma) and controls by Targeted Aqueous Profiling	nan	LC-MS	Saliva	case vs.control group	30235319
METAC_1110	258	oral cancer	Oral cavity squamous cell carcinoma	8618	Oral cavity squamous cell carcinoma		F&M	79	Control		F&M	20	Metabolites differentiating between OCC (Oral cavity squamous cell carcinoma) and controls by NMR	nan	¹H NMR	Saliva	case vs.control group	30235319
METAC_1111	258	oral cancer	Oral cavity squamous cell carcinoma	8618	Oral cavity squamous cell carcinoma		F&M	79	Control		F&M	20	Metabolites differentiating between OCC (Oral cavity squamous cell carcinoma) and controls by Global Aqueous Profiling	nan	LC-MS	Saliva	case vs.control group	30235319
METAC_1112	221	leukemia	acute myeloid leukemia	1240	acute myeloid leukemia	54 (18–68)	F&M	10	Control		F&M	10	Differentially expressed metabolites between the AML (acute myeloid leukemia) patients and controls	nan	GC-TOF-MS	Serum	case vs.control group	34564403
METAC_1113	266	leukemia	acute myeloid leukemia	1240	RUNX1-RUNX1T1 groups			3	FLT3-ITD/TKD groups			4	Differentially expressed metabolites between the AML patients with RUNX1-RUNX1T1 and FLT3-ITD/TKD groups	nan	GC-TOF-MS	Serum	case vs.control group	34564403
METAC_1114	266	leukemia	acute myeloid leukemia	1240	RUNX1-RUNX1T1 groups			3	others groups			7	Differentially expressed metabolites between the AML with RUNX1-RUNX1T1 and others groups	nan	GC-TOF-MS	Serum	case vs.control group	34564403
METAC_1115	242	leukemia	acute myeloid leukemia	1240	FLT3-ITD/TKD groups			4	others groups			6	Differentially expressed metabolites between the AML patients with FLT3-ITD/TKD  and others groups	nan	GC-TOF-MS	Serum	case vs.control group	34564403
METAC_1116	246	leukemia	chronic myeloid leukemia	1240	PIO+IMA (Imatinib + Pioglitazone) groups			10	IMA (Imatinib) group			7	Proposed metabolites elected by fold change (FC) threshold ≥ 1.5 and p-value < 0.05 to IMA (Imatinib) and PIO+IMA (Imatinib + Pioglitazone) groups.	nan	HESI-Q-Orbitrap®-MS	Plasma	case vs.control group	34302533
METAC_1117	246	leukemia	chronic myeloid leukemia	1240	PIO+IMA (Imatinib + Pioglitazone) groups			10	Discontinuation groups			10	Proposed metabolites elected by fold change (FC) threshold ≥ 2.0 and p-value < 0.01 to PIO+IMA (Imatinib + Pioglitazone) and Discontinuation groups.	nan	HESI-Q-Orbitrap®-MS	Plasma	case vs.control group	34302533
METAC_1118	221	leukemia	acute myeloid leukemia	1240	acute myeloid leukemia		F&M	14	healthy control		F&M	16	Biomarkers identified in ESI + and ESI- model for AML	23 metabolites were identified by using the human metabolite database based on PLS-DA (partial least squares discriminant analysis) and independent sample test.	UHPLC-MS	Plasma	case vs.control group	33358300
METAC_1119	220	leukemia	Acute lymphoblastic leukemia	1240	Acute lymphoblastic leukemia	23-58(40.1)	F&M	19	healthy control	18-58(39.8)	F&M	19	Differential metabolites between healthy controls and ALL patients.	nan	¹H NMR	Plasma	case vs.control group	33295915
METAC_1120	263	leukemia	Acute lymphoblastic leukemia	1240	post-induction fatigue	8.90 (3.16 – 17.93)	F&M	86	diagnostic ALL	8.39 (2.61 – 17.48)	F&M	86	CSF metabolites associated with post-induction fatigue in the discovery cohort	nan	UPLC-MS/MS	Cerebrospinal fuid	case vs.control group	32889041
METAC_1121	263	leukemia	Acute lymphoblastic leukemia	1240	post-induction fatigue	9.09 (3.22 – 18.07)	F&M	85	diagnostic ALL	8.57 (2.67 – 17.63)	F&M	85	CSF metabolites associated with post-induction fatigue in the replication cohort	nan	UPLC-MS/MS	Cerebrospinal fuid	case vs.control group	32889041
METAC_1122	224	leukemia	acute myeloid leukemia	1240	AML responders after seven-day valproic acid therapy		F&M	18	AML responders before seven-day valproic acid therapy		F&M	18	Significantly altered serum metabolites of AML responders after seven-day valproic acid therapy	Twenty-three metabolites were significantly altered by seven-day valproic acid treatment (p < 0.05, q < 0.05), where the majority of altered metabolites belonged to lipid (especially fatty acid metabolism) and amino acid pathways, including several carnitines.	UPLC-MS	Serum	case vs.control group	31658693
METAC_1123	224	leukemia	acute myeloid leukemia	1240	AML non-responders after seven-day valproic acid therapy		F&M	26	AML non-responders before seven-day valproic acid therapy		F&M	26	Significantly altered serum metabolites of AML non-responders after seven-day valproic acid therapy	Twenty-three metabolites were significantly altered by seven-day valproic acid treatment (p < 0.05, q < 0.05), where the majority of altered metabolites belonged to lipid (especially fatty acid metabolism) and amino acid pathways, including several carnitines.	UPLC-MS	Serum	case vs.control group	31658693
METAC_1124	223	leukemia	acute myeloid leukemia	1240	after AML chemotherapy		F&M	10	before AML chemotherapy		F&M	10	List of the 9 significantly different metabolites before and after AML chemotherapy	Only 9 metabolites including imidazole lactate, glycerol 3-phosphate, three fatty acids, and four lysolipids in the blood serum were significantly changed before and post chemotherapy, suggesting their important roles during the development of RAML(refractory acute myeloid leukemia).	UPLC/MS/MS;UHLC/MS/MS; GC/MS	Serum	case vs.control group	35540790
METAC_1125	234	leukemia	chronic myeloid leukemia	1240	chronic myeloid leukemia			26	healthy control			26	Identification of plasma differential metabolites in chronic myeloid leukemia (CML) patients (n = 26)	We identified 9 metabolites that differentiated CML patients from healthy controls, including lactic acid, isoleucine, glycerol, glycine, myristic acid, D-sorbitol, D-galactose, D-glucose, and myo-inositol.	GC-MS	Plasma	case vs.control group	29316075
METAC_1126	265	leukemia	chronic myeloid leukemia	1240	post TKI treatment of SCML			112	pre TKI treatment of SCML			112	Changes of potential diagnostic biomarkers in pre-and post TKI treatment of SCML (sensitive to TKI treatment).	nan	GC-MS	Plasma	case vs.control group	29316075
METAC_1127	265	leukemia	chronic myeloid leukemia	1240	post TKI treatment of RCML			82	pre TKI treatment of RCML			82	Changes of potential diagnostic biomarkers in pre-and post TKI treatment of RCML (resistant to TKI treatment).	nan	GC-MS	Plasma	case vs.control group	29316075
METAC_1128	220	leukemia	acute lymphoblastic leukemia	1240	acute lymphoblastic leukemia		F&M	47	healthy control		F&M	60	Biomarker  by serum metabolomics of childhood acute lymphoblastic leukemia	Thirty metabolites (17 detected in positive mode and 13 in negative mode) were differentially expressed between patients with ALL and control patients; these metabolites were selected as potential biomarkers.	UPLC-MS	Serum	case vs.control group	24909874
METAC_1129	234	leukemia	chronic myeloid leukemia	1240	chronic myeloid leukemia	37.6 ± 13.4	F&M	26	healthy control	35.2 ± 9.2	F&M	18	The relative abundance of the identified compounds/peaks differentiating UCML (untreated CML patients) from HC (healthy control)	nan	GC/TOFMS	Plasma	case vs.control group	20949032
METAC_1130	265	leukemia	chronic myeloid leukemia	1240	CML sensitive to imatinib	38.1 ± 15.7	F&M	19	untreated chronic myeloid leukemia	37.6 ± 13.4	F&M	26	The relative abundance of the identified compounds/peaks differentiating SCML (CML sensitive to imatinib) from UCML (untreated CML patients)	nan	GC/TOFMS	Plasma	case vs.control group	20949032
METAC_1131	265	leukemia	chronic myeloid leukemia	1240	CML resistant to imatinib	39.2 ± 14.1	F&M	14	healthy control	35.2 ± 9.2	F&M	18	The relative abundance of the identified compounds/peaks differentiating RCML (CML resistant to imatinib) from HC (healthy control)	nan	GC/TOFMS	Plasma	case vs.control group	20949032
METAC_1132	227	leukemia	chronic myeloid leukemia	1240	RCML(CML resistant to imatinib) BC (blast crisis)		F&M	7	RCML CP (chronic phase) patients		F&M	7	The relative abundance of the identified compounds/peaks differentiating RCML(CML resistant to imatinib) BC (blast crisis) from RCML CP (chronic phase) patients	nan	GC/TOFMS	Plasma	case vs.control group	20949032
METAC_1133	93	breast cancer	HER2-positive breast cancer	1612	HER2-positive breast cancer	52 (47–65)	F	20	Normal control	51 (42–67)	F	30	Differential metabolites identified from metabolomics profiling between HER2 breast caner and normal control	nan	UPLC-TOF-MS	Serum	case vs.control group	34994982
METAC_1134	269	breast cancer	Triple negative breast cancer	1612	Triple negative responder	53 (31–76)	F	13	Triple negative non-responder	48 (33–58)	F	8	Significant metabolites in Triple negative patients before starting the therapy detected between response and non-response groups	nan	LC-HRMS	Plasma	case vs.control group	35338693
METAC_1135	248	breast cancer	Luminal B breast cancer	1612	Luminal B responder	49 (33–62)	F	25	Luminal B non-responder	52 (34–76)	F	23	Significant metabolites in luminal B patients before starting the therapy detected between response and non-response groups	nan	LC-HRMS	Plasma	case vs.control group	35338693
METAC_1136	269	breast cancer	Triple negative breast cancer	1612	Triple negative responder	53 (31–76)	F	13	Triple negative non-responder	48 (33–58)	F	8	Significant metabolites in Triple negative patients after received taxol & presurgery detected between response and non-response groups	nan	LC-HRMS	Plasma	case vs.control group	35338693
METAC_1137	27	breast cancer	nan	1612	Breast Cancer	54.5 ± 14.6	F	169	healthy control	49.8 ± 10.1	F	152	Summary of the 18 identified metabolites between breast cancer and healthy control	nan	UPLC-MS/MS	Plasma	case vs.control group	35454947
METAC_1138	225	breast cancer	nan	1612	Anti-Her2 therapy 		F	30	other therapy		F	148	Metabolomics according to therapy against Anti-Her2	nan	LC-MS/MS	Plasma	case vs.control group	35467121
METAC_1139	70	breast cancer	nan	1612	endocrine therapy		F	135	other therapy		F	43	Diferences in the metabolomics for patients with only endocrine therapy	nan	LC-MS/MS	Plasma	case vs.control group	35467121
METAC_1140	46	colorectal cancer	nan	9256	Colorectal cancer	61.2 (29-94)	F&M	67	healthy control	30.1 (23-42)	F&M	21	Differential urine metabolites between CRC (Colorectal cancer) patients and healthy controls	A total of 48 difffferential metabolites were identifified in CRC compared to controls.	UPLC-TQMS	Urine	case vs.control group	35521635
METAC_1141	240	breast cancer	nan	1612	allergy patients		F	9	non-allergy patients		F	5	Metabolites and PEGylated Liposomal Doxorubicin-Induced Immediate Hypersensitivity	nan	LC-MS/MS	Plasma	case vs.control group	35529437
METAC_1142	64	lung cancer	early-stage lung cancer	1324	early-stage lung cancer	61.25 ± 6.09	F&M	8	healthy control	59.6 ± 5.45	F&M	15	Metabolites between early-stage lung cancer (ESLC) and healthy control	nan	LC-MS	Stool	case vs.control group	35586253
METAC_1143	255	lung cancer	non-early-stage lung cancer	1324	non-early-stage lung cancer	57.82 ± 9.1	F&M	22	healthy control	59.6 ± 5.45	F&M	15	Metabolites between non-early-stage lung cancer and healthy control	nan	LC-MS	Stool	case vs.control group	35586253
METAC_1144	255	lung cancer	non-early-stage lung cancer	1324	non-early-stage lung cancer	57.82 ± 9.1	F&M	22	early-stage lung cancer	61.25 ± 6.09	F	8	Metabolites between non-early-stage lung cancer and early-stage lung cancer (ESLC)	nan	LC-MS	Stool	case vs.control group	35586253
METAC_1145	46	colorectal cancer	nan	9256	Colorectal cancer	56.67	F&M	30	normal controls	59.27	F&M	33	The potential metabolic biomarkers in CRC (Colorectal cancer) and NC (normal control) groups.	Regarding the fecal metabolome, twenty-nine metabolites were identified as having significantly changed, showing increased levels of adrenic acid, decanoic acid, arachidonic acid, and tryptophan but a reduction in various monosaccharides in the fecal samples of CRC patients.	UPLC-MS/MS	Stool	case vs.control group	35600308
METAC_1146	27	breast cancer	nan	1612	Breast Cancer	53.35 ± 12.26	F	55	healthy control		F	55	Metabolites between breast cancer and healthy controls	nan	UHPLC/Q-TOF-MS	Plasma	case vs.control group	35629952
METAC_1147	170	prostate cancer	nan	10283	prostate cancer	68.53 ± 7.58	M	62	benign prostatic hyperplasia	65.15 ± 7.46	M	75	Metabolic changes in serum samples between prostate cancer and benign prostatic hyperplasia	nan	¹H NMR	Serum	case vs.control group	35715864
METAC_1148	171	prostate cancer	nan	10283	prostate cancer bone metastasis	73.82 ± 8.17	M	50	benign prostatic hyperplasia	65.15 ± 7.46	M	75	Metabolic changes in serum samples between prostate cancer with bone metastasis and benign prostatic hyperplasia	nan	¹H NMR	Serum	case vs.control group	35715864
METAC_1149	171	prostate cancer	nan	10283	prostate cancer bone metastasis	73.82 ± 8.17	M	50	prostate cancer	68.53 ± 7.58	M	62	Metabolic changes in serum samples between prostate cancer with bone metastasis and prostate cancer	nan	¹H NMR	Serum	case vs.control group	35715864
METAC_1150	249	lung cancer	Early Stage Non-Small Cell Lung Cancer	1324	After Surgical Resection	64.4 ± 7.5	F&M	35	Before Surgical Resection	64.4 ± 7.5	F&M	35	Metabolites in Exhaled breath condensate of Early Stage Non-Small Cell Lung Cancer Patients Before and After Surgical Resection	nan	LC-QTOF-MS;NMR	Breath sample	case vs.control group	35719971
METAC_1151	249	lung cancer	Early Stage Non-Small Cell Lung Cancer	1324	After Surgical Resection	66.7 ± 6.8	F&M	15	Before Surgical Resection	66.7 ± 6.8	F&M	15	Metabolites in Sputum of Early Stage Non-Small Cell Lung  Cancer Patients Before and After Surgical Resection	nan	LC-QTOF-MS;NMR	Sputum	case vs.control group	35719971
METAC_1152	235	colorectal cancer	nan	9256	After treatment		F&M	20	Before treatment		F&M	20	Differentially expressed metabolites in  CRC (Colorectal cancer) patients before and after treatment	nan	UPLC-TOF-MS/MS	Serum	case vs.control group	35720415
METAC_1153	145	lung cancer	non-small cell lung cancer	1324	non-small cell lung cancer	58.98±9.27	F&M	55	Control	60.80±7.09	F&M	15	Differential metabolites in serum samples between the LC (lung cancer) patients and healthy controls	nan	LC-MS	Serum	case vs.control group	35735103
METAC_1154	145	lung cancer	non-small cell lung cancer	1324	non-small cell lung cancer tumor tissue	63.05±10.27	F&M	40	Pericarcinous tissue	63.05±10.27	F&M	40	Differential metabolites in tumor samples between the LC (lung cancer) patients and healthy controls	nan	LC-MS	Lung tissue	case vs.control group	35735103
METAC_1156	46	colorectal cancer	nan	9256	colorectal cancer		F&M	40	Control		F&M	40	Differentially metabolites in fecal between colorectal cancer (CRC) and normal colonoscopy	nan	UPLC-MS/MS	Stool	case vs.control group	35736483
METAC_1157	46	colorectal cancer	nan	9256	colorectal cancer		F&M	40	advanced adenoma		F&M	40	Differentially metabolites in fecal between colorectal cancer (CRC) and advanced adenoma (AA)	nan	UPLC-MS/MS	Stool	case vs.control group	35736483
METAC_1158	254	bladder cancer	muscle-invasive bladder cancer	11054	neoadjuvant chemotherapy (NAC) sensitive group	66.5 (39–75)	M	6	neoadjuvant chemotherapy (NAC) resistant group	64.5 (49–77)	M	12	Identified metabolites between the neoadjuvant chemotherapy (NAC) sensitive and resistant muscle-invasive bladder cancer groups by 1H-NMR	nan	¹H NMR	Serum	case vs.control group	35736490
METAC_1159	243	lymphoma	Follicular lymphoma	60058	Follicular lymphoma	59 (31–83)	F&M	29	controls	45 (24–60)	F&M	11	Unpaired t-test of metabolite concentrations in Follicular lymphoma (FL) cases relative to controls.	nan	¹H NMR	Lymph node	case vs.control group	35585165
METAC_1160	256	lymphoma	diffuse large B cell (DLBCL)	60058	non-Hodgkin’s lymphoma	29–64	F&M	15	healthy control	29–66	F&M	34	Significant metabolites that differ between healthy control and non-Hodgkin’s lymphoma (NHL) urine samples	Uni- and multivariate data analysis showed 18 endogenous metabolites, including amino acids and their metabolites, sugars, small organic acids, and vitamins, as statistically significant for group differentiation.	GC-MS	Urine	case vs.control group	32897412
METAC_1161	238	lymphoma	Diffuse Large B-Cell Lymphoma (DLBCL)	60058	Diffuse Large B-Cell Lymphoma (DLBCL)	62.2 ± 10.46	F&M	13	controls	57.0 ± 12.87	F&M	96	Differences in plasma metabolites between Diffuse Large B-Cell Lymphoma (DLBCL) and the controls	nan	GC-MS	Plasma	case vs.control group	31248049
METAC_1162	243	lymphoma	Follicular Lymphoma (FL)	60058	Follicular Lymphoma (FL)	47.9 ± 8.36	F&M	8	controls	57.0 ± 12.87	F&M	96	Differences in plasma metabolites between Follicular Lymphoma (FL) and the controls	nan	GC-MS	Plasma	case vs.control group	31248049
METAC_1163	233	lymphoma	Chronic Lymphocytic Leukemia (CLL)	60058	Chronic Lymphocytic Leukemia (CLL)	62.0 ± 15.23	F&M	6	controls	57.0 ± 12.87	F&M	96	Differences in plasma metabolites between Chronic Lymphocytic Leukemia (CLL) and the controls	nan	GC-MS	Plasma	case vs.control group	31248049
METAC_1164	253	lymphoma	Multiple Myeloma (MM)	60058	Multiple Myeloma (MM)	61.7 ± 7.00	F&M	9	controls	57.0 ± 12.87	F&M	96	Differences in plasma metabolites between Multiple Myeloma (MM) and the controls	nan	GC-MS	Plasma	case vs.control group	31248049
METAC_1165	245	lymphoma	Hodgkin Lymphoma (HL)	60058	Hodgkin Lymphoma (HL)	38.2 ± 12.22	F&M	10	controls	57.0 ± 12.87	F&M	96	Differences in plasma metabolites between Hodgkin Lymphoma (HL) and the controls	nan	GC-MS	Plasma	case vs.control group	31248049
METAC_1166	237	lymphoma	cutaneous T-cell lymphoma	60058	cutaneous T-cell lymphoma	54.6 ± 14.6	F&M	31	controls	53.9 ± 13.9	F&M	31	Serum metabolites compared between cutaneous T-cell lymphoma and controls	A total of 51 CTCL-regulated metabolites were identified, among which 15 differential metabolites have an AUC > 0.9 in receiver operating characteristic (ROC) curve analysis.	GC-MS;UHPLC-QTOF-MS	Serum	case vs.control group	29413580
METAC_1167	239	lymphoma	diffuse large B-cell lymphoma	60058	refractory/early relapse (REF/REL) diffuse large B-cell lymphoma	67 (29–85)	F&M	27	long-term progression-free (CURED) diffuse large B-cell lymphoma	61 (20–88)	F&M	60	Metabolite differentce between refractory/early relapse (REF/REL) and long-term progression-free (CURED)	Among discriminating metabolites higher in the REF/REL group were the amino acids lysine and arginine, the degradation product cadaverine and a compound in oxidative stress (2-hydroxybutyrate). In contrast, the amino acids aspartate, valine and ornithine, and a metabolite in the glutathione cycle, pyroglutamate, were higher in CURED patients.	¹H NMR	Serum	case vs.control group	26887805
